



US007371837B2

(12) **United States Patent**
Yuen et al.

(10) **Patent No.:** **US 7,371,837 B2**

(45) **Date of Patent:** **May 13, 2008**

(54) **HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF**

(75) Inventors: **Kwok Yung Yuen**, Hong Kong (CN); **Chiu Yat Patrick Woo**, Hong Kong (CN); **Kar Pui Susanna Lau**, Hong Kong (CN); **Kwok Hung Chan**, Hong Kong (CN)

(73) Assignee: **The University of Hong Kong**, Hong Kong (HK)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 212 days.

(21) Appl. No.: **11/129,741**

(22) Filed: **May 16, 2005**

(65) **Prior Publication Data**

US 2006/0034853 A1 Feb. 16, 2006

Related U.S. Application Data

(63) Continuation-in-part of application No. 10/895,064, filed on Jul. 21, 2004.

(51) **Int. Cl.**
C07H 21/02 (2006.01)
C12N 15/00 (2006.01)
A61K 39/00 (2006.01)
A61K 39/12 (2006.01)

(52) **U.S. Cl.** **536/23.1**; 435/320.1; 530/185.1; 530/186.1

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2005/0266397 A1* 12/2005 Exker et al. 435/5

OTHER PUBLICATIONS

Zhao et al., "DNA Vaccine of SARS-Cov S Gene Induces Antibody Response in Mice"; *Acta Biochim et Biophysica Sinica* 2004, 36(1):37-41 CN 31-1300/Q.

Yount et al., "Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59", *Journal of Virology*, vol. 76, No. 21, pp. 11065-11078 (Nov. 2002).

Entraz Accession No. NC 001846, Jul. 7, 1997.

Woo et al., "Phylogenetic and recombination analysis of coronavirus HKU1, a novel coronavirus from patients with pneumonia", *Arch Virol.*, vol. 150, pp. 2299-2311 (2005).

* cited by examiner

Primary Examiner—Bruce Campell

Assistant Examiner—Bo Peng

(74) *Attorney, Agent, or Firm*—Dickstein Shapiro LLP

(57) **ABSTRACT**

The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus-HKU1 ("CoV-HKU1"), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. Further study on nasopharyngeal aspirates from patients with community-acquired pneumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.

8 Claims, 201 Drawing Sheets

SEQ:1	1	TCGTGCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTTGGCCCGCAAACAT	58
SEQ:2	1	R A M P N I L R I V S S L V L A R K H	19
	59	GAATTTGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTT	118
	20	E F C C S H G D R F Y R L A N E C A Q V	39
	119	TTGAGTGAAATAGTTATGTGTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGT	178
	40	L S E I V M C G G C Y Y V K P G G T S S	59
	179	GGTGATGCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATGTCAGGCTGTTACTGCT	238
	60	G D A T T A F A N S V F N I C Q A V T A	79
	239	AATGTTTGTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAAT	298
	80	N V C S L M A C N G H K I E D L S I R N	99
	299	TTACAAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTT	358
	100	L Q K R L Y S N V Y R T D Y V D Y T F V	119
	359	AATGAGTATTATGAATTTTATGTAAGCATTTTAG	393
	120	N E Y Y E F L C K H F	130

FIG. 1

SEQ:3 1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTCAGATCTCAT 60
E * E R I A S V P S I S L R S L V R S H
N K S E L R P Y R L S A Y D L L S D L I
I R A N C V R T V Y Q L T I S C Q I S L

61 TAAATCTAAACTTTTTAAACAAGATTCCCTGTTATCCATGCTTGTGAGTGTGGTTAATC 120
* I * T F * T R F P V I H A C E C G L I
K S K L F K Q D S L L S M L V S V V * S
N L N F L N K I P C Y P C L * V W F N H

121 ATAATCTGTATTTTACTTTCCACACTTTTCATCTCTCTGCCAGTGACGTGTTGGTTGTC 180
I I L Y P T F H T F H L S A S D V L V V
* S C I L L S T L F I S L P V T C W L S
N L V F Y F P H F S S L C Q * R V G C P

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAACCAGCAAATACGGTCTCGGCTTCAA 240
L S V P P I G R N D * N Q Q I R S R L Q
S A S L P * V A M I K T S K Y G L G F K
Q R P S H R S Q * L K P A N T V S A S S

241 GTGGGCGCCAGAATTTTCGTTGGCTGCTTCCGGATGCAGCGGAGGAGTTGGCTAGTCCCTAT 300
V G A R I S L A A S G C S G G V G * S Y
W A P E F R W L L P D A A E E L A S P M
G R Q N F V G C F R M Q R R S W L V L *

301 GAAGTCAGATGAGGGTGGGTTATGCCCTCTACTGGTCAAGCGATGGAAGTGTGGATT 360
E V R * G W V M P L Y W S S D G K C W I
K S D E G G L C P S T G Q A M E S V G F
S Q M R V G Y A P L L V K R W K V L D S

361 CGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGGACAAGAATGGCATGT 420
R L * * S C E D R L S L H S W T R M A C
V Y D N H V K I D C R C I L G Q E W H V
F M I I M * R * I V A A F L D K N G M C

421 GCAGTCAAATCTTATCCGTGATATTTTGTTCATGAAGATCTACATGTTGTAGAAGTTCT 480
A V K S Y P * Y F C S * R S T C C R S S
Q S N L I R D I F V H E D L H V V E V L
S Q I L S V I F L F M K I Y M L * K F *

481 AACTAAAACAGCCGTAAGTCCGGTACGGCAATTTTAATTAATCACCTTTGCATAGCTT 540
N * N S R K V R Y G N F N * I T F A * L
T K T A V K S G T A I L I K S P L H S L
L K Q P * S P V R Q F * L N H L C I A W

FIG. 2

541 GGGTGGTTTTCTAAAGGGTATGTTATGGGCTTGTCCGTTCATACAAGACTAAACGTTA 600
G W F S * R V C Y G L V P F I Q D * T L
G G F P K G Y V M G L F R S Y K T K R Y
V V F L K G M L W A C S V H T R L N V M

601 TGTTGTACATCATCTTTCTATGACTACATCTACTACTAATTTGGTGAAGATTTTTGGG 660
C C T S S F Y D Y I Y Y * F W * R F F G
V V H H L S M T T S T T N F G E D F L G
L Y I I F L * L H L L L I L V K I F W V

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTCCACAAATGGTTCAATTCTGTAG 720
L D C T F W F Y A I L C S Q M V S I L *
W I V P F G F M P S Y V H K W F Q F C R
G L Y L L V L C H L M F T N G F N S V G

721 GTTGATATTTGAAGAGAGTGATTTAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780
V V Y * R E * F N N F K F * I * * L * F
L Y I E E S D L I I S N F K F D D Y D F
C I L K R V I * * F Q I L N L M I M I L

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGGTAATATTCACAAAA 840
* C R R C L C * G S C * A * R * I F T K
S V E D A Y A E V H A E P K G K Y S Q K
V * K M L M L R F M L S L K V N I H K K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAACCCGCTACTTTTTGTAGACCAGTA 900
S L C F T * T I S W Y * T R T F C R P V
A Y A L L R Q Y R G I K P V L F V D Q Y
L M L Y L D N I V V L N P Y F L * T S M

901 TGGTTGTGACTATCTGGTAAATTAGCAGATTGTCTTCAAGCTTATGGTCATTATTCTTT 960
W L * L F W * I S R L S S S L W S L F F
G C D Y S G K L A D C L Q A Y G H Y S L
V V T I L V N * Q I V F K L M V I I L C

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGTGACTTTGATATTGTAGT 1020
A R Y E T K A V C M A C Q L * L * Y C S
Q D M R Q K Q S V W L A N C D F D I V V
K I * D K S S L Y G L P I V T L I L * W

1021 GGCTTGGCATGTAGTTCCGTGATTACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080
G L A C S S * F T I C Y A P A D Y S Y Y
A W H V V R D S R F V M R L Q T I A T I
L G M * F V I H D L L C A C R L * L L F

FIG. 2 CONT.

1081 TTGTGGTATTAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGATGTAGTTAT 1140
L W Y * I C C T T Y R R C S R W R C S Y
C G I K Y V A Q P T E D V V D G D V V I
V V L N M L H N L Q K M * * M E M * L Y

1141 ACGTGAACCTGTACATTTATTATCTGCTGATGCAATAGTTTAAAGCTTCCTAGTTTGAT 1200
T * T C T F I I C * C N S F K A S * F D
R E P V H L L S A D A I V L K L P S L M
V N L Y I Y Y L L M Q * F * S F L V * *

1201 GAAAGTTATGACTCATATGGATGATTTTTCTATTAAATCTATATATAATGTTGATTGTG 1260
E S Y D S Y G * F F Y * I Y I * C * F V
K V M T H M D D F S I K S I Y N V D L C
K L * L I W M I F L L N L Y I M L I C V

1261 TGATTGTGGTTTTGTTATGCAGTATGGTTATGTAGATTGTTTTAATGATAATTGTGATTT 1320
* L W F C Y A V W L C R L F * * * L * F
D C G F V M Q Y G Y V D C F N D N C D F
I V V L L C S M V M * I V L M I I V I F

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTTCTTGTCATTGTGTGTACAGT 1380
L W L G F R * Y D G W F F L S I V L Y S
Y G W V S G N M M D G F S C P L C C T V
M V G F Q V I * W M V F L V H C V V Q F

1381 TTATGACTCTAGCGAAGTTAAAGCCCAATCATCTGGTGTATTTCCTGAAAATCCTGTGTT 1440
L * L * R S * S P I I W C Y S * K S C V
Y D S S E V K A Q S S G V I P E N P V L
M T L A K L K P N H L V L F L K I L C Y

1441 ATTTACTAATAGTACTGATACTGTTAACCATGATTCTTTAATTGTATGGTTATTCTGT 1500
I Y * * Y * Y C * P * F F * F V W L F C
F T N S T D T V N H D S F N L Y G Y S V
L L I V L I L L T M I L L I C M V I L S

1501 CACACCATTGGTTCTGTATATATTGGTCGCCGCTCCTGGATTGTGGATTCTATAAT 1560
H T I W F L Y I L V A A S W I V D S Y N
T P F G S C I Y W S P R P G L W I P I I
H H L V L V Y I G R R V L D C G F L * L

1561 TAAATCTTCAGTCAAGTCTTATGATGATTTGGTTTATTCAGGTGTAGTAGTTGTAAATC 1620
* I F S Q V L * * F G L F R C S R L * I
K S S V K S Y D D L V Y S G V V G C K S
N L Q S S L M M I W F I Q V * * V V N L

FIG. 2 CONT.

1621 TATTGTTAAAGAACTGCTCTTATTACTCATGCACCTTTACTTAGATTATGTTCAATGTAA 1680
 Y C * R N C S Y Y S C T L L R L C S M *
 I V K E T A L I T H A L Y L D Y V Q C K
 L L K K L L L L L M H F T * I M F N V S

1681 GTGTGGTAATCTTGAACAAAATCATATTCTTGGCGTTAATAATTCTTGGGTAGGCAACT 1740
 V W * S * T K S Y S W R * * F L V * A T
 C G N L E Q N H I L G V N N S W C R Q L
 V V I L N K I I F L A L I I L G V G N C

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTCTAAAAATATTGACTTGTGTTGTTAAGCG 1800
 V A * * R * L * Y A S K K Y * L V C * A
 L L N R G D Y N M L L K N I D L F V K R
 C L I E V I I I C F * K I L T C L L S V

1801 TCGTGCTGATTTTCTTCAAGTTTGCAGTTTGTGGAGATGGTTTTGTACCTTTTTTACT 1860
 S C * F C L Q V C S L W R W F C T F F T
 R A D F A C K F A V C G D G F V P F L L
 V L I L L A S L Q F V E M V L Y L F Y *

1861 AGATGGTTTAAATCCCCGTAGTTATTATCTAATTCAGAGTGGTATTTTCTTTACATCTTT 1920
 R W F N S P * L L S N S E W Y F L Y I F
 D G L I P R S Y Y L I Q S G I F F T S L
 M V * F P V V I I * F R V V F S L H L *

1921 GATGTCTCAATTTTCAACAAGAAGTTTCTGATATGTGTTTAAAAATGTGTATTTTGTAT 1980
 D V S I F T R S F * Y V F K N V Y F V Y
 M S Q P S Q E V S D M C L K M C I L F M
 C L N F H K K F L I C V * K C V F C L W

1981 GGACAGAGTTTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGGTTGGTTACTCA 2040
 G Q S F S C Y I L Y R A L C * * V G Y S
 D R V S V A T F Y I E H Y V N R L V T Q
 T E F Q L L H F I * S I M L I G W L L N

2041 ATTTAAGTTATTGGGTACTACACTTGTTAATAAAATGGTTAATGGTTTAAATACCATGTT 2100
 I * V I G Y Y T C * * N G * L V * Y H V
 F K L L G T T L V N K M V N W P N T M L
 L S Y W V L H L L I K W L I G L I P C *

2101 AGATGCTAGTGCACCTGCTACAGGCTGGCTTCTTTACCAATTATTGAATGGTCTTTTTGT 2160
 R C * C T C Y R L A S L P I I E W S F C
 D A S A P A T G W L L Y Q L L N G L F V
 M L V H L L Q A G F F T N Y * M V F L *

FIG. 2 CONT.

2161 AGTATCTCAAGCCAACTTTAATTTTGTGCTTTAATACCTGATTATGCTAAAATTTAGT 2220
S I S S Q L * F C C F N T * L C * N F S
V S Q A N F N F V A L I P D Y A K I L V
Y L K P T L I L L L * Y L I M L K F * L

2221 TAATAAATTTTACACTTTTTTTAAGTTATTATTAGAGTGTGTTACAGTTGATGTTTAA 2280
* * I L H F F * V I I R V C Y S * C F K
N K F Y T F F K L L L E C V T V D V L K
I N F T L F L S Y Y * S V L Q L M F * K

2281 AGATATGCCTGTTCTTAAACTATTAATGGTTTAGTTTGTATTGTAGGCAATAAGTTT 2340
R Y A C S * N Y * W F S L Y C R Q * V L
D M P V L K T I N G L V C I V G N K F Y
I C L F L K L L M V * F V L * A I S F I

2341 TAACGTTAGTACAGGGTTAATTCCTGGTTTTGTTTTACCATGTAATGCACAGGAACA 2400
* R * Y R V N S W F C F T M * C T G T T
N V S T G L I P G F V L P C N A Q E Q Q
T L V Q G * F L V L F Y H V M H R N N K

2401 AATTTATTTTTTGAAGCGTTGCAGAATCTGTTATAGTAGAAGATGATGTTATTGAGA 2460
N L F F * R R C R I C Y S R R * C Y * E
I Y F F E G V A E S V I V E D D V I E N
F I F L K A L Q N L L * * K M M L L R M

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAA 2520
C Q I F F I I L * V L S T T * I C R K N
V K S S L S S Y E Y C Q P P K S V E K I
S N L L Y H L M S I V N H L N L * K K F

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAATTTTTCCCTATTGTC 2580
L Y Y R * Y V H G * V W * * I F P Y C H
C I I D N M Y M G K C G D K F P P I V M
V L * I I C T W V S V V I N F S L L S *

2581 GAATGATAAAAATATTTGTCTTTTAGATCAGGCTTGGCGTTTTCCATGTGCAGGTAGA 2640
E * * K Y L S F R S G L A F S M C R * K
N D K N I C L L D Q A W R F P C A G R K
M I K I F V F * I R L G V F H V Q V E K

2641 AGTTAATTTTAAACGAGAAACCTGTTTATGGAGATCCGTCCTTGTGACAGTTAAGGT 2700
S * F * R E T C C Y G D S V F D D S * G
V N F N E K P V V M E I P S L M T V K V
L I L T R N L L L W R P R L * * Q L R L

FIG. 2 CONT.

2701 TATGTTTGATTAGATTCTACTTTTGATGATATTTTAGGTAAAGTTTGTTCAGAATTGA 2760
Y V * F R F Y F * * Y F R * S L F R I *
M F D L D S T F D D I L G K V C S E F E
C L I * I L L L M I F * V K F V Q N L K

2761 AGTAGAAAAGGGTGTACTGTAGATGATTTTGTCTGCTGTTTGTGATGCTATAGAGAA 2820
S R K G C Y C R * F C C C C L * C Y R E
V E K G V T V D D F V A V V C D A I E N
* K R V L L * M I L L L L F V M L * R M

2821 TGCTTTAAACTCTTGTAAGAGCATCCAGTGGTGGTTATCAAGTTCGTGCATTTTAA 2880
C F K L L * R A S S G W L S S S C I F K
A L N S C K E H P V V G Y Q V R A F L N
L * T L V K S I Q W L V I K F V H F * I

2881 TAACTTAATGAGAATGTTGTTTATTATTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940
* T * * E C C L F I * * G W * * S N G L
K L N E N V V Y L F D E A G D E A M A S
N L M R M L F I Y L M R L V M K Q W P L

2941 TCGTATGTATGTACTTTTGCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000
S Y V L Y F C Y * G C * R R Y Q * * S C
R M Y C T F A I E D V E D V I S S E A V
V C I V L L L L R M L K T L S V V K L S

3001 CGAAGATACTATTGATGGTGTGTTGAAGACACTATTAATGACGATGAAGATGTTGTTAC 3060
R R Y Y * W C R * R H Y * * R * R C C Y
E D T I D G V V E D T I N D D E D V V T
K I L L M V S L K T L L M T M K M L L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3181 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

FIG. 2 CONT.

3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3361 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3420
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3421 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATAACGATGAAGAGATTGTTAC 3480
W * Q * R * R C C Y W * Q * R * R D C Y
G D N D D E D V V T G D N N D E E I V T
V T M T M K M L L L V T I T M K R L L L

3481 TGGTGACAATGATGACCAAATTGTTGTTACTGGTGATGATGTAGATGATATTGAAAGTAT 3540
W * Q * * P N C C Y W * * C R * Y * K Y
G D N D D Q I V V T G D D V D D I E S I
V T M M T K L L L L V M M * M I L K V F

3541 TTATGACTTTGATACTTATAAAGCTCTTTTAGTTTTAATGATGTCTATAATGATGCTTT 3600
L * L * Y L * S S F S F * * C L * * C F
Y D F D T Y K A L L V F N D V Y N D A L
M T L I L I K L F * F L M M S I M M L C

3601 GTTTGTAGTTATGGTTCTAGTGTGAAACAGAAACATATTTTAAAGTTAATGGTTTATG 3660
V C * L W F * C * N R N I F * S * W F M
F V S Y G S S V E T E T Y F K V N G L W
L L V M V L V L K Q K H I L K L M V Y G

3661 GTCACCTACTATTACACATACTAATGTTGGTTGCGTTCTGTGTTACTTGTAAATGCAGAA 3720
V T Y Y Y T Y * L L V A F C V T C N A E
S P T I T H T N C W L R S V L L V M Q K
H L L L H I L I V G C V L C Y L * C R N

3721 ATTACCTTTAAGTTAAGGATTTAGCTATTGAAAATATGTGGTTATCTTATAAGGTGGG 3780
I T F * V * G F S Y * K Y V V I L * G G
L P F K F K D L A I E N M W L S Y K V G
Y L L S L R I * L L K I C G Y L I R W V

FIG. 2 CONT.

3781 TTATAATCAAAGTTTGTGGATTATTTACTGACCACTATTCCTAAAGCTATTGTTTGGCC 3840
L * S K F C * L F T D H Y S * S Y C F A
Y N Q S F V D Y L L T T I P K A I V L P
I I K V L L I I Y * P L F L K L L F C L

3841 TCAAGGTGGTTTTGTAGCTGATTTTGCTTATTGGTTTTTAAACCAGTTTGATATTAATGC 3900
S R W F C S * F C L L V F K P V * Y * C
Q G G F V A D F A Y W F L N Q F D I N A
K V V L * L I L L I G F * T S L I L M R

3901 GTATGCTAATGGTGTGTTTAAAAATGGTTTTTCTTTTGATTTAAATGGTTGGATGC 3960
V C * L V L F K M W F F F * F K W F G C
Y A N W C C L K C G F S F D L N G L D A
M L I G V V * N V V F L L I * M V W M L

3961 TTTGTTTTTTTATGGAGATATTGTGTCTCATGTTTGTAAAGTGGACATAATATGACTCT 4020
F V F L W R Y C V S C L * V W T * Y D S
L F F Y G D I V S H V C K C G H N M T L
C F F M E I L C L M F V S V D I I * L *

4021 AATAGCAGCGGACTTACCTTGTACATTACATTTTTTCATTATTTGATGACAATTTTGTGC 4080
N S S G L T L Y I T F F I I * * Q F L C
I A A D L P C T L H F S L F D D N F C A
* Q R T Y L V H Y I F H Y L M T I F V L

4081 TTTTGCACCCCTAAAAAATTTTATTGCTGCATGTGCTGGATGTAAACGTTTGTCA 4140
F L H P * K N F Y C C M C C G C K R L S
F C T P K K I F I A A C A V D V N V C H
F A P L K K F L L L H V L W M * T F V I

4141 TTCTGTAGCTGTTATAGGTGATGAACAAATAGATGGTAAGTTTGTACTAAATTTAGTGG 4200
F C S C Y R * * T N R W * V C Y * I * W
S V A V I G D E Q I D G K F V T K F S G
L * L L * V M N K * M V S L L L N L V V

4201 TGATAAATTTGATTTTATAGTAGGTTATGGAATGTCATTTAGTATGTCTTCTTTGAGTT 4260
* * I * F Y S R L W N V I * Y V F F * V
D K F D F I V G Y G M S F S M S S F E L
I N L I L * * V M E C H L V C L L L S Y

4261 ACCTCAATTGTATGGTTTGTGTATAACACCTAATGTATGTTTGTAAAGGTGATATTAT 4320
T S I V W F V Y N T * C M F C * R * Y Y
P Q L Y G L C I T P N V C F V K G D I I
L N C M V C V * H L M Y V L L K V I L *

FIG. 2 CONT.

4321 AAATGTTGCTAGACTTGTAAAGCTGATGTTATTGTTAATCCTGCTAATGGGCATATGCT 4380
 K C C * T C * S * C Y C * S C * W A Y A
 N V A R L V K A D V I V N P A N G H M L
 M L L D L L K L M L L L I L L M G I C S

4381 CCATGGTGGTGGAGTTGCAAAGCTATAGCTGTAGCTGCAGGTAAAAAATTTCTAAAGA 4440
 P W W W S C K S Y S C S C R * K I F * R
 H G G G V A K A I A V A A G K K F S K E
 M V V E L Q K L * L * L Q V K N F L K K

4441 AACTGCTGCTATGGTTAAATCTAAAGGTGTTTGCCAAGTAGGAGATTGTTATGTTTCTAC 4500
 N C C Y G * I * R C L P S R R L L C F Y
 T A A M V K S K G V C Q V G D C Y V S T
 L L L W L N L K V F A K * E I V M F L P

4501 CGGTGTAATTATGTAAACAATTCTTAATATTGTAGGCCCTGATGCTAGACAAGATGG 4560
 R W * I M * N N S * Y C R P * C * T R W
 G G K L C K T I L N I V G P D A R Q D G
 V V N Y V K Q F L I L * A L M L D K M E

4561 AAGACAATCTTATGTTTTGTTAGCACGTGCTTATAAGCATCTTAATAATTATGATTGTTG 4620
 K T I L C F V S T C L * A S * * L * L L
 R Q S Y V L L A R A Y K H L N N Y D C C
 D N L M F C * H V L I S I L I I M I V V

4621 TTTGTCTACTCTCATATCGGCTGGTATATTTAGTGTTCCTGCTGATGTGTCATTAECTTA 4680
 F V Y S H I G W Y I * C S C * C V I N L
 L S T L I S A G I F S V P A D V S L T Y
 C L L S Y R L V Y L V F L L M C H * L T

4681 CCTTCTAGGTGTTGTTGATAAACAAGTTATCCTTGTAGTAATAATAAGAAGATTTGA 4740
 P S R C C * * T S Y P C * * * * R R F *
 L L G V V D K Q V I L V S N N K E D F D
 F * V L L I N K L S L L V I I K K I L I

4741 TATTATTCAAAAATGTCAAATTACTTCAGTTGTTGGTACTAAAGCATTGGCTGTTAGATT 4800
 Y Y S K M S N Y F S C W Y * S I G C * I
 I I Q K C Q I T S V V G T K A L A V R L
 L F K N V K L L Q L L V L K H W L L D *

4801 AACTGCTAATGTAGGCCGTGTTATTAATTTGAGACAGATGCATACAAACTTTTTTTGAG 4860
 N C * C R P C Y * I * D R C I Q T F F E
 T A N V G R V I K F E T D A Y K L F L S
 L L M * A V L L N L R Q M H T N F F * V

FIG. 2 CONT.

4861 TGGTGATGATTGTTTTGTTTCAAATTCCTCTGTATACAAGAAGTTTTATTGCTTCGTCA 4920
W * * L F C F K F F C Y T R S F I A S S
G D D C F V S N S S V I Q E V L L L R H
V M I V L F Q I L L L Y K K F Y C F V M

4921 TGATATACAATTGAATAATGACGTTTCGTGATTATTTGTTGTCTAAGATGACTAGTCTTCC 4980
* Y T I E * * R S * L F V V * D D * S S
D I Q L N N D V R D Y L L S K M T S L P
I Y N * I M T F V I I C C L R * L V F L

4981 TAAAGATTGGCGTCTTATCAATAAATTTGATGTTATTAACGGTGTAAAAGTAACTGTTAAGTA 5040
* R L A S Y Q * I * C Y * R C * N C * V
K D W R L I N K F D V I N G V K T V K Y
K I G V L S I N L M L L T V L K L L S I

5041 TTTTGAGTGTCTAATTCATTATATATAGTAGCAGGGTAAAGACTTTGGTTATGTATG 5100
F * V S * F Y L Y M * S G * R L W L C M
F E C P N S I Y I C S Q G K D F G Y V C
L S V L I L F I Y V V R V K T L V M Y V

5101 TGATGGTCTTTTTATAAAGCAACTGTTAATCAAGTTTGTGTTTTATTAGCTAAGAAGAT 5160
* W F F L * S N C * S S L C F I S * E D
D G S F Y K A T V N Q V C V L L A K K I
M V L F I K Q L L I K F V F Y * L R R *

5161 AGATGTTTTGCTTACTGTAGATGGTGAATTTTAAATCTATTTCTTACTGTAGGTGA 5220
R C F A Y C R W C * F * I Y F S Y C R *
D V L L T V D G V N F K S I S L T V G E
M F C L L * M V L I L N L F L L L * V K

5221 AGTTTTTGGTAAAATACTGGTAATGTTTTCTGTGATGGCATTGATGTTACTAAGTTAAA 5280
S F W * N T W * C F L * W H * C Y * V K
V F G K I L G N V F C D G I D V T K L K
F L V K Y L V M F S V M A L M L L S * S

5281 GTGTAGTGATTTTTATGCCGATAAAAATTTTATATCAGTATGAAAATTTGTCTTTAGCTGA 5340
V * * F L C R * N F I S V * K F V F S *
C S D F Y A D K I L Y Q Y E N L S L A D
V V I F M P I K F Y I S M K I C L * L I

5341 TATTTCTGCTGTACAAAGTTCATTTGGGTTTGATCAGCAACAATTGCTTGCTTATTATAA 5400
Y F C C T K F I W V * S A T I A C L L *
I S A V Q S S F G F D Q Q Q L L A Y Y N
F L L Y K V H L G L I S N N C L L I I I

FIG. 2 CONT.

5401 TTTTAAACAGTATGTAATGGTCTGTAGTTGTTAACGGTCCATTTTTCTTTTGAACA 5460
F F N S M * M V C S C * R S I F F F * T
F L T V C K W S V V V N G P F F S F E Q
F * Q Y V N G L * L L T V H F F L L N S

5461 GTCTCATAATAATTGTTATGTGAATGTAGCTTGTCTTATGTTGCAGCATATAATCTTAA 5520
V S * * L L C E C S L S Y V A A Y * S *
S H N N C Y V N V A C L M L Q H I N L K
L I I I V M * M * L V L C C S I L I L N

5521 ATTTAATAAATGGCAGTGGCAGGAAGCATGGTATGAATTCGTGCTGGCAGACCACATAG 5580
I * * M A V A G S M V * I S C W Q T T *
F N K W Q W Q E A W Y E F R A G R P H R
L I N G S G R K H G M N F V L A D H I G

5581 GTTAGTTGCTCTTGTTTTAGCTAAAGGTCATTTTAAATTTGATGAACCATCAGATGCTAC 5640
V S C S C F S * R S F * I * * T I R C Y
L V A L V L A K G H F K F D E P S D A T
* L L L F * L K V I L N L M N H Q M L L

5641 TGATTTTATTCGTGTGTTTTGAAACAAGCTGATTATCAGGTGCAATTTGTGAATTAGA 5700
* F Y S C C F E T S * F I R C N L * I R
D F I R V V L K Q A D L S G A I C E L E
I L F V L F * N K L I Y Q V Q F V N * N

5701 ACTTATTTGTGATTGTGGTATTAAACAAGAAAGTCGTGTGGTGTGATGCTGTTATGCA 5760
T Y L * L W Y * T R K S C W C * C C Y A
L I C D C G I K Q E S R V G V D A V M H
L F V I V V L N K K V V L V L M L L C I

5761 TTTTGGTACATTAGCAAAGACTGATCTTTTAAATGGTTATAAGATTGGCTGTAATTGTGC 5820
F W Y I S K D * S F * W L * D W L * L C
F G T L A K T D L F N G Y K I G C N C A
L V H * Q R L I F L M V I R L A V I V Q

5821 AGGTAGAATTGCCATTGTACTAAATGAATGTACCATTTTTGATTTGTTCTAATACTCC 5880
R * N C P L Y * I E C T I F D L F * Y S
G R I V H C T K L N V P F L I C S N T P
V E L S I V L N * M Y H F * F V L I L L

5881 TCTGAGTAAGGATTACCTGATGATGTTGTTGCAGCTAACATGTTTATGGGTGTAGGTGT 5940
S E * G F T * * C C C S * H V Y G C R C
L S K D L P D D V V A A N M F M G V G V
* V R I Y L M M L L Q L T C L W V * V *

FIG. 2 CONT.

5941 AGGCCATTATACACATTTGAAATGTGGTTCACCTTACCAACATTATGATGCTTGTAGTGT 6000
R P L Y T F E M W F T L P T L * C L * C
G H Y T H L K C G S P Y Q H Y D A C S V
A I I H I * N V V H L T N I M M L V V L

6001 TAAAAAATATACAGGTGTTAGTGGTGTAACTGACTGCTTGTATCTTAAAAATTTAAC 6060
* K I Y R C * W L F N * L L V S * K F N
K K Y T G V S G C L T D C L Y L K N L T
K N I Q V L V V V * L T A C I L K I * P

6061 CCAGACTTTTACATCTATGTTGACTAATTATTTTTGGATGATGTGAAATGGTTGCTTA 6120
P D F Y I Y V D * L F F G * C * N G C L
Q T F T S M L T N Y F L D D V E M V A Y
R L L H L C * L I I F W M M L K W L L I

6121 TAACCCTGATCTTTCACAATATTATGTGATAATGGTAAGTATTATACAAAACCTATTAT 6180
* P * S F T I L L * * W * V L Y K T Y Y
N P D L S Q Y Y C D N G K Y Y T K P I I
T L I F H N I I V I M V S I I Q N L L *

6181 AAAGGCTCAGTTTAAACCATTGCTAAAGTTGACGGTGTTTATACTAACTTTAAGTTAGT 6240
K G S V * T I C * S * R C L Y * L * V S
K A Q F K P F A K V D G V Y T N F K L V
R L S L N H L L K L T V F I L T L S * L

6241 TGGACATGATATTTGTGCTCAATTGAATGATAAGTTAGGTTTAAATGTAGATTGCCGTT 6300
W T * Y L C S I E * * V R F * C R F A V
G H D I C A Q L N D K L G F N V D L P F
D M I F V L N * M I S * V L M * I C R L

6301 TGTGAGTACAAAGTAACAGTCTGGCCTGTAGCTACTGGTGATGTTGTTTTGGCATCTGA 6360
C * V Q S N S L A C S Y W * C C F G I *
V E Y K V T V W P V A T G D V V L A S D
L S T K * Q S G L * L L V M L F W H L M

6361 TGATTTATATGTGAAACGTTATTTTAAAGGATGTGAAACTTTTGGTAAGCCTGTTATTTG 6420
* F I C E T L F * R M * N F W * A C Y L
D L Y V K R Y F K G C E T F G K P V I W
I Y M * N V I L K D V K L L V S L L F G

6421 GTTTTGTGATGATGAAGCATCATTTGAATTCCTTACTTATTTTAAATAAACCTAGTTTAA 6480
V L S * * S I I E F S Y L F * * T * F *
F C H D E A S L N S L T Y F N K P S F K
F V M M K H H * I L L L I L I N L V L N

FIG. 2 CONT.

6481 ATCTGAAAATAGATATAGTGTGTTTGTCTGTTGATTCTGTATCTGAGGAGTCACAAGGTAA 6540
I * K * I * C F V C * F C I * G V T R *
S E N R Y S V L S V D S V S E E S Q G N
L K I D I V F C L L I L Y L R S H K V M

6541 TGTGGTTACTTCTGTTATGGAATCGCAGATTAGTACTAAAGAGGTTAAGTTAAAGGGTGT 6600
C G Y F C Y G I A D * Y * R G * V K G C
V V T S V M E S Q I S T K E V K L K G V
W L L L L W N R R L V L K R L S * R V L

6601 TAGAAAGACTGTAAAATAGAAGATGCTATTATTGTTAATGATGAAAATAGTTCTATTAA 6660
* K D C * N R R C Y Y C * * * K * F Y *
R K T V K I E D A I I V N D E N S S I K
E R L L K * K M L L L L M M K I V L L R

6661 GGTGTTAAAAGTTTATCTTTAGTTGATGTTTGGGATATGTATTTGACAGGTTGTGATTA 6720
G C * K F I F S * C L G Y V F D R L * L
V V K S L S L V D V W D M Y L T G C D Y
L L K V Y L * L M F G I C I * Q V V I M

6721 TGTGTTTGGGTTGCTAATGAATGTCACGCCTAGTTAAATCACCAACAGTTAGGGAATA 6780
C C L G C * * I V T P S * I T N S * G I
V V W V A N E L S R L V K S P T V R E Y
L F G L L M N C H A * L N H Q Q L G N I

6781 TATACGATATGGTATTAAACCTATTACTATACCTATAGATTTGTTATGTTTAAAGAGATGA 6840
Y T I W Y * T Y Y Y T Y R F V M F K R *
I R Y G I K P I T I P I D L L C L R D D
Y D M V L N L L L Y L * I C Y V * E M I

6841 TAATCAAACCTTTTAGTTCCTAAAATTTTTAAAGCAAGAGCTATAGAATTTTATGGTTT 6900
* S N S F S S * N F * S K S Y R I L W F
N Q T L L V P K I F K A R A I E F Y G F
I K L F * F L K F L K Q E L * N F M V F

6901 TTGGAAGTGGTGTGTTTATTATGTTTTAGTTTATTACATTTTACAAATGATAAAACCAT 6960
F E V V V Y L C F * F I T P Y K * * N H
L K W L F I Y V F S L L H F T N D K T I
* S G C L F M F L V Y Y I L Q M I K P F

6961 TTTTATACTACAGAAATAGCTTCTAAGTTTACTTTTAAATTTGTTTTGTTTGGCTCTTAA 7020
F L Y Y R N S F * V Y F * F V L F G S *
F Y T T E I A S K F T F N L F C L A L K
F I L Q K * L L S L L L I C F V W L L K

FIG. 2 CONT.

7021 AAATGCTTTTCAGACATTTAGATGGAGTATATTTATAAAAAGGTTTTCTTGTGTAGCCAC 7080
 K C F S D I * M E Y I Y K R F S C C S H
 N A F Q T F R W S I F I K G F L V V A T
 M L F R H L D G V Y L * K V F L L * P L

7081 TGTGTTTTGTTTTGGTTAATTTTTGTATATAAATGTTATTTTTAGTGACTTTTATCT 7140
 C V F V L V * F F V Y K C Y F * * L L S
 V F L F W F N F L Y I N V I F S D F Y L
 C F C F G L I F C I * M L F L V T F I F

7141 TCCTAATATTAGTGTTTTTCTATTTTTGTGGGAAGAATTGTTATGTGGATAAAGGCTAC 7200
 S * Y * C F S Y F C G K N C Y V D K G Y
 P N I S V F P I F V G R I V M W I K A T
 L I L V F F L F L W E E L L C G * R L L

7201 TTTTGGTTTGGTTACAATTTGTGATTTTTATTCTAAGTTAGGTGTAGGTTTACAAGTCA 7260
 F W F G Y N L * F L F * V R C R F Y K S
 F G L V T I C D F Y S K L G V G F T S H
 L V W L Q P V I F I L S * V * V L Q V I

7261 TTTTGTAAATGGTAGTTTTATATGTGAATTGTGTCATTCTGGTTTTGATATGTTGGATAC 7320
 F L * W * F Y M * I V S F W F * Y V G Y
 F C N G S F I C E L C H S G F D M L D T
 F V M V V L Y V N C V I L V L I C W I H

7321 ATATGCAGCTATAGATTTTTGTTTCAGTATGAAGTAGATAGACGTGTTTTATTTGATTATGT 7380
 I C S Y R F C S V * S R * T C F I * L C
 Y A A I D F V Q Y E V D R R V L F D Y V
 M Q L * I L F S M K * I D V F Y L I M L

7381 TAGTTTAGTCAAATTAATTGTTGAACTCGTTATTGGTTATTCATTATACACAGTATGGTT 7440
 * F S Q I N C * T R Y W L F I I H S M V
 S L V K L I V E L V I G Y S L Y T V W F
 V * S N * L L N S L L V I R Y T Q Y G F

7441 TTATCCATTATTTGTCTTATTGGTTTACAATTTACTACATGGTTGCCTGATTGTGT 7500
 L S I I L S Y W F T I I Y Y M V A * F V
 Y P L F C L I G L Q L F T T W L P D L F
 I H Y F V L L V Y N Y L L H G C L I C L

7501 TATGTTAGAAACTATGCATTGGTTGATTAGATTTATTGTATTTGTAGCTAATATGTTACC 7560
 Y V R N Y A L V D * I Y C I C S * Y V T
 M L E T M H W L I R F I V F V A N M L P
 C * K L C I G * L D L L Y L * L I C Y L

FIG. 2 CONT.

7561	TGCTTTTGTCTTGTGCGGTTTTATATAGTTGTTACTGCTATGTATAAAGTAGTTGGTTT C F C L V A V L Y S C Y C Y V * S S W F A F V L L R F Y I V V T A M Y K V V G F L L S C C G F I * L L L L C I K * L V L	7620
7621	TATTAGGCATATTGTCTATGGTTGTAATAAAGCTGGTTGTTTATTTTGTATAAACGAAA Y * A Y C L W L * * S W L F I L L * T K I R H I V Y G C N K A G C L F C Y K R N L G I L S M V V I K L V V Y F V I N E I	7680
7681	TTGTAGTGTTCGTGTTAAGTGTAGTACTATTGTTGGTGGTGAATTCGTTATTATGATAT L * C S C * V * Y Y C W W C N S L L * Y C S V R V K C S T I V G G V I R Y Y D I V V F V L S V V L L L V V * F V I M I L	7740
7741	TACTGCTAATGGTGGTACTGGTTTTTGTGTTAAACATCAATGGAATTGTTTAAATGCCA Y C * W W Y W F L C * T S M E L F * L P T A N G G T G F C V K H Q W N C F N C H L L M V V L V F V L N I N G I V L I A I	7800
7801	TTCTTTTAAACCAGGTAACACTTTTATAACTGTAGAAGCTGCTATAGAACTTTCTAAAGA F F * T R * H F Y N C R S C Y R T F * R S F K P G N T F I T V E A A I E L S K E L L N Q V T L L * L * K L L * N F L K S	7860
7861	GCTTAAACGACCTGTAAATCCAACGTGCTTACATTATGTAGTTACTGATATTAAGCA A * T T C K S N * C F T L C S Y * Y * A L K R P V N P T D A S H Y V V T D I K Q L N D L * I Q L M L H I M * L L I L S K	7920
7921	AGTTGGTTGTATGATGCGTTTGTCTATGATAGAGATGGACAGCGTGTACGATGATGT S W L Y D A F V L * * R W T A C L R * C V G C M M R L F Y D R D G Q R V Y D D V L V V * C V C S M I E M D S V F T M M L	7980
7981	TGATGCTAGTTTATTGTAGATATTAATAATCTGTTACATTCTAAAGTTAAAGTTGTTCC * C * F I C R Y * * S V T F * S * S C S D A S L F V D I N N L L H S K V K V V P M L V Y L * I L I I C Y I L K L K L F L	8040
8041	TAATTTGTATGTAGTTGTAGTAGAGAGTGATGCTGATAGAGCTAATTTTCTGAATGCTGT * F V C S C S R E * C * * S * F S E C C N L Y V V V V E S D A D R A N F L N A V I C M * L * * R V M L I E L I F * M L L	8100

FIG. 2 CONT.

8101 TGTGTTTTATGCACAATCATTGTATAGGCCTATATTACTTGTAGACAAAAAGTTAATTAC 8160
C V L C T I I V * A Y I T C R Q K V N Y
V F Y A Q S L Y R P I L L V D K K L I T
C F M H N H C I G L Y Y L * T K S * L L

8161 TACAGCTTGTAAATGGTATCTCTGTAACCCAGACTATGTTTGTATGTTTATGTTGATACTTT 8220
Y S L * W Y L C N P D Y V * C L C * Y F
T A C N G I S V T Q T M F D V Y V D T F
Q L V M V S L * P R L C L M F M L I L L

8221 TATGTCTCATTGTTGATGTGATAGAAAGAGTTTTAATAATTTGTTAACATTGCTCATGC 8280
Y V S F * C * * K E F * * F C * H C S C
M S H F D V D R K S F N N F V N I A H A
C L I L M L I E R V L I I L L T L L M L

8281 TTCTCTTAGAGAGGGTGTGCAATTAGAAAAGTTTTAGATACTTTTGTGGGATGTGTACG 8340
F S * R G C A I R K G F R Y F C G M C T
S L R E G V Q L E K V L D T F V G C V R
L L E R V C N * K R F * I L L W D V Y V

8341 TAAATGTTGTTCCATTGATTCAGATGTTGAAACAAGATTTACTAAATCTATGATATC 8400
* M L F H * F R C * N K I Y Y * I Y D I
K C C S I D S D V E T R F I T K S M I S
N V V P L I Q M L K Q D L L L N L * Y L

8401 TGCAGTAGCTGCTGGTTTGAATTTACTGATGAAAATTATAACAATTTGGTACCTACATA 8460
C S S C W F G I Y * * K L * Q F G T Y I
A V A A G L E F T D E N Y N N L V P T Y
Q * L L V W N L L M K I I T I W Y L H I

8461 TTTAAAGAGTGATAATTTGTAGCTGCTGATTTAGGTGTTCTTATACAGAATGGTGCTAA 8520
F K E * * Y C S C * F R C S Y T E W C *
L K S D N I V A A D L G V L I Q N G A K
* R V I I L * L L I * V F L Y R M V L S

8521 GCATGTACAGGGTAATGTTGCTAAGGCAGCTAATATTTCTTGTATATGGTTTATTGATGC 8580
A C T G * C C * G S * Y F L Y M V Y * C
H V Q G N V A K A A N I S C I W F I D A
M Y R V M L L R Q L I F L V Y G L L M L

8581 TTTAATCAACTTACTGCTGATTTACAGCATAAATAAAAAAGCATGTGTTAAACTGG 8640
F * S T Y C * F T A * I K K S M C * N W
F N Q L T A D L Q H K L K K A C V K T G
L I N L L L I Y S I N * K K H V L K L A

FIG. 2 CONT.

8641 CTTGAAGTTAAAATTGACTTTTAAATAAGCAAGAGGCAAGTGTCCCTATTCTTACAACACC 8700
L E V K I D F * * A R G K C P Y S Y N T
L K L K L T F N K Q E A S V P I L T T P
* S * N * L L I S K R Q V S L F L Q H P

8701 CTTTTCACTTAAAGGAGGTGTGTATTGAGTAATTTGTTATATATATTATTTTTGTTAG 8760
L F T * R R C C I E * F V I Y I I F C *
F S L K G G V V L S N L L Y I L F F V S
F H L K E V L Y * V I C Y I Y Y F L L V

8761 TTTAATCTGTTTTATATTATTGTGGGCTTTATTGCCTACATATAGTGTTTATAAGTCTGA 8820
F N L F Y I I V G F I A Y I * C L * V *
L I C F I L L W A L L P T Y S V Y K S D
* S V L Y Y C G L Y C L H I V F I S L I

8821 TATTCAATTTGCCTGCTTATGCTAGTTTTAAAGTTATTGATAATGGTGTGTTAGAGATAT 8880
Y S F A C L C * F * S Y * * W C C * R Y
I H L P A Y A S F K V I D N G V V R D I
F I C L L M L V L K L L I M V L L E I F

8881 TTCAGTTAATGATTTATGTTTTGCTAATAAATTTTTCCAATTTGATCAATGGTATGAGTC 8940
F S * * F M F C * * I F P I * S M V * V
S V N D L C F A N K F F Q F D Q W Y E S
Q L M I Y V L L I N F S N L I N G M S P

8941 CACTTTTGGGTCTGTTTACTATCATAATTCTATGGATTGCCCTATTGTAGTGGCAGTTAT 9000
H F W V C L L S * F Y G L P Y C S G S Y
T F G S V Y Y H N S M D C P I V V A V M
L L G L F T I I I L W I A L L * W Q L W

9001 GGATGAAGATATCGGTTCTACTATGTTTAAATGTTCCCTACTAAAGTTTTGAGACATGGCTT 9060
G * R Y R F Y Y V * C S Y * S F E T W L
D E D I G S T M F N V P T K V L R H G F
M K I S V L L C L M F L L K F * D M A F

9061 TCATGTTTTACATTTTTTAACTTATGCATTTGCTAGTGATAGTTCAGTGCTATAACCC 9120
S C F T F F N L C I C * * * C S V L Y T
H V L H F L T Y A F A S D S V Q C Y T P
M F Y I F * L M H L L V I V F S A I H H

9121 ACATATTCAGATTTCTTATAATGATTTTTATGCTAGTGGTTGTGTTTTATCATCTTTGTG 9180
T Y S D F L * * F L C * W L C F I I F V
H I Q I S Y N D F Y A S G C V L S S L C
I F R F L I M I F M L V V V F Y H L C V

FIG. 2 CONT.

9181 TACTATGTTTAAAAGAGGTGATGGTACACCACATCCTTATTGTTATTTCAGATGGTGTAT 9240
 Y Y V * K R * W Y T T S L L L F R W C Y
 T M F K R G D G T P H P Y C Y S D G V M
 L C L K E V M V H H I L I V I Q M V L *

9241 GAAGAATGCTTCTTTGTATACATCTTTGGTCCACATACACGTTATAGCCTTGCTAATTC 9300
 E E C F F V Y I F G S T Y T L * P C * F
 K N A S L Y T S L V P H T R Y S L A N S
 R M L L C I H L W F H I H V I A L L I L

9301 TAATGGTTTTATAAGATTTCTGATGTTATTAGTGAAGGTATTGTACGTATTGTAAGAAC 9360
 * W F Y K I S * C Y * * R Y C T Y C K N
 N G F I R F P D V I S E G I V R I V R T
 M V L * D F L M L L V K V L Y V L * E R

9361 GCGCTCTATGACTTATTGTAGAGTGGGTGCATGTGAATACGCCGAAGAGGGTATATGTTT 9420
 A L Y D L L * S G C M * I R R R G Y M F
 R S M T Y C R V G A C E Y A E E G I C F
 A L * L I V E W V H V N T P K R V Y V L

9421 TAATTTAATAGTTCCTGGGTTTTGAATAATGATTATTATAGAAGTATGCCTGGAACTTT 9480
 * F * * F L G F E * * L L * K Y A W N F
 N F N S S W V L N N D Y Y R S M P G T F
 I L I V P G F * I M I I I E V C L E L F

9481 TTGTGGTAGAGATCTTTTGTATTGTTTATCAATTTTTAGTAGTTAATTCGTCCTAT 9540
 L W * R S F * F V L S I F * * F N S S Y
 C G R D L F D L F Y Q F F S S L I R P I
 V V E I F L I C F I N F L V V * F V L *

9541 AGATTTCTTTTCTTACTGCTAGTCTATTTTTGGAGCTATATTGGCTATAGTTGTGT 9600
 R F L F S Y C * F Y F W S Y I G Y S C C
 D F F S L T A S S I F G A I L A I V V V
 I S F L L L L V L F L E L Y W L * L L S

9601 CTTGGTTTTTTATTATTTAATAAACTTAAGCGTGCTTTTGGAGATTATACTAGTGTGT 9660
 L G F L L F N K T * A C F W R L Y * C C
 L V F Y Y L I K L K R A F G D Y T S V V
 W F F I I * * N L S V L L E I I L V L *

9661 AGTATAAATGTTGTGTTGGTGTATTAATTTCTTATGCTTTTTGTTTTTCAAGTTTA 9720
 S Y K C C C L V Y * F S Y A F C F S S L
 V I N V V V W C I N F L M L F V F Q V Y
 L * M L L F G V L I F L C F L F F K F I

FIG. 2 CONT.

9721	TCCTATTTGTCATGTGTTTATGCTTGTGTTTTATTTTTATGTAACATTGTATTTTCCTTC S Y L C M C L C L F L F L C N I V F S F P I C A C V Y A C F Y F Y V T L Y F P S L F V H V F M L V F I F M * H C I F L L	9780
9781	TGAAATTAGTGAATTATGCATTGCAATGGATTGTTATGTATGGTCTATAATGCCTTT * N * C N Y A F A M D C Y V W C Y N A F E I S V I M H L Q W I V M Y G A I M P F K L V * L C I C N G L L C M V L * C L P	9840
9841	TTGGTTTTGTGTCACATATGTAGCTATGGTTATGCAAACCATGTTTTATGGTTATTTTC L V L C H I C S Y G Y C K P C F M V I F W F C V T Y V A M V I A N H V L W L F S G F V S H M * L W L L Q T M F Y G Y F H	9900
9901	ATATTGTAGGAAAATTGGTGTAAATGTATGTAGTGATAGTACATTGAAGAAACATCTCT I L * E N W C * C M * * * Y I * R N I S Y C R K I G V N V C S D S T F E E T S L I V G K L V L M Y V V I V H L K K H L L	9960
9961	TACTACTTTTATGATTACTAAAGATTCTTATTGTAGATTAAGAATTCTGTTTCTGATGT Y Y F Y D Y * R F L L * I K E F C F * C T T F M I T K D S Y C R L K N S V S D V L L L * L L K I L I V D * R I L F L M L	10020
10021	TGCCTACAATAGATATTTGAGTTTGTATAATAAGTATCGTTACTATAGTGGTAAATGGA C L Q * I F E F V * * V S L L * W * N G A Y N R Y L S L Y N K Y R Y Y S G K M D P T I D I * V C I I S I V T I V V K W I	10080
10081	TACTGCTGCCTATAGAGAAGCGGCGTGTCTCAGTTAGCTAAAGCTATGGAAACATTAA Y C C L * R S G V F S V S * S Y G N I * T A A Y R E A A C S Q L A K A M E T F N L L P I E K R R V L S * L K L W K H L I	10140
10141	TCACAATAATGGTAATGATGTCTTATACCAACCTCCTACAGCATCTGTTTCTACATCTTT S Q * W * * C L I P T S Y S I C F Y I F H N N G N D V L Y Q P P T A S V S T S F T I M V M M S Y T N L L Q H L F L H L F	10200
10201	TTTGCAATCAGGTATTGTAAGATGGTATCTCCTACGTCAAAAATTGAACCTTGATTGT F A I R Y C K D G I S Y V K N * T L Y C L Q S G I V K M V S P T S K I E P C I V C N Q V L * R W Y L L R Q K L N L V L L	10260

FIG. 2 CONT.

10261 TAGTGTTACTTATGGTAGTATGACTTTGAATGGTTTATGGTTAGATGACAAAGTTTATTG 10320
* C Y L W * Y D F E W F M V R * Q S L L
S V T Y G S M T L N G L W L D D K V Y C
V L L M V V * L * M V Y G * M T K F I V

10321 TCCTCGTCATGTTATATGTTTCATCCTCTAATATGAACGAACCTGATTATTCTGCCTTATT 10380
S S S C Y M F I L * Y E R T * L F C L I
P R H V I C S S S N M N E P D Y S A L L
L V M L Y V H P L I * T N L I I L P Y C

10381 GTGTAGAGTTACTCTAGGTGATTTTACTATAATGTCTGGTCGGATGAGTTAACAGTTGT 10440
V * S Y S R * F Y Y N V W S D E F N S C
C R V T L G D F T I M S G R M S L T V V
V E L L * V I L L * C L V G * V * Q L C

10441 GTCTTACCAGATGCAGGGCTGTCAACTTGTGTTTGACAGTCTCTTTACAAAATCCTTACAC 10500
V L P D A G L S T C F D S L F T K S L H
S Y Q M Q G C Q L V L T V S L Q N P Y T
L T R C R A V N L F * Q S L Y K I L T L

10501 TCCAAAATATACTTTTGGTAATGTTAAACCTGGTGAACCTTTTACTGTTTTAGCTGCGTA 10560
S K I Y F W * C * T W * N F Y C F S C V
P K Y T F G N V K P G E T F T V L A A Y
Q N I L L V M L N L V K L L L F * L R I

10561 TAAATGGCCGACCACAAGGGCATTTCATGTTACTATGCGTAGTAGTTATACTATTAAAGG 10620
* W P T T R G I S C Y Y A * * L Y Y * R
N G R P Q G A F H V T M R S S Y T I K G
M A D H K G H F M L L C V V V I L L K V

10621 TTCTTTTTTGTGTGGGTCATGTGGATCTGTTGGTTATGTATTAACAGGTGATAGTGTTAA 10680
F F F V W V M W I C W L C I N R * * C *
S F L C G S C G S V G Y V L T G D S V K
L F C V G H V D L L V M Y * Q V I V L S

10681 GTTTGTATATATGCATCAATTAGAGCTCAGTACTGGTTGTCACACTGGCACTGATTTTAC 10740
V C I Y A S I R A Q Y W L S H W H * F Y
F V Y M H Q L E L S T G C H T G T D F T
L Y I C I N * S S V L V V T L A L I L L

10741 TGGTAATTTTTATGGTCCATATAGAGATGCTCAAGTTGTACAGTTGCCAGTTAAGGACTA 10800
W * F L W S I * R C S S C T V A S * G L
G N F Y G P Y R D A Q V V Q L P V K D Y
V I F M V H I E M L K L Y S C Q L R T T

FIG. 2 CONT.

10801 CGTCCAGACTGTTAATGTTATTGCTTGGCTCTATGCAGCTATACTTAATAATTGTGCTTG 10860
R P D C * C Y C L A L C S Y T * * L C L
V Q T V N V I A W L Y A A I L N N C A W
S R L L M L L L G S M Q L Y L I I V L G

10861 GTTTGTACAAAATGATGTTTGTCTACTGAAGATTTTAAATGTTGGGCTATGGCAAATGG 10920
V C T K * C L F Y * R F * C L G Y G K W
F V Q N D V C S T E D F N V W A M A N G
L Y K M M F V L L K I L M F G L W Q M V

10921 TTTTAGCCAAGTAAAAGCAGATCTTGTCTTAGATGCTTTGGCTTCAATGACAGGTGTTTC 10980
F * P S K S R S C L R C F G F N D R C F
F S Q V K A D L V L D A L A S M T G V S
L A K * K Q I L S * M L W L Q * Q V F L

10981 TATTGAACTTTATTGGCTGCTATTAAGCGTCTATATATGGGATTTCAAGGTCGTCAAAT 11040
Y * N F I G C Y * A S I Y G I S R S S N
I E T L L A A I K R L Y M G F Q G R Q I
L K L Y W L L L S V Y I W D F K V V K Y

11041 ACTAGGAAGTTGTACTTTTGAAGATGAATTGGCACCTTCTGACGTTTATCAACAATTGGC 11100
T R K L Y F * R * I G T F * R L S T I G
L G S C T F E D E L A P S D V Y Q Q L A
* E V V L L K M N W H L L T F I N N W L

11101 TGGTGTAAATTGCAATCTAAAACAAAAGATTATTAAAGAAACAATTTATTGGATTTT 11160
W C * I A I * N K K I Y * R N N L L D F
G V K L Q S K T K R F I K E T I Y W I L
V L N C N L K Q K D L L K K Q F I G F *

11161 GATATCTACATTTTGTGTTAGTTGTATAATTTCTGCATTTGTTAAATGGACTATATTTAT 11220
D I Y I F V * L Y N F C I C * M D Y I Y
I S T F L F S C I I S A F V K W T I F M
Y L H F C L V V * F L H L L N G L Y L C

11221 GTATATTAATACACATATGATTGGTGTACATTATGTGTACTTTGTTTGTAGTTTTAT 11280
V Y * Y T Y D W C Y I M C T L F C * F Y
Y I N T H M I G V T L C V L C F V S F M
I L I H I * L V L H Y V Y F V L L V L *

11281 GATGTACTAGTTAAACATAAGCATTTTTATTGACTATGTATATAATTCCTGTACTCTG 11340
D V T S * T * A F L F D Y V Y N S C T L
M L L V K H K H F Y L T M Y I I P V L C
C Y * L N I S I F I * L C I * F L Y S V

FIG. 2 CONT.

11341 TACCTTGTTTTATGTAAATTATTTAGTGTGTTATAAGGAAGGTTTTAGAGGTTTACTTA 11400
Y L V L C K L F S C L * G R F * R F Y L
T L F Y V N Y L V V Y K E G F R G F T Y
P C F M * I I * L F I R K V L E V L L M

11401 TGTCTGGCTCTCATATTTTGTTCCTGCTGTGAATTTTACTTATGTTTATGAAGTATTTTA 11460
C L A L I F C S C C E F Y L C L * S I L
V W L S Y F V P A V N F T Y V Y E V F Y
S G S H I L F L L * I L L M F M K Y F M

11461 TGGTTGTATTTTATGTGTTTTTGTCTATTTTATAACTATGCATAGTATTAATCATGACAT 11520
W L Y F M C F C Y F Y N Y A * Y * S * H
G C I L C V F A I F I T M H S I N H D I
V V F Y V F L L F L * L C I V L I M T F

11521 TTTTCTTTGATGTTTTTGGTTGGTAGAATAGTTACTTTAATTTCTATGTTGGTATTTTGG 11580
F F F D V F G W * N S Y F N F Y V V F W
F S L M F L V G R I V T L I S M W Y F G
F L * C F W L V E * L L * F L C G I L G

11581 GTCGAATTTAGAAGAGGATGTTTTGTTATTTATTACAGCCTTTTTAGGTACTTATACATG 11640
V E F R R G C F V I Y Y S L F R Y L Y M
S N L E E D V L L F I T A F L G T Y T W
R I * K R M F C Y L L Q P F * V L I H G

11641 GACCACTATTTTGTCTATTAGCTATAGCAAAAATTTGTTGCTAATGGTTGCTGTTAATAT 11700
D H Y F V I S Y S K N C C * L V V C * Y
T T I L S L A I A K I V A N W L S V N I
P L F C H * L * Q K L L L I G C L L I Y

11701 ATTTTATTTTACAGATGTACCTTATATTAATTTGATTTCTCTTGAGTTACTTATTTATAGG 11760
I L F Y R C T L Y * I D S L E L L I Y R
F Y F T D V P Y I K L I L L S Y L F I G
F I L Q M Y L I L N * F S * V T Y L * G

11761 GTATATTTTATCTTGTATTGGGGATTTTCTCTCTTTTAAACAGTGTTTTATAGAATGCC 11820
V Y F I L L L G I F L S F K Q C F * N A
Y I L S C Y W G F F S L L N S V F R M P
I F Y L V I G D F S L F * T V F L E C L

11821 TATGGGTGTTTATAATTATAAAAATTTCTGTTCAAGAATTCGGTTATATGAATGCTAATGG 11880
Y G C L * L * N F C S R I A L Y E C * W
M G V Y N Y K I S V Q E L R Y M N A N G
W V F I I I K F L F K N C V I * M L M A

FIG. 2 CONT.

11881	CTTACGTCACCTCGTAATAGTTTTGAGGCTATTTTGTAAATTTAAAACTGCTTGAAT L T S T S * * F * G Y F V K F K T A W N L R P P R N S F E A I L L N L K L L G I Y V H L V I V L R L F C * I * N C L E *	11940
11941	AGGTGGCGTGCCAGTTATTGAAGTCTCCCAAATTCATCAAATTTGACTGATGTGAAATG R W R A S Y * S L P N S I K I D * C E M G G V P V I E V S Q I Q S K L T D V K C V A C Q L L K S P K F N Q N * L M * N V	12000
12001	TGCTAATGTTGTTTTGTAAATTTTACAGCATTGTCATGTTGCTTCTAATTTCTAAGTT C * C C F V K L F T A F A C C F * F * V A N V V L L N C L Q H L H V A S N S K L L M L F C * I V Y S I C M L L L I L S C	12060
12061	GTGGCAGTATTGTAGTGTTTTACATAATGAAATACTATCTACTTCAGATTTGAGTGTAGC V A V L * C F T * * N T I Y F R F E C S W Q Y C S V L H N E I L S T S D L S V A G S I V V F Y I M K Y Y L L Q I * V * L	12120
12121	TTTTGATAAGCTTGCTCAATTATTGATTGTTTTATTGCGCAATCCTGCTGCAGTTGATAC F * * A C S I I D C F I R Q S C C S * Y F D K L A Q L L I V L F A N P A A V D T L I S L L N Y * L F Y S P I L L Q L I L	12180
12181	TAAGTGTCTTGCAAGTATAGATGAAGTTAGCGATGATTATGTTCAAGATAGTACCGTTTT * V S C K Y R * S * R * L C S R * Y R F K C L A S I D E V S D D Y V Q D S T V L S V L Q V * M K L A M I M F K I V P F C	12240
12241	GCAGGCTTTGCAAAGTGAGTTTGTAAATATGGCTAGTTTTGTTGAATATGAAGTCGCAAA A G F A K * V C K Y G * F C * I * S R K Q A L Q S E F V N M A S F V E Y E V A K R L C K V S L * I W L V L L N M K S Q R	12300
12301	GAAAAATTTGGCTGATGCTAAAAATAGTGGTTCTGTTAATCAACAACAGATAAAACAGTT E K F G * C * K * W F C * S T T D K T V K N L A D A K N S G S V N Q Q Q I K Q L K I W L M L K I V V L L I N N R * N S *	12360
12361	AGAAAAAGCATGTAATATAGCTAAGTCTGTGTATGAACGTGATAAAGCTGTAGCTCGCAA R K S M * Y S * V C V * T * * S C S S Q E K A C N I A K S V Y E R D K A V A R K K K H V I * L S L C M N V I K L * L A N	12420

FIG. 2 CONT.

12421 ACTTGAACGTATGGCAGACCTAGCACTTACTAACATGTATAAAGAGGCTCGGATTAATGA 12480
T * T Y G R P S T Y * H V * R G S D * *
L E R M A D L A L T N M Y K E A R I N D
L N V W Q T * H L L T C I K R L G L M I

12481 TAAGAAGAGTAAAGTTGTTCCGCTTTGCAGACAATGCTTTTTAGCATGGTTCGTA AAT 12540
* E E * S C F R F A D N A F * H G S * I
K K S K V V S A L Q T M L P S M V R K L
R R V K L F P L C R Q C F L A W F V N W

12541 GGATAATCAGGCTTTAAATTCTATTCTGATAATGCTGTAAAGGTTGTGTACCTTTGAG 12600
G * S G F K F Y S G * C C * R L C T F E
D N Q A L N S I L D N A V K G C V P L S
I I R L * I L F W I M L L K V V Y L * V

12601 TGCTATTCCAGCATTGGCTGCTAATACTTTAACTATAGTAATACCAGATAAACAAGTTT 12660
C Y S S I G C * Y F N Y S N T R * T S F
A I P A L A A N T L T I V I P D K Q V F
L F Q H W L L I L * L * * Y Q I N K F L

12661 TGATAAAGTTGTTGATAATGTTTATGTTACATATGCTGGTAGTGTATGGCATATACAGAC 12720
* * S C * * C L C Y I C W * C M A Y T D
D K V V D N V Y V T Y A G S V W H I Q T
I K L L I M F M L H M L V V Y G I Y R L

12721 TGTTCAAGATGCTGATGGTATTAATAAACAGTTAACTGATATTAGTGTGATTCTAATTG 12780
C S R C * W Y * * T V N * Y * C * F * L
V Q D A D G I N K Q L T D I S V D S N W
F K M L M V L I N S * L I L V L I L I G

12781 GCCTCTTGTTATCATTGCGAACAGGTATAATGAAGTTGCTAATGCTGTTATGCAGAATAA 12840
A S C Y H C E Q V * * S C * C C Y A E *
P L V I I A N R Y N E V A N A V M Q N N
L L L S L R T G I M K L L M L L C R I M

12841 TGAGTTGATGCCTCATAAATTA AAAATACAAGTTGTTAATAGTGGTTCTGATATGAATTG 12900
* V D A S * I K N T S C * * W F * Y E L
E L M P H K L K I Q V V N S G S D M N C
S * C L I N * K Y K L L I V V L I * I V

12901 TAATATCCTACTCAATGTTATTATAATAATGGTAGTAGTGGTAGAATAGTTTATGCTGT 12960
* Y S Y S M L L * * W * * W * N S L C C
N I P T Q C Y Y N N G S S G R I V Y A V
I F L L N V I I I M V V V V E * F M L F

FIG. 2 CONT.

12961 TCTTAGTGATGTTGATGGTCTTAAGTATACTAAGATAATGAAAGATGATGGAAATTGTGT 13020
S * * C * W S * V Y * D N E R * W K L C
L S D V D G L K Y T K I M K D D G N C V
L V M L M V L S I L R * * K M M E I V L

13021 TGTTTTAGAGCTTGATCCTCCTTGTAATTTTCTATACAAGATGTTAAGGGACTTAAAAT 13080
C F R A * S S L * I F Y T R C * G T * N
V L E L D P P C K F S I Q D V K G L K I
F * S L I L L V N F L Y K M L R D L K L

13081 TAAGTATCTTTATTTTATAAAGGATGTAACACTTTAGCTAGAGGGTGGGTTGTGGTAC 13140
* V S L F Y * R M * H F S * R V G C W Y
K Y L Y F I K G C N T L A R G W V V G T
S I F I L L K D V T L * L E G G L L V L

13141 TTTATCTTCAACAATTAGATTGCAGGCTGGTGTGCTACTGAGTATGCAGCTAATTCTTC 13200
F I F N N * I A G W C C Y * V C S * P F
L S S T I R L Q A G V A T E Y A A N S S
Y L Q Q L D C R L V L L L S M Q L I L L

13201 TATACTTTCATTATGTGCATTTTCTGTAGATCCTAAGAAACTTATTTAGATTATATACA 13260
Y T F I M C I F C R S * E N L F R L Y T
I L S L C A F S V D P K K T Y L D Y I Q
Y F H Y V H F L * I L R K L I * I I Y N

13261 ACAAGGTGGTGTACCTATAAATTAATGTGTAAAATGCTCTGTGATCATGCTGGTACTGG 13320
T R W C T Y N * L C * N A L * S C W Y W
Q G G V P I I N C V K M L C D H A G T G
K V V Y L * L I V L K C S V I M L V L V

13321 TATGGCCACTACTATTAACCTGAGGCTACTATTAACCAAGATTCTTATGGTGGTGCCTC 13380
Y G H Y Y * T * G Y Y * P R F L W W C L
M A I T I K P E A T I N Q D S Y G G A S
W P L L L N L R L L L T K I L M V V P Q

13381 AGTTTGTATTATTATGCCGTGCAGTGTAGAGCATCCAGATGTAGATGGTATATGTAAATT 13440
S L Y L L P C T C R A S R C R W Y M * I
V C I Y C R A R V E H P D V D G I C K L
F V F I A V H V * S I Q M * M V Y V N Y

13441 ACGTGGTAAATTTGTACAAGTCCCTTTGGGTATAAAAAGATCCTATTCTTTATGTGTTAAC 13500
T W * I C T S P F G Y K R S Y S L C V N
R G K F V Q V P L G I K D P I L Y V L T
V V N L Y K S L W V * K I L F F M C * H

FIG. 2 CONT.

13501 ACATGATGTTTGTCAAGTCTGTGGTTTTTGGAGAGATGGCAGTTGTTCTCTGTAGGTTT 13560
T * C L S S L W F L E R W Q L F L C R F
H D V C Q V C G F W R D G S C S C V G S
M M F V K S V V F G E M A V V P V * V Q

13561 AAGTGTGCTGTTCAATCTAAAGATTTAAATTTTTTAAACGGGTTCCGGGTTACTAGTGTG 13620
K C R C S I * R F K F F K R V R G T S V
S V A V Q S K D L N F L N G F G V L V *
V S L F N L K I * I F * T G S G Y * C E

13621 AATGCCCGCTAGTACCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTT 13680
N A R L V P C A S G L S T D V Q L R A F
M P G * Y P V L V V Y L L M F N * G H L
C P A S T L C * W F I Y * C S I K G I *

13681 GACATTTGTAATACCAATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGT 13740
D I C N T N R A G I G L Y Y K V N C C R
T F V I P I E L V * V Y I I K * I V A V
H L * Y Q * S W Y R F I L * S E L L P F

13741 TTTACGCTATAGATGACGACGGTAATAAATGGATAAGTCTTTGTTGTCAAAGAATC 13800
F Q R I D D D G N K L D K F F V V K R T
F S V * M T T V I N W I S S L L S K E L
S A Y R * R R * * I G * V L C C Q K N *

13801 AATTTAGAAGTTTATAATAAAGAGAAAACCTTATTATGAGTTGACTAAAAGTTGGTGGTT 13860
N L E V Y N K E K T Y Y E L T K S C G V
I * K F I I K R K L I M S * L K V V V L
F R S L * * R E N L L * V D * K L W C C

13861 GTGGCTGAACATGATTTCTTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTT 13920
V A E H D F F T F D I D G S R V P H I V
W L N M I S L H L I L M V V A C H I * F
G * T * F L Y I * Y * W * S R A T Y S S

13921 CGTAGGAATCTTTCAAAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGAT 13980
R R N L S K Y T M L D L C Y A L R H F D
V G I F Q S I L C * I F A M H C V I L I
* E S F K V Y Y V R S L L C I A S F * S

13981 CGTAATGATTTGTTCAATATTGTGTGAAATCTTTGTGAGTATGCTGATTGTAAAGAATCC 14040
R N D C S I L C E I L C E Y A D C K E S
V M I V Q Y C V K F F V S M L I V K N P
* * L F N I V * N S L * V C * L * R I L

FIG. 2 CONT.

14041 TACTTTTCTAAGAAAGATTGGTATGATTTTGTGAAAATCCTGATATTATAATATATAT 14100
 Y F S K K D W Y D F V E N P D I I N I Y
 T F L R K I G M I L L K I L I L L I Y I
 L F * E R L V * F C * K S * Y Y * Y I *

14101 AAAAAATTAGGCCCTATTTTAAATAGAGCTTTACTTAATACTGTCATTTTGCAGACACC 14160
 K K L G P I F N R A L L N T V I F A D T
 K N * A L F L I E L Y L I L S F L Q T P
 K I R P Y F * * S F T * Y C H F C R H L

14161 TTAGTTGAAGTAGGTTTAGTGGTGGTTTAACTTTAGATAACCAAGATTTGTATGGTCAA 14220
 L V E V G L V G V L T L D N Q D L Y G Q
 * L K * V * L V F * L * I T K I C M V N
 S * S R F S W C F N F R * P R F V W S M

14221 TGGTATGATTTTGGTATTTTATACAAACAGCCCCAGGGTTTGGTGTGGCAGTTGCAGAT 14280
 W Y D F G D F I Q T A P G F G V A V A D
 G M I L V I L Y K Q P Q G L V W Q L Q I
 V * F W * F Y T N S P R V W C G S C R F

14281 TCTTACTATTCTTATATGATGCCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTA 14340
 S Y Y S Y M M P M L T M C H V L D C E L
 L T I L I * C L C * L C V M Y * I V N Y
 L L F L Y D A Y V D Y V S C I R L * I I

14341 TTTGTAAATGATAGTTATAGACAATTCGATCTTGACAGTATGATTTTACTGATTACAAG 14400
 F V N D S Y R Q P D L V Q Y D F T D Y K
 L L M I V I D N S I L Y S M I L L I T S
 C * * * L * T I R S C T V * F Y * L Q V

14401 TTAGAGTTGTTTAAATAAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTG 14460
 L E L F N K Y F K Y W G M K Y H P N T V
 * S C L I S I L S I G V * S I I L I L W
 R V V * * V F * V L G Y E V S S * Y C G

14461 GATTGTGATAATGATAGGTGATTATTTCATTGTGCTAATTTTAAATACTATTTAGTATG 14520
 D C D N D R C I I H C A N F N I L F S M
 I V I M I G V L F I V L I L I Y Y L V W
 L * * * * V Y Y S L C * F * Y T I * Y G

14521 GTTTTACCTAATACTTGTTTTGGTCCCTTGTAGACAAATTTTGTAGATGGTGTACCG 14580
 V L P N T C F G P L V R Q I F V D G V P
 F Y L I L V L V P L L D K F L * M V Y R
 F T * Y L F W S P C * T N F C R W C T V

FIG. 2 CONT.

14581 TTTGTTGTTTCTATTGGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACTTAGATGTT 14640
F V V S I G Y H Y K E L G V V M N L D V
L L F L L V T I T K S * V * L * T * M L
C C F Y W L P L Q R V R C S Y E L R C *

14641 GACACACACCGTTATCGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCT 14700
D T H R Y R L S L K D L L L Y A A D P A
T H T V I V C L L K I Y F F M Q Q I L L
H T P L S F V S * R F T S L C S R S C Y

14701 ATGCACGTTGCATCTGCTAGTGTCTGCTTGTATTACGAACTTGTGTTTTAGTGTAGCT 14760
M H V A S A S A L L D L R T C C F S V A
C T L H L L V L C L I Y E L V V L V * L
A R C I C * C S A * F T N L L F * C S C

14761 GCCATTACAAGTGGTATAAAAATTTCAAACCTGTAAAACCAGGTAACCTTAACCAAGACTTT 14820
A I T S G I K F Q T V K P G N F N Q D F
P L Q V V * N F K L * N Q V T L T K T F
H Y K W Y K I S N C K T R * L * P R L L

14821 TACGAGTTTGTAAAAGTAAAGGCTTGTAAAAGAGGGTAGTACAGTTGATTGAAACAT 14880
Y E F V K S K G L F K E G S T V D L K H
T S L L K V K A C L K R V V Q L I * N I
R V C * K * R L V * R G * Y S * F E T F

14881 TTTTCTTTACTCAAGATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAAT 14940
F F F T Q D G N A A I T D Y N Y Y K Y N
F S L L K M V M L Q L L I I I I I S I I
F L Y S R W * C C N Y * L * L L * V * F

14941 TTACCTACTATGGTTGATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATAT 15000
L P T M V D I K Q L L F V L E V V Y K Y
Y L L W L I L S S Y C L Y * K L F I N I
T Y Y G * Y * A V I V C I R S C L * I F

15001 TTTGAAATTTATGATGGTGGTTGTATACCAGCATCACAAAGTTATTGTTAATAATTATGAT 15060
F E I Y D G G C I P A S Q V I V N N Y D
L K F M M V V V Y Q H H K L L L I I M I
* N L * W W L Y T S I T S Y C * * L * *

15061 AAAAGTCTGGTTATCCATTTAATAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTA 15120
K S A G Y P F N K F G K A R L Y Y E A L
K V L V I H L I N L V K P D F I M R H Y
K C W L S I * * I W * S Q T L L * G I I

FIG. 2 CONT.

15121 TCATTGAGGAACAGAATGAAATTTATGCATATACTAAACGTAATGTTCTGCCACCTTA 15180
S F E E Q N E I Y A Y T K R N V L P T L
H L R N R M K F M H I L N V M F C P P *
I * G T E * N L C I Y * T * C S A H L N

15181 ACTCAAATGAATTTAAAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGT 15240
T Q M N L K Y A I S A K N R A R T V A G
L K * I * N M L S V L R I E L A L * Q V
S N E F K I C Y Q C * E * S S H C S R C

15241 GTTTCTATTCTTAGTACTATGACAGGCCGAATGTTCCATCAAAAATGTTTGAAGAGTATA 15300
V S I L S T M T G R M F H Q K C L K S I
F L F L V L * Q A E C S I K N V * R V *
F Y S * Y Y D R P N V P S K M F E E Y S

15301 GCAGTACCCGAGGTGTTCTCTGTTATAGGAACCACTAAATTTTATGGTGGTGGGAC 15360
A A T R G V P V V I G T T K F Y G G W D
Q L P E V F L L L * E P L N F M V V G T
S Y P R C S C Y R N H * I L W W L G R

15361 GATATGTTACGTCACTTATAAAGGATGTTGACAACCCTGTTCTTATGGGTTGGGATTAT 15420
D M L R H L I K D V D N P V L M G W D Y
I C Y V I L * R M L T T L F L W V G I I
Y V T S S Y K G C * Q P C S Y G L G L S

15421 CCTAAATGTGATCGTGCTATGCCAAATATTTGCGTATTGTTAGTAGTTTAGTTTGGCC 15480
P K C D R A M P N I L R I V S S L V L A
L N V I V L C Q I F C V L L V V * F W P
* M * S C Y A K Y F A Y C * * F S F G P

15481 CGCAAACATGAATTTTGTGTTACACATGGTGATAGATTTTATCGCCTTGCGAATGAATGT 15540
R K H E F C C S H G D R F Y R L A N E C
A N M N F V V H M V I D F I A L R M N V
Q T * I L L F T W * * I L S P C E * M C

15541 GCTCAAGTTTGTAGTGAATAGTTATGTGTGGCGGTTGCTATTATGTTAAGCCTGGTGGT 15600
A Q V L S E I V M C G G C Y Y V K P G G
L K F * V K * L C V A V A I M L S L V V
S S F E * N S Y V W R L L L C * A W W Y

15601 ACTAGCAGTGGTGATGCAACTACTGCTTTTGCTAATCTGTTTTTAATATATGTCAGGCT 15660
T S S G D A T T A F A N S V F N I C Q A
L A V V M Q L L L L L I L F L I Y V R L
* Q W * C N Y C F C * F C F * Y M S G C

FIG. 2 CONT.

15661 GTTACTGCTAATGTTTGTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGT 15720
V T A N V C S L M A C N G H K I E D L S
L L L M F V L L W P V M A I R L K I * V
Y C * C L F S Y G L * W P * D * R F K Y

15721 ATACGCAATTTACAAAAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTAT 15780
I R N L Q K R L Y S N V Y R T D Y V D Y
Y A I Y K N A Y T L M F I V Q I M L I I
T Q F T K T L I L * C L S Y R L C * L Y

15781 ACATTTGTTAATGAGTATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGT 15840
T F V N E Y Y E F L C K H F S M M I L S
H L L M S I M N F Y V S I L V * * F * V
I C * * V L * I F M * A F * Y D D F E *

15841 GATGATGGTGTGTCTGTTATACTCTGATTATGCTAGTAAGGTTATATAGCTAATATA 15900
D D G V V C Y N S D Y A S K G Y I A N I
M M V L S V I T L I M L V R V I * L I *
* W C C L L * L * L C * * G L Y S * Y K

15901 AGTGTTTTTCAACAAGTTTTGTACTATCAGAATAATGTCTTTATGCTGAATCTAAATGT 15960
S V F Q Q V L Y Y Q N N V F M S E S K C
V F F N K F C T I R I M S L C L N L N V
C F S T S F V L S E * C L Y V * I * M L

15961 TGGGTTGAAAATGATATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTA 16020
W V E N D I T N G P H E F C S Q H T M L
G L K M I L L M V L M N F V P N I L C *
G * K * Y Y * W S S * I L F P T Y Y V S

16021 GTTAAGATAGATGGTGATTATGTTTATTACCATATCCAGATCCTTCTAGAATTTTAGGA 16080
V K I D G D Y V Y L P Y P D P S R I L G
L R * M V I M F I Y H I Q I L L E F * E
* D R W * L C L F T I S R S F * N F R S

16081 GCTGGTTGTTTTGTTGATGATTATTGAAGACTGACAGTGTCTTTTGATAGAGCGCTTT 16140
A G C F V D D L L K T D S V L L I E R F
L V V L L M I Y * R L T V F F * * S A L
W L F C * * F I E D * Q C S F D R A L C

16141 GTAAGTCTAGCTATAGATGCTTACCCTTTAGTACATCATGAAAATGAAGAATACCAAAAA 16200
V S L A I D A Y P L V H H E N E E Y Q K
* V * L * M L T L * Y I M K M K N T K K
K S S Y R C L P F S T S * K * R I P K S

FIG. 2 CONT.

16201 GTCTTTCGTGTATATTTAGAATATATAAAAAAACTGTATAATGATCTTGGTACTCAGATC 16260
V F R V Y L E Y I K K L Y N D L G T Q I
S F V Y I * N I * K N C I M I L V L R S
L S C I F R I Y K K T V * * S W Y S D L

16261 TTAGATAGTTATAGTGTATTTTAAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCA 16320
L D S Y S V I L S T C D G L K F T E E S
* I V I V L F * V L V M V * S L L K N H
R * L * C Y F K Y L * W F K V Y * R I I

16321 TTTTACAAGAATATGTATTTAAAAAGTGCCGTGATGCAGAGTGTAGGTGCATGCCTTGT 16380
F Y K N M Y L K S A V M Q S V G A C V V
F T R I C I * K V P * C R V * V H A L F
L Q E Y V F K K C R D A E C R C M R C L

16381 TGTTTCATCACAACCTTCTTTGCGTTTGGCAGTTGTATACGTAAGCCTTTGTTATGTTGT 16440
C S S Q T S L R C G S C I R K P L L C C
V H H K L L C V V A V V Y V S L C Y V V
F I T N F F A L W Q L Y T * A F V M L *

16441 AAATGTTGTTATGACCATGTTATGGCAACTAATCATAAATATGTTTTGAGTGTCTCACCT 16500
K C C Y D H V M A T N H K Y V L S V S P
N V V M T M L W Q L I I N M F * V S H L
M L L * P C Y G N * S * I C F E C L T L

16501 TACGTTTGTAAATGCACCTAACTGTGATGTGAGTGTGATGCACCAAATTATATTTGGGCGGT 16560
Y V C N A P N C D V S D V T K L Y L G G
T F V M H L T V M * V M S P N Y I W A V
R L * C T * L * C E * C H Q I I F G R Y

16561 ATGTCTTACTATTGTGAAAACCATAAACCCATTATTCATTTAAGTTAGTTATGAATGGT 16620
M S Y Y C E N H K P H Y S F K L V M N G
C L T I V K T I N P I I H L S * L * M V
V L L L * K P * T P L F I * V S Y E W Y

16621 ATGGTCTTTGGTTTGTATAAACAATCTTGACGGGTTACCTTATATAGATGATTTTAAAT 16680
M V F G L Y K Q S C T G S P Y I D D P N
W S L V C I N N L A R V H L I * M I L I
G L W F V * T I L H G F T L Y R * F * *

16681 AAGATAGCTAGTTGTAATGGACAGAAGTTGATGATTATGTTCTGGCAAATGAGTGTATT 16740
K I A S C K W T E V D D Y V L A N E C I
R * L V V N G Q K L M I M F W Q M S V L
D S * L * M D R S * * L C S G K * V Y *

FIG. 2 CONT.

16741 GAACGTTTAAAGTTATTGCTGCGAGAACTCAAAGGCAACTGAAGAGGCTTTTAAACAA 16800
E R L K L F A A E T Q K A T E E A F K Q
N V * S Y L L Q K L K R Q L K R L L N K
T F K V I C C R N S K G N * R G F * T K

16801 AGCTATGCTTCTGCTACCATTCAAGAGATTGTTAGTGATAGAGAAGTTATTTTGTGTTGG 16860
S Y A S A T I Q E I V S D R E V I L C W
A M L L L P F K R L L V I E K L F C V G
L C F C Y H S R D C * * * R S Y F V L G

16861 GAGACAGGTAAAGTTAAACCACCCTTAATAAAAAATTATGTTTTACAGGCTACCATTTT 16920
E T G K V K P P L N K N Y V F T G Y H F
R Q V K L N H H L I K I M F S Q A T I L
D R * S * T T T * * K L C F H R L P F Y

16921 ACTAGTACTGGTAAGACAGTTTTAGGTGAGTATGTTTTGATAAAAGTGAATTAAC 16980
T S T G K T V L G E Y V F D K S E L T N
L V L V R Q F * V S M F L I K V N * L T
* Y W * D S F R * V C F * * K * I N * R

16981 GGTGTGATTACCGCGCTACAACACTTATAAACTTTCTATAGGTGATGTTTTGTTTTTA 17040
G V Y Y R A T T T Y K L S I G D V F V L
V C I T A L Q L L I N F L * V M F L F *
C V L P R Y N Y L * T F Y R * C F C F N

17041 ACATCACATTCTGTAGCTAGTTAAGTGACCTACACTGTCCCACAAGAGAACTATGCT 17100
T S H S V A S L S A P T L V P Q E N Y A
H H I L * L V * V H L H L S H K R T M L
I T F C S * F K C T Y T C P T R E L C *

17101 AGTATAAGATTTTCTAGTGTTTATAGTGTTCCATTGGTGTTTCAAATAATGTTGCTAAT 17160
S I R F S S V Y S V P L V F Q N N V A N
V * D F L V F I V F H W C F K I M L L I
Y K I F * C L * C S I G V S K * C C * L

17161 TATCAGCACATTGGAATGAAACGTTATTGCACTGTTCAAGGTCCCCCTGGTACGGGAAAG 17220
Y Q H I G M K R Y C T V Q G P P G T G K
I S T L E * N V I A L F K V P L V R E S
S A H W N E T L L H C S R S P W Y G K V

17221 TCTCATCTTGCTATAGTCTAGCTGTTTATTACTACACAGCACGTGTAGTTTACTGCT 17280
S H L A I G L A V Y Y Y T A R V V Y T A
L I L L * V * L F I T T Q H V * F I L L
S S C Y R S S C L L L H S T C S L Y C C

FIG. 2 CONT.

17281 GCTAGTCATGCTGCTGTAGATGCATTGTGTGAAAAAGCTTATAAGTTTTTAAATATTAAC 17340
A S H A A V D A L C E K A Y K F L N I N
L V M L L * M H C V K K L I S F * I L T
* S C C C R C I V * K S L * V F K Y * R

17341 GATTGTACACGTATTATTCTGCTAAAGTTCGTGTAGATTGTTATGATAAGTTTAAAT 17400
D C T R I I P A K V R V D C Y D K F K I
I V H V L F L L K F V * I V M I S L K L
L Y T Y Y S C * S S C R L L * * V * N *

17401 AATGATACCACTTGTAAGTATGTTTTTACCACAATAAATGCATTACCAGAGTTGGTTACA 17460
N D T T C K Y V F T T I N A L P E L V T
M I P L V S M F L P Q * M H Y Q S W L Q
* Y H L * V C F Y H N K C I T R V G Y R

17461 GATATTGTTGTTGTTGATGAAGTTAGTATGCTTACTAATTATGAATTGCTCTGTATAAAT 17520
D I V V V D E V S M L T N Y E L S V I N
I L L L L M K L V C L L I M N C L L * M
Y C C C * * S * Y A Y * L * I V C Y K C

17521 GCTCGTATTAAAGCTAAACATTATGTATATATTTGGAGATCCTGCTCAATTACCTGCACCA 17580
A R I K A K H Y V Y I G D P A Q L P A P
L V L K L N I M Y I L E I L L N Y L H H
S Y * S * T L C I Y W R S C S I T C T T

17581 CGTGTGCTGTTGAGCAAGGTTCTTTAGAACCTAGGCACTTCAATTCTATTACTAAAATA 17640
R V L L S K G S L E P R H F N S I T K I
V C C * A R V L * N L G T S I L L L K *
C A V E Q G F F R T * A L Q F Y Y * N N

17641 ATGTGTTGTTTAGGTCCTGATATCTTTTGGGAAATGTTATAGGTGCTCCTAAAGAAAT 17700
M C C L G P D I F L G N C Y R C P K E I
C V V * V L I S F W E I V I G V L K K L
V L F R S * Y L F G K L L * V S * R N C

17701 GTAGAACTGTTTCAGCATTGGTTTATGATAATAAACTCAAGGCTAAAAATGATAATAGT 17760
V E T V S A L V Y D N K L K A K N D N S
* K L F Q H W F M I I N S R L K M I I V
R N C F S I G L * * * T Q G * K * * * F

17761 TCATTATGTTTTAAAGTATATTTTAAAGGACAGACAACACATGAGAGTTCAAGTGCTGTA 17820
S L C F K V Y F K G Q T T H E S S S A V
H Y V L K Y I L R D R Q H M R V Q V L *
I M F * S I F * G T D N T * E F K C C K

FIG. 2 CONT.

17821 AATATTCAACAGATATATCTAATTAGTAAATTTTTAAAAAGCTAATCCAGTTTGAATAGT 17880
N I Q Q I Y L I S K F L K A N P V W N S
I F N R Y I * L V N F * K L I Q F G I V
Y S T D I S N * * I F K S * S S L E * C

17881 GCTGTTTTATTAGTCCTTATAATAGTCAGAATTATGTTGCTAAGCGTGTTTTAGGTGTT 17940
A V F I S P Y N S Q N Y V A K R V L G V
L F L L V L I I V R I M L L S V F * V F
C F Y * S L * * S E L C C * A C F R C S

17941 CAAACAAAAGTCTAGATTCTGCTCAAGGTTCCGAATATGATTATGTTATATATTCACAA 18000
Q T Q T V D S A Q G S E Y D Y V I Y S Q
K H K L * I L L K V R N M I M L Y I H K
N T N C R F C S R F G I * L C Y I F T N

18001 ACAGCAGAAACAGCCCATCTGTTAATGTTAATCGATTTAATGTTGCCATAACTAGAGCC 18060
T A E T A H S V N V N R F N V A I T R A
Q Q K Q P I L L M L I D L M L P * L E P
S R N S P F C * C * S I * C C H N * S Q

18061 AAGAAGGGCATTTTTTGTGTTATGAGTAATATGCAATTATTGAATCTCTTAATTTTATT 18120
K K G I F C V M S N M Q L F E S L N F I
R R A F F V L * V I C N Y L N L L I L L
E G H F L C Y E * Y A I I * I S * F Y Y

18121 ACTCTACCTTTAGATAAAAATCAAATCAAACCTTACCTCGTTTGCATTGCACAATAAT 18180
T L P L D K I Q N Q T L P R L H C T T N
L Y L * I K F K I K L Y L V C I A Q L I
S T F R * N S K S N F T S F A L H N * S

18181 CTTTTAAAGATTGTAGTAAAGTTGCTTAGGTTATCATCCAGCGCATGCCCCCTCATT 18240
L F K D C S K S C L G Y H P A H A P S F
F L K I V V K V A * V I I Q R M P P H F
F * R L * * K L L R L S S S A C P L I F

18241 TTAGCAGTTGATGATAAATAAGGTTAATGAAAATTGGCTGTAAATTTAAATATTGTT 18300
L A V D D K Y K V N E N L A V N L N I C
* Q L M I N I R L M K I W L * I * I F V
S S * * * I * G * * K F G C K F K Y L *

18301 GAACCTGTTTTAACATATTCTCGTTTAAATATCTCTTATGGGTTTTAAATTAGATTGACT 18360
E P V L T Y S R L I S L M G F K L D L T
N L F * H I L V * Y L L W V L N * I * L
T C F N I F S F N I S Y G F * I R F D S

FIG. 2 CONT.

18361 CTTGATGGTTATTCTAAATTGTTTATTACTAAAGATGAAGCCATTAAACGTGTAGAGGT 18420
L D G Y S K L F I T K D E A I K R V R G
L M V I L N C L L L K M K P L N V L E V
* W L F * I V Y Y * R * S H * T C * R L

18421 TGGGTTGGTTTTGATGTTGAGGGCGCTCATGCTACTCGCGAAAACATTGGAACAACTTT 18480
W V G F D V E G A H A T R E N I G T N F
G L V L M L R A L M L L A K T L E Q T F
G W F * C * G R S C Y S R K H W N K L S

18481 CCACTGCAAATAGGTTTTCAACTGGTGTGGATTTTGTAGTTGAAGCTACTGGCTTATTT 18540
P L Q I G F S T G V D F V V E A T G L F
H C K * V F Q L V W I L * L K L L A Y L
T A N R F F N W C G F C S * S Y W L I C

18541 GCTGAGAGAGATTGTTATACTTTTAAAAAACTGTAGCTAAAGCTCCTCCTGGTGA AAAA 18600
A E R D C Y T F K K T V A K A P P G E K
L R E I V I L L K K L * L K L L L V K N
* E R L L Y F * K N C S * S S S W * K I

18601 TTTAAACATTTAATACCCCTTATGTCAAAGGTCAAAGTGGGATATTGTTAGAATTAGA 18660
F K H L I P L M S K G Q K W D I V R I R
L N I * Y P L C Q K V K S G I L L E L E
* T F N T P Y V K R S K V G Y C * N * N

18661 ATTGTTCAAATGTTATCTGATTATCTTTTAGACCTTTCTGATAGTGTAGTATTATTACT 18720
I V Q M L S D Y L L D L S D S V V F I T
L F K C Y L I I F * T F L I V * Y L L L
C S N V I * L S F R P F * * C S I Y Y L

18721 TGGTCTGCCAGTTTTGAACTTACTTGTTTAAGGTATTTTGCTAAATTAGGCAGAGAGCTT 18780
W S A S P E L T C L R Y F A K L G R E L
G L P V L N L L V * G I L L N * A E S L
V C Q F * T Y L F K V F C * I R Q R A *

18781 AATTGTAATGTGTGTTCTAATCGTGCTACATGCTACAATTCTAGAACTGGTTATTATGGT 18840
N C N V C S N R A T C Y N S R T G Y Y G
I V M C V L I V L H A T I L E L V I M V
L * C V F * S C Y M L Q F * N W L L W L

18841 TGTGGGCCCATAGTTATACTTGTGATTATGTGTATAATCCACTTATTGTAGATATACAA 18900
C W R H S Y T C D Y V Y N P L I V D I Q
V G A I V I L V I M C I I H L L * I Y N
L A P * L Y L * L C V * S T Y C R Y T T

FIG. 2 CONT.

18901 CAGTGGGGTTATACAGGTTCTTTAACTAGTAATCAGATATAATTTGTAATGTACATAAA 18960
Q W G Y T G S L T S N H D I I C N V H K
S G V I Q V L * L V I T I * F V M Y I K
V G L Y R F F N * * S R Y N L * C T * R

18961 GGTGCACATGTTGCGTCAGCTGATGCAATTATGACTCGTTGTTAGCAATCTATGATTGT 19020
G A H V A S A D A I M T R C L A I Y D C
V H M L R Q L M Q L * L V V * Q S M I V
C T C C V S * C N Y D S L F S N L * L F

19021 TTTTGTAATCTGTTAATTGGAATTTAGAGTATCCAATAATTTCTAATGAGGTCAGTATA 19080
F C K S V N W N L E Y P I I S N E V S I
F V N L L I G I * S I Q * F L M R S V *
L * I C * L E F R V S N N F * * G Q Y K

19081 AATACATCTTGTAGGTTATTGTCAGCGTGCATGCTTAAAGCTGCCATGCTATGTAATAGA 19140
N T S C R L L Q R V M L K A A M L C N R
I H L V G Y C S V S C L K L P C Y V I D
Y I L * V I A A C H A * S C H A M * * I

19141 TACAACCTATGTTATGACATAGGCAATCCTAAAGGTTTGTCTGTGTCAAGATTATGAA 19200
Y N L C Y D I G N P K G L A C V K D Y E
T T Y V M T * A I L K V * L V S K I M N
Q L M L * H R Q S * R F S L C Q R L * I

19201 TTTAAATTTTATGATGCTTTTCCTGTAGCCAAGTCTGTAAACAGTTATTTTATGTCTAT 19260
F K F Y D A F P V A K S V K Q L F Y V Y
L N F M M L F L * P S L L N S Y F M S M
* I L * C F S C S Q V C * T V I L C L *

19261 GATGTGCATAAAGATAATTTAAAGATGTTTATGTATGTTTGGAAATGTAATGTTGAT 19320
D V H K D N P K D G L C M F W N C N V D
M C I K I I L K M V Y V C F G I V M L I
C A * R * F * R W F M Y V L E L * C * *

19321 AAATATCCATCTAATCAATTGTTTGTAGATTTGACACTCGAGTGTAAATAAATTAAC 19380
K Y P S N S I V C R F D T R V L N K L N
N I H L I Q L F V D L T L E C * I N * T
I S I * F N C L * I * H S S V K * I K P

19381 CTTCTGGATGTAATGGTGGTAGTTTGTATGTTAATAAACATGCATTCCATACTAATCCT 19440
L P G C N G G S L Y V N K H A F H T N P
F L D V M V V V C M L I N M H S I L I L
S W M * W W * F V C * * T C I P Y * S F

FIG. 2 CONT.

19441 TTTACTAGAACTGTTTTGAAAATCTTAAGCCTATGCCTTTTTCTATTATTAGATACG 19500
 F T R T V F E N L K P M P F F Y Y S D T
 L L E L F L K I L S L C L F S I I Q I R
 Y * N C F * K S * A Y A F F L L F R Y A

19501 CCTTGTGTGTACGTAGATGGTTTAGAATCTAAACAAGTTGATTACGTTCCCTTTAAGAAGC 19560
 P C V Y V D G L E S K Q V D Y V P L R S
 L V C T * M V * N L N K L I T F L * E A
 L C V R R W F R I * T S * L R S F K K R

19561 GCCACTTGTATCACACGGTGAATCTAGGTGGAGCTGTTTGTCAAAGCATGCTGAAGAA 19620
 A T C I T R C N L G G A V C S K H A E E
 P L V S H G V I * V E L F V Q S M L K N
 H L Y H T V * S R W S C L F K A C * R I

19621 TATTGTAACCTTGAGTCTTATAATATAGTTACTACAGCAGGCTTTACTTTTTGGGTT 19680
 Y C N Y L E S Y N I V T T A G F T F W V
 I V T T L S L I I * L L Q Q A L L F G F
 L * L P * V L * Y S Y Y S R L Y F L G L

19681 TATAAGAATTTGATTTTTATAATTTATGAACACTTTTACTACGTTACAGAGTTTAGAA 19740
 Y K N F D F Y N L W N T F T T L Q S L E
 I R I L I F I I Y G T L L L R Y R V * K
 * E F * F L * F M E H F Y Y V T E F R K

19741 AACGTAATATATAACTTGGTTAATGTTGGTCATTATGATGGACGTACAGGTGAATTACCT 19800
 N V I Y N L V N V G H Y D G R T G E L P
 T * Y I T W L M L V I M M D V Q V N Y L
 R N I * L G * C W S L * W T Y R * I T L

19801 TGTGCTATTATGAATGACAAAGTTGTTGTTAAGATTAATAATGTAGATACTGTTATTTTT 19860
 C A I M N D K V V V K I N N V D T V I F
 V L L * M T K L L L R L I M * I L L F L
 C Y Y E * Q S C C * D * * C R Y C Y F *

19861 AAAAATAATACATCATTTCCTACTAATATAGCTGTTGAATTGTTTACAAAACGTAGTATC 19920
 K N N T S F P T N I A V E L F T K R S I
 K I I H H F L L I * L L N C L Q N V V S
 K * Y I I S Y * Y S C * I V Y K T * Y P

19921 CGGCACCACCCTGAACCTAAGATTCTTAGAAAATTGAACATTGATATTTGTTGGAAGCAT 19980
 R H H P E L K I L R N L N I D I C W K H
 G T T L N L R F L E I * T L I F V G S M
 A P P * T * D S * K F E H * Y L L E A C

FIG. 2 CONT.

19981 GTCCTGTGGGATTATGTTAAAGATAGTTTGTGTTTGTAGTTCCACTTATGGTGTGTTGTA 20040
V L W D Y V K D S L F C S S T Y G V C K
S C G I M L K I V C F V V P L M V F V N
P V G L C * R * F V L * F H L W C L * I

20041 TACACAGATTGAAGTTCATCGAAAATTGAAATATACTTTTTGATGGTCGTGACACTGGC 20100
Y T D L K F I E N L N I L F D G R D T G
T Q I * S S S K I * I Y F L M V V T L A
H R F E V H R K F E Y T F * W S * H W R

20101 GCTTTAGAAGCTTTTAGAAAAGCAAGAAATGGTGTTTTTATTAGTACTGAAAAATTAAGT 20160
A L E A F R K A R N G V F I S T E K L S
L * K L L E K Q E M V F L L V L K N * V
F R S F * K S K K W C F Y * Y * K I K *

20161 AGGTTATCAATGATTAAGGTCGCAACGAGCTGATTTAAATGGTGTGATTGTGGATAAA 20220
R L S M I K G P Q R A D L N G V I V D K
G Y Q * L K V R N E L I * M V * L W I K
V I N D * R S A T S * F K W C D C G * S

20221 GTTGGAGAACTCAAAGTTGAGTTTTGTTTCGCTATGAGAAAAGATGGTGACGATGTTATC 20280
V G E L K V E F W F A M R K D G D D V I
L E N S K L S F G S L * E K M V T M L S
W R T Q S * V L V R Y E K R W * R C Y L

20281 TTCAGCCGAACAGACAGCCTATGCTCAAGCCATTACTGGAGCCCAAGGTAATCTAGGT 20340
F S R T D S L C S S H Y W S P Q G N L G
S A E Q T A Y A Q A I T G A H K V I * V
Q P N R Q P M L K P L L E P T R * S R W

20341 GGTAATTGCGCGGTAATGTCATTGGTAATGATGCTCTAACACGTTTTACTATCTTTACT 20400
G N C A G N V I G N D A L T R F T I F T
V I A R V M S L V M M L * H V L L S L L
* L R G * C H W * * C S N T F Y Y L Y S

20401 CAGAGTCGTGATTGTCAAGTTTTGAACCTCGCTCAGATTTAGAACGGGATTTTATTGAT 20460
Q S R V L S S F E P R S D L E R D F I D
R V V Y C Q V L N L A Q I * N G I L L I
E S C I V K F * T S L R F R T G F Y * Y

20461 ATGGATGATAATCTGTTTATTGCTAAATATGGTTTGAAGACTATGCATTTGATCATATA 20520
M D D N L F I A K Y G L E D Y A F D H I
W M I I C L L L N M V * K T M H L I I *
G * * S V Y C * I W F R R L C I * S Y S

FIG. 2 CONT.

20521	GTTTATGGTAGTTTAAACCATAAAGTTATAGGAGGTTTCATTGCTTATAGGCTTATTT V Y G S F N H K V I G G L H L L I G L F F M V V L T I K L * E V C I C L * A Y F L W * F * P * S Y R R F A F A Y R L I S	20580
20581	CGTAGGAAAAAAAAAATCTAATTTGTTAATTCAGAGTTTTTACAGTATGATTCTAGTATT R R K K K S N L L I Q E F L Q Y D S S I V G K K N L I C * F K S F Y S M I L V F * E K K I * F V N S R V F T V * F * Y S	20640
20641	CATTCAATTTTATTACTGATCAGGAGTGTGGTAGTAGTAAGAGTGGTTGTACAGTTATT H S Y F I T D Q E C G S S K S V C T V I I H I L L L I R S V V V V R V F V Q L L F I F Y Y * S G V W * * * E C L Y S Y *	20700
20701	GATTTATTATTAGATGATTTTGTCTTATTGTTAAGTCATTAATTTGAGTTGTGTTAGT D L L L D D F V S I V K S L N L S C V S I Y Y * M I L F L L L S H * I * V V L V F I I R * F C F Y C * V I K F E L C * *	20760
20761	AAAGTGTAAATATTAATGTGATTTTAAAGATTTTCAATTTATGTTGTGGTGAATGAT K V V N I N V D F K D F Q F M L W C N D K L L I L M L I L R I F N L C C G V M I S C * Y * C * F * G F S I Y V V V * * *	20820
20821	AATAAAATATGACTTTTTATCCTAAAATGCAAGCCACTAATGATTGGAACCTGGCTAT N K I M T F Y P K M Q A T N D W K P G Y I K L * L F I L K C K P L M I G N L A I * N Y D F L S * N A S H * * L E T W L F	20880
20881	TCTATGCCTGTTTTGTATAAGTATTTGAATGTTCCATTAGAGAGAGTCTCTTTATGGAAT S M P V L Y K Y L N V P L E R V S L W N L C L F C I S I * M F H * R E S L Y G I Y A C F V * V F E C S I R E S L F M E L	20940
20941	TATGGTAAACCTATTAATTTGCCTACAGGCTGTATGATGAATGTTGCTAAGTACACTCAA Y G K P I N L P T G C M M N V A K Y T Q M V N L L I C L Q A V * * M L L S T L N W * T Y * F A Y R L Y D E C C * V H S I	21000
21001	TTATGTCAGTATTTGAATACTACAACATTAGCTGTTCTGTTAATATGCGTGTTTTACAT L C Q Y L N T T T L A V P V N M R V L H Y V S I * I L Q H * L F L L I C V F Y I M S V F E Y Y N I S C S C * Y A C F T F	21060

FIG. 2 CONT.

21061 TTAGGTGCAGGGTCTGATAAAGAAGTAGCTCCAGGTTCTGCTGTTTTAAGACAGTGGTTA 21120
L G A G S D K E V A P G S A V L R Q W L
* V Q G L I K K * L Q V L L F * D S G Y
R C R V * * R S S S R F C C F K T V V T

21121 CCATCTGGTAGTATTCTGTAGATAATGATTTAAACCCATTGTAGCGATAGTTTAGTT 21180
P S G S I L V D N D L N P F V S D S L V
H L V V F L * I M I * T H L L A I V * L
I W * Y S C R * * F K P I C * R * F S Y

21181 ACTTATTTGGAGATTGTATGACTTTACCATTTGATTGTCATTGGGATTTGATAATATCT 21240
T Y F G D C M T L P F D C H W D L I I S
L I L E I V * L Y H L I V I G I * * Y L
L F W R L Y D F T I * L S L G F D N I *

21241 GATATGTATGATCCTCTTACTAAAAATATTGGTGATTATAATGTGAGTAAGGATGGGTTT 21300
D M Y D P L T K N I G D Y N V S K D G F
I C M I L L L K I L V I I M * V R M G F
Y V * S S Y * K Y W * L * C E * G W V F

21301 TTTACTTACATTTGTCATTTAATTCGTGATAAATTATCTTTGGGTGGTAGTGTAGCTATA 21360
F T Y I C H L I R D K L S L G G S V A I
L L T F V I * F V I N Y L W V V V * L *
Y L H L S F N S * * I I F G W * C S Y K

21361 AAAATTACAGAGTTTTCTTGGAAATGCTGATTTATATAAATTAATGAGTTGTTTTGCATTT 21420
K I T E F S W N A D L Y K L M S C F A F
K L Q S F L G M L I Y I N * * V V L H F
N Y R V F L E C * F I * I N E L F C I L

21421 TGGACAGTTTTTTGTTACTAATGTAATGCTTCTTCTAGTGAAGGTTTTTAATAGGTATA 21480
W T V F C T N V N A S S S E G F L I G I
G Q F F V L M * M L L L V K G F * * V *
D S F L Y * C K C F F * * R V F N R Y K

21481 AATTACCTGGGTAATCTTCTTTGAAATAGATGGCAATGTTATGCATGCTAACTATTTG 21540
N Y L G K S S F E I D G N V M H A N Y L
I T W V N L L L K * M A M L C M L T I C
L P G * I F F * N R W Q C Y A C * L F V

21541 TTTTGGAGAAATAGTACAACATGGAATGGCGGTCTTATAGTTTATTTGATATGACTAAA 21600
F W R N S T T W N G G A Y S L F D M T K
F G E I V Q H G M A V L I V Y L I * L N
L E K * Y N M E W R C L * F I * Y D * I

FIG. 2 CONT.

21601 TTTTCTTTGAAATTGGCTGGCACTGCTGTGTTAATTTAAGACCAGATCAATTAATGAT 21660
F S L K L A G T A V V N L R P D Q L N D
F L * N W L A L L L L I * D Q I N * M I
F F E I G W H C C C * F K T R S I K * F

21661 TTAGTTTATTCTCTTATTGAAAGAGGTAAATTATTAGTTCGCGATACGCGTAAAGAGATT 21720
L V Y S L I E R G K L L V R D T R K E I
* F I L L L K E V N Y * F A I R V K R F
S L F S Y * K R * I I S S R Y A * R D F

21721 TTTGTTGGTGATAGTCTTGAAATACTTGTAGATCTCATTAATCTAAACTATGTTAAT 21780
F V G D S L V N T C * I S L N L N Y V N
L L V I V L * I L V R S H * I * T M L I
C W * * S C K Y L L D L I K S K L C * L

21781 TATTTTTTTATTTTTTTATTTCTGTTATGGTTTTAATGAACCTCTTAATGTTGTGTCTCA 21840
Y F F I F L F L L W F * * T S * C C V S
I F L F F Y F C Y G F N E P L N V V S H
F F Y F F I S V M V L M N L L M L C L I

21841 TTAAACCATGACTGGTTTTTATTTGGTGATAGTCGTTCTGATTGTAACCATATTAATAA 21900
F K P * L V F I W * * S F * L * P Y * *
L N H D W F L F G D S R S D C N H I N N
* T M T G F Y L V I V V L I V T I L I I

21901 TTTAAAAATAAAAATTTGATTATTTGGATATTCACCCTAGTTTGTGCAACAATGGTAA 21960
F K N * K F * L F G Y S P * F V Q Q W *
L K I K N F D Y L D I H P S L C N N G K
* K L K I L I I W I F T L V C A T M V R

21961 GATTTTCATCTAGTGCCGGTGATTCTATTTTTAAGAGTTTTCATTTCACTCGATTTTATAA 22020
D F I * C R * F Y F * E F S F H S I L *
I S S S A G D S I F K S F H F T R F Y N
F H L V P V I L F L R V F I S L D F I I

22021 TTACACTGGCGAAGGTGATCAAATTATTTTTTATGAGGGTGTAAATTTAATCCTTATCA 22080
L H W R R * S N Y F L * G C * F * S L S
Y T G E G D Q I I F Y E G V N F N P Y H
T L A K V I K L F F M R V L I L I L I I

22081 TAGATTTAAGTGTTTTCTTAATGGTAGTAAATGATGTATGGCTTCTTAACAAGGTAAGATT 22140
* I * V F S * W * * * C M A S * Q G K I
R F K C F P N G S N D V W L L N K V R F
D L S V F L M V V M M Y G F L T R * D F

FIG. 2 CONT.

22141 TTATCGTGCCTTATATTCTAATATGGCCTTTTTTCGTTATCTTACTTTTGTGATATCC 22200
L S C L I F * Y G L F S L S Y F C * Y S
Y R A L Y S N M A F F R Y L T F V D I P
I V P Y I L I W P F F V I L L L L I F L

22201 TTATAATGTTTCTCTTCTAAGTTAATTCTTGTAAGTATATTTTACTTAACAA 22260
L * C F S F * V * F L * K * Y F I T * Q
Y N V S L S K F N S C K S D I L S L N N
I M F L F L S L I L V K V I F Y H L T I

22261 TCCTATTTTATTAATTATTCTAAGGAAGTTATTTTACTTTATTAGGTTGTTCTCTTA 22320
S Y F Y * L F * G S L F Y F I R L F S L
P I F I N Y S K E V Y F T L L G C S L Y
L F L L I I L R K F I L L Y * V V L F I

22321 TTTAGTACCGCTTTGCCTTTTAAATCTAACTTTAGTCAGTACTATTATAACATAGATAC 22380
F S T A L P F * I * L * S V L L * H R Y
L V P L C L F K S N F S Q Y Y Y N I D T
* Y R F A F L N L T L V S T I I T * I L

22381 TGGCTCTGTTTATGGTTTTTCTAATGTTGTTTATCCTGATTAGACTGTATTTATATTC 22440
W L C L W F F * C C L S * F R L Y L Y F
G S V Y G F S N V V Y P D L D C I Y I S
A L F M V F L M L F I L I * T V F I F L

22441 TCTTAAACCAGGTTCTTATAAAGTTTCCACCACTGCACCTTTTTTATCCTTACCTACTAA 22500
S * T R F L * S F H H C T F F I L T Y *
L K P G S Y K V S T T A P F L S L P T K
L N Q V L I K F P P L H L F Y P Y L L K

22501 AGCTCTCTGTTTGTATAAATCTAAACAATTTGTACCTGTACAGGTTGTTGATTCTAGATG 22560
S S L F * * I * T I C T C T G C * F * M
A L C F D K S K Q F V P V Q V V D S R W
L S V L I N L N N L Y L Y R L L I L D G

22561 GAACAACGAGCGTGCCTCAGATATTTCTTTATCTGTTGCATGTCAATTGCCATATTGTTA 22620
E Q R A C L R Y F F I C C M S I A I L L
N N E R A S D I S L S V A C Q L P Y C Y
T T S V P Q I F L Y L L H V N C H I V I

22621 TTTTCGCAATTCTTCTGCTAATTATGTTGGCAAGTATGATATTAACCACGGTGATAGTGG 22680
F S Q F F C * L C W Q V * Y * P R * * W
F R N S S A N Y V G K Y D I N H G D S G
F A I L L L I M L A S M I L T T V I V V

FIG. 2 CONT.

22681	TTTTATTTCTATTTTATCTGGTCTTTTATATAATGTTTCTTGATTTTCATATTATGGTGT F Y F Y F I W S F I * C F L Y F I L W C F I S I L S G L L Y N V S C I S Y Y G V L F L F Y L V F Y I M F L V F H I M V Y	22740
22741	ATTTTATATGATAATTTTACATCCATTTGGCCCTATTATTCTTTTGGTAGGTGTCCTAC I F I * * F Y I H L A L L F F W * V S Y F L Y D N F T S I W P Y Y S F G R C P T F Y M I I L H P F G P I I L L V G V L H	22800
22801	ATCTTCTATTATTAACATCCAATTTGTGTTTATGATTTTTTGCCTATTATTTTACAAGG I F Y Y * T S N L C L * F F A Y Y F T R S S I I K H P I C V Y D F L P I I L Q G L L L L N I Q F V F M I F C L L F Y K V	22860
22861	TATTTTATTATGTTTAGCTTTACTTTTTGTGTTTTTCTATTATTTTGTATATAACGA Y F I M F S F T F C C F S I I F V I * R I L L C L A L L F V V F L L F L L Y N D F Y Y V * L Y F L L F F Y Y F C Y I T I	22920
22921	TAAATCTCATAAATCTAAACATGTTATTAATTTATTTTGCCTACAACATTAGCT * I S L N L N M L L I I F I L P T T L A K S H * I * T C Y * L F L F C L Q H * L N L I K S K H V I N Y F Y F A Y N I S C	22980
22981	GTTATAGGTGATTTAATTGTTACTAATTTTGTCTATTAATGATTTAAACACCACAGTTCT V I G D F N C T N F A I N D L N T T V P L * V I L I V L I L L L M I * T P Q F L Y R * F * L Y * F C Y * * F K H H S S S	23040
23041	CGCATAAGTGAGTATGTTGTGGATGTTTCTTATGGTTTGGGTACATATTATATACTTGAT R I S E Y V V D V S Y G L G T Y Y I L D A * V S M L W M F L M V W V H I I Y L I H K * V C C G C F L W F G Y I L Y T * S	23100
23101	CGTGTTTATTTAAATACTACTATATTATTACTGGTTATTTCCCTAAATCTGGTGCCAAT R V Y L N T T I L F T G Y F P K S G A N V F I * I L L Y Y L L V I S L N L V P I C L F K Y Y Y I I Y W L F P * I W C Q F	23160
23161	TTTAGGATCTATCTTTAAAAGGTACTACATATTGAGTACTCTTGGTATCAGAAACCC F R D L S L K G T T Y L S T L W Y Q K P L G I Y L * K V L H I * V L F G I R N P * G S I F K R Y Y I F E Y S L V S E T L	23220

FIG. 2 CONT.

23221	TTTTATCTGATTTTAATAATGGTATTTTTCTAGAGTTAAGAATACTAAGTTGTATGTT F L S D F N N G I F S R V K N T K L Y V F Y L I L I M V F F L E L R I L S C M L F I * F * * W Y F F * S * E Y * V V C *	23280
23281	AATAAACTTTGTATAGTGAGTTTAGTACTATAGTTATAGGTAGTGTTTTTATTAACAAC N K T L Y S E F S T I V I G S V F I N N I K L C I V S L V L * L * V V F L L T T * N F V * * V * Y Y S Y R * C F Y * Q L	23340
23341	TCTTACTATTGTGTTCACCTCATAATGGTGTTTTGGAGATTACAGCTTGCAATAC S Y T I V V Q P H N G V L E I T A C Q Y L I L L L F N L I M V F W R L Q L V N T L Y Y C C S T S * W C F G D Y S L S I H	23400
23401	ACTATGTGTGAGTATCCTCATACTATTGTAAATCTAAAGGTAGTTCTCGTAATGAATCT T M C E Y P H T I C K S K G S S R N E S L C V S I L I L F V N L K V V L V M N L Y V * V S S Y Y L * I * R * F S * * I L	23460
23461	TGGCATTTTGATAAATCTGAACCTTTGTGTCTGTCAAGAAAATTTACTTATAATGTT W H F D K S E P L C L F K K N F T Y N V G I L I N L N L C V C S R K I L L I M F A F * * I * T F V S V Q E K F Y L * C F	23520
23521	TCTACAGATTGGTTGTATTTTCATTTTATCAAGAACGTGGCACTTTTATGCTTATTAT S T D W L Y F H F Y Q E R G T F Y A Y Y L Q I G C I F I F I K N V A L F M L I M Y R L V V F S F L S R T W H F L C L L C	23580
23581	GCTGATTCTGGCATGCCTACTACTTTTTTATTTAGTTTGTATCTTGGTACTCTTTTATCT A D S G M P T T F L F S L Y L G T L L S L I L A C L L L F Y L V C I L V L F Y L * F W H A Y Y F F I * F V S W Y S F I S	23640
23641	CATTATTATGTTTTGCCTTTGACTTGTAAATGCTATATCTTCTAATACTGATAATGAGACT H Y Y V L P L T C N A I S S N T D N E T I I M F C L * L V M L Y L L I L I M R L L L C F A F D L * C Y I F * Y * * * D F	23700
23701	TTACAATATTGGGTCACACCTTTGTCTAAACGCCAATATCTTCTTAAATTTGACAACCGT L Q Y W V T P L S K R Q Y L L K F D N R Y N I G S H L C L N A N I F L N L T T V T I L G H T F V * T P I S S * I * Q P W	23760

FIG. 2 CONT.

23761 GGTGTTATTACTAATGCTGTTGATTGTTCTAGTAGTTTCTTTAGCGAGATTCAATGTAATA 23820
G V I T N A V D C S S S F F S E I Q C K
V L L L M L L I V L V V S L A R F N V K
C Y Y * C C * L F * * F L * R D S M * N

23821 ACTAAATCTTTATTACCTAATACTGGTGGTTATGACTTATCTGGTTTTACTGTTAAGCCT 23880
T K S L L P N T G V Y D L S G F T V K P
L N L Y Y L I L V F M T Y L V L L L S L
* I F I T * Y W C L * L I W F Y C * A C

23881 GTTGCAACTGTACATCGTCGTATTCTGATTACCTGATTGTGACATTGATAAATGGCTT 23940
V A T V H R R I P D L P D C D I D K W L
L Q L Y I V V F L I Y L I V T L I N G L
C N C T S S Y S * F T * L * H * * M A *

23941 AACAAATTTAATGTACCCTCACCTCTTAATGGGAACGTAATAATTTTTCTAATGCAAC 24000
N N F N V P S P L N W E R K I F S N C N
T I L M Y P H L L I G N V K F F L I A T
Q F * C T L T S * L G T * N F F * L Q L

24001 TTTAATTTGAGTACTTTGCTTCGTTTAGTTCATACTGATTCTTTTTCTTGAATAATTTT 24060
F N L S T L L R L V H T D S F S C N N F
L I * V L C F V * F I L I L F L V I I L
* F E Y F A S F S S Y * F F F L * * F *

24061 GATGAATCTAAGATATATGGTAGTTGTTTTAAGAGTATTGTTTTAGATAAATTTGCCATA 24120
D E S K I Y G S C F K S I V L D K F A I
M N L R Y M V V V L R V L F * I N L P Y
* I * D I W * L F * E Y C F R * I C H T

24121 CCCAACTCCAGACGATCTGATTGCAAGTTGGGCAAGTTCTGGTTTTCTGCAATCTTCTAAT 24180
P N S R R S D L Q L G S S G F L Q S S N
P T P D D L I C S W A V L V F C N L L I
Q L Q T I * F A V G Q F W F S A I F * L

24181 TATAAAATGACACTACTTCTAGTTCTTGCAATTGTATTATAGTTGCTGCAATTAAT 24240
Y K I D T T S S S C Q L Y Y S L P A I N
I K L T L L L V L V N C I I V C L Q L M
* N * H Y F * F L S I V L * F A C N * C

24241 GTTACTATTAATAATTATAATCCTTCTTCTGGAATAGAAGGTATGGTTTTAATAATTTT 24300
V T I N N Y N P S S W N R R Y G F N N F
L L L I I I I L L L G I E G M V L I I L
Y Y * * L * S F F L E * K V W F * * F *

FIG. 2 CONT.

24301 AATTTGAGCTCTCATAGTGTGTTTACTCACGTTATTGTTTTCTGTTAATAATACTTTT 24360
N L S S H S V V Y S R Y C F S V N N T F
I * A L I V L F T H V I V F L L I I L F
F E L S * C C L L T L L F F C * * Y F L

24361 TGTCTTGTGCTAAACCTTCTTTTGTCTCAAGTTGCAAGAGTCATAAACCCACTTCTGCT 24420
C P C A K P S F A S S C K S H K P P S A
V L V L N L L L L Q V A R V I N H L L L
S L C * T F F C F K L Q E S * T T F C F

24421 TCCTGTCCTATTGGTACTAATTATCGTTCTTGTGAGAGTACTACTGTACTCGACCACACT 24480
S C P I G T N Y R S C E S T T V L D H T
P V L L V L I I V L V R V L L Y S T T L
L S Y W Y * L S P L * E Y Y C T R P H *

24481 GACTGGTGTAGGTGTTCTTGTTTACCTGATCCTATAACTGCTTATGACCCTAGGTCTTGT 24540
D W C R C S C L P D P I T A Y D P R S C
T G V G V L V Y L I L * L L M T L G L V
L V * V F L F T * S Y N C L * P * V L F

24541 TCTCAAAAAAGTCTCTGGTTGGTGTGGTGAACATTGTGCAGGGTTCGGTGTGATGAA 24600
S Q K K S L V G V G E H C A G F G V D E
L K K S L W L V L V N I V Q G S V L M K
S K K V S G W C W * T L C R V R C * * R

24601 GAAAAGTGTGGTGTATTGGATGGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCC 24660
E K C G V L D G S Y N V S C L C S T D A
K S V V Y W M D H I M F L V F V V L M P
K V W C I G W I I * C F L S L * Y * C L

24661 TTTCTAGGTGGTCTTATGACACTTGCCTCAGTAACAACCGTTGTAATATTTTTTCTAAT 24720
F L G W S Y D T C V S N N R C N I F S N
F * V G L M T L A S V T T V V I F F L I
S R L V L * H L R Q * Q P L * Y F F * F

24721 TTTATTTTAAATGGTATCAATAGTGGTACCCTTGTCTAATGATTATTATGCAGCCTAAT 24780
F I L N G I N S G T T C S N D L L Q P N
L F * M V S I V V P L V L M I Y C S L I
Y F K W Y Q * W Y H L F * * F I A A * Y

24781 ACTGAAGTTTTACTGATGTTTGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGT 24840
T E V F T D V C V D Y D L Y G I T G Q G
L K F L L M F V L I T T F M V L Q D K V
* S F Y * C L C * L R P L W Y Y R T R Y

FIG. 2 CONT.

24841 ATTTTAAAGAAGTTTCTGCTGTTTATTATAATAGTTGGCAAATCTTTTGTATGATTCT 24900
I F K E V S A V Y Y N S W Q N L L Y D S
F L K K F L L F I I I V G K I F C M I L
F * R S F C C L L * * L A K S F V * F *

24901 AATGGCAACATTATTGGTTTTAAAGATTTTGTACTAATAAAACATATAATATTTTCCTT 24960
N G N I I G F K D F V T N K T Y N I F P
M A T L L V L K I L L L I K H I I F S L
W Q H Y W F * R F C Y * * N I * Y F P L

24961 TGTATGCAGGAAGAGTTTCTGCTGCTTTTCATCAAATGCTTCCTCTTTGGCTTTACTT 25020
C Y A G R V S A A F H Q N A S S L A L L
V M Q E E F L L L F I K M L P L W L Y F
L C R K S F C C F S S K C F L F G F T L

25021 TATCGTAATTTAAATGTAGCTATGTTTTGAATAATATTTCTTTAACTACTCAGCCATAT 25080
Y R N L K C S Y V L N N I S L T T Q P Y
I V I * N V A M F * I I F L * L L S H I
S * F K M * L C F E * Y F F N Y S A I F

25081 TTTGATAGTTATCTTGGTTGCGTTTTTAATGCTGATAATTTAACTGATTATTCTGTTTCT 25140
F D S Y L G C V F N A D N L T D Y S V S
L I V I L V A F L M L I I * L I I L F L
* * L S W L R F * C * * F N * L F C F F

25141 TCTTGTCTCTTCGCATGGTAGTGGTTTTTGTGTTGATTATAACTCACCTTCTTCTTCC 25200
S C A L R M G S G F C V D Y N S P S S S
L V L F A W V V V F V L I I T H L L L P
L C S S H G * W F L C * L * L T F F F L

25201 TCTTCGCGTCGTAACGTAGAAGTATTTCTGCTTCTTATCGTTTTGTTACTTTTGAACCC 25260
S S R R K R R S I S A S Y R F V T F E P
L R V V N V E V F L L L I V L L L L N P
F A S * T * K Y F C F L S F C Y F * T L

25261 TTTAATGTCAGTTTTGTTAATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAA 25320
F N V S F V N D S I E S V G G L Y E I K
L M S V L L M T V L S L W V V F M R S K
* C Q F C * * Q Y * V C G W S L * D Q N

25321 ATTCCCACTAACTTTACTATAGTTGGTCAAGAGGAATTTATTCAAACATAATTCTCCTAAA 25380
I P T N F T I V G Q E E F I Q T N S P K
F P L T L L * L V K R N L F K L I L L K
S H * L Y Y S W S R G I Y S N * F S * S

FIG. 2 CONT.

25381 GTTACTATTGATTGTTCTTTATTGTCTGTTCTAATTATGCAGCTTGCCATGACTTATTG 25440
V T I D C S L F V C S N Y A A C H D L L
L L L I V L Y L S V L I M Q L A M T Y C
Y Y * L F F I C L F * L C S L P * L I V

25441 TCAGAGTATGGCACTTTTTGTGATAATATTAATAGTATTTAGATGAAGTTAATGGTTTA 25500
S E Y G T F C D N I N S I L D E V N G L
Q S M A L F V I I L I V F * M K L M V Y
R V W H F L * * Y * * Y F R * S * W F T

25501 CTTGATACTACTCAATTGCATGTAGCTGATACTCTTATGCAAGGTGTCACACTTAGCTCC 25560
L D T T Q L H V A D T L M Q G V T L S S
L I L L N C M * L I L L C K V S H L A P
* Y Y S I A C S * Y S Y A R C H T * L Q

25561 AATCTTAATACTAATTGCAATTTGATGTTGATAATATTAATTTAAATCCCTAGTTGGA 25620
N L N T N L H F D V D N I N F K S L V G
I L I L I C I L M L I I L I L N P * L D
S * Y * F A F * C * * Y * F * I P S W M

25621 TGTTTAGGTCCCACTGCGGTTCTTCTCTCGTTCCTTTTTTTGAAGATTTATTGTTTGAC 25680
C L G P H C G S S S R S F F E D L L F D
V * V H T A V L L L V L F L K I Y C L T
F R S T L R F F F S F F F * R F I V * Q

25681 AAAGTTAACTTTTCAGATGTTGGTTTTGTTGAAGCTTATAACAATTGTTACTGGTGGTAGT 25740
K V K L S D V G F V E A Y N N C T G G S
K L N F Q M L V L L K L I T I V L V V V
S * T F R C W F C * S L * Q L Y W W * *

25741 GAAATTAGAGATCTTCTTTGTGTACAATCCTTTAATGGTATTAAAGTTTGCCTCCTATT 25800
E I R D L L C V Q S F N G I K V L P P I
K L E I F F V Y N P L M V L K F C L L F
N * R S S L C T I L * W Y * S F A S Y F

25801 TTGTCTGAATCTCAAATTTCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTTCCA 25860
L S E S Q I S G Y T T A A T V A A M F P
C L N L K F L V T P Q P L L L L L C F H
V * I S N F W L H H S R Y C C C Y V S T

25861 CCATGGTCAGCAGCAGCTGGCATAACCATTTCTCTTAATGTACAATATAGAATTAATGGT 25920
P W S A A A G I P F S L N V Q Y R I N G
H G Q Q Q L A Y H F L L M Y N I E L M V
M V S S S W H T I F S * C T I * N * W F

FIG. 2 CONT.

25921 TTGGGTGTTACTATGGATGTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTTAAT 25980
L G V T M D V L N K N Q K L I A T A F N
W V L L W M F L I K I K S * * L L L L I
G C Y Y G C S * * K S K V D S Y C F * *

25981 AATGCTCTTCTTTCTATTTCAGAATGGTTTTAGTGCTACCAACTCTGCACTTGCTAAAATA 26040
N A L L S I Q N G F S A T N S A L A K I
M L F F L F R M V L V L P T L H L L K Y
C S S F Y S E W F * C Y Q L C T C * N T

26041 CAAAGTGTGTTAATTCTAATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAAT 26100
Q S V V N S N A Q A L N S L L Q Q L F N
K V L L I L M L K H L I V C Y S N Y L I
K C C * F * C S S T * * F V T A I I * *

26101 AAATTTGGTGCAATTAGTTCTTCTTTACAAGAAATTTATCTCGTCTCGATGCTTTAGAG 26160
K F G A I S S S L Q E I L S R L D A L E
N L V Q L V L L Y K K F Y L V S M L * R
I W C N * F F F T R N F I S S R C F R G

26161 GCTCAGGTCAGATTGATAGGCTTATTAATGGTCGTTAACTGCTTTAAATGCTTATGTC 26220
A Q V Q I D R L I N G R L T A L N A Y V
L R F R L I G L L M V V * L L * M L M S
S G S D * * A Y * W S F N C F K C L C L

26221 TCTCAACAGCTTAGTGATATTCTCTTGTAATAATTTGGTGCTGCTTTAGCTATGGAGAAG 26280
S Q Q L S D I S L V K F G A A L A M E K
L N S L V I F L L * N L V L L * L W R R
S T A * * Y F S C K I W C C F S Y G E G

26281 GTTAATGAGTGTGTTAAAAGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCAT 26340
V N E C V K S Q S P R I N F C G N G N H
L M S V L K V N L L V L I F V V M V I I
* * V C * K S I S S Y * F L W * W * S Y

26341 ATTTTGTCAATTAGTTCAAAATGCTCCTTATGGTTTGTGTTTATGCATTTAGTTATAAA 26400
I L S L V Q N A P Y G L L F M H F S Y K
F C H * F K M L L M V C C L C I L V I N
F V I S S K C S L W F V V Y A F * L * T

26401 CCTATTTCTTTTAAAAGTGTTTTAGTAAGTCTGTTTGTGTATATCAGGTGATGTAGGT 26460
P I S F K T V L V S P G L C I S G D V G
L F L L K L F * * V L V C V Y Q V M * V
Y F F * N C F S K S W F V Y I R * C R Y

FIG. 2 CONT.

26461 ATTGCACCTAAACAAGGGTATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGT 26520
I A P K Q G Y F I K H N D H W M F T G S
L H L N K G I L L N I M I I G C S L V V
C T * T R V F Y * T * * S L D V H W * F

26521 TCCTACTATTATCCTGAACCAATTCAGATAAAAAATGTTGTTTTATGAATACTTGTCTCT 26580
S Y Y Y P E P I S D K N V V F M N T C S
L T I I L N Q F Q I K M L F L * I L V L
L L L S * T N F R * K C C F Y E Y L F C

26581 GTTAATTTTACTAAAGCGCCTCTTGTTTATTTGAATCATTCTGTACCAAATGTCTGAT 26640
V N F T K A P L V Y L N H S V P K L S D
L I L L K R L L F I * I I L Y Q N C L I
* F Y * S A S C L F E S F C T K I V * F

26641 TTTGAATCTGAGTTATCTCATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTTGACT 26700
F E S E L S H W F K N Q T S I A P N L T
L N L S Y L I G L K I K H P L R L I * L
* I * V I S L V * K S N I H C A * F D F

26701 TTAAATCTTCATACTATTAATGCTACTTTTTAGATTGTATTATGAGATGAATCTTATT 26760
L N L H T I N A T F L D L Y Y E M N L I
* I F I L L M L L F * I C I M R * I L F
K S S Y Y * C Y F F R F V L * D E S Y S

26761 CAAGAGTCTATTAAGTCTTTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATAT 26820
Q E S I K S L N N S Y I N L K D I G T Y
K S L L S L * I I V I S I L K I * V H M
R V Y * V F E * * L Y Q S * R Y R Y I *

26821 GAAATGTATGTA AAAATGGCCTTGGTATGTTGGCTACTAATTTCTTTTTCATTATAATA 26880
E M Y V K W P W Y V W L L I S F S F I I
K C M * N G L G M F G Y * F L F H L * Y
N V C K M A L V C L A T N F F F I Y N I

26881 TTCCTTGATGCTCTTTTTATATGTTGTTGTTACTGGTTGTTGTTCTGCATGTTTGTAGT 26940
F L V L L F F I C C C T G C G S A C F S
S L Y C S F L Y V V V L V V V L H V L V
P C I A L F Y M L L Y W L W F C M F * *

26941 AAATGTCATAATGTTGTGATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCT 27000
K C H N C C D E Y G G H H D F V I K T S
N V I I V V M S M V V I M I L L S K H L
M S * L L * * V W W S S * F C Y Q N I S

FIG. 2 CONT.

27001	CATGATGATTAGAATCTCTTGTTCAGATCTCATTAAATCTAAACTTTATTTATGGACGTTT H D D * N L L S D L I K S K L Y L W T F M M I R I S C Q I S L N L N F I Y G R L * * L E S L V R S H * I * T L F M D V W	27060
27061	GGAGACCTAGCTACACACATTCTCTTGTATTAGAGAATTGGTGTACAAACCTGAAG G D L A T H I L L L L E N L V L Q T L K E T * L H T F S C Y * R I W C Y K P * R R P S Y T H S L V I R E P G V T N L E D	27120
27121	ATTTGTGTCTAAAGTATAATTACTGTCAACCTATTGTTGGTTACTGTATTGTACCTTTAA I C V * S I I T V N L L L V T V L Y L * F V S K V * L L S T Y C W L L Y C T F K L C L K Y N Y C Q P I V G Y C I V P L N	27180
27181	ATGTTTGGTGTGCAAGTTTGGCAAATTTGCTTCTCACTTTACATTACGTAGTCACGATA M F G V A S L A N L L L T L H Y V V T I C L V S Q V W Q I C F S L Y I T * S R Y V W C R K F G K F A S H F T L R S H D I	27240
27241	TTTCCCATAGTAATAATTTTGGTGTGTAAGTACTTTACTACTTATGGTAATACTGTTT F P I V I I L V L * L V L L L M V I L F F P * * * F W C C N * F Y Y L W * Y C F S H S N N F G V V T S F T T Y G N T V S	27300
27301	CTGAGGCTGTGTCTAGATTAGTTGAATCAGCTTCTGAATTTATTGTTTGGCGTGCAGAGG L R L C L D * L N Q L L N L L F G V Q R * G C V * I S * I S F * I Y C L A C R G E A V S R L V E S A S E F I V W R A E A	27360
27361	CACTTAATAAGTATGGTTGATTATTTTCAATGATACTGCTTGGTACATAGGACAGATT H L I S M V D L F F N D T A W Y I G Q I T * * V W L I Y F S M I L L G T * D R F L N K Y G * F I F Q * Y C L V H R T D F	27420
27421	TTAGTTTTAGTTTTATTTTGTCTTATTTCTTTAATCTTTGTTGTTGCTTTTTAGCAACT L V L V L F C L I S L I F V V A F L A T * F * F Y F V L F L * S L L L L F * Q L S F S F I L S Y F F N L C C C F F S N Y	27480
27481	ATTAAGCTTTGTATGCAACTTTTGTGGTTTTTGTAAATTTCTTTATTATTTTACCTTCGGCT I K L C M Q L C G F C N F F I I S P S A L S F V C N F V V F V I S L L F H L R L * A L Y A T L W F L * F L Y Y F T F G L	27540

FIG. 2 CONT.

27541 TACGTTTATAAAAAGAGGTATGCAGTTGTATAAGTCTTATAGTGAACAAGTTATACCACCC 27600
Y V Y K R G M Q L Y K S Y S E Q V I P P
T F I K E V C S C I S L I V N K L Y H P
R L * K R Y A V V * V L * * T S Y T T H

27601 ACTTCAGATTATTTAATCTAAATCTAAACATTATGAATAAATCTTTTCTTCCTCAATTTA 27660
T S D Y L I * I * T L * I N L F F L N L
L Q I I * S K S K H Y E * I F S S S I Y
F R L F N L N L N I M N K S F L P Q F T

27661 CTTCTGATCAAGCTGTTACATTCTTAAAAGAATGGAATTTCTCTTTGGGTGTAATACTAC 27720
L L I K L L H S * K N G I S L W V * Y Y
F * S S C Y I L K R M E F L F G C N T T
S D Q A V T F L K E W N F S L G V I L L

27721 TTTTATTACTATCATATTGCAGTTCGGTTATACGAGCCGTAGTATGTTTGTATTACTTA 27780
F L L L S Y C S S V I R A V V C L F I L
F Y Y Y H I A V R L Y E P * Y V C L S Y
F I T I I L Q F G Y T S R S M F V Y L I

27781 TCAAGATGATTATTCTTTGGCTTATGTGGCCATTGACTATCACCTTGACTATATTTAATT 27840
S R * L F F G L C G H * L S P * L Y L I
Q D D Y S L A Y V A I D Y H L D Y I * L
K M I I L W L M W P L T I T L T I F N C

27841 GTTTTATGCTTTGAATAATGCTTTTCTTGCAATTTCTATAGTGTACTATTATTCTA 27900
V F M L * I M L F L H F L * C L L L F L
F L C F E * C F S C I F Y S V Y Y Y F Y
F Y A L N N A F L A F S I V F T I I S I

27901 TTGTTATATGGATTCTTTATTTTGTAAATAGTATTCCGGCTTTTATTAGAACTGGCAGTT 27960
L L Y G F F I L L I V F G F L L E L A V
C Y M D S L F C * * Y S A F Y * N W Q L
V I W I L Y F V N S I R L F I R T G S W

27961 GGTGGAGTTTAAATCCAGAGACCAATAATCTTATGTGTATTGATATGAAAGGCAAGATGT 28020
G G V L I Q R P I I L C V L I * K A R C
V E F * S R D Q * S Y V Y * Y E R Q D V
W S F N P E T N N L M C I D M K G K M F

28021 TTGTTAGGCCAGTTATTGAGGACTATCACACATTAAGTCTACTGTTATTTCGGTGCATC 28080
L L G Q L L R T I T H * L L L L F V V I
C * A S Y * G L S H I N C Y C Y S W S S
V R P V I E D Y H T L T A T V I R G H L

FIG. 2 CONT.

28081 TTTATATACAGGGTGTCAAACCTGGCACTGGTTATACTCTTTCAGATTGCCCCGTATATG 28140
F I Y R V S N L A L V I L F Q I C P Y M
L Y T G C Q T W H W L Y S F R F A R I C
Y I Q G V K L G T G Y T L S D L P V Y V

28141 TTACTGTAGCTAAGGTGCAAGTACTTTGTACCTATAAACGTGCCTTTTTAGATAAGTTAG 28200
L L * L R C K Y F V P I N V P F * I S *
Y C S * G A S T L Y L * T C L F R * V R
T V A K V Q V L C T Y K R A F L D K L D

28201 ATGTTAATAGTGGTTTTGCTGTTTTGTTAAGTCTAAAGTTGGTAACTATCGTTTACCGT 28260
M L I V V L L P L L S L K L V T I V Y R
C * * W F C C F C * V * S W * L S F T V
V N S G F A V F V K S K V G N Y R L P S

28261 CTAGTAAACCTAGTGGTATGGATACTGCCTTGTTAAGAGCTTAAATCTAAACTATTAGGA 28320
L V N L V V W I L P C * E L K S K L L G
* * T * W Y G Y C L V K S L N L N Y * D
S K P S G M D T A L L R A * I * T I R M

28321 TGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGAA 28380
C L I L P V I M L E V E A P L E I V Q E
V L Y S R S L C W K * K L L W K S F R N
S Y T P G H Y A G S R S S S G N R S G I

28381 TCCTCAAGAAAACCTCTTGGGCTGACCAATCTGAGCGAAATTACCAAACCTTTAATAGAG 28440
S S R K L L G L T N L S E I T K P L I E
P Q E N F L G * P I * A K L P N L * * R
L K K T S W A D Q S E R N Y Q T F N R G

28441 GCAGAAAACCCAACCTAAATTCACTGTGTCTACTCAACCACAAGGAAATACTATCCCAC 28500
A E K P N L N S L C L L N H K E I L S H
Q K N P T * I H C V Y S T T R K Y Y P T
R K T Q P K F T V S T Q P Q G N T I P H

28501 ATTATTCCTGGTTCTCCGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCAG 28560
I I P G S P G S L N F K K V E T L N F Q
L F L V L R D H S I S K R * R L * I F R
Y S W F S G I T Q F Q K G R D F K F S D

28561 ATGGTCAAGGAGTTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAAAGGATATTGGT 28620
M V K E F P L L S E Y P L L K Q K D I G
W S R S S H C F R S T P F * S K R I L V
G Q G V P I A F G V P P S E A K G Y W Y

FIG. 2 CONT.

28621 ATAGACACAGCCGGCGTTCTTTTAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCGA 28680
I D T A G V L L K Q L M V N K S S C Y R
* T Q P A F F * N S * W S T K A V V T E
R H S R R S F K T A D G Q Q K Q L L P R

28681 GATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCCC 28740
D G I S T I S V P A H M P M H P M V N P
M V F L L S R Y R P I C Q C I L W * I P
W Y F Y Y L G T G P Y A N A S Y G E S L

28741 TCGAAGGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTTT 28800
S K G S S G L L I T K L T L L L P P M F
R R G L L G C * S P S * H F Y S L R C F
E G V F W V A N H Q A D T S T P S D V S

28801 CGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATTT 28860
R Q G I L L L K K L S L L G F R L V R F
V K G S Y Y S R S Y P Y * V S A W Y D F
S R D P T T Q E A I P T R F P P G T I L

28861 TGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGTCGCTTCTAATAGTCGACCAGTT 28920
C L K A I M L K A Q E G L L L I V D Q V
A S R L L C * R L R K V C F * * S T R F
P Q G Y Y V E G S G R S A S N S R P G S

28921 CACGTTCTCAATCACGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATTCTAATTTTA 28980
H V L N H V D P I I V H * V E V I L I L
T F S I T W T Q * S F I K * K * F * F *
R S Q S R G P N N R S L S R S N S N F R

28981 GACATTCAGATTCTATAGTAAACCTGATATGGCTGATGAGATCGCTAATCTTGTTTTAG 29040
D I Q I L * * N L I W L M R S L I L F *
T F R F Y S K T * Y G * * D R * S C F S
H S D S I V K P D M A D E I A N L V L A

29041 CCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATCA 29100
P S L V K I L N L S K S L S K M P R K S
Q A W * R F * T S A S H * A K C Q G N Q
K L G K D S K P Q Q V T K Q N A K E I R

29101 GGCATAAAATTTTAAACAAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 29160
G I K F * Q N L A K S E L L I N I V M F
A * N F N K T S P K A N S * * T L * C S
H K I L T K P R Q K R T P N K H C N V Q

FIG. 2 CONT.

29161	AACAGTGTTTTGGTAAAAGAGGACCTTCTCAAAATTTGGTAATGCTGAAATGTTAAAGC N S V L V K E D L L K I L V M L K C * S T V F W * K R T F S K F W * C * N V K A Q C F G K R G P S Q N F G N A E M L K L	29220
29221	TTGGTACTAATGATCCTCAGTTTCTATTCTTGCAGAATTAGCTCCTACACCAGGTGCTT L V L M I L S F L F L Q N * L L H Q V L W Y * * S S V S Y S C R I S S Y T R C F G T N D P Q F P I L A E L A P T P G A F	29280
29281	TTTTCTTTGGTTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTTA F S L V L N * T W L K E I P R L T H L L F L W F * I R L G * K R F R G * L T C * F F G S K L D L V K R D S E A D S P V K	29340
29341	AAGATGTTTTTGAACCTTCATTATTCTGGTTCTATTAGGTTTGATAGTACTTTACCAGGCT K M F L N F I I L V L L G L I V L Y Q A R C F * T S L F W F Y * V * * Y F T R L D V F E L H Y S G S I R F D S T L P G F	29400
29401	TTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTACGTTAATTCTAATCAGA L R Q L * K F L K R I * M L T L I L I R * D N Y E S S * R E F K C L R * F * S E E T I M K V L E E N L N A Y V N S N Q N	29460
29461	ACACTGATTCTGATTCTGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTAC T L I L I R * V L N L S V K E V L N N Y H * F * F V E F * T S A * K R C * T I T T D S D S L S S K P Q R K R G V K Q L P	29520
29521	CAGAACAGTTTGACTCTCTTAATTTAAGTCTGGTACTCAGCACATTTCAAATGATTTTA Q N S L T L L I * V L V L S T F Q M I L R T V * L S * F K C W Y S A H P K * F Y E Q F D S L N L S A G T Q H I S N D F T	29580
29581	CTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTTG L L R I I V Y L L L L M I L M * K T L L S * G S * F T C Y S * * S L C R R L C C P E D H S L L A T L D D P Y V E D S V A	29640
29641	CTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTCGCTATTATTCCGGAAT L N E N E S * F D T R W * P L A I I R N L M R M N P N S T L G G N P S L L F G I * * E * I L I R H * V V T P R Y Y S E *	29700

FIG. 2 CONT.

29701	AGGACACTCTCTATCAGAATGAATTCTTGCTGTAATAACAGATAGAGTAGGTTGTTACAG R T L S I R M N S C C N N R * S R L L Q G H S L S E * I L A V I T D R V G C Y R D T L Y Q N E F L L * * Q I E * V V T D	29760
29761	ACTATATATTAATTAGTAGAAAATTTATATTTAGACATTGATTGTTAGAGTAGTTATAA T I Y * L V E I L Y L D I * L L E * L * L Y I N * * K F Y I * T F D C * S S Y K Y I L I S R N F I F R H L I V R V V I R	29820
29821	GGTTTAGCTGTAGTATAAACGCCTCCGGGAAGAGCTATCAATTGTAGTGTTTAATATATA G L A V V * T P P G R A I N C S V * Y I V * L * Y K R L R E E L S I V V F N I Y F S C S I N A S G K S Y Q L * C L I Y I	29880
29881	TATTAGTATATGATTGAAATTAATTATAGCCTTTGGAGGAATTACAAAAAAAAAAAAA Y * Y M I E I N Y S L L E E L Q K K K K I S I * L K L I I A F W R N Y K K K K K L V Y D * N * L * P F G G I T K K K K K	29940
29941	AA	29942

FIG. 2 CONT.

1 CTTATTCTCGCTTAACGCAGGCATGGCAGATAGTGAATGCTAGAGAACAGTCTAGAGTA 60
Y S R I A D T G D I L K R D R T L D *
I L A F Q T R V T * * S V I E Q * I E
F L L S N R G Y R R D A * S R K D S R M

61 ATTTAGATTTGAAAAATTTGTTCTAAGGGACAATAGGTACGAACACTCACACCAAATTAG 120
* I * V K * V L N G T I W A Q S H P K I
N F R F K K F L I G Q * G H K H T H N L
L D L S K L C S E R N D M S T L T T * D

121 TATTAGAACATAAAATGAAAGGTGTGAAAAGTAGAGAGACGGTCACTGCACAACCAACAG 180
M I K Y K V K W V K * R E A L S T N T T
* L R T N * K G C K E D R Q W H R T P Q
Y D Q I K S E V S K M E R G T V H Q N D

181 GAGTCGCAGGGAGGGTATCCAGCGTTACTAATTTTGGTCGTTTATGCCAGAGCCGAAGTT 240
R L T G G M P R L S * F W C I R D R S *
G * R G E W L D C H N F G A F V T E A E
E A D R G Y T A I I L V L L Y P R P K L

241 CACCCGCGGTCTTAAAGCAACCGACGAAGGCCTACGTCCCTCCTCAACCGATCAGGATA 300
T P A L I E N A A E P H L P P T P * D *
L P R W F K T P Q K R I C R L L Q S T R
H A G S N R Q S S G S A A S S N A L G I

301 CTTCAGTCTACTCCCACCCAATACGGGGAGATGACCAGTTCGCTACCTTTCACAACCTAA 360
S T L H P H T I G R * Q D L S P F H Q I
H L * I L T P * A G R S T L R H F T N S
F D S S P P N H G E V P * A I S L T P N

361 GCAAATACTATTAGTACACTTCTATCTAACAGCGGTAAGAACCTGTTCTTACCGTACA 420
R K H Y D H S S L N D S C E Q V L I A H
E N I I I M H L Y I T A A N K S L F P M
T * S L * T F I S Q R Q M R P C S H C T

421 CGTCAGTTTGAATAGGCACTATAAAAAACAAGTACTTCTAGATGTACAACATCTTCAAGA 480
A T L D * G H Y K Q E H L D V H Q L L E
H L * I K D T I N K N M F I * M N Y F N
C D F R I R S I K T * S S R C T T S T R

481 TTGATTTTGTGGCATTTCAGGCCATGCCGTTAAAAATTAATTTAGTGGAAACGTATCGAA 540
L * F L R L T R Y P L K L * I V K A Y S
* S F C G Y L G T R C N * N F * R Q M A
V L V A T F D P V A I K I L D G K C L K

FIG. 3

541 CCCACCAAAGGATTCCCATACAATACCCGAACAGGCAAGTATGTTCTGATTGCAAT 600
 P H N E * L T H * P S T G N M C S * V N
 Q T T K R F P I N H A Q E T * V L S F T
 P P K G L P Y T I P K N R E Y L V L R *

601 ACAACATGTAGTAGAAAAGATACTGATGTAGATGATGATTAAAACCACTTCTAAAAACCC 660
 H Q V D D K * S * M * * * N Q H L N K P
 I N Y M M K R H S C R S S I K T F I K Q
 T T C * R E I V V D V V L K P S S K K P

661 AACCTAACATGGAAAACCAAATACGGTAGAATACAAGTGTTTACCAAAGTTAAGACATC 720
 N S Q V K Q N * A M K H E C I T E I R Y
 T P N Y R K T K H W R I N V F P K L E T
 Q I T G K P K I G D * T * L H N * N Q L

721 CAACATATAACTTCTCTCACTAAATTTATAAGTTTAAAATTTAAACTACTAATACTAAA 780
 T T Y Q L S H N L L K L N * I Q H N H N
 P Q I N F L T I * Y N * I K F K I I I I
 N Y I S S L S K I I E F K L N S S * S K

781 ATCACATCTTCTACGAATACGACTCCAAGTACGACTCGGATTCCATTATAAGTGTTTT 840
 * H L L H K H Q P E H Q A * L Y I N V F
 K T Y F I S I S L N M S L R F T F I * L
 L T S S A * A S T * A S G L P L Y E C F

841 TCGAATACGAAATGAATCTGTTATAGCACCATAATTTGGGCATGAAAAACATCTGGTCAT 900
 L K H K V * V I D H Y * V R V K Q L G T
 F S I S * K S L I T T N F G Y K K Y V L
 A * A K S L C Y R P I L G T S K T S W Y

901 ACCAACACTGATAAGACCATTTAATCGTCTAACAGAAGTTCGAATACCAGTAATAAGAAA 960
 H N H S N Q Y I L L N D E L K H D N N K
 I T T V I R T F * C I T K L S I T M I R
 P Q S * E P L N A S Q R * A * P * * E K

961 CGTTCATACTCTGTTTTCGTCAGACATACCGAACGGTTAACACTGAAACTATAACATCA 1020
 A L Y S V F A T Q I A Q W N H S Q Y Q L
 Q L I H S L L L R Y P K G I T V K I N Y
 C S I L C F C D T H S A L Q S K S I T T

1021 CCGAACCGTACATCAAGCACTAAGTGCTAAACAATACGCGGACGTCTGATATCGATGATA 1080
 P K A H L E H N V I Q * A G A S * L * *
 H S P M Y N T I * S K N H A Q L S Y S S
 A Q C T T R S E R N T I R R C V I A V I

FIG. 3 CONT'D

1081 AACACCATAATTTATACAACGTGTTGGATGTCTTCTACATCATCTACCTCTACATCAATA 1140
K H Y * I H Q V V * L L H L L H L H L *
N T T N F I N C L R C F I Y Y I S I Y N
Q P I L Y T A C G V S S T T S P S T T I

1141 TGCACCTGGACATGTAAATAATAGACGACTACGTTATCAAATTTGAAGGATCAAACATA 1200
V H V Q V N I I Q Q H L L K L A E * N S
Y T F R Y M * * R S I C Y N * L K R T Q
R S G T C K N D A S A I T K F S G L K I

1201 CTTTCAATACTGAGTATACCTACTAAAAAGATAATTTAGATATATATTACAACTAAACAC 1260
S L * S E Y P H N K * * I * I Y H Q N T
H F N H S M H I I K R N F R Y I I N I Q
F T I V * I S S K E I L D I Y L T S K H

1261 ACTAACACCAAAAACAATAGTCATACCAATACATCTAACAAAATTACTATTAACTAAACATA 1320
H N H N Q * A T H N H L N N * H Y N H N
T I T T K N H L I T I Y I T K I I I T I
S Q P K T I C Y P * T S Q K L S L Q S K

1321 AATACCAACCCAAAGTCCATTATACTACCTACCAAAAAGAACAGGTAACACAACATGTCA 1380
K H N P K L Y Y S P H N K K D M T N Y L
K I T P N * T I H H I T K R T W Q T T C
* P Q T E P L I I S P K E Q G N H Q V T

1381 AATACTGAGATCGCTTCAATTTCCGGTTAGTAGACCACAATAAGGACTTTTAGGACACAA 1440
K H S * R L * L G I M Q H * E Q F D Q T
N I V R A F N F G L * R T N N R F I R H
* S E L S T L A W D D P T I G S F G T N

1441 TAAATGATTATCATGACTATGACAATTGGTACTAAGAAAATTAACATAACCAATAAGACA 1500
I * * Y Y Q Y Q * G H N K * N T H N N Q
* K S I T S I S N V M I R K I Q I T I R
N V L L V S V T L W S E K L K Y P * E T

1501 GTGTGGTAAACCAAGAACATATATAACCAGCGCGCAGGACCTAACACCTAAGGATATTA 1560
* V M Q N K Y I N T A A D Q I T S E * L
D C W K T R T Y I P R R T R S Q P N R Y
V G N P E Q I Y Q D G R G P N H I G I I

1561 ATTTAGAAGTCAGTTCAGAATACTACTAAACCAATAAGTCCACATCATCCAACATTTAG 1620
* I K L * T K H H N P K N L H L L N Y I
N F R * D L R I I I Q N I * T Y Y T T F
L D E T L D * S S K T * E P T T P Q L D

FIG. 3 CONT'D

1621 ATAACAATTTCTTTGACGAGAATAATGAGTACGTGAAATGAATCTAATACAAGTTACATT 1680
* Q * L F Q E * * E H V K S L N H E I Y
R N N F F S S K N S M C K V * I I N L T
I T L S V A R I V * A S * K S * T * H L

1681 CACACCATTAGAACTTGTGTTTAGTATAAGAACCGCAATTATTAAGAACCACATCCGTTGA 1740
T H Y D Q V F D Y E Q R * Y N K T Y A V
L T T I K F L I M N K A N I I R P T P L
H P L R S C F * I R P T L L E Q H L C S

1741 CAACGAATTATCTCCACTAATATTATACGAAGATTTTTTATAACTGAACAAACAATTCGC 1800
T A * Y L H N Y Y A E L F Y Q S T Q * A
Q Q K I S T I I I H K * F I N V Q K N L
N S L L P S * L I S R F F I S K N T L R

1801 AGCAGACTAAAACGAACGTTCAAACGTCAAACACCTCTACCAAAACATGGAAAAATGA 1860
D H Q N Q K C T Q L K H L H N Q V K K V
T T S I K S A L K C N T S I T K Y R K *
R A S K A Q L N A T Q P S P K T G K K S

1861 TCTACCAAATTAAGGGCATCAATAATAGATTAAGTCTCACCATAAAAAGAAATGTAGAAA 1920
L H N L E G Y N N D L E S H Y K R * M K
* I T * N G T T I I * N L T T N E K C R
S P K I G R L * * R I * L P I K K V D K

1921 CTACAGAGTTAAAAGTGTCTTCAAAGACTATACACAAATTTTTACACATAAAAACAATA 1980
S T E I K V L L K Q Y T N L F T Y K T *
Q H R L K * L F N R I H T * F H T N Q K
I D * N E C S T E S I H K F I H I K N I

1981 CCTGTCTCAAAGTCAACGATGTAATAATATCTCGTAATACAATTATCCAACCAATGAGT 2040
P C L K L Q * M K Y L A N H * Y T P * E
H V S N * N S C K I Y L M I N I P Q N S
S L T E T A V N * I S C * T L L N T V *

2041 TAAATTCAATAACCCATGATGTGAACAATTATTTTACCAATTAACCAAATTATGGTACAA 2100
I * T I P Y * V Q * Y F P * N T * Y W T
L K L * Q T S C K N I F H N I P K I G H
N L N N P V V S T L L I T L Q N L V M N

2101 TCTACGATCACGTGGACGATGTCCGACCGAAGAAATGGTTAATAACTTACCAGAAAAACA 2160
L H * H V Q * L S A E K G I I S H D K Q
* I S T C R S C A P K K V L * Q I T K K
S A L A G A V P Q S R * W N N F P R K T

FIG. 3 CONT'D

2161 TCATAGAGTTCGGTTGAAATTAAAACAACGAAATTATGGACTAATACGATTTTAAAATCA 2220
L I E L W S * N Q Q K L V Q N H * F K L
Y Y R L G V K I K N S * Y R I I S F N *
T D * A L K L K T A K I G S * A L I K T

2221 ATTATTTAAAATGTGAAAAAATTCATAATAATCTCACACAATGTCAACTACAAAATTT 2280
* Y I K C K K * T I I L T H * L Q H K L
N I F K V S K K L * * * L T N C N I N *
L L N * V K K L N N N S H T V T S T K F

2281 TCTATACGGACAAGAATTTTGATAATTACCAAATCAAACATAACATCCGTTATTCAAAT 2340
L Y A Q E * F * * H N L K Y Q L C Y T K
F I H R N K F S N I T * N T N Y A I L K
S I G T R L V I L P K T Q I T P L L N *

2341 ATTGCAATCATGTCCCAATTAAGGACCAAAACAAAATGGTACATTACGTGTCCTTGTGTGT 2400
Y R * Y L T L E Q N Q K V M Y H V P V V
I V N T C P * N R T K N * W T I C L F L
L T L V P N I G P K T K G H L A C S C C

2401 TTAATAAAAAAACTTCCGCAACGTCTTAGACAATATCATCTTCTACTACAATAACTCTT 2460
F K N K Q L R Q L I Q * L L L H H * Q S
L N I K K F A N C F R N Y Y F I I N N L
I * K K S P T A S D T I T S S S T I S F

2461 ACAGTTTAGAAGAAATAGTAGAATACTCATAACAGTTGGTGGATTTAGACATCTTTTTTA 2520
H * I K K I M K H T N D V V * I Q L F F
I D F R R * * R I L I T L W R F R Y F F
T L D E K D D * S Y Q * G G L D T S F I

2521 AACATAATATCTATTATACATGTACCCATTACACCCACTATTTAAAAGGGATAACAGTA 2580
K Y * L Y Y T C P Y T H H Y I K G * Q *
N T N Y I I H V H T L T T I F K E R N D
Q I I S L I Y M P L H P S L N K G I T M

2581 CTTACTATTTTTATAAACAGAAAATCTAGTCCGAACCGCAAAAGGTACACGTCATCTTT 2640
S H Y F Y K D K L D P K A N E M H L Y F
H I I F I N T K * I L S P T K W T C T S
F S L F I Q R K S * A Q R K G H A P L F

2641 TCAATTAATAATGTCTCTTTGGACAACAATACCTCTAAGGCAGAACTACTGTCAATCCA 2700
L * N * R S V Q Q * P S E T K S S L * P
F N I K V L F R N N H L N R R Q H C N L
T L K L S F G T T I S I G D K I V T L T

FIG. 3 CONT'D

2701 ATACAACTAAATCTAAGATGAAAACACTACTATAAAATCCATTTCAAACAAGTCTTAAACT 2760
* T Q N L N * K Q H Y K L Y L K N L I Q
N H K I * I R S K I I N * T F N T * F K
I N S K S E V K S S I K P L T Q E S N S

2761 TCATCTTTTCCCACAATGACATCTACTAAAACAACGACAACAACACTACGATATCTCTT 2820
L L F P H * Q L H N Q Q Q Q K H H * L S
F Y F L T N S Y I I K N S N N T I S Y L
T S F P T V T S S K T A T T Q S A I S F

2821 ACGAAATTTGAGAACATTTCTCGTAGGTCACCAACCAATAGTTCAAGCACGTAAAAATTT 2880
H K L S K Y L A D L P Q N D L E H M K L
I S * V R T F L M W H N T I L N T C K *
A K F E Q L S C G T T P * * T R A N K F

2881 ATTTGAATTACTCTTACAACAAATAAATAAACTACTCCGACCACTACTTCGTTACCGGAG 2940
Y V * H S H Q K N I Q H P Q H H L L P R
I F K I L I N N I * K I L S T I F C H G
L S L S F T T * K N S S A P S S A I A E

2941 AGCATACATAACATGAAAACGATAACTCCTACAACCTTCTGCAATAGTCATCACTTCGACA 3000
E Y T N Y K Q * Q P H Q L R * * Y H L Q
R T H I T S K S N L I N F V N D T T F S
R I Y Q V K A I S S T S S T I L L S A T

3001 GCTTCTATGATAACTACCACAGCAACTTCTGTGATAATTACTGCTACTTCTACAACAATG 3060
R L Y * Q H H R Q L C * * H R H L H Q *
D F I S N I T D N F V S N I V I F I N N
S S V I S P T T S S V I L S S S S T T V

3061 ACCACTGTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3120
Q H C H R H L H Q * Q H C H R H L H Q *
S T V I V I F I N N S T V I V I F I N N
P S L S S S S T T V P S L S S S S T T V

3121 ACCACTGTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3180
Q H C H R H L H Q * Q H C H R H L H Q *
S T V I V I F I N N S T V I V I F I N N
P S L S S S S T T V P S L S S S S T T V

3181 ACCACTGTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3240
Q H C H R H L H Q * Q H C H R H L H Q *
S T V I V I F I N N S T V I V I F I N N
P S L S S S S T T V P S L S S S S T T V

FIG. 3 CONT'D

3241 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3300
Q H C H R H L H Q * Q H C H R H L H Q *
S T V I V I F I N N S T V I V I F I N N
P S L S S S S T T V P S L S S S S T T V

3301 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3360
Q H C H R H L H Q * Q H C H R H L H Q *
S T V I V I F I N N S T V I V I F I N N
P S L S S S S T T V P S L S S S S T T V

3361 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTACTGCTACTTCTACAACAATG 3420
Q H C H R H L H Q * Q H C H R H L H Q *
S T V I V I F I N N S T V I V I F I N N
P S L S S S S T T V P S L S S S S T T V

3421 ACCACTGTTACTGCTACTTCTACAACAATGACCACTGTTATTGCTACTTCTCTAACAATG 3480
Q H C H R H L H Q * Q H C Y R H L S Q *
S T V I V I F I N N S T V I V I F L N N
P S L S S S S T T V P S L L S S S I T V

3481 ACCACTGTTACTACTGGTTTAAACAACAATGACCACTACTACATCTACTATAACTTTCATA 3540
Q H C H H G F Q Q * Q H H H L H Y Q F Y
S T V I I V L N N N S T I I Y I I N F T
P S L S S W I T T V P S S T S S I S L I

3541 AATACTGAAACTATGAATATTTTCGAGAAAATCAAAAATTACTACAGATATTACTACGAAA 3600
K H S Q Y K Y L E K L K * H H R Y H H K
N I V K I S I F S K * N K I I D I I I S
* S K S V * L A R K T K L S T * L S A K

3601 CAAACAATCAATACCAAGATCACAACCTTGTCTTTGTATAAAAATTTCAATTACCAAATAC 3660
T Q * N H N * H Q F L F M N * L * H N I
Q K N T I T R T N F C F C I K F N I T *
N T L * P E L T S V S V Y K L T L P K H

3661 CAGTGGATGATAATGTGTATGATTAACAACCAACGCAAGACACAATGAACATTACGTCTT 3720
T V * * * V Y * N N T A N Q T V Q L A S
P * R S N C M S I T P Q T R H * K Y H L
D G V I V C V L Q Q N R E T N S T I C F

3721 TAATGGAAAATTCAAATTCCTAAATCGATAACTTTTATACACCAATAGAATATTCCACCC 3780
I V K * T * P N L * Q F Y T T I K Y P P
F * R K L K L I * S N F I H P * R I L H
N G K L N L S K A I S F I H N D * L T P

FIG. 3 CONT'D

3781 AATATTAGTTTCAAACAACATAATAAATGACTGGTGATAAGGATTTTCGATAACAAAACGG 3840
N Y D F N Q Q N N V S W * E * L * Q K A
T I I L T K N I I * Q G S N R F S N N Q
* L * L K T S * K S V V I G L A I T K G

3841 AGTTCACCAAAAACATCGACTAAAACGAATAACCAAAAATTTGGTCAAACATAAATTACG 3900
E L H N Q L Q N Q K N T K L G T Q Y * H
R L T T K Y S I K S I P K * V L K I N I
* P P K T A S K A * Q N K F W N S I L A

3901 CATACGATTAACCACAACAAATTTTACACCAAAAAGAAAACATAAATTTACCAAACTACG 3960
T H * N T N N L I H N K K Q N L H N P H
R I S I P T T * F T T K R K I * I T Q I
Y A L Q H Q K F H P K E K S K F P K S A

3961 AAACAAAAAATACCTCTATAACACAGAGTACAAACATTCACACCTGTATTATACTGAGA 4020
K T K K H L Y Q T E H K Y T H V Y Y S E
S Q K K I S I N H R M N T L T S M I H S
K N K * P S I T D * T Q L H P C L I V R

4021 TTATCGTCGCCTGAATGGAACATGTAATGTAAAAAGTAATAAATACTGTAAAAACAGC 4080
L L L P S V K Y M V N K M I Q H C N K H
* Y C R V * R T C * M K * * K I V I K T
I A A S K G Q V N C K E N N S S L K Q A

4081 AAAACGTGGGGATTTTTTAAAAATAACGACGTACACGACACCTACATTGCAAAACAGT 4140
K K C G * F F K * Q Q M H Q P H L R K D
S K A G R F F N K N S C T S H I Y V N T
K Q V G L F I K I A A H A T S T F T Q *

4141 AAGACATCGACAATATCCACTACTGTTTATCTACCATTCAAACAATGATTTAAATCACC 4200
N Q L Q * L H H V F L H Y T Q * * I * H
M R Y S N Y T I F L Y I T L K N S F K T
E T A T I P S S C I S P L N T V L N L P

4201 ACTATTTAAACTAAAATATCATCCAATACCTTACAGTAAATCATAACAGAAACTCAA 4260
H Y I Q N * L L N H F T M * Y T K K Q T
T I F K I K Y Y T I S H * K T H R R K L
S L N S K I T P * P I D N L I D E K S N

4261 TGGAGTTAACATACCAAAACACATATTGTGGATTACATACAAAACAATTTCCACTATAATA 4320
V E I T H N T Y L V * H I N Q * L H Y *
* R L Q I T Q T Y C R I Y T K N F T I N
G * N Y P K H I V G L T H K T L P S I I

FIG. 3 CONT'D

4321 TTTACAACGATCTGAACAATTTGACTACAATAACAATTAGGACGATTACCCGTATACGA 4380
L H Q * V Q * L Q H * Q * D Q * H A Y A
Y I N S S K N F S I N N N I R S I P M H
F T A L S T L A S T I T L G A L P C I S

4381 GGTACCACCACCTCAACGTTTTCGATATCGACATCGACGTCCATTTTTTAAAAGATTTCT 4440
G H H H L Q L L * L Q L Q L Y F I K * L
E M T T S N C F S Y S Y S C T F F K R F
W P P P T A F A I A T A A P L F N E L S

4441 TTGACGACGATACCAATTTAGATTTCCACAAACGGTTCATCCTCTAACAAATACAAAGATG 4500
F Q Q * P * I * L H K G L L L N N H K *
F S S S H N F R F T N A L Y S I T I N R
V A A I T L D L P T Q W T P S Q * T E V

4501 GCCACCATTTAATACATTTTGTGAAGAATTATAACATCCGGGACTACGATCTGTTCTACC 4560
R H Y I I Y F L E * Y Q L G Q H * V L H
G T T F * T F C N K I N Y A R I S S L I
P P L N H L V I R L I T P G S A L C S P

4561 TTCTGTAGAAATACAAAACAATCGTGACGAATATTCGTAGAATTATTAATACTAACAAC 4620
F V I K H K T L V H K Y A D * Y N H N N
S S L R I N Q * C T S I L M K I I I I T
L C D * T K N A R A * L C R L L * S Q Q

4621 AAACAGATGAGAGTATAGCCGACCATATAAATCACAAGGACGACTACACAGTAATTGAAT 4680
N T * E * I P Q Y I * H E Q Q H T M L K
T Q R S E Y R S T Y K T N R S I H * * S
K D V R M D A P I N L T G A S T D N V *

4681 GGAAGATCCACAACAACACTATTTGTTCAATAGGAACAATCATTATTATTCTTCTAAAAC 4740
G E L H Q Q Y V L * G Q * Y Y Y L L N Q
V K * T N N I F L N D K N T I I F F I K
R R P T T S L C T I R T L L L L S S K S

4741 ATAATAAGTTTTTACAGTTAATGAAGTCAACAACCATGATTTTCGTAACCGACAATCTAA 4800
Y * E F I D F * K L Q Q Y * L M P Q * I
I N N L F T L N S * N N T S F C Q S N S
I I * F H * I V E T T P V L A N A T L N

4801 TTGACGATTACATCCGGCACAATAATTTAAACTCTGTCTACGTATGTTTGAAAAAAACTC 4860
L Q * H L G H * * I Q S L H M C V K K S
* S S I Y A T N N F K L C I C V F K K Q
V A L T P R T I L N S V S A Y L S K K L

FIG. 3 CONT'D

4861 ACCACTACTAACAAAACAAAGTTTAAGAAGACAATATGTTCTTCAAATAACGAAGCAGT 4920
H H H N N Q K L N K Q * V L L K I A E D
T T I I T K N * I R R N Y L F N * Q K T
P S S Q K T E F E E T I C S T K N S R *

4921 ACTATATGTTAACTTATTACTGCAAGCACTAATAAACAACAGATTCTACTGATCAGAAGG 4980
H Y V I S Y H R E H N N T T * S S * D E
M I Y L Q I I V N T I I Q Q R L H S T K
S I C N F L S T R S * K N D L I V L R G

4981 ATTTCTAACCGCAGAATAGTTATTTAAACTACAATAATTGCCACAATTTTGACAATTCAT 5040
* L N A D * * Y I Q H * * R H * F Q * T
R F I P T K D I F K I N N V T N F S N L
L S Q R R I L L N S T I L P T L V T L Y

5041 AAAACTCACAGGATTAAGATAAATATATACATCAGTCCCATTTCTGAAACCAATACATAC 5100
N Q T D * N * K Y I Y D P Y L S Q N H I
I K L T R I R N I Y T T L T F V K T I Y
K S H G L E I * I H L * P L S K P * T H

5101 ACTACCAAGAAAAATATTTGTTGACAATTAGTTCAAACACAAAATAATCGATTCTTCTA 5160
H H N K K Y L L Q * D L K H K I L * S S
T I T R K I F C S N I L N T N * * S L L
S P E K * L A V T L * T Q T K N A L F I

5161 TCTACAAAACGAATGACATCTACCACAATTTAAATTTAGATAAAGAGAATGACATCCACT 5220
L H K A * Q L H H * N * I * K E * Q L H
Y I N Q K S Y I T N I K F R N R K S Y T
S T K S V T S P T L K L D I E R V T P S

5221 TCAAAAACCATTTTATGAACCATTACAAAAGACTACCGTAACTACAATGATTCAATTT 5280
L K Q Y F V Q Y H K R H H C Q H * * T L
F N K T F Y K T I N E T I A N I N S L *
T K P L I S P L T K Q S P M S T V L N F

5281 CACATCACTAAAAATACGGCTATTTTAAAAATATAGTCATACTTTTAAACAGAAATCGACT 5340
T Y H N K H R Y F K I D T H F N T K L Q
L T T I K I G I F N * I L I F I Q R * S
H L S K * A S L I K Y * Y S F K D K A S

5341 ATAAAGACGACATGTTTCAAGTAAACCCAACTAGTCGTTGTTAACGAACGAATAATATT 5400
Y K Q Q V F N M Q T Q D A V I A Q K N Y
I N R S Y L T * K P K I L L L Q K S I I
I E A T C L E N P N S * C C N S A * * L

FIG. 3 CONT'D

5401 AAAAAATGTCATACATTTACCAGACATCAACAATTGCCAGGTAAGAAAAAGAAAACTTGT 5460
N K L L I Y I T Q L Q * R D M K K K Q V
I K * C Y T F P R Y N N V T W K K R K F
K K V T H L H D T T T L P G N K E K S C

5461 CAGAGTATTATTAACAATACACTTACATCGAACAGAATACAACGTCGTATAATTAGAATT 5520
T E Y Y N N H S H L K D * T A A Y * D *
L R M I I T I H I Y S T K H Q L M N I K
D * L L Q * T F T A Q R I N C C I L R L

5521 TAAATTATTTACCGTCACCGTCCTTCGTACCATACTTAAAGCAGCACCCTCTGGTGTATC 5580
I * Y I A T A P L M T H I E H Q C V V Y
F K I F P L P L F C P I F K T S A S W M
N L L H C H C S A H Y S N R A P L G C L

5581 CAATCAACGAGAACAATAATCGATTTCAGTAAAATTTAAACTACTTGGTAGTCTACGATG 5640
T L Q E Q K L * L D N * I Q H V M L H *
P * N S K N * S F T M K F K I F W * I S
N T A R T K A L P * K L N S S G D S A V

5641 ACTAAAATAAGCACAAACAACTTTGTTTCGACTAAATAGTCCACGTTAAACACTTAATCT 5700
Q N * E H Q K S V L Q N I L H L K H I L
S I K N T N N Q F L S I * * T C N T F *
S K I R T T K F C A S K D P A I Q S N S

5701 TGAATAAACACTAACACCATAATTTGTTCTTTTCAGCACAACCACAACACTACGACAATACGT 5760
V * K H N H Y * V L F D H Q H Q H Q * A
F K N T I T T N F L F T T N T N I S N H
S I Q S Q P I L C S L R T P T S A T I C

5761 AAAACCATGTAATCGTTTCTGACTAGAAAAATTACCAATATTCTAACCGACATTAACACG 5820
N Q Y M L L S Q D K * H N Y S Q S Y N H
M K T C * C L S I K K I T I L N A T I T
K P V N A F V S R K L P * L I P Q L Q A

5821 TCCATCTTAACAGGTAACATGATTTAACTTACATGGTAAAACTAAACAAGATTATGAGG 5880
L Y F Q G N Y * I S H V M K S K N * Y E
C T S N D M T S F Q I Y W K Q N T R I S
P L I T W Q V L N F T G N K I Q E L V G

5881 AGACTCATTCTAAATGGACTACTACAACAACGTCGATTGTACAAATACCCACATCCACA 5940
E S Y P N V Q H H Q Q L * C T * P H L H
R Q T L I * R I I N N C S V H K H T Y T
R L L S K G S S T T A A L M N I P T P T

FIG. 3 CONT'D

5941 TCCGGTAATATGTGTAAACTTTACACCAAGTGAATGGTTGTAATACTACGAACATCACA 6000
L G N Y V N S I H N V K G V N H H K Y H
Y A M I C M Q F T T * R V L M I I S T T
P W * V C K F H P E G * W C * S A Q L T

6001 ATTTTTTATATGTCCACAATCACCAACAAATTGACTGACGAACATAGAATTTTTAAATTG 6060
* F I Y L H * H N N L Q S S T D * F N L
N F F I C T N T T T * S V A Q I K F I *
L F Y V P T L P Q K V S Q K Y R L F K V

6061 GGTCTGAAAATGTAGATACAACCTGATTAATAAAAAACCTACTACAACCTTTACCAACGAAT 6120
G S K * M * T S * N N K P H H Q F P Q K
G L S K C R H Q S I I K Q I I N F H N S
W V K V D I N V L * K K S S T S I T A *

6121 ATTGGGACTAGAAAGTGTATAATAACACTATTACCATTTCATAATATGTTTTGGATAATA 6180
Y G Q D K V I N N H Y H Y T N Y L V * *
I V R I K * L I I T I I T L I I C F R N
L G S R E C Y * Q S L P L Y * V F G I I

6181 TTTCCGAGTCAAATTTGGTAAACGATTTCAACTGCCACAAATATGATTGAAATTCATCA 6240
L P E T * V M Q * L Q R H K Y * S * T L
Y L S L K F W K S F N V T N I S V K L *
F A * N L G N A L T S P T * V L K L N T

6241 ACCTGTACTATAAACACGAGTTAACTTACTATTCAATCCAAAATTACATCTAAACGGCAA 6300
Q V H Y K H E I S H Y T L N * H L N A T
N S M I N T S L Q I I L * T K I Y I Q R
P C S I Q A * N F S L N P K L T S K G N

6301 ACAACTCATGTTTCATTGTCAGACCGGACATCGATGACCACTACAACAAAACCGTAGACT 6360
Q Q T C L L L R A Q L * Q H H Q K P M Q
K N L V F Y C D P R Y S S T I N N Q C R
T S Y L T V T Q G T A V P S T T K A D S

6361 ACTAAATATACACTTTGCAATAAAATTCCTACACTTTGAAAACCATTCGGACAATAAAC 6420
H N I H S V N N * L I H F K Q Y A Q * K
I I * I H F T I K F S T F S K T L R N N
S K Y T F R * K L P H S V K P L G T I Q

6421 CAAAACAGTACTACTTCGTAGTAACTTAAGAGAATGAATAAAATTTGGATCAAAT 6480
T K D H H L M M S N E * K N * Y V * N *
P K T M I F C * Q I R K S I K I F R T K
N Q * S S A D N F E R V * K L L G L K L

FIG. 3 CONT'D

6481 TAGACTTTTATCTATATACACAAAACAGACAACCTAAGACATAGACTCCTCAGTGTCCATT 6540
I Q F Y I Y H K T Q Q N Q I Q P T V L Y
F R F I S I T N Q R N I R Y R L L * L T
D S F L Y L T K D T S E T D S S D C P L

6541 ACACCAATGAAGACAATACCTTAGCGTCTAATCATGATTTCTCCAATTCAATTTCCACA 6600
H P * K Q * P I A S * Y * L P * T L P H
I H N S R N H F R L N T S F L N L * L T
T T V E T I S D C I L V L S T L N F P T

6601 ATCTTTCTGACAATTTTATCTTCTACGATAATAACAATTACTACTTTTATCAAGATAATT 6660
* F S Q * F L L H * * Q * H H F Y N * *
N S L S N F Y F I S N N N I I F I T R N
L F V T L I S S A I I T L S S F L E I L

6661 CCAACAATTTTCAAATAGAAATCAACTACAACCCCTATACATAAACTGTCCAACACTAAT 6720
P Q * F N I K L Q H K P Y T N S L N H N
L N N F T * R * N I N P I H I Q C T T I
T T L L K D K T S T Q S I Y K V P Q S *

6721 ACAACAAACCCAACGATTACTTAACAGTGGGATCAATTTAGTGGTTGTCAATCCCTTAT 6780
H Q K P Q * H I T V G L * I V L L * P I
I N N P N S I F Q * A * N F * W C N P F
T T Q T A L S N D R R T L D G V T L S Y

6781 ATATGCTATACCATAATTTGGATAATGATATGGATATCTAAACAATACAAATTTCTCTACT 6840
Y V I H Y * V * * * V * L N T I N L L H
I Y S I T N F R N S Y R Y I Q * T * S I
I R Y P I L G I V I G I S K N H K L S S

6841 ATTAGTTTGAGAAAATCAAGGATTTTAAAAATTCGTTCTCGATATCTTAAAATACCAAA 6900
Y D F E K L E * F K * L L L * L I K H N
I I L S K * N R F N K F C S S Y F K I T
L * V R K T G L I K L A L A I S N * P K

6901 AAACCTCACCAACAAATAAATACAAAATCAAATAATGTAAAATGTTTACTATTTTGGTA 6960
K S T T T * K H K * N I V N * L H Y F W
K Q L P Q K N I N K T * * M K C I I F G
K F H N N I * T K L K N C K V F S L V M

6961 AAAAAATATGATGTCTTTATCGAAGATTCAAATGAAAATTAACAAAACAAACCGAGAATT 7020
K K Y * L F L K * T * K * N T K N P E *
N K I S C F Y S R L K S K I Q K T Q S K
K * V V S I A E L N V K L K N Q K A R L

FIG. 3 CONT'D

7021 TTTACGAAAAGTCTGTAAATCTACCTCATATAAATATTTTCCAAAAGAACAACATCGGTG 7080
F H K E S M * I S Y I * L L N E Q Q L W
F I S K L C K S P T Y K Y F T K K N Y G
F A K * V N L H L I N I F P K R T T A V

7081 ACACAAAAACAAAACCAAATTAATAAATATTTTACAATAAAAATCACTGAAAATAGA 7140
Q T K T K T * N K T Y L H * K * H S K D
S H K Q K P K I K Q I Y I N N K T V K I
T N K N Q N L K K Y I F T I K L S K * R

7141 AGGATTATAATCACAAAAAGGATAAAAAACCCCTTCTTAACAATACACCTATTTCCGATG 7200
E * Y * H K E * K Q P F F Q * T S L P *
K R I N T N K R N K H S S N N H P Y L S
G L I L T K G I K T P L I T I H I F A V

7201 AAAACCAACCAATGTTAAACACTAAAAATAAGATTCAATCCACATCCAAAATGTTTCAGT 7260
K Q N P * L K H N K N * T L H L N * L D
S K T Q N C N T I K I R L * T Y T K C T
K P K T V I Q S K * E L N P T P K V L *

7261 AAAACATTACCATCAAAATATACACTTAACACAGTAAGACCAAACTATACAACCTATG 7320
N K Y H Y N * I H I T D N Q N Q Y T P Y
M K T I T T K Y T F Q T M R T K I H Q I
K Q L P L K I H S N H * E P K S I N S V

7321 TATACGTCGATATCTAAAACAAGTCATACTTCATCTATCTGCACAAAATAAACTAATACA 7380
M H L * L N Q E T H L L Y V H K I Q N H
C I C S Y I K N L I F Y I S T N * K I I
Y A A I S K T * Y S T S L R T K N S * T

7381 ATCAAATCAGTTTAATTAACAACTTGAGCAATAACCAATAAGTAATATGTGTACATACCAA 7440
* N L * I L Q Q V R * Q N N M I C L I T
N T * D F * N N F E N N T I * * V C Y P
L K T L N I T S S T I P * E N Y V T H N

7441 AATAGGTAATAAAACAGAATAACCAAAATGTTAATAAATGATGTACCAACGGACTAAACAA 7500
K D M I K D * Q N V I I * * M T A Q N T
K I W * K T K N T * L * K S C P Q R I Q
* G N N Q R I P K C N N V V H N G S K N

7501 ATACAATCTTTGATACGTAACCAACTAATCTAAATAACATAAACATCGATTATACAATGG 7560
* T L F * A N T S * I * Q I Q L * Y T V
K H * F S H M P Q N S K N Y K Y S I H *
I N S V I C Q N I L N I T N T A L I N G

FIG. 3 CONT'D

7561 ACGAAAACAGAACAACGCCAAAATATATCAACAATGACGATACATATTTTCATCAACCAA 7620
Q K Q R T A T K Y L Q * Q * T Y L L Q N
R S K D Q Q P K I Y N N S S H I F Y N T
A K T K N R N * I T T V A I Y L T T P K

7621 ATAATCCGTATAACAGATACCAACATTATTTGACCAACAAATAAAACAATATTTGCTTT 7680
* * A Y Q R H N Y Y L Q N N I K N Y V F
K N P M N D I T T I F S T T * K T I F S
I L C I T * P Q L L A P Q K N Q * L R F

7681 AACATCACAAGCACAATTCACATCATGATAACAACCACCACATTAAGCAATAATACTATA 7740
N Y H E H * T Y Y * Q Q H H L E N N H Y
I T T N T N L T T S N N T T Y N T I I I
Q L T R T L H L V I T P P T I R * * S I

7741 ATGACGATTACCACCATGACCAAAAACACAATTGTAGTTACCTTAACAAAATTAACGGT 7800
* Q * H H Y Q N K H * V D I S N N * N G
N S S I T T S T K T N F M L P I T K I A
V A L P P V P K Q T L C * H F Q K L Q W

7801 AAGAAAATTTGGTCCATTGTGAAAATATTGACATCTTCGACGATATCTTGAAAGATTCT 7860
N K * V L Y C K * L Q L L Q * L V K * L
M R K F W T V S K Y S Y F S S Y F K R F
E K L G P L V K I V T S A A I S S E L S

7861 CGAATTTGCTGGACATTTAGGTTGACTACGAAGTGAATACATCAATGACTATAATTCGT 7920
A * V V Q L D L Q H K V N H L * Q Y * A
L K F S R Y I W S I S * M I Y N S I N L
S L R G T F G V S A E C * T T V S I L C

7921 TCAACCAACATACTACGCAAACAAGATACTATCTCTACCTGTCGCACAAATGCTACTACA 7980
L Q N Y S A N T R H Y L H V A H K R H H
L N T T H H T Q E I I S I S L T N V I I
T P Q I I R K N * S L S P C R T * S S T

7981 ACTACGATCAAATAAACATCTATAATTATTAGACAATGTAAGATTTCATTTCAACAAGG 8040
Q H * N I Q L Y * Y D T V N * L * L Q E
N I S T * K Y I N I I Q * M R F N F N N
S A L K N T S I L L R N C E L T L T T G

8041 ATTAACATACATCAACATCATCTCTCACTACGACTATCTCGATTAAAAGACTTACGACA 8100
* N T H L Q L L S H H Q Y L * N E S H Q
R I Q I Y N Y Y L T I S I S S I K Q I S
L K Y T T T T S L S A S L A L K R F A T

FIG. 3 CONT'D

8101 ACACAAAATACGTGTTAGTAACATATCCGGATATAATGAACATCTGTTTTTCAATTAATG 8160
Q T K H V I M T Y A * I V Q L C F T L *
N H K I C L * Q I P R Y * K Y V F L * N
T N * A C D N Y L G I N S T S L F N I V

8161 ATGTCGAACATTACCATAGACATTGGGTCTGATACAAACTACAAATACAACATGAAA 8220
* L K Y H Y R Q L G S * T Q H K H Q Y K
S C S T I T D R Y G L S H K I N I N I S
V A Q L P I E T V W V I N S T * T S V K

8221 ATACAGAGTAAAACACTACAACATCTTTCTCAAATTTATAAAACAATTGTAACGAGTACG 8280
* T E N Q H Q Y F S N * Y N Q * C Q E H
K H R M K I N I S L T K I I K N V N S M
I D * K S T S L F L K L L K T L M A * A

8281 AAGAGAATCTCTCCACACGTTAATCTTTTCCAAAATCTATGAAAACACCCTACACATGC 8340
K E * L P H A I L F P K L Y K Q P I H V
S R K S L T H L * F L N * I S K H S T Y
E R L S P T C N S F T K S V K T P H T R

8341 ATTTACAACAAGGTAACACTAAGTCTACAACCTTTGTTCTAAATAATGATTTAGATACTATAG 8400
Y I N N W Q N L H Q F L I * * * I * S I
T F T T G N I * I N F C S K N S F R H Y
L H Q E M S E S T S V L N I V L D I I D

8401 ACGTCATCGACGACCAAACCTTAAATGACTACTTTTAAATATTGTTAAACCATGGATGTAT 8460
Q L L Q Q N P I * Q H F N Y C N P V * M
R C Y S S T Q F K S I F I I V I Q Y R C
A T A A P K S N V S S F * L L K T G V Y

8461 AAATTTCTCACTATTATAACATCGACGACTAAATCCACAAGAATATGTCTTACCACGATT 8520
N L S H Y Y Q L Q Q N L H E * V S H H *
I * L T I I N Y S S I * T N K Y L I T S
K F L S L I T A A S K P T R I C F P A L

8521 CGTACATGTCCCATTACAACGATTCGTCGATTATAAAGAACATATACCAAATAACTACG 8580
A H V P Y H Q * P L * Y K K Y I T * Q H
L M Y L T I N S L C S I N R T Y P K N I
C T C P L T A L A A L I E Q I H N I S A

8581 AAAATTAGTTGAATGACGACTAAATGTCGTATTTAATTTTTTTTCGTACACAATTTTGACC 8640
K * D V * Q Q N V A Y I L F L M H * F Q
S K I L K S S I * L M F * F F C T N F S
K L * S V A S K C C L N F F A H T L V P

FIG. 3 CONT'D

8641 GAACTTCAATTTTAACTGAAAATTATTCGTTCTCCGTTACAGGGATAAGAATGTTGTGG 8700
S S T L I S K * Y A L P L H G * E * L V
A Q L * F Q S K I L L L C T D R N K C C
K F N F N V K L L C S A L T G I R V V G

8701 GAAAAGTGAATTTCTCCACAACATAACTCATTAAACAATATATATAATAAAAAACAATC 8760
R K V * L L H Q I S Y N T I Y I I K Q *
G K * K F S T N Y Q T I Q * I Y * K K N
K E S L P P T T N L L K N Y I N N K T L

8761 AAATTAGACAAAATATAATAACACCCGAAATAACGGATGTATATCACAATATTCAGACT 8820
N L R N * I I T P K I A * M Y H K Y T Q
T * D T K Y * Q P S * Q R C I T N I L R
K I Q K I N N H A K N G V Y L T * L D S

8821 ATAAGTAAACGGACGAATACGATCAAAATTTCAATAACTATTACCACAACAATCTCTATA 8880
Y E N A Q K H * N * L * Q Y H H Q * L Y
I N M Q R S I S T K F N N I I T N N S I
I * K G A * A L K L T I S L P T T L S I

8881 AAGTCAATTACTAAATACAAAACGATTATTTAAAAAGGTTAAACTAGTTACCATACTCAG 8940
K L * H N I N Q * Y I K G I Q D I T H T
N * N I I * T K S I F K E L K I L P I L
E T L S K H K A L L N K W N S * H Y S D

8941 GTGAAAACCCAGACAAATGATAGTATTAAGATACCTAACGGGATAACATCACCGTCAATA 9000
W K Q T Q K S D Y N * P N G * Q L P L *
G S K P R N V I M I R H I A R N Y H C N
V K P D T * * * L E I S Q G I T T A T I

9001 CCTACTTCTATAGCCAAGATGATACAAATTACAAGGATGATTTCAAAACTCTGTACCGAA 9060
P H L Y R N * * T * H E * * L K S V H S
H I F I D T R S H K I N R S F N Q S M A
S S S I P E V I N L T G V L T K L C P K

9061 AGTACAAAATGTA AAAAATTGAATACGTAACGATCACTATCACAAGTCACGATATGTGG 9120
E H K V N K L K H M Q * H Y H E T S Y V
K M N * M K * S I C K S T I T N L A I C
* T K C K K V * A N A L S L T * H * V G

9121 TGTATAAGTCTAAAGAATATTACTAAAAATACGATCACCAACACAAAATAGTAGAAACAC 9180
V Y E S K K Y H N K H * H N H K I M K T
W M N L N R I I I K I S T T T N * * R Q
C I * I E * L S K * A L P Q T K D D K H

FIG. 3 CONT'D

9181 ATGATACAAATTTTCTCCACTACCATGTGGTGTAGGAATAACAATAAGTCTACCACAATA 9240
Y * T * F L H H Y V V D K N N N L H H *
T S H K F S T I T C W M R I T I * I T N
V I N L L P S P V G C G * Q * E S P T I

9241 CTTCTTACGAAGAACATATGTAGAAACCAAGGTGTATGTGCAATATCGGAACGATTAAG 9300
S S H K K T Y M K P E V Y V N Y G Q * N
H L I S R Q I C R Q N W M C T I A K S I
F F A E K Y V D K T G C V R * L R A L E

9301 ATTACCAAAATATTCTAAAGGACTACAATAATCACTTCCATAACATGCATAACATTCTTG 9360
* H N * L I E Q H * * H L Y Q V Y Q L F
R I T K Y S K R I N N T F T N Y T N Y S
L P K I L N G S T I L S P I T R I T L V

9361 CGCGAGATACTGAATAACATCTCACCCACGTACTTATGCGGCTTCTCCCATATACAAA 9420
A S * S K N Y L P H M H I R R L P Y I N
R A R H S I T S H T C T F V G F L T Y T
R E I V * Q L T P A H S Y A S S P I H K

9421 ATTAAAATTATCAAGGACCCAAAACCTTACTAATAATATCTTCATACGGACCTTGAAA 9480
* N * Y N R P K S Y H N N Y F Y A Q F K
K I K I T G P N Q I I I I I S T H R S S
L K L L E Q T K F L S * * L L I G P V K

9481 AACACCATCTCTAGAAAACTAAACAAAATAGTTAAAAAATCATCAAATTAAGCAGGATA 9540
K H Y L D K Q N T K D I K * Y N L E D *
K T T S I K K I Q K I L K K T T * N T R
Q P L S R K S K N * * N K L L K I R G I

9541 TCTAAAGAAAAGAGAATGACGATCAAGATAAAAACCTCGATATAACCGATATCAACAACA 9600
L N R K E * Q * N * K Q L * I P * L Q Q
Y I E K R K S S T R N K S S Y Q S Y N N
S K K E R V A L E I K P A I N A I T T T

9601 GAACCAAAAAATAATAAATTTTGAATTCGCACGAAAACCTCTAATATGATCACAACA 9660
R P K K N N L L V * A H K Q L N Y * H Q
D Q N K I I * Y F K L T S K S I I S T N
K T K * * K I F S L R A K P S * V L T T

9661 TCAATATTTACAACAACAAACCACATAATTAAGAATACGAAAAACAAAAGTTCAAAT 9720
L * L H Q Q K T Y * N E * A K Q K E L K
Y N Y I N N N P T N I K K H K K N K L N
T I F T T T Q H I L K R I S K T K * T *

FIG. 3 CONT'D

9721 AGGATAAACACGTACACAAATACGAACAAAAATAAAAATACATTGTAACATAAAAGGAAG 9780
D * K H M H K H K N K N K H L M T N E K
I R N T C T N I S T K I K I Y C Q I K R
G I Q A H T * A Q K * K * T V N Y K G E

9781 ACTTTAATCACATTAATACGTAAACGTTACCTAACAATACATACCACGATATTACGGAAA 9840
Q F * H L * A N A I S Q * T H H * L A K
R F N T Y N H M Q L P N N H I T S Y H R
S I L T I I C K C H I T I Y P A I I G K

9841 AACCAAAACACAGTGTATACATCGATACCAATAACGTTTGGTACAAAATACCAATAAAAG 9900
K T K H * M H L * P * Q L G H K I T I K
K P K T D C I Y S H N N C V M N * P * K
Q N Q T V Y T A I T I A F W T K H N N E

9901 TATAACATCCTTTTAAACCACAATTACATACATCACTATCATGTAAACTTCTTTGTAGAGA 9960
M N Y S F Q H * H I Y H Y Y M Q L F M E
* I T P F N T N I Y T T I T C K F F C R
Y Q L F I P T L T H L S L V N S S V D R

9961 ATGATGAAAATACTAATGATTTCTAAGAATAACATCTAATTTCTTAAGACAAAGACTACA 10020
* * K * S * * L N K N Y I L S N Q K Q H
K S S K H N S F I R I T S * L I R N R I
V V K I I V L S E * Q L N F F E T E S T

10021 ACGGATGTTATCTATAAACTCAAACATATTATTCATAGCAATGATATCACCATTTTACCT 10080
Q R C Y I N S N T Y Y T D N S Y H Y F P
N G V I S I Q T Q I I L I T V I T T F H
A * L L Y K L K Y L L Y R * * L P L I S

10081 ATGACGACGATATCTCTTCGCCGACACAAGAGTCAATCGATTTTCGATACCTTTGTAAATT 10140
Y Q Q R Y L L P T N E T L * L * P F M *
I S S G I S F R R T R L * S F S H F C K
V A A * L S A A H E * N A L A I S V N L

10141 AGTGTTATTACCATTACTACAGAATATGGTTGGAGGATGTCGTAGACAAAGATGTAGAAA 10200
D C Y H Y H H R I G V E * L M Q K * M K
I V I I T I I D * V L R R C C R N R C R
* L L P L S T K Y W G G V A D T E V D K

10201 AAACGTTAGTCCATAACATTTCTACCATAGAGGATGCAGTTTTTAACTTGGAACATAACA 10260
K A I L Y Q L S P I E * T L F Q V K Y Q
K Q L * T N Y L H Y R R R * F N F R T N
K C D P I T F I T D G V D F I S G Q I T

FIG. 3 CONT'D

10261 ATCACAATGAATACCATCATACTGAAACTTACCAAATACCAATCTACTGTTTCAAATAAC 10320
* H * K H Y Y S K S H N I T L H C L K N
N T N S I T T H S Q I T * P * I V F N I
L T V * P L I V K F P K H N S S L T * Q

10321 AGGAGCAGTACAATATACAAGTAGGAGATTATACTTGCTTGGACTAATAAGACGGAATAA 10380
D E D H * I N M R * Y S R V Q N N Q R I
T R T M N Y T * G R I H V F R I I R G *
G R * T I H E D E L I F S G S * E A K N

10381 CACATCTCAATGAGATCCACTAAAATGATATTACAGACCAGCCTACTCAAATGTCAACA 10440
T Y L * E L H N * * L T Q D S S N L L Q
Q T S N S * T I K S Y H R T P H T * C N
H L T V R P S K V I I D P R I L K V T T

10441 CAGAATGGTCTACGTCCCGACAGTTGAACAAAACGTGACAGAGAAATGTTTTAGGAATGTG 10500
T K G S A P S D V Q K S L R K V F D K C
H R V L H L A T L K N Q C D R * L I R V
D * W I C P Q * S T K V T E K C F G * V

10501 AGGTTTTATATGAAAACCATTACAATTTGGACCACTTTGAAAATGACAAAATCGACGCAT 10560
E L I Y K Q Y H * V Q H F K * Q K L Q T
S W F I S K T I N F R T F S K S N * S R
G F Y V K P L T L G P S V K V T K A A Y

10561 ATTACCGGCTGGTGTCCCGTAAAGTACAATGATACGCATCATCAATATGATAAATTTCC 10620
Y H G V V L P M E H * * A Y Y N Y * * L
I I A S W L P C K M N S H T T T I S N F
L P R G C P A N * T V I R L L * V I L P

10621 AAGAAAAACACACCCAGTACACCTAGACAACCAATACATAATTGTCCACTATCACAATT 10680
N K K T H T M H I Q Q N H I L L H Y H *
T R K Q T P * T S R N T I Y * C T I T N
E K K H P D H P D T P * T N V P S L T L

10681 CAAACATATATACGTAGTTAATCTCGAGTCATGACCAACAGTGTGACCGTGACTAAAATG 10740
T Q I Y A D I L A * Y Q N D C Q C Q N *
L K Y I H M L * L E T S T T V S A S I K
N T Y I C * N S S L V P Q * V P V S K V

10741 ACCATTAAAAATACCAGGTATATCTCTACGAGTTCAACATGTCAACGGTCAATTCCTGAT 10800
Q Y N K H D M Y L H E L Q V T A L * P S
S T I K I T W I S I S L N Y L Q W N L V
P L K * P G Y L S A * T T C N G T L S *

FIG. 3 CONT'D

10801 GCAGTCTGACAATTACAATAACGAACCGAGATACGTCGATATGAATTATTAACACGAAC 10860
R G S Q * H * Q K A R H L * V * Y N H K
V D L S N I N N S P E I C S Y K I I T S
T W V T L T I A Q S * A A I S L L Q A Q

10861 CAAACATGTTTTACTACAAACAAGATGACTTCTAAAATTACAAACCCGATACCGTTTACC 10920
T Q V F H H K N * Q L N * H K P * P L H
P K Y L I I N T R S F I K I N P S H C I
N T C F S T Q E V S S K L T Q A I A F P

10921 AAAATCGTTTCATTTTCGTCTAGAACAGAATCTACGAAACCGAAGTTACTGTCCACAAG 10980
N * G L L L L D Q R L H K P K L S L H K
T K A L Y F C I K D * I S Q S * H C T N
K L W T F A S R T K S A K A E I V P T E

10981 ATAACTTTGAAATAACCGACGATAATTCGCAGATATATACCCTAAAGTTCCAGCAGTTTA 11040
* Q F K I P Q * * A D I Y P I E L D D F
R N F S * Q S S N L T * I H S K L T T L
I S V K N A A I L R R Y I P N * P R * I

11041 TGATCCTTCAACATGAAAACCTTACTTAACCGTGAAGACTGCAAATAGTTGTTAACCG 11100
V L F N Y K Q L H I P V K Q R K D V I P
Y * S T T S K F I F Q C R R V N I L L Q
S P L Q V K S S S N A G E S T * * C N A

11101 ACCACAATTTAACGTTAGATTTTGTTTTCTAAAATAATTTCTTTTGTAAATAACCTAAAA 11160
Q H * I A I * F L F I * * L F L K N S K
S T N F Q L R F C F S K N F F C N I P N
P T L N C D L V F L N I L S V I * Q I K

11161 CTATAGATGTA AAAACAATCAACATATTAAGACGTAACAATTTACCTGATATAAATA 11220
S I * M K T * N Y L K Q M Q * I S * I *
Q Y R C K Q K T T Y N R C K N F P S Y K
I D V N K N L Q I I E A N T L H V I N I

11221 CATATAATTATGTGTATACTAACCACAATGTAATACACATGAAACAAAACATCAAATA 11280
T Y * Y V Y S Q H * M I H V K N Q * N *
H I N I C M H N T N C * T Y K T K N T K
Y I L V C I I P T V N H T S Q K T L K I

11281 CTACAATGATCAATTTGTATTTCGTA AAAATAAACTGATACATATATTAAGGACATGAGAC 11340
S T V L * V Y A N K N S * T Y L E Q V R
H H * * N F M L M K I Q S H I Y N R Y E
I N S T L C L C K * K V I Y I I G T S Q

FIG. 3 CONT'D

11341 ATGGAACAAAATACATTTAATAAATCAACAAATATTCCTTCCAAAATCTCCAAAATGAAT 11400
Y R T K H L N N L Q K Y P L N * L N * K
T G Q K I Y I I * N N I L F T K S T K S
V K N * T F * K T T * L S P K L P K V *

11401 ACAGACCGAGAGTATAAAAACAAGGACGACACTTAAAATGAATACAAATACTTCATAAAAT 11460
H R A R M N Q E Q Q S N * K H K H L I K
I D P E * I K N R S H I K S I N I F Y K
T Q S E Y K T G A T F K V * T * S T N *

11461 ACCAACATAAAAATACACAAAACGATAAAAATATTGATACGTATCATAATTAGTACTGTA 11520
H N Y K I H K Q * K * L * A Y Y * D H C
I T T N * T N K S N K Y S H M T N I M V
P Q I K H T K A I K I V I C L I L * S M

11521 AAAAAGAAACTACAAAAACCAACCATCTTATCAATGAAATTAAGATACACCATAAAACC 11580
K K K S T K P Q Y F L * K L K * T T N Q
N K R Q H K Q N T S Y N S * N R H P I K
K E K I N K T P L I T V K I E I H Y K P

11581 CAGCTTAAATCTTCTCTACAAAACAATAAATAATGTCCGAAAATCCATGAATATGTAC 11640
T S N L L P H K T I * * L R K L Y K Y M
P R I * F L I N Q * K N C G K * T S I C
D F K S S S T K N N I V A K K P V * V H

11641 CTGGTGATAAAACAGTAATCGATATCGTTTTTAAACAACGATTAACCAACAGACAATTATA 11700
S W * K T M L * L L F Q Q * N T T Q * Y
P G S N Q * * S Y C F N N S I P Q R N I
V V I K D N A I A F I T A L Q N D T L I

11701 TAAAATAAAATGTCTACATGGAATATAATTTAACTAAGAGAACTCAATGAATAAATATCC 11760
I K N * L H V K Y * I S E R S N S I * L
Y K I K C I Y R I N F Q N E Q T V * K Y
N * K V S T G * I L N I R K L * K N I P

11761 CATATAAAATAGAACAATAACCCCTAAAAGAGAGAAAATTTGTCACAAAATCTTACGG 11820
T Y K I K N N P I K R E K L C H K * F A
P I N * R T I P S K E R K * V T N K S H
Y I K D Q * Q P N K E R K F L T K L I G

11821 ATACCACAAATATTAATATTTTAAAGACAAGTTCTTAACGCAATATACTTACGATTACC 11880
* P H K Y N Y F K Q E L I A N Y S H * H
R H T N I I I F N R N L F Q T I H I S I
I P T * L * L I E T * S N R * I F A L P

FIG. 3 CONT'D

11881 GAATGCAGGTGGAGCATTATCAAAACTCCGATAAAAACAATTTAAATTTTGACGAACCTTA 11940
S V D V E Y Y N Q P * K T L N L V A Q F
A * T W R T I T K L S N Q * I * F Q K S
K R G G R L L K S A I K N F K F S S P I

11941 TCCACCGCACGGTCAATAACTTCAGAGGGTTTAAGTTAGTTTAACTGACTACACTTTAC 12000
L H R A L * Q L R G F E I L I S Q H S I
Y T A H W N N F D G L N L * F Q S I H F
P P T G T I S T E W I * D F N V S T F H

12001 ACGATTACAACAAAACAATTTAACAAATGTCGTAAACGTACAACGAAGATTAAGATTCAA 12060
H * H Q K T L N N V A N A H Q K * N * T
T S I N N Q * I T * L M Q M N S R I R L
A L T T K N F Q K C C K C T A E L E L N

12061 CACCGTCATAACATCACAAAATGTATTACTTTATGATAGATGAAGTCTAAACTCACATCG 12120
T A T N Y H K V Y H F V I * K L N S H L
Q P L I T T N * M I F Y * R S * I Q T Y
H C Y Q L T K C L S I S D V E S K L T A

12121 AAAACTATTCGAACGAGTTAATAACTAACAATAAGCGGTTAGGACGACGTCAACTATG 12180
K Q Y A Q E I I S Q K I R W D Q Q L Q Y
S K I L K S L * Q N N * E G I R S C N I
K S L S A * N N I T K N A L G A A T S V

12181 ATTCACAGAACGTTTCATATCTACTTCAATCGCTACTAATAACAAGTTCTATCATGGCAAAA 12240
* T D Q L Y L H L * R H N H E L Y Y R K
S L T K C T Y I F N A I I I N L I T G N
L H R A L I S S T L S S * T * S L V T K

12241 CGTCCGAAACGTTTCACTCAAACATTTATACCGATCAAAACAACCTATACTTCAGCGTTT 12300
A P K A F H T Q L Y P * N Q Q I H L R L
Q L S Q L T L K Y I H S T K N F I F D C
C A K C L S N T F I A L K T S Y S T A F

12301 CTTTTTAAACCGACTACGATTTTATCACCAAGACAATTAGTTGTTGTCTATTTTGTCAA 12360
S F N P Q H * F Y H N Q * D V V S L V T
L F I Q S I S F I T T R N I L L L Y F L
F F K A S A L F L P E T L * C C I F C N

12361 TCTTTTTCGTACATTATATCGATTTCAGACACATACTTGCCTATTTTCGACATCGAGCGTT 12420
L F L M Y Y L * T Q T H V H Y L Q L E C
* F F C T I Y S L R H I F T I F S Y S A
S F A H L I A L D T Y S R S L A T A R L

FIG. 3 CONT'D

12421 TGAACCTGCATACCGTCTGGATCGTGAATGATTGTACATATTCTCCGAGCCTAATTACT 12480
V Q V Y P L G L V * * C T Y L P E S * H
F K F T H C V * C K S V H I F L S P N I
S S R I A S R A S V L M Y L S A R I L S

12481 ATTCTTCTCATTTCACAAAGGCGAAACGTCTGTTACGAAAAATCGTACCAAGCATTAA 12540
Y S S Y L Q K R K A S L A K * C P E Y I
I L L T F N N G S Q L C H K K A H N T F
L F L L T T E A K C V I S K L M T R L N

12541 CCTATTAGTCCGAAATTTAAGATAAGACCTATTACGACAATTTCCAACACATGGAAACTC 12600
P Y D P K L N * E P Y H Q * L N H V K S
Q I I L S * I R N Q I I S N F T T Y R Q
S L * A K F E I R S L A T L P Q T G K L

12601 ACGATAAGGTCGTAACCGACGATTATGAAATGATATCATTATGGTCTATTTGTTCAAAA 12660
H * E L M P Q * Y K L * L L V L Y V L K
T S N W C Q S S I S * S Y Y Y W I F L N
A I G A N A A L V K V I T I G S L C T K

12661 ACTATTTCAACAACCTATTACAAATACAATGTATACGACCATCACATACCGTATATGTCTG 12720
Q Y L Q Q Y H K H * M H Q Y H I A Y V S
K I F N N I I N I N C I S T T Y P M Y L
S L T T S L T * T V Y A P L T H C I C V

12721 ACAAGTCTACGACTACCATAATTATTGTCAATTGACTATAATCACAACCTAAGATTAAC 12780
Q E L H Q H Y * Y V T L Q Y * H Q N * N
S N L I S I T N I F L * S I N T N I R I
T * S A S P I L L C N V S I L T S E L Q

12781 CGGAGAACAATAGTAACGCTTGCCATATTACTTCAACGATTACGACAATACGTCTTATT 12840
A E Q * * Q S C T Y H L Q * H Q * A S Y
P R K N D N R V P I I F N S I S N H L I
G R T I M A F L Y L S T A L A T I C F L

12841 ACTCAACTACGGAGTATTTAATTTTATGTTCAACAATTATCACCAAGACTATACTTAAC 12900
H T S A E Y I L F V L Q * Y H N Q Y S N
I L Q H R M F * F Y L N N I T T R I H I
S N I G * L N F I C T T L L P E S I F Q

12901 ATTATAAGGATGAGTTACAATAATATTATTACCATCATCACCATCTTATCAAAATACGACA 12960
Y Y E * E I N N Y Y H Y Y H Y F L K H Q
T I N R S L T I I I I T T T T S Y N I S
L I G V * H * * L L P L L P L I T * A T

FIG. 3 CONT'D

12961 AGAATCACTACAACACTACCAGAATTCATATGATTCTATTACTTTCTACTACCTTTAACACA 13020
E * H H Q H D * T Y * S L S L H H F N H
N K T I N I T K L I S L Y H F I I S I T
R L S T S P R L Y V L I I F S S P F Q T

13021 ACAAAATCTCGAACTAGGAGGAACATTTAAAAGATATGTTCTACAATCCCTGAATTTTA 13080
Q K L A Q D E K Y I K * V L H * P V * F
N N * L K I R R T F K R Y L I N L S K F
T K S S S G G Q L N E I C S T L P S L I

13081 ATTCATAGAAATAAAATAATTTCTACATTGTGAAATCGATCTCCCACCCAACAACCATG 13140
* T D K N * * L I Y C K L * L T P Q Q Y
N L I K I K N F S T V S * S S P P N N T
L Y R * K I L P H L V K A L P H T T P V

13141 AAATAGAAGTTGTTAATCTAACGTCGGACCACAACGATGACTCATACTCGATTAAGAAG 13200
K I K L L * I A P Q H Q * Q T H L * N K
S * R * C N S Q L S T N S S L I C S I R
K D E V I L N C A P T A V S Y A A L E E

13201 ATATGAAAGTAATACACGTAAGACATCTAGGATTCTTTGAATAAAATCTAATATATGT 13260
* V K M I H M K Q L D * S F K N L N Y V
R Y K * * T C K R Y I R L F S I * I I Y
I S E N H A N E T S G L F V * K S * I C

13261 TGTTCCACCACATGGATATTAATTAACACAATTTTACGAGACACTAGTACGACCATGACC 13320
V L H H V * L * N H * F A R H D H Q Y Q
L L T T Y R Y N I T N F H E T I M S T S
C P P T G I I L Q T L I S Q S * A P V P

13321 ATACCGGTAATGATAATTTGGACTCCGATGATAATGGTTCTAAGAATACCACCACGGAG 13380
Y P W * * * V Q P * * * G L N K H H H R
T H G N S N F R L S S N V L I R I T T G
I A M V I L G S A V I L W S E * P P A E

13381 TCAAACATAAATAACGGCACGTGCACATCTCGTAGGTCTACATCTACCATATACATTTAA 13440
L K Y K N G H V H L A D L H L H Y I Y I
* N T N I A T C T Y L M W I Y I T Y T F
T Q I * Q R A R T S C G S T S P I H L N

13441 TGCACCATTTAAACATGTTTCAGGAAACCCATATTTTCTAGGATAAGAAATACACAATTG 13500
V H Y I Q V L G K P Y L L D * E K H T L
* T T F K Y L D R Q T Y F I R N K I H *
R P L N T C T G K P I F S G I R * T N V

FIG. 3 CONT'D

13501 TGTACTACAAACAGTTTCAGACACCAAAAAACCTCTCTACC GTCAACAAGGACACATCCAAG 13560
V H H K D L R H N K S L H C N N R H L N
C M I N T L D T T K P S I A T T G T Y T
C S T Q * T Q P K Q L S P L Q E Q T P E

13561 TTCACAGCGACAAGTTAGATTTCTAAATTTAAAAAATTTGCCCAAGCCCATGATCACAC 13620
L H R Q E I * L N L N K L R T R P V L T
* T D S N L R F I * I K * V P E P Y * H
L T A T * D L S K F K K F P N P T S T H

13621 TTACGGGCCGATCATGGGACACGATCACCAAATAGATGACTACAAGTTAATCCCGTAAA 13680
F A R S T G Q A L P K D V S T * N L A N
S H G A L V R H * H N I * Q H E I L P M
I G P * Y G T S T T * R S I N L * P C K

13681 CTGTAAACATTATGGTTATCTCGACCATATCCAAATATAATATTTCACTTAACAACGGCA 13740
S M Q L V L L A P I P K Y * L T F Q Q R
Q C K Y Y W Y L Q Y L N I N Y L S N N G
V N T I G I S S T Y T * I I F H I T A T

13741 AAAGTCGCATATCTACTGCTGCCATTATTTAACCTATTCAAGAAACAACAGTTTCTTGA 13800
K * R I S S S P L L N S L N K T T L L V
N E A Y L H R R Y Y I P Y T R Q Q * F F
K L T Y I V V T I F Q I L E K N D F S S

13801 TTAATCTTCAAATATTATTTCTCTTTTGAATAATACTCAACTGATTTTCAACACCACAA 13860
L K S T * L L S F V * * S N V L L Q P T
* N L L K Y Y L S F K N H T S * F N H H
I * F N I I F L F S I I L Q S F T T T N

13861 CACCGACTTGTACTAAAGAAATGTAACACTATACTACCATCAGCGCACGGTGTATATCAA 13920
T A S C S K K V N S I S P L R T G C I T
Q P Q V H N R * M Q Y Q H Y D R A V Y L
H S F M I E K C K I N I T T A H W M Y N

13921 GCATCCTTAGAAAGTTTCATATGATACAATCTAGAAACGATACGTAACGCAGTAAACTA 13980
R L F R E F Y V I N S R Q * A N R * K S
E Y S D K L T Y * T L D K S H M A D N Q
T P I K * L I S H * I K A I C Q T M K I

13981 GCATTACTAACAAGTTATAACACACTTTAAGAAACACTCATACTAGACTAACATTTCTTAGG 14040
R L S Q E I N H S I R Q S Y A S Q L S D
D Y H N N L I T H F E K H T H Q N Y L I
T I I T * Y Q T F N K T L I S I T F F G

FIG. 3 CONT'D

14041 ATGAAAAGATTCTTTCTAACCATACTAAAACAACCTTTTAGGACTATAATAATTATATATA 14100
* K E L F S Q Y S K T S F G S I I L I Y
R S K * S L N T H N Q Q F D Q Y * * Y I
V K R L F I P I I K N F I R I N N I Y I

14101 TTTTITAATCCGGGATAAAAATTATCTCGAAATGAATTATGACAGTAAAAACGTCTGTGG 14160
L F N P G I K L L A K S L V T M K A S V
Y F I L G * K * Y L K V * Y Q * K Q L C
F F * A R N K I S S * K I S D N K C V G

14161 AATCAACTTCATCCAAATCAACCACAAAATTGAAATCTATTGGTTCTAAACATACCAGTT 14220
K T S T P K T P T K V K S L W S K Y P *
R L Q L L N L Q H K L K L Y G L N T H D
* N F Y T * N T N * S * I V L I Q I T L

14221 ACCATACTAAAACCACTAAAATATGTTTGTGCGGGTCCCAAACCACACCGTCAACGTCTA 14280
H Y S K P S K I C V A G P N P T A T A S
I T H N Q H N * V F L G L T Q H P L Q L
P I I K T I K Y L C G W P K T H C N C I

14281 AGAATGATAAGAATATACTACGGATACAACCTGATACACAGTACATAATCTAACACTTAAT 14340
E * * E * I I G I N V I H * T N S Q S N
N K S N K Y S A * T S * T D H I L N H I
R V I R I H H R H Q S H T M Y * I T F *

14341 AAACAATTACTATCAATATCTGTTAAGCTAGAACATGTCATACTAAAATGACTAATGTTC 14400
N T L S L * L C N S R T C Y S K V S * L
I Q * H Y N Y V I R D Q V T H N * Q N C
K N I I T I S L E I K Y L I I K S I V L

14401 AATCTCAACAAATTATTCATAAAATTCATAACCCCATACTTCATAGTAGGATTATGACAC 14460
N S N N L L Y K L Y Q P I F Y * G L V T
T L T T * Y T N * T N P Y S T D D * Y Q
* L Q K I L I K L I P T H L I M R I S H

14461 CTAACACTATTACTATCCACATAATAAGTAACACGATTAATAATTATATGATAAATCATAC 14520
S Q S L S L H I I * Q A L K L I S N L I
P N H Y H Y T Y * E N H * N * Y V I * Y
I T I I I P T N N M T S I K I Y * K T H

14521 CAAAATGGATTATGAACAAAACCAGGGGAACAATCTGTTTAAAAACATCTACCACATGGC 14580
T K G L V Q K P G R T L C I K T S P T G
P K V * Y K N Q D G Q * V F K Q L H H V
N * R I S T K T G K N S L N K Y I T Y R

FIG. 3 CONT'D

14581 AAACAACAAAGATAACCAATGGTAATGTTTCTCAATCCACATCAATACTTGAATCTACAA 14640
N T T E I P * W * L S N P T T I F K S T
T Q Q K * Q N G N C L T L H L * S S L H
K N N R N T V M V F L * T Y N H V * I N

14641 CTGTGTGGCAATAGCAACAGAGAATTTCTAAATGAAGAAATACGTCGTCTAGGACGA 14700
S V C R * R K D R L S K S R * A A S G A
Q C V G N D N T E * L N V E K H L L D Q
V C V T I T Q R K F I * K K I C C I R S

14701 TACGTGCAACGTAGACGATCACGAGACGAACTAAATGCTTGAACAACAAAATCACATCGA 14760
I C T A D A L A R S S K R V Q Q K L T A
* A R Q M Q * H E A Q N V F K N N * H L
H V N C R S T S Q K I * S S T T K T Y S

14761 CGGTAATGTTACCCATATTTTAAAGTTTGACATTTTGGTCCATGAAAATTGGTTCTGAAA 14820
A M V L P I F N * V T F G P L K L W S K
Q W * L H Y L I E F Q L V L Y S * G L S
G N C T T Y F K L S Y F W T V K V L V K

14821 ATGCTCAAACAATTTTCATTTCCGAACAAATTTCTCCCATCATGTCAACTAAACTTTGTA 14880
* S N T L L L P K N L S P L V T S K F C
K R T Q * F Y L S T * L P Y Y L Q N S V
V L K N F T F A Q K F L T T C N I Q F M

14881 AAAAAGAAATGAGTTCTACCATTACGACGTTAATGACTAATATTAATAATATTCATATTA 14940
K K K V * S P L A A I V S * L * * L Y L
N K R * E L H Y H Q L * Q N Y N N Y T Y
K E K S L I T I S C N S I I I I I L I I

14941 AATGGATGATACCAACTATAATTCGTCAATAACAAACATAATCTTCAACAAATATTTATA 15000
K G V I T S I L C N N N T N S T T * L Y
N V * * P Q Y * A T I T Q I L L Q K Y I
* R S H N I N L L * Q K Y * F N N I F I

15001 AAACTTAAATACTACCACCAACATATGGTCGTAGTGTCAATAACAATTATTAATACTA 15060
K S I * S P P Q I G A D C T I T L L * S
N Q F K H H H N Y V L M V L * Q * Y N H
K F N I I T T T Y W C * L N N N I I I I

15061 TTTTCAGACCAATAGGTAAATTTATTAACCATTTCCGGTCTGAAATAATACTCCGTAAT 15120
L L A P * G N L L N P L A L S * * S A N
Y F H Q N D M * Y I Q Y L W V K N H P M
F T S T I W K I F K T F G S K I I L C *

FIG. 3 CONT'D

15121 AGTAAACTCCTTGTCTTACTTTTAAATACGTATATGATTTGCATTACAAGACGGGTGGAAT 15180
D N S S C F S I * A Y V L R L T R G V K
I M Q P V S H F K H M Y * V Y H E A W R
* K L F L I F N I C I S F T I N Q G G *

15181 TGAGTTTACTTAAATTTTATACGATAGTCACGATTCTTATCTCGAGCGTGACATCGTCCA 15240
V * I F K F Y A I L A L F L A R V T A P
L E F S N L I H * * H * S Y L E C Q L L
S L H I * F I S D T S L I S S A S Y C T

15241 CAAAGATAAGAATCATGATACTGTCCGGCTTACAAGGTAGTTTTTACAAACTTCTCATAT 15300
T E I R L V I V P R I N W * F H K F L I
H K * E * Y * S L G P T G D F I N S S Y
N R N K T S H C A S H E M L F T Q L T Y

15301 CGTCGATGGGCTCCACAAGGACAACAATATCCTTGGTGATTTAAAATACCACCAACCCTG 15360
A A V R P T G T T I P V V L N * P P Q S
L L * G L H E Q Q * L F W * I K H H N P
C S G S T N R N N Y S G S F K I T T P V

15361 CTATACAATGCAGTAGAATATTTCTACAACCTGTTGGGACAAGAATACCCAACCCTAATA 15420
S I N R * R I F S T S L G T R I P Q S *
R Y T V D D * L P H Q C G Q E * P N P N
I H * T M K Y L I N V V R N K H T P I I

15421 GGATTTTACTAGCAGGATACGGTTTATAAAAACGCATAACAATCATCAAATCAAACCGG 15480
G L H S R A I G F I K R I T L L K T K A
D * I H D H * A L Y K A Y Q * Y N L K P
R F T I T S H W I N Q T N N T T * N Q G

15481 GCGTTTGTACTTAAAACAACAAGTGTACCACTATCTAAAATAGCGGAACGCTTACTTACA 15540
R L C S N Q Q E C P S L N * R R A F S H
G C V H I K N N V H H Y I K D G Q S H I
A F M F K T T * M T I S K I A K R I F T

15541 CGAGTTCAAACCTCACTTTATCAATACACACCGCCAACGATAATACAATTCGGACCACCA 15600
A * T K L S I T I H P P Q * * T L G P P
H E L K S H F L * T H R N S N H * A Q H
S L N Q T F Y N H T A T A I I N L R T T

15601 TGATCGTCACCACTACGTTGATGACGAAAACGATTAAGACAAAATTATATACAGTCCGA 15660
V L L P S A V V A K A L E T K L I H * A
Y * C H H H L * Q K Q * N Q K * Y I D P
S A T T I C S S S K S I R N K I Y T L S

FIG. 3 CONT'D

15661 CAATGACGATTACAAACAAGAGAATACCGGACATTACCGGTATTCTAACTTCTAAATTC 15720
T V A L T Q E R I A Q L P W L I S S K L
Q * Q * H K N E * P R Y H G Y S Q L N L
N S S I N T R K H G T I A M L N F I * T

15721 TATGCGTTAAATGTTTTTGC GAATATGAGATTACAAATAGCATGTCTAATACA ACTAATA 15780
I R L K C F R K Y E L T * R V S * T S *
Y V C N V F V S I S * H K D Y L N H Q N
Y A I * L F A * V R I N I T C I I N I I

15781 TGTAACAATTACTCATAACTTAAAAATACATTTCGTAAAATCATACTACTAAA CTCA 15840
V N T L S Y * S N K H L C K L I I I K L
Y M Q * H T N H I K I Y A N * Y S S K S
C K N I L I I F K * T L M K T H H N Q T

15841 CTACTACCACAACAGACAATATTGAGACTAATACGATCATCCCAATATATCGATTATAT 15900
S S P T T Q * L E S * A L L P * I A L I
H H H H Q R N Y S Q N H * Y P N Y L * Y
I I T N D T I V R I I S T L T I Y S I Y

15901 TCACAAAAAGTTGTTCAAACATGATAGTCTTATTACAGAAAATACAGACTTAGATT TACA 15960
L T K * C T K Y * * F L T K I D S D L H
L H K E V L K T S D S Y H R * T Q I * I
T N K L L N Q V I L I I D K H R F R F T

15961 ACCCAACTTTTACTATAATGATTACCAGGAGTACTTAAAACAAGGGTTGTATGATACAAT 16020
Q T S F S I V L P G * S N Q E W C V I N
N P Q F H Y * * H D E H I K N G V Y * T
P N F I I N S I T R M F K T G L M S H *

16021 CAATTCTATCTACCACTAATACAAATAAATGGTATAGGTCTAGGAAGATCTTAAATCCT 16080
T L I S P S * T * K G Y G S G E L I K P
L * S L H H N H K N V M D L D K * F K L
N L Y I T I I N I * W I W I R R S N * S

16081 CGACCAACAAAACA ACTACTAAATAACTTCTGACTGTCACAAGAAA ACTATCTCGCGAAA 16140
A P Q K T S S K N F V S L T R K I S R K
L Q N N Q Q H N I S S Q C H E K S L A S
S T T K N I I * Q L S V T N K Q Y L A K

16141 CATTGAGATCGATATCTACGAATGGGAAATCATGTAGTACTTTTACTTCTTATGGTTTTT 16200
T L R A I S A * G K T C * S F S S Y W F
Q L D L * L H K G K L V D H F H L I G F
Y T * S Y I S V R * Y M M F I F F V L F

FIG. 3 CONT'D

16201 CAGAAAGCACATATAAATCTTATATATTTTTTTGACATATTACTAGAACCATGAGTCTAG 16260
T K R T Y K S Y I F F S Y L S R P V * I
L R E H I N L I Y L F V T Y H D Q Y E S
D K T Y I * F I Y F F Q I I I K T S L D

16261 AATCTATCAATATCACAATAAAATTCATGAACACTACCAAATTTCAAATGACTTCTTAGT 16320
K S L * L T I K L V Q S P K F N V S S D
R L Y N Y H * K L Y K H H N L T * Q L I
* I T I T N N * T S T I T * L K S F F *

16321 AAAATGTTCTTATACATAAAATTTTTTCACGGCACTACGTCTCACATCCACGTACGCAACAA 16380
N * L F I Y K F L A T I C L T P A H T T
M K C S Y T N L F H R S A S H L H M R Q
K V L I H I * F T G H H L T Y T C A N N

16381 ACAAGTAGTGTTTGAAGAAACGCAACACCGTCAACATATGCATTCCGAAACAATACAACA 16440
Q E D C V E K R Q P L Q I R L G K N H Q
K N M V F K K A N H C N Y V Y A K T I N
T * * L S R Q T T A T T Y T L R Q * T T

16441 TTTACAACAATACTGGTACAATACCGTTGATTAGTATTTATACAAAACCTCACAGAGTGGA 16500
L H Q * S W T I A V L * L Y T K L T E G
Y I N N H G H * P L * D Y I H K S H R V
F T T I V M N H C S I M F I N Q T D * R

16501 ATGCAAAACATTACGTGGATTGACACTACACTCACTACAGTGGTTTAATATAAACCCGCCA 16560
* T Q L A G L Q S T L S T V L N Y K P P
K R K Y H V * S H H S H H * W I I N P R
V N T I C R V T I H T I D G F * I Q A T

16561 TACAGAATGATAACACTTTTGGTATTTGGGGTAATAAGTAAATTCATCAACTACTTACCA 16620
I D * * Q S F W L G W * E N L N T I F P
Y T K S N H F G Y V G N N M * T L * S H
H R V I T F V M F G M I * K L * N H I T

16621 TACCAGAAACCAACATATTTGTTAGAACGTGCCCAAGTGAATATATCTACTAAAATTA 16680
I T K P K Y L C D Q V P E G * I S S K L
Y P R Q N T Y V I K C P N V K Y L H N *
H D K T Q I F L R A R T * R I Y I I K I

16681 TTCTATCGATCAACATTTACCTGTCTTCACTACTAATACAAGACCGTTTACTCACATAA 16740
L I A L Q L H V S T S S * T R A F S H I
Y S L * N Y I S L L Q H N H E P L H T Y
L Y S T T F P C F N I I I N Q C I L T N

FIG. 3 CONT'D

16741 CTTGCAAATTTCAATAAACGACGTCTTTGAGTTTTCCGTTGACTTCTCCGAAAATTTGTT 16800
S R K F N N A A S V * F A V S S A K L C
Q V N L T I Q Q L F E F P L Q L P K * V
F T * L * K S C F S L L C S F L S K F L

16801 TCGATACGAAGACGATGGTAAGTTCTCTAACAACTACTATCTCTTCAATAAACACAACC 16860
L * A E A V M * S I T L S L S T I K H Q
F S H K Q * W E L S Q * H Y L L * K T N
A I S R S G N L L N N T I S F N N Q T P

16861 CTCTGTCCATTCAATTTGGTGGTGAATTATTTTTAATACAAAAGTGCCGATGGTAAAA 16920
S V P L T L G G S L L F * T K V P * W K
P S L Y L * V V V * Y F N H K * L S G N
L C T F N F W W K I F I I N E C A V M K

16921 TGATCATGACCATTCTGTCAAAATCCACTCATACAAAAATTTTTCACTTAATTGATTG 16980
V L V P L V T K P S Y T K S L L S N V L
* * Y Q Y S L K L H T H K Q Y F H I L *
S T S T L C N * T L I N K I F T F * S V

16981 CCACACATAATGGCGCGATGTTGATGAATATTTGAAAGATATCCACTACAAAACAAAAT 17040
P T Y * R A V V V * L S E I P S T K T K
R H T N G R * L * K Y V K * L H H K Q K
T H I V A S C S S I F K R Y T I N K N *

17041 TGTAGTGTAAAGACATCGATCAAATTCACGTGGATGTGAACAGGGTGTCTCTTGATACGA 17100
V D C E T A L K L A G V S T G C S F * A
L M V N Q L * N L H V * V Q G V L S S H
C * M R Y S T * T C R C K D W L L V I S

17101 TCATATTCTAAAAGATCACAAATATCACAAGGTAACCACAAAGTTTTATTACAACGATTA 17160
L I L N E L T * L T G N T N * F L T A L
* Y L I K * H K Y H E M P T E F Y H Q *
T Y S K R T N I T N W Q H K L I I N S I

17161 ATAGTCGTGTAACCTTACTTTGCAATAACGTGACAAGTTCAGGGGACCATGCCCTTTC 17220
* * C M P I F R * Q V T * P G G P V P F
N D A C Q F S V N N C Q E L D G Q Y P F
I L V N S H F T I A S N L T G R T R S L

17221 AGAGTAGAACGATATCCAGATCGACAAAATAATGATGTGTCGTGCACATCAAATATGACGA 17280
D * R A I P R A T * * * V A R T T * V A
T E D Q * L D L Q K N S C L V H L K Y Q
R M K S Y T * S N I V V C C T Y N I S S

FIG. 3 CONT'D

17281 CGATCAGTACGACGACATCTACGTAACACACTTTTTCGAATATTCAAAAAATTATAATTG 17340
A L * A A T S A N H S F A * L N K F I L
Q * D H Q Q L H M T H F L K Y T K L Y *
S T M S S Y I C Q T F F S I L K * I N V

17341 CTAACATGTGCATAATAAGGACGATTTCAAGCACATCTAACAATACTATTCAAATTTTAA 17400
S Q V R I I G A L T R T S Q * S L N L I
R N Y V Y * E Q * L E H L N N H Y T * F
I T C T N N R S F N T Y I T I I L K F N

17401 TTACTATGGTGAACATTATACAAAAATGGTGTATTATTACGTAATGGTCTCAACCAATGT 17460
L S V V Q L Y T K V V I F A N G S N T V
* H Y W K Y T H K * W L L H M V L T P *
I I G S T L I N K G C Y I C * W L Q N C

17461 CTATAACAACAACAACACTACTTCAATCATAACGAATGATTAATACTTAACAGACAATATTA 17520
S I T T T S S T L I S V L * S N D T I F
L Y Q Q Q Q H L * Y A * * N H I T Q * L
I N N N N I F N T H K S I I F Q R N Y I

17521 CGAGCATAATTTTCGATTTGTAATACATATATAACCTCTAGGACGAGTTAATGGACGTGGT 17580
A R I L A L C * T Y I P S G A * N G A G
H E Y * L * V N H I Y Q L D Q E I V Q V
S T N F S F M I Y I N S I R S L * R C W

17581 GCACACGACAACCTCGTTCCCAAGAAATCTTGGATCCGTGAAGTTAAGATAATGATTTTAT 17640
R T S N L L P E K S G L C K L E I V L I
V H A T S C P N K L V * A S * N * * * F
T H Q Q A L T R * F R P V E I R N S F Y

17641 TACACAACAAATCCAGGACTATAGAAAAACCCTTTAACAATATCCACAGGATTTCTTTAA 17700
I H Q K P G S I K K P F Q * L H G L S I
L T N N L D Q Y R K P F N N Y T D * L F
H T T * T R I D K Q S I T I P T R F F N

17701 CATCTTTGACAAAGTCGTAACCAATACTATTATTGAGTTCGGATTTTACTATTATCA 17760
T S V T E A N T * S L L S L A L F S L L
Q L F Q K L M P K H Y Y V * P * F H Y Y
Y F S N * C Q N I I I F E L S F I I I T

17761 AGTAATACAAAATTTATATAAAAATCCCTGTCTGTGTGTACTCTCAAGTTCACGACAT 17820
E N H K L T Y K L P C V V C S L E L A T
N M I N * L I N * P V S L V H S N L H Q
* * T K F Y I K L S L C C M L T * T S Y

FIG. 3 CONT'D

17821 TTATAAGTTGTCTATATAGATTAATCATTAAAAATTTTCGATTAGGTCAAACCTTATCA 17880
F I * C I Y R I L L N K F A L G T Q F L
L Y E V S I D L * Y I K L L * D L K S Y
I N L L Y I * N T F K * F S I W N P I T

17881 CGACAAAAATAATCAGGAATATTATCAGTCTTAATACAACGATTTCGCACAAAATCCACAA 17940
A T K I L G * L L * F * T A L R T K P T
H Q K * * D K Y Y D S N H Q * A H K L H
S N K N T R I I T L I I N S L T N * T N

17941 GTTTGTGTTTGACATCTAAGACGAGTTCCAAGCCTTATACTAATACAATATATAAGTGT 18000
* V C V T S E A * P E S Y S * T I Y E C
E F V F Q L N Q E L N P I H N H * I N V
L C L S Y I R S L T R F I I I N Y I * L

18001 TGTCGCTTTGTTCGGTAAGACAATTACAATTAGCTAAATTACAACGGTATTGATCTCGG 18060
V A S V A W E T L T L R N L T A M V L A
F L L F L G N Q * H * D I * H Q W L * L
C C F C G M R N I N I S K I N G Y S S G

18061 TTCTTCCCGTAAAAAACACAATACTCATTATACGTTAATAAACTTAGAGAATTAATAA 18120
L F P M K Q T I L L I C N N S D R L K I
W S P C K K H * S Y Y A I I Q I E * N *
L L A N K T N H T I H L * K F R K I K N

18121 TGAGATGGAATCTATTTTAAGTTTTAGTTTTGAAATGGAGCAAACGTAACGTGTTGATTA 18180
V R G K S L I * F * V K G R K C Q V V L
* E V K L Y F E F D F K V E N A N C L *
S * R * I F N L I L S * R T Q M A C S I

18181 GAAAAATTTCTAACATCATTTTCAACGAATCCAATAGTAGGTTCGCGTACGGGGAGTAAA 18240
R K L S Q L L L Q K P * * G A C A G E N
D K * L N Y Y F N S L N D D L A H G R M
K K F I T T F T A * T I M W R M G G * K

18241 AATCGTCAACTACTATTTATATTCCAATTACTTTTAAACCGACATTTAAATTTATAACA 18300
K A T S S L Y L T L S F K A T F K F I Q
K L L Q H Y I Y P * H F N P Q L N L Y K
* C N I I F I L N I F I Q S Y I * I N T

18301 CTTGGACAAAATTGTATAAGAGCAAATTATAGAGAATACCCAAAATTTAATCTAAACTGA 18360
S G T K V Y E R K I D R I P K L N S K V
H V Q K L M N E N L I E * P N * I L N S
F R N * C I R T * Y R K H T K F * I Q S

FIG. 3 CONT'D

18361 GAACTACCAATAAGATTTAACAAATAATGATTTCTACTTCGGTAATTTGCACAATCTCCA 18420
R S P * E L N N I V L S S A M L R T L P
E Q H N N * I T * * * L H L W * V H * L
K I T I R F Q K N S F I F G N F T N S T

18421 ACCCAACCAAAACTACAACCTCCGCGAGTACGATGAGCGCTTTTGTAACTTGTGTTGAAA 18480
Q T P K S T S P A * A V R S F M P V F K
N P Q N Q H Q P R E H * E R F C Q F L S
P N T K I N L A S M S S A F V N S C V K

18481 GGTGACGTTTATCCAAAAAGTTGACCACACCTAAAACATCAACTTCGATGACCGAATAAA 18540
G S C I P K E V P T S K T T S A V P K N
E V A F L N K L Q H P N Q L Q L * Q S I
W Q L Y T K * S T H I K Y N F S S A * K

18541 CGACTCTCTCTAACAAATATGAAAATTTTTTTGACATCGATTTTCGAGGAGGACCACTTTTT 18600
A S L S Q * V K L F V T A L A G G P S F
Q Q S L N N Y K * F F Q L * L E E Q H F
S L S I T I S K F F S Y S F S R R T F F

18601 AAATTGTAAATTATGGGAATACAGTTTTCCAGTTTTCCACCTATAACAATCTTAATCT 18660
N L C K I G R I D F P * F H S I T L I L
I * V N L V G * T L L D F T P Y Q * F *
K F M * Y G K H * F T L L P I N N S N S

18661 TAACAAGTTTACAATAGACTAATAGAAAATCTGGAAAGACTATCACATCATAAATAATGA 18720
I T * I N D S * R K S R E S L T T N I V
F Q E F T I Q N D K L G K Q Y H L I * *
N N L H * R I I K * V K R I T Y Y K N S

18721 ACCAGACGGTCAAACTTGAATGAACAAATCCATAAAACGATTTAATCCGTCTCTCGAA 18780
Q D A L K S S V Q K L Y K A L N P L S S
K T Q W N Q V * K N L T N Q * I L C L A
P R G T K F K S T * P I K S F * A S L K

18781 TTAACATTACACACAAGATTAGCACGATGTACGATGTTAAGATCTTGACCAATAATACCA 18840
L Q L T H E L R A V H * L E L V P * * P
* N Y H T N * D H * M S C N * F Q N N H
I T I H T R I T S C A V I R S S T I I T

18841 ACAACCGCGGTATCAATATGAACACTAATACACATATTAGGTGAATAACATCTATATGTT 18900
Q Q R W L * V Q S * T Y L G S I T S I C
N N A G Y N Y K H N H T Y D V * Q L Y V
T P A M T I S T I I H I I W K N Y I Y L

FIG. 3 CONT'D

18901 GTCACCCCAATATGTCCAAGAAATTGATCATTAGTGCTATATTAAACATTACATGTATTT 18960
C H P * V P E K V L L * S I I Q L T C L
V T P N Y L N K L * Y D R Y L K Y H V Y
L P T I C T R * S T I V I Y N T I Y M F

18961 CCACGTGTACAACGCAGTCGACTACGTTAATACTGAGCAACAAATCGTTAGATACTAACA 19020
P A C T A D A S A I I V R Q K A I * S Q
L H V H Q T L Q H L * S E N N L L R H N
T C M N R * S I C N H S T T * C D I I T

19021 AAAACATTTAGACAATTAACCTTAAATCTCATAGGTTATTAAGATTACTCCAGTCATAT 19080
K Q L D T L Q F K S Y G I I E L S T L I
N K Y I Q * N S N L T D L L K * H P * Y
K T F R N I P I * L I W Y N R I L D T Y

19081 TTATGTAGAACATCCAATAACGTGCGACAGTACGAATTCGACGGTACGATACATTATCT 19140
F V D Q L N N C R T M S L A A M S H L L
L Y M K Y T I A A H * A * L Q W A I Y Y
I C R T P * Q L T D H K F S G H * T I S

19141 ATGTTGAATACAATACTGTATCCGTTAGGATTTCCAAATCGAACACAGTTTCTAATACTT 19200
Y L K H * S M P L G L P K A Q T L S * S
I C S I N H C L C D * L N L K H * L N H
V V * T I V Y A I R F T * S T D F I I F

19201 AAATTTAAAATACTACGAAAAGGACATCGGTTGAGACAATTTGTCAATAAAAATACAGATA 19260
N L N * S A K G T A L D T L C N N * T *
I * I K H H K E Q L W T Q * V T I K H R
K F K I I S K R Y G L R N F L * K I D I

19261 CTACACGTATTTCTATTAATAAATTTCTACCAAATACATACAAAACCTTAACATTACAACATA 19320
S T C L S L K L S P K H I N Q F Q L T S
H H A Y L Y N * L H N I Y T K S N Y H Q
I H M F I I K F I T * T H K P I T I N I

19321 TTTATAGGTAGATTAAGTTAACAAACATCTAAACTGTGAGCTCACAATTTATTTAATTTG 19380
L Y G D L E I T Q L N S V R T N F L N F
Y I D M * N L Q K Y I Q C E L T L Y I L
F I W R I * N N T S K V S S H * I F * V

19381 GAAGGACCTACATTACCACCATCAAACATACAATTTTGTACGTAAGGTATGATTAGGA 19440
R G P H L P P L K Y T L L C A N W V L G
G E Q I Y H H Y N T H * Y V H M G Y * D
K R S T I T T T Q I N I F M C E M S I R

FIG. 3 CONT'D

19441 AAATGATCTTGACAAAAAAGCTTTTAGAATTCGGATACGGAAAAAAGATAATAAGTCTATGC 19500
 K V L V T K S F R L G I G K K * * E S V
 K * * F Q K Q F D * A * A K K R N N L Y
 K S S S N K F I K L R H R K E I I * I R

19501 GGAACACACATGCATCTACCAAACTTTAGATTTGTTCAACTAATGCAAGGAAATCTCTCG 19560
 G Q T Y T S P K S D L C T S * T G K L L
 A K H T R L H N L I * V L Q N R E K L F
 R T H V Y I T * F R F L N I V N R * S A

19561 CGGTGAACATAGTGTGCCACATTAGATCCACCTCGACAAACAAGTTTCGTACGACTTCTT 19620
 A V Q I V R H L R P P A T Q E F C A S S
 R W K Y * V T Y D L H L Q K N L A H Q L
 G S T D C P T I * T S S N T * L M S F F

19621 ATAACATTGATGGAACCTCAGAATATTATATCAATGATGTCGTCCGAAATGAAAAACCCAA 19680
 Y Q L * R S D * L I T V V A P K V K Q T
 I N Y S G Q T K Y Y L * * L L S * K K P
 I T V V K L R I I Y N S C C A K S K P N

19681 ATATTCTTAAAACTAAAAATATTAAATACCTTGTGAAAATGATGCAATGTCTCAAATCTT 19740
 * L F K S K * L K H F V K V V N C L K S
 K Y S N Q N K Y N I S C K * * T V S N L
 I L I K I K I I * P V S K S R * L T * F

19741 TTGCATTATATATTGAACCAATTACAACCAGTAATACTACCTGCATGTCCACTTAATGGA 19800
 F T I Y L K T L T P * * S P R V P S N G
 F R L I Y S P * H Q D N H H V Y L H I V
 V Y Y I V Q N I N T M I I S T C T F * R

19801 ACACGATAATACTTACTGTTTCAACAACAATTCTAATTATTACATCTATGACAATAAAAA 19860
 Q A I I F S L T T T L I L L T S V T I K
 K H * * S H C L Q Q * S * Y H L Y Q * K
 T S N H I V F N N N L N I I Y I S N N K

19861 TTTTATTATGTAGTAAAGGATGATTATATCGACAACCTTAACAAATGTTTTCATCATAG 19920
 L F L V D N G V L I A T S N N V F R L I
 * F Y Y M M E * * Y L Q Q I T * L V Y Y
 F I I C * K R S I Y S N F Q K C F T T D

19921 GCCGTGGTGGGACTTGAATTCTAAGAATCTTTAAACTTGTAACATAAACAACCTTCGTA 19980
 R C W G S S L I R L F K F M S I Q Q F C
 G A G G Q V * S E * F N S C Q Y K N S A
 P V V R F K L N K S I Q V N I N T P L M

FIG. 3 CONT'D

19981 CAGGACACCCTAATACAATTTCTATCAAACAAAACATCAAGGTGAATACCACAAACATTT 20040
T R H S * T L S L K N Q L E V * P T Q L
H G T P N H * L Y N T K Y N W K H H K Y
D Q P I I N F I T Q K T T G S I T N T F

20041 ATGTGTCTAAACTTCAAGTAGCTTTTAAACTTATATGAAAACTACCAGCACTGTGACCG 20100
Y V S K F N M S F K F I S K S P R S V P
I C L N S T * R F N S Y V K Q H D H C Q
V C I Q L E D F I Q I Y K K I T T V S A

20101 CGAAATCTTCGAAAATCTTTTCGTTCTTTACCACAAAATAATCATGACTTTTAAATCA 20160
A K S A K L F A L F P T K I L V S F N L
R K L L K * F L L F H H K * * Y Q F I L
S * F S K S F C S I T N K N T S F F * T

20161 TCCAATAGTACTAATTTCCAGGCGTTGCTCGACTAAATTTACCACACTAACACCTATTT 20220
L N D I I L P G C R A S K F P T I T S L
Y T I L S * L D A V L Q N L H H S Q P Y
P * * H N F T R L S S I * I T H N H I F

20221 CAACCTCTTGAGTTTCAACTCAAAACCAAGCGATACTCTTTTCTACCCTGCTACAATAG 20280
T P S S L T S N Q N A I L F S P S S T I
L Q L V * L Q T K T R * S F L H H R H *
N S F E F N L K P E S H S F I T V I N D

20281 AAGTCGGCTTGCTGTCGGATACGAGTTCGGTAATGACCTCGGGTGTCCATTAGATCCA 20340
K L R V S L R H E L W * Q L G C P L R P
R * G F L C G I S L G N S S G V L Y D L
E A S C V A * A * A M V P A W L T I * T

20341 CCATTAACGCGCCCATACAGTAACCATTACTACGAGATTGTGCAAAATGATAGAAATGA 20400
P L Q A P L T M P L S A R V R K V I K V
H Y N R P Y H * Q Y H H E L V N * * R *
T I A R T I D N T I I S * C T K S D K S

20401 GTCTCAGCACATAACAGTTCAAAACCTGGAGCGAGTCTAAATCTTGCCCTAAAATAACTA 20460
* L R T N D L K S G R E S K S R S K I S
E S D H I T L N Q V E S L N L V P N * Q
L T T Y Q * T K F R A * I * F P I K N I

20461 TACCTACTATTAGACAAATAACGATTTATACCAAATCTTCTGATACGTAACCTAGTATAT 20520
I S S L R N I A L Y P K S S * A N S * I
Y P H Y D T * Q * I H N L L S H M Q D Y
H I I I Q K N S F I T * F V I C K I M Y

FIG. 3 CONT'D

20521 CAAATACCATCAAATTTGGTATTTCAATATCCTCCAAACGTAACGAATATCCGAATAAA 20580
 T * P L K L W L T I P P K C K S I P K N
 L K H Y N * G Y L * L L N A N A * L S I
 N I T T K V M F N Y S T Q M Q K Y A * K

20581 GCATCCITTTTTTTTAGATTAAACAATTAAGTTCTCAAAAATGTCATACTAAGATCATAA 20640
 R L F F F D L K N I * S N K C Y S E L I
 E Y S F F I * N T L E L T K V T H N * Y
 T P F F F R I Q * N L L K * L I I R T N

20641 GTAAGTATAAAATAATGACTAGTCCTCACACCATCATCATTCTCACAAACATGTCATAA 20700
 * E Y K I V S * S H P L L L L T Q V T I
 E N M N * * Q D P T H Y Y Y S H K Y L *
 M * I K N S I L L T T T T L T N T C N N

20701 CTAATAATAATCTACTAAAACAAGATAACAATTCAGTAATTTAAACTCAACACAATCA 20760
 S K N N S S K T E I T L D N F K L Q T L
 Q N I I L H N Q K * Q * T M L N S N H *
 I * * * I I K N R N N L * * I Q T T N T

20761 TTTCAACAATTATAATTACAACAAAATTCCTAAAAGTTAAATACAACACCACATTACTA 20820
 L T T L I L T S K L S K * N I N H H L S
 Y L Q * Y * H Q N * P N E I * T T T Y H
 F N N I N I N I K L I K L K H Q P T I I

20821 TTATTTTAATACTGAAAAATAGGATTTTACGTTCCGGTGATTACTAACCTTTGGACCGATA 20880
 L L I I V K * G L I C A V L S Q F G P *
 Y Y F * S K K D * F A L W * H N S V Q S
 I F N H S K I R F H L G S I I P F R A I

20881 AGATACGGACAAAACATATTATCAAACTTACAAGGTAATCTCTCTCAGAGAAATACCTTA 20940
 E I G T K Y L Y K F T G N S L T E K H F
 N * A Q K T Y T N S H E M L S L R K I S
 R H R N Q I L I Q I N W * L S D R * P I

20941 ATACCATTGGATAATTAACGGATGTCGACATACTACTTACAACGATTCATGTGAGTT 21000
 * P L G I L K G V P Q I I F T A L Y V *
 N H Y V * * N A * L S Y S S H Q * T C E
 I T F R N I Q R C A T H H I N S L V S L

21001 AATACAGTCATAAACTTATGATGTTGTAATCGACAAGGACAATTATACGCACAAAATGTA 21060
 N H * Y K F V V V N A T G T L I R T K C
 I I D T N S Y * L M L Q E Q * Y A H K V
 * T L I Q I S C C * S N R N I H T N * M

FIG. 3 CONT'D

21061 AATCCACGTCCCAGACTATTTCTTCATCGAGGTCCAAGACGACAAAATTCTGTCCACCAAT 21120
K P A P D S L S T A G P E A T K L C H N
N L H L T Q Y L L L E L N Q Q K L V T T
* T C P R I F F Y S W T R S N * S L P *

21121 GGTAGACCATCATAAGAACATCTATTACTAAATTTGGGTAAACAATCGCTATCAAATCAA 21180
G D P L I R T S L S K F G N T L S L K T
V M Q Y Y E Q L Y H N L G M Q * R Y N L
W R T T N K Y I I I * V W K N A I T * N

21181 TGAATAAAACCTCTAACATACTGAAATGGTAAACTAACAGTAACCCTAAACTATTATAGA 21240
V * K P S Q I V K G N S Q * Q S K I I D
* K N Q L N Y S K V M Q N D N P N S L I
S I K S I T H S * W K I T M P I Q Y Y R

21241 CTATACATACTAGGAGAATGATTTTTATAACCACTAATATTACACTCATTCTACCCAAA 21300
S I Y S G R V L F I P S * L T L L S P N
Q Y T H D E * * F Y Q H N Y H S Y P H T
I H I I R K S F I N T I I I H T L I P K

21301 AAATGAATGTAAACAGTAAATTAAGCACTATTTAATAGAAACCCACCATCACATCGATAT 21360
K V * M Q * K I R S L N D K P P L T A I
K * K C K D N L E H Y I I K P H Y H L *
K S V N T M * N T I F * R Q T T T Y S Y

21361 TTTTAATGTCTCAAAGAACCTTACGACTAAATATATTTAATTACTCAACAAAACGTAAA 21420
F I V S N E Q F A S K Y L N I L Q K A N
L F * L T K K S H Q N I Y I L S N N Q M
F N C L K R P I S I * I F * H T T K C K

21421 ACCTGTCAAAAAACATGATTACATTTACGAAGAAGATCACTTCCCAAAAATTATCCATAT 21480
Q V T K Q V L T F A E E L S P N K I P I
K S L K K Y * H L H K K * H L T K L L Y
P C N K T S I Y I S R R T F P K * Y T Y

21481 TTAATGGACCCATTTAGAAGAAAACCTTTATCTACCGTTACAATACGTACGATTGATAAAC 21540
F * R P L D E K S I S P L T I C A L * K
L N G P Y I K K Q F L H C H * A H * S N
I V Q T F R R K F Y I A I N H M S V I Q

21541 AAAACCTCTTTATCATGTTGTACCTTACCGCCACGAATATCAAATAAACTATACTGATTT 21600
N Q L F L V V H F P P A * L K N S I V L
T K S F Y Y L M S H R H K Y N I Q Y S *
K P S I T C C P I A T S I T * K I H S F

FIG. 3 CONT'D

21601 AAAAGAAACTTTAACCGACCGTGACGACAACAATTAATTCCTGGTCTAGTTAATTTACTA 21660
N E K F N A P V A T T L K L G S * N F S
I K K S I P Q C Q Q Q * N L V L D I L H
K R Q F Q S A S S N N I * S W I L * I I

21661 AATCAAATAAGAGAATAACTTTCTCCATTTAATAATCAAGCGCTATGCGCATTCTCTAA 21720
K T * E R I S L P L N N T R S V R L S I
N L K N E * Q F L Y I I L E R Y A Y L S
* N I R K N F S T F * * N A I R T F L N

21721 AAACAACCACTATCAGAACATTTATGAACAATCTAGAGTAATTTAGATTGGATAACAATTA 21780
K T P S L R T F V Q * I E N F R F * T L
K Q Q H Y D Q L Y K N S R M L D L S H *
K N T I T K Y I S T L D * * I * V I N I

21781 ATAAAAAATAAAAAAATAAAGACAATACCAAATTAATTTGGAGAATTACAACACAGAGT 21840
* K K I K K N R N H N * H V E * H Q T E
N N K * K K I E T I T K I F R K I N H R
I K K N K * K Q * P K L S G R L T T D *

21841 AAATTTGGTACTGACCAAAAATAAACCACTATCAGCAAGACTAACATTGGTATAATTATT 21900
N L G H S T K I Q H Y D N Q N Y G Y * Y
M * V M V P K * K T I T T R I T V M N I
K F W S Q N K N P S L R E S Q L W I L L

21901 AAATTTTAAATTTTAAACTAATAAACCTATAAGTGGGATCAAACACGTTGTTACCATT 21960
N L F * F N Q N N P Y E G * N T C C H Y
I * F N F I K I I Q I N V R T Q A V I T
K F I L F K S * K S I * G L K H L L P L

21961 CTAAGTAGATCACGGCCACTAAGATAAAAAATCTCAAAAGTAAAGTGAGCTAAAATATT 22020
S K M * H R H N * K * S N E N * E I K Y
L N * R T G T I R N K L T K M E S S K I
I E D L A P S E I K L L K * K V R N * L

22021 AATGTGACCGCTTCCACTAGTTTAATAAAAAATACTCCACAATTAATAATTAGGAATAGT 22080
N C Q R L H D F * K K H P H * N * D K D
I V S A F T I L N N K I L T N I K I R I
* V P S P S * I I K * S P T L K L G * *

22081 ATCTAAATTCACAAAAGGATTACCATCATTACTACATACCGAAGAATTGTTCCATTCTAA 22140
Y I * T N E * H Y Y H H I A E * C P L I
M S K L T K R I T T I I Y P K K V L Y S
L N L H K G L P L L S T H S R L L T L N

FIG. 3 CONT'D

22141 AATAGCACGGAATATAAGATTATACCGGAAAAAGCAATAGAATGAAAACAACTATAAGG 22200
K D H R I N * Y P R K E N D * K Q Q Y E
K I T G * I R I H G K K T I K S K N I N
* R A K Y E L I A K K R * R V K T S I G

22201 AATATTACAAAGAGAAAGATTCAAATTAAGAACATTTTCACTATAAAAATAGTGAATTGTT 22260
K Y H K E K * T * N K Y F H Y K I V * C
R I I N R K R L K I R T F T I N * * K V
* L T E R E L N L E Q L L S I K D S L L

22261 AGGATAAAAAATAATTAATAAGATTCTTCAAATAAAAATGAAATAATCCAACAAGAGAAAT 22320
D * K * * N N * P L K N * K I L N N E K
I R N K N I I R L F N I K S * * T T R K
G I K I L * E L S T * K V K N P Q E R *

22321 AAATCATGGCGAAACGGAAAAATTTAGATTGAAATCAGTCATGATAATATTGTATCTATG 22380
N L V A K G K * I * S * D T S N Y C L Y
I * Y R K A K K F R V K T L V I I V Y I
K T G S Q R K L D L K L * Y * * L M S V

22381 ACCGAGACAAATACCAAAAAGATTACAACAAATAGGACTAAATCTGACATAAATATAAAG 22440
Q S Q K H N K * H Q K D Q N L S Y K Y K
S A R N I T K R I N N I R I * V T N I N
P E T * P K E L T T * G S K S Q I * I E

22441 AGAATTTGGTCCAAGAATATTTCAAAGGTGGTGACGTGGAAAAAATAGGAATGGATGATT 22500
E * V L N K Y L K W W Q V K K I R V * *
R K F W T R I F N G G S C R K * G * R S
R L G P E * L T E V V A G K K D K G V L

22501 TCGAGAGACAAAATCTTTAGATTTGTTAAACATGGACATGTCCAACAACCTAAGATCTAC 22560
L E R N Q Y I * V I Q V Q V P Q Q N * I
F S E T K I F R F L K Y R Y L N N I R S
A R Q K S L D L C N T G T C T T S E L H

22561 CTTGTTGCTCGCACGGAGTCTATAAAGAAATAGACAACGTACAGTTAACGGTATAACAAT 22620
S C R A H R L Y K K I Q Q M D I A M N N
P V V L T G * I N R * R N C T L Q W I T
F L S R A E S I E K D T A H * N G Y Q *

22621 AAAAGCGTTAAGAAGACGATTAATACAACCGTTTCACTATAAATGGTGCCACTATCACC 22680
N E C N K Q * N H Q C T H Y * G R H Y H
I K A I R R S I I N A L I I N V V T I T
K R L E E A L * T P L Y S I L W P S L P

FIG. 3 CONT'D

22681 AAAATAAGATAAAAATAGACCAGAAAATATATTACAAAGAACATAAAGTATAATACCACA 22740
N * K * K I Q D K I Y H K K Y K M N H H
T K N R N * R T K * I I N R T N * I I T
K I E I K D P R K Y L T E Q I E Y * P T

22741 TAAAAATATACTATTAAAAATGTAGGTAAACCGGATAATAAGAAAACCATCCACAGGATG 22800
I K I H Y N * M W K A R N N K Q Y T D *
Y K * I I I K C G N P G I I R K T P T R
N K Y S L K V D M Q G * * E K P L H G V

22801 TAGAAGATAATAATTTGTAGGTTAAACACAAATACTAAAAAACGGATAATAAAATGTTCC 22860
M K * * * V D L K H K H N K A * * K V L
C R R N N F M W N T N I I K Q R N N * L
D E I I L C G I Q T * S K K G I I K C P

22861 ATAAAAATAACAAATCGAAATGAAAAACAACAAAAGATAATAAAAAACAATATATTGCT 22920
Y K I I N L K V K Q Q K E I I K T I Y R
T N * * T * S * K K N N K * * K Q * I V
I K N H K A K S K T T K R N N K N Y L S

22921 ATTTAGAGTAATTTAGATTTGTACAATAATTAATAAAAAATAAACGGATGTTGTAATCGA 22980
Y I E N F R F M N N I I K I K G V V N A
I F R M L D L C T I L * K * K A * L M L
L D * * I * V H * * N N K N Q R C C * S

22981 CAATATCCACTAAAATTAACATGATTAACAAAGATAATTACTAAATTTGTGGTGTCAAGGA 23040
T I P S K L Q V L K A I L S K F V V T G
Q * L H N * N Y * N Q * * H N L C W L E
N Y T I K I T S I K S N I I * V G C N R

23041 GCGTATTCACCTACACAACACCTACAAAGAATACCAAACCCATGTATAATATATGAACCTA 23100
R M L S Y T T S T E * P K P V Y * I S S
E C L H T H Q P H K K H N P Y M N Y V Q
A Y T L I N H I N R I T Q T C I I Y K I

23101 GCACAAATAAATTTATGATGATATAATAAATGACCAATAAAGGGATTTAGACCACGGTTA 23160
R T * K F V V I N N V P * K G L D P A L
D H K N L Y * * I I * Q N N G * I Q H W
T N I * I S S Y * K S T I E R F R T G I

23161 AAATCCCTAGATAGAAAATTTCCATGATGTATAAACTCATGAGAAACCATAGTCTTTGGG 23220
K L S R D K F P V V Y K L V R Q Y * F G
N * P D I K L L Y * M N S Y E K T D S V
K P I * R * F T S C I Q T S K P I L F G

FIG. 3 CONT'D

23221 AAAAATAGACTAAAATTATTACCATAAAAAAGATCTCAATTCCTTATGATTCAACATACAA 23280
K K D S K L L P I K E L T L F V L N Y T
R K I Q N * Y H Y K K * L * S Y * T T H
K * R I K I I T N K R S N L I S L Q I N

23281 TTATTTTGAACATATCACTCAAATCATGATATCAATATCCATCACAAAATAATTGTTG 23340
L L V K Y L S N L V I T I P L T K I L L
* Y F K T Y H T * Y * L * L Y H K * * C
I F S Q I T L K T S Y N Y T T N K N V V

23341 AGAATATGATAACAACAAGTTGGAGTATTACCACAAAACCTCTAATGTCGAACAGTTATG 23400
E * V I T T * G * L P T K S I V A Q * Y
S K Y * Q Q E V E Y H H K P S * L K D I
R I S N N N L R M I T N Q L N C S T L V

23401 TGATACACTCATAGGAGTATGATAAACATTTAGATTTCCATCAAGAGCATTACTTAGA 23460
V I H S Y G * V I Q L D L P L E R L S D
C * T H T D E Y * K Y I * L Y N E Y H I
S H T L I R M S N T F R F T T R T I F R

23461 ACCGTAAAACATTTAGACTTGGAAACACAGACAAGTTCTTTTTAAAATGAATATTACAA 23520
Q C K S L D S G K H R N L F F K V * L T
K A N Q Y I Q V K T D T * S F N * K Y H
P M K I F R F R Q T Q E L F I K S I I N

23521 AGATGTCTAACCAACATAAAAAGTAAAAATAGTTCTTGCACCGTGAAAAATACGAATAATA 23580
E V S Q N Y K * K * * S R P V K * A * *
K * L N T T N E N K D L V H C K K H K N
R C I P Q I K M K I L F T A S K I S I I

23581 CGACTAAGACCGTACGGATGATGAAAAATAAATCAAACATAGAACCATGAGAAAATAGA 23640
A S E P M G V V K K N L K Y R P V R K D
H Q N Q C A * * K K I * N T D Q Y E K I
S I R A H R S S K * K T Q I K T S K * R

23641 GTAATAATACAAAACGAAACTGAACATTACGATATAGAAGATTATGACTATTACTCTGA 23700
* * * T K G K V Q L A I D E L V S L S V
E N N H K A K S K Y H * I K * Y Q Y H S
M I I N Q R Q S T I S Y R R I S I I L S

23701 AATGTTATAACCCAGTGTGGAAACAGATTGCGGTTATAGAAGAATTTAAACTGTGGCA 23760
K C Y Q T V G K D L R W Y R R L N S L R
K V I N P * V K T * V G I D E * I Q C G
* L I P D C R Q R F A L I K K F K V V T

FIG. 3 CONT'D

23761 CCACAATAATGATTACGACAACCTAACAAGATCATCAAAGAAATCGCTCTAAGTTACATTT 23820
P T I V L A T S Q E L L K K L S I * H L
H H * * * H Q Q N N * Y N R * R S E I Y
T N N S I S N I T R T T E K A L N L T F

23821 TGATTTAGAAATAATGGATTATGACCACAAACTGAATAGACCAAAATGACAATTCGGA 23880
V L D K N G L V P T * S K D P K V T L G
F * I K I V * Y Q H K H S I Q N * Q * A
S F R * * R I S T N I V * R T K S N L R

23881 CAACGTTGACATGTAGCAGCATAAGGACTAAATGGACTAACACTGTAACCTATTTACCGAA 23940
T A V T C R R I G S K G S Q S M S L H S
Q Q L Q V D D Y E Q N V Q N H C Q Y I A
N C S Y M T T N R I * R I T V N I F P K

23941 TTGTTAAAATTACATGGGAGTGGAGAATTAACCCCTGCATTTTAAAAAAGATTAACGTTG 24000
L L K L T G E G R L Q S R L I K E L Q L
* C N * H V R V E * N P V Y F K K * N C
V I K I Y G * R K I P F T F N K R I A V

24001 AAATTAACTCATGAAACGAAGCAAAATCAAGTATGACTAAGAAAAAGAACATTATTAATA 24060
K L K L V K S R K T * V S E K E Q L L K
S * N S Y K A E N L E Y Q N K K K Y Y N
K I Q T S Q K T * N M S I R K R T I I K

24061 CTACTTAGATTCTATATACCATCAACAAAATTCTCATAACAAAATCTATTTAAACGGTAT 24120
S S D L I Y P L Q K L L I T K S L N A M
Q H I * S I H Y N N * S Y Q K L Y I Q W
I F R L Y I T T T K L T N N * I F K G Y

24121 GGGTTGAGTCTGCTAGACTAAACGTCAACCCGTCAAGACCAAAAGACGTTAGAAGATTA 24180
G L E L R D S K C N P L E P K R C D E L
V W S W V I Q N A T P C N Q N E A I K *
G V G S S R I Q L Q A T R T K Q L R R I

24181 ATATTTTAACTGTGATGAAGATCAAGAACAGTTAACATAATATCAAACGGACGTTAATTA 24240
* L I S V V E L E Q * N Y * L K G A I L
N Y F Q C * K * N K D I T N Y N A Q L *
I F N V S S R T R T L Q I I T Q R C N I

24241 CAATGATAATTATTAATATTAGGAAGAAGAACCCTTATCTTCATACCAAAATTTATTAATA 24300
T V I L L * L G E E Q F L L Y P K L L K
H * * * Y N Y D K K K S Y F T H N * Y N
N S N I I I I R R R P I S P I T K I I K

FIG. 3 CONT'D

24301 TTAAACTCGAGAGTATCACAAACAATGAGTGCAATAACAAAAAGACAATTATTATGAAAA 24360
L K L E * L T T * E R * Q K E T L L V K
* N S S E Y H Q K S V N N N K Q * Y Y K
I Q A R M T N N V * T I T K R N I I S K

24361 ACAGGAACACGATTTGGAAGAAAACGAAGTTCAACGTTCTCAGTATTTGGTGAAGACGA 24420
Q G Q A L G E K A E L Q L L * L G G E A
K D K H * V K K Q K L N C S D Y V V K Q
T R T S F R R K S * T A L T M F W R R S

24421 AGGACAGGATAACCATGATTAATAGCAAGAACAACCTCTCATGATGACATGAGCTGGTGTGA 24480
E Q G I P V L * R E Q S L V V T S S W V
K R D * Q Y * N D N K H S Y * Q V R G C
G T R N T S I I T R T L T S S Y E V V S

24481 CTGACCACATCCACAAGAACAATGGACTAGGATATTGACGAATACTGGGATCCAGAACA 24540
S Q H L H E Q K G S G I V A * S G L D Q
Q S T Y T N K N V Q D * L Q K H G * T K
V P T P T R T * R I R Y S S I V R P R T

24541 AGAGTTTTTTTTTCAGAGACCAACCACAACCCTTGTAACACGTCCTCAAGCCACAACCTACTT 24600
E * F F D R T P T P S C Q A P N P T S S
N E F F T E P Q H Q H V N H L T R H Q H
R L F L R Q N T N T F M T C P E T N I F

24601 CTTTTCACACCACATAACCTACCTAGTATATTACAAAGAACAGAAACATCATGACTACGG 24660
S F H P T N S P D Y L T E Q R Q L V S A
L F T H H I P H I M Y H K K D K Y Y Q H
F L T T Y Q I S * I I N R T K T T S I G

24661 AAAGATCCAACCAGAATACTGTGAACGCAGTCATTGTTGGCAACATTATAAAAAAGATTA 24720
K R P Q D * S V Q T L L L R Q L I K E L
R E L N T K H C K R * Y C G N Y Y K K *
K * T P R I V S A D T V V T T I N K R I

24721 AAATAAAATTTACCATAGTTATCACCATGGTGAACAAGATTACTAAATAACGTCGGATTA 24780
K I K F P I L L P V V Q E L S K N C G L
N * K L H Y * Y H Y W K N * H N I A A *
K N * I T D I T T G S T R I I * Q L R I

24781 TGACTTCAAAAATGACTACAAAACAACCTAATGCTGGAAATACCATAATGTCCTGTTCCA 24840
V S T K V S T Q T S * S R * P I V P C P
Y Q L K * Q H K H Q N R G K H Y * L V L
S F N K S I N T N I V V K I T N C S L T

FIG. 3 CONT'D

24841 TAAAAATTTCTTCAAAGACGACAAATAATATTATCAACCGTTTTAGAAAACATACTAAGA 24900
I K L S T E A T * * L L Q C F R K Y S E
Y K * L L K Q Q K N Y Y N A F D K T H N
N K F F N R S N I I I T P L I K Q I I R

24901 TTACCGTTGTAATAACCAAAATTTCTAAAACAATGATTATTTTGTATATTATAAAAAGGGA 24960
L P L M I P K L S K T V L L V Y L I K G
* H C C * Q N * L N Q * * Y F M Y Y K G
I A V N N T K F I K N S I F C I I N B R

24961 ACAATACGTCCTTCTCAAAGACGACGAAAAGTAGTTTTACGAAGGAGAAACCGAAATGAA 25020
Q * A P L T E A A K * * F A E E K A K S
K N H L F L K Q Q K E D F H K R K P K V
T I C S S N R S S K M L I S G R Q S * K

25021 ATAGCATTAAATTTTACATCGATACAAAACCTTATTATAAAGAAATGATGAGTCGGTATA 25080
* R L K F H L * T K F L I E K V V * G Y
K D Y N L I Y S H K S Y Y K K L * E A M
I T I * F T A I N Q I I N R * S S L W I

25081 AACTATCAATAGAACCAACGCAAAAATACGACTATTAAATGACTAATAAGACAAAGA 25140
K S L * R P Q T K L A S L K V S * E T E
N Q Y N D Q N R K * H Q Y N L Q N N Q K
K I T I K T A N K I S I I * S I I R N R

25141 AGAACACGAGAAGCGTACCCATCACCAAAAACACAATAATATTGAGTGAAGAAGAAGG 25200
E Q A R R M P L P K Q T S * L E G E E E
K K H E E C P Y H N K H Q N Y S V K K K
R T S K A H T T T K T N I I V * R R R G

25201 AGAAGCGCAGCATTTGCATCTTCATAAAGACGAAGAATAGCAAAACAATGAAAACCTGGG 25260
E E R R L R L L I E A E * R K T V K S G
R K A D Y V Y F Y K Q K K D N Q * K Q V
R R T T F T S T N R S R I T K N S K F G

25261 AAATTACAGTCAAAACAATTACTGTCTATAACTCAGACACCCACCAGAAATACTCTAGTTT 25320
K L T L K T L S L I S D T P P R * S I L
R * H * N Q * H C Y Q T Q P H D K H S *
K I D T K N I V T N L R H T T K I L D F

25321 TAAGGGTGATTGAAATGATATCAACCGTTCTCCTTAAATAAGTTTGATTAAGAGGATTT 25380
I G V L K V I T P * S S N I * V L E G L
F E W * S * * L Q D L P I * E F * N E *
N G S V K S Y N T L L F K N L S I R R F

FIG. 3 CONT'D

25381 CAATGATAACTAACAAGAAATAAACAGACAAGATTAATACGTGCGAACGGTACTGAATAAC 25440
T V I S Q E K N T Q E L * A A Q W S K N
L * * Q N N K I Q R N * N H L K G H S I
N S N I T R * K D T R I I C S A M V * Q

25441 AGTCTCATACCGTGAAAAACACTATTATAATTATCATAAAATCTACTTCAATTACCAAAT 25500
D S Y P V K Q S L I L L I K S S T L P K
T L T H C K K H Y Y * Y Y K L H L * H N
* L I A S K T I I N I T N * I F N I T *

25501 GAACTATGATGAGTTAACGTACATCGACTATGAGAATACGTTCCACAGTGTGAATCGAGG 25560
S S V V * N C T A S V R I C P T V S L E
V Q Y * E I A H L Q Y E * A L H * V * S
K I S S L Q M Y S I S K H L T D C K A G

25561 TTAGAATTATGATTAAACGTAAAACTACAAC TATTATAATTA AAAATTTAGGGATCAACCT 25620
L R L V L K C K S T S L I L K L D R T P
W D * Y * N A N Q H Q Y Y * N * I G L Q
I K I S I Q M K I N I I N I K F G * N S

25621 ACAAATCCAGGTGTGACGCCAAGAAGAAGAGCAAGAAAAAACTTCTAAATAACAACTG 25680
H K P G C Q P E E E R E K K S S K N N S
I N L D V S R N K K E N K K Q L N I T Q
T * T W V A T R R R T R K K F I * Q K V

25681 TTTC AATTTGAAAGTCTACAACCAAAAACA ACTTCGAATATTGTTAACATGACCACCATCA 25740
L T L S E S T P K T S A * L L Q V P P L
C L * V K L H Q N Q Q L K Y C N Y Q H Y
F N F K * I N T K N F S I V I T S T T T

25741 CTTTAATCTCTAGAAGAAACACATGTTAGGAAATTACCATAATTTCAAACCGAGGATAA 25800
S I L S R R Q T C D K L P I L T K G G I
H F * L D E K H V I R * H Y * L K A E *
F N S I K K T Y L G K I T N F N Q R R N

25801 AACAGACTTAGAGTTTAAAGACCAATGTGGTGTGCGCGATGACAACGACGATACAAAGGT 25860
K D S D * I E P * V V A A V T A A I N G
K T Q I E F K Q N C W L R * Q Q Q * T E
Q R F R L N R T V G C G S S N S S H K W

25861 GGTACCAGTCGTCGTCGACCGTATGGTAAAAGAGAATTACATGTTATATCTTAATTACCA 25920
G H D A A A P M G N E R L T C Y L I L P
V M T L L L Q C V M K E * H V I Y F * H
W P * C C S A Y W K R K I Y L I S N I T

FIG. 3 CONT'D

25921 AACCCACAATGATACCTACAAGAATTATTTTGTAGTTTCAACTATCGATGACGAAAATTA 25980
K P T V I S T R L L F * F N I A V A K L
N P H * * P H E * Y F D F T S L * Q K *
Q T N S H I N K I F I L L Q Y S S S K I

25981 TTACGAGAAGAAAGATAAGTCTTACCAAAATCACGATGGTTGAGACGTGAACGATTTTAT 26040
L A R R E I * F P K L A V L E A S A L I
Y H E E K * E S H N * H * W S Q V Q * F
I S K K R N L I T K T S G V R C K S F Y

26041 GTTTCACAACAATTAAGATTACGAGTTCGTGAATTATCAAACAATGTCGTTAATAAATTA 26100
C L T T L E L A * A S L L K N C C N N L
V F H Q * N * H E L V * Y N T V A I I *
L T N N I R I S L C K I T Q * L L * K I

26101 TTTAAACCACGTTAATCAAGAAGAAATGTTCTTTAAATAGAGCAGAGCTACGAAATCTC 26160
L N P A I L E E K C S I K D R R S A K S
Y I Q H L * N K K V L F K I E D R H K L
F K T C N T R R * L F N * R T E I S * L

26161 CGAGTCCAAGTCTAACTATCCGAATAATTACCAGCAAATGACGAAATTTACGAATACAG 26220
A * T * I S L S I L P R K V A K F A * T
P E P E S Q Y A * * H D N L Q K L H K H
S L N L N I P K N I T T * S S * I S I D

26221 AGAGTTGTGGAATCACTATAAAGAGAACATTTTAAACCACGACGAAATCGATACCTCTTC 26280
E * C S L S I E R T F N P A A K A I S F
R E V A * H Y K E Q L I Q H Q K L * P S
R L L K T I N R K Y F K T S S * S H L L

26281 CAATTACTCACACAATTTTCAGTTAGAGGAGCATAATTAAAAACACCATTACCATTAGTA 26340
T L S H T L L * D G R I L K Q P L P L *
P * H T H * F D I E E Y * N K H Y H Y D
N I L T N F T L R R T N I K T T I T I M

26341 TAAAACAGTAATCAAGTTTACGAGGAATACCAAAACAACAATACGTAAAATCAATATTT 26400
I K D N T * F A G * P K N N I C K L * L
Y K T M L E F H E K H N T T * A N * N Y
N Q * * N L I S R I T Q Q K H M K T I F

26401 GGATAAAGAAAATTTTGACAAAATCATTGACCAAAACACATATAGTCCACTACATCCA 26460
G I E K L V T K T L G P K H I D P S T P
V * K K * F Q K L L D Q N T Y I L H H L
R N R K F S N * Y T R T Q T Y * T I Y T

FIG. 3 CONT'D

26461 TAACGTGGATTGTGCCATAAAATAATTTGTATTACTAGTAACCTACAAGTGACCATCA 26520
I A G L C P Y K I L C L S * Q I N V P L
Y Q V * V L T N * * V Y H D N S T * Q Y
N C R F L P I K N F M I I M P H E S T T

26521 AGAATGATAATAGGACTTGGTTAAAGTCTATTTTTACAACAAAATACTTATGAACAAGA 26580
E * * * G S G I E S L F T T K I F V Q E
N K S N D Q V L K L Y F H Q K * S Y K N
R V I I R F W N * I F I N N K H I S T R

26581 CAATTAATAATGATTTGCGGAGAACAAATAAACTTAGTAAGACATGGTTTTAACAGACTA 26640
T L K V L A G R T * K F * E T G F N D S
Q * N * * L A E Q K N S D N Q V L I T Q
N I K S F R R K N I Q I M R Y W F Q R I

26641 AAACCTAGACTCAATAGAGTAACCAAATTTTAGTTTGTAGGTAACGCGGATTAACCTGA 26700
K S D S N D * Q N L F * V D M A G L K V
N Q I Q T I E N T * F D F M W Q A * N S
K F R L * R M P K F I L C G N R R I Q S

26701 AATTTAGAAGTATGATAATTACGATGAAAAAATCTAAACATAATACTCTACTTAGAATAA 26760
K F R * V I L A V K K S K Y * S I F R I
K L D E Y * * H * K K L N T N H S S D *
* I K M S N I S S K * I Q I I L H I K N

26761 GTTCTCAGATAATTCAGAAACTTATTATCAATATAGTTAGAATTTCTATATCCATGTATA 26820
* S D I L D K F L L * I L R L S I P V Y
E L T * * T K S Y Y N Y * D * L Y L Y M
L L R N L R Q I I T I D I K F I Y T C I

26821 CTTTACATACATTTTACCGGAACCATACAAACCGATGATTAAGAAAAAGTAAATATTAT 26880
S I Y T F H G Q Y T Q S S I E K E N I I
H F T H L I A K T H K A V L K K K M * L
F H I Y F P R P I N P * * N R K * K Y Y

26881 AAGGAACATAACGAGAAAAAATATACAACAACATGACCAACCAAGACGTACAAAATCA 26940
N R T N S K K I H Q Q V P Q P E A H K L
I G Q I A R K * I N N Y Q N H N Q M N *
E K Y Q E K K Y T T T S T T T R C T K T

26941 TTTACAGTATTAACAACACTACTCATACCACCAGTAGTACTAAAACAATAGTTTTGTAGA 27000
L H * L Q Q S S Y P P * * S K T I L V D
Y I D Y N N H H T H H D D H N Q * * F M
F T M I T T I L I T T M M I K N D F C R

FIG. 3 CONT'D

27001 GTACTACTAATCTTAGAGAACAGTCTAGAGTAATTTAGATTTGAAATAAATACCTGCAAA 27060
* S S * F R K D S R M L D L S * K H V N
E H H N S D R T L D * * I * V K N I S T
M I I L I E Q * I E N F R F K I * P R K

27061 CCTCTGGATCGATGTGTGTAAGAGAACAATAATCTCTTAAACCACAATGTTTGGAACTTC 27120
P S R A V C M R K N N S F K T N C V K F
Q L G L * V C E R T I L S N P T V F R S
S V * S C V N E Q * * L I Q H * L G Q L

27121 TAAACACAGATTTTCATATTAATGACAGTTGGATAACAACCAATGACATAACATGGAAT 27180
I Q T * L I I V T L R N N T V T N Y R *
S K H R F Y L * Q * G I T P * Q I T G K
N T D L T Y N S D V * Q Q N S Y Q V K L

27181 TACAAACCACAGCGTTCAAACCGTTTAAACGAAGAGTGAATGTAATGCATCAGTGCTAT 27240
I N P T A L K A F K S R V K C * T T V I
F T Q H R L N P L N A E * K V N R L * S
H K T D C T Q C I Q K E S * M V Y D R Y

27241 AAAGGGTATCATTATTAACCAACCAACATTGATCAAAATGATGAATACCATTATGACAAA 27300
N G M T I I K T N Y S T K S S I T I S N
I E W L L L K P T T V L K V V * P L V T
K G Y Y Y N Q H Q L * N * * K H Y Y Q K

27301 GACTCCGACACAGATCTAATCAACTTAGTCGAAGACTTAAATAACAAACCGCACGTCTCC 27360
R L S H R S * N F * S R F K N N P T C L
E S A T D L N T S D A E S N I T Q R A S
Q P Q T * I L Q I L K Q I * Q K A H L P

27361 GTGAATTATTCATACCAACTAAATAAAAAGTTACTATGACGAACCATGTATCCTGTCTAA 27420
C K I L I T S K N K L S V A Q Y M P C I
A S L L Y P Q N I K * H Y Q K T C L V S
V * Y T H N I * K E I I S S P V Y S L N

27421 AATCAAAATCAAAATAAAACAGAATAAAGAAATTAGAAACAACAACGAAAAAATCGTTGA 27480
K T K T K N Q R I E K I K T T A K K A V
K L K L K I K D * K K L R Q Q Q K K L L
* N * N * K T K N R * D K N N S K * C S

27481 TAATTCGAAACATACGTTGAAACACCAAAAACATTAAAGAAATAATAAAGTGGAGCCGA 27540
I L S Q I C S Q P K Q L K K I I E G E A
* * A K Y A V K H N K Y N R * * K V K P
N L K T H L K T T K T I E K N N * R R S

FIG. 3 CONT'D

27541 ATGCAAATATTTTCTCCATACGTCACATATTCAGAATATCACTTGTTCATATGGTGGG 27600
* T * L L P I C N Y L D * L S C T I G G
K R K Y F L Y A T T Y T K Y H V L * V V
V N I F S T H L Q I L R I T F L N Y W G

27601 TGAAGTCTAATAAATTAGATTTAGATTTGTAATACTTATTTAGAAAAGAAGGAGTTAAAT 27660
V E S * K I * I * V N H I F R K K R L K
W K L N N L R F R F M I F L D K R G * N
S * I I * D L D L C * S Y I K E E E I *

27661 GAAGACTAGTTCGACAATGTAAGAATTTTCTTACCTTAAAGAGAAAACCCACATTATGATG 27720
S R I L S N C E * F F P I E R Q T Y Y *
V E S * A T V N K F S H F K E K P T I S
K Q D L Q * M R L L I S N R K P H L V V

27721 AAAAATAATGATAGTATAACGTCAGCCAATATGCTCGGCATCATACAAACAAATAGAAT 27780
K K N S D Y Q L E T I R A T T H K N I K
S K I V I M N C N P * V L R L I N T * R
K * * * * I A T R N Y S G Y Y T Q K D *

27781 AGTCTACTAATAAGAAACCGAATACACCGGTAAGTACTGATAGTGAAGTATATAAATTAA 27840
D L H N N K P K H P W Q S D G Q S Y K I
I L I I I R Q S I H G N V I V K V I N L
* S S * E K A * T A M S * * R S * I * N

27841 CAAAAATACGAAACTTATTACGAAAAGAACGTAAAAGATATCACAAATGATAATAAAGAT 27900
T K I S Q I I S K K C K R Y H K S N N R
Q K * A K F L A K R A N E I T N V I I E
N K H K S Y H K E Q M K * L T * * * K *

27901 AACAATATACCTAAGAAATAAAACAATTATCATAAGCCGAAAAATAATCTTGACCGTCAA 27960
N N Y P N K I K N I T N P K K N S S A T
I T I H I R * K T L L I R S K I L V P L
Q * I S E K N Q * Y Y E A K * * F Q C N

27961 CCACCTCAAAATTAGGTCTCTGGTTATTAGAATACACATAACTATACTTTCCGTTCTACA 28020
P P T K I W L G I I K H T N I H F A L H
Q H L K L G S V L L R I H I S I F P L I
T S N * D L S W Y D * T Y Q Y S L C S T

28021 AACAATCCGGTCAATAACTCCTGATAGTGTGTAATTGACGATGACAATAAGCACCAGTAG 28080
K N P W N N L V I V C * S S S N N T T M
N T L G T I S S * * V N V A V T I R P *
Q * A L * Q P S D C M L Q * Q * E H D D

FIG. 3 CONT'D

28081 AAATATATGTCCACAGTTTGAACCGTGACCAATATGAGAAAGTCTAAACGGGCATATAC 28140
K I Y L T D F K A S T I S K * I Q G Y I
R * I C P T L S P V P * V R E S K G T Y
K Y V P H * V Q C Q N Y E K L N A R I H

28141 AATGACATCGATTCCACGTTTCATGAAACATGGATATTTGCACGGAAAAATCTATTCAATC 28200
N S Y S L H L Y K T G I F T G K * I L *
T V T A L T C T S Q V * L R A K K S L N
* Q L * P A L V K Y R Y V H R K L Y T L

28201 TACAATTATCACAAAACGACAAAACAATTCAGATTTCAACCATTGATAGCAAATGGCA 28260
I N I T T K S N K N L R F N T V I T * R
S T L L P K A T K T L D L T P L * R K G
H * Y H N Q Q K Q * T * L Q Y S D N V T

28261 GATCATTGGATCACCATACCTATGACGGAACAATTCTCGAATTTAGATTTGATAATCCT 28320
R T F R T T H I S G Q * S S L D L S N P
D L L G L P I S V A K N L A * I * V I L
* Y V * H Y P Y Q R T L L K F R F * * S

28321 ACAGAATATGAGGGCCAGTAATACGACCTTCATCTTCGAGGAGACCTTTAGCAAGTCCTT 28380
H R I S G T M I S S T S A G R S I T * S
I D * V G P * * A P L L L E E P F R E P
T K Y E R D N H Q F Y F S R Q F D N L F

28381 AGGAGTTCCTTTGAAGAACCCGACTGGTTAGACTCGCTTTAATGGTTTGGAAATTATCTC 28440
D E L F S R P S V L R L S I V L G K I S
I R L F V E Q A S W D S R F * W V K L L
G * S F K K P Q G I Q A F N G F R * Y L

28441 CGTCTTTTGGGTTGGATTTAAGTGACACAGATGAGTTGGTGTTCCTTTATGATAGGGTG 28500
A S F G L R F E S H R S L W L S I S D W
P L F V W G L N V T D V * G C P F V I G
C F F G V * I * Q T * E V V L F Y * G V

28501 TAATAAGGACCAAGAGGCCCTAGTGAGTTAAAGTTTTTCCATCTCTGAAATTTAAAAGTC 28560
M I G P E G P D S L K L F T S V K F K *
C * E Q N E P I V * N * F P L S K L N E
N N R T R R S * E I E F L Y L S * I K L

28561 TACCAGTTCCTCAAGGGTAACGAAAGCCTCATGGGGGAAGACTTCGTTTTCTATAACCA 28620
I T L S N G N S E S Y G R R F C F S I P
S P * P T G M A K P T G G E S A F P Y Q
H D L L E W Q K R L V G K Q L L L I N T

FIG. 3 CONT'D

28621 TATCTGTGTCCGCCCAAGAAAATTTTGTGCGACTACCCAGTTGTTTTCGTCAACAATGGCT 28680
I S V A P T R K F C S I T L L L L Q * R
Y L C L R R E K L V A S P * C F C N N G
Y V C G A N K * F L Q H D V F A T T V S

28681 CTACCATAAAGATGATAGAGCCATGGCCGGTATACGGTTACGTAGGATACCACTTAGGG 28740
S P I E V I E T G A W I G I C G I T F G
L H Y K * * R P V P G Y A L A D * P S D
I T N R S D R Y R G M H W H M R H H I G

28741 AGCTTCCCCAGAAGACCCCAACGATTAGTGGTTCGACTGTGAAGATGAGGGAGGCTACAAA 28800
E F P D E P N S I V L S V S R S G G I N
R S P T K Q T A L * W A S V E V G E S T
R L P R R P Q * D G L Q C K * E R R H K

28801 GCAGTTCCTAGGATGATGAGTTCTTCGATAGGGATGATCCAAAGCGGACCATGCTAAA 28860
R * P I R S S L F S D R S P K R R T R N
E D L S G V V * S A I G V L N G G P V I
T L P D * * E L L * G * * T E A Q Y S K

28861 ACGGAGTCCGATAATACAACCTCCGAGTCCCTCCAGACGAAGATTATCAGCTGGTCCAA 28920
Q R L A I I N F A * S P R S R I T S W T
K G * P * * T S P E P L D A E L L R G P
A E L S N H Q L S L F T Q K * Y D V L N

28921 GTGCAAGAGTTAGTGCACCTGGGTTATTAGCAAGTAATTCATCTTCATTAAGATTAAAAT 28980
* T R L * T S G I I T * * T S T I R I K
E R E * D R P G L L R E N L L L L E L K
V N E I V H V W Y D N M L Y F Y N * N *

28981 CTGTAAGTCTAAGATATCATTTTGGACTATACCGACTACTCTAGCGATTAGAACAAAATC 29040
S M * I R Y Y F R I H S I L D S I K N *
L C E S E I T F G S I A S S I A L R T K
V N L N * L L V Q Y P Q H S R * D Q K L

29041 GGTTCGAACCATTTCTAAGATTTGGAGTCGTTTCAGTGATTCGTTTTACGGTTCCTTTAGT 29100
G L K T F I R F R L L D S L L I G L F D
A L S P L S E L G * C T V L C F A L S I
W A Q Y L N * V E A L * * A F H W P F *

29101 CCGTATTTTAAAATGTTTTGGAGCGGTTTTTCGCTTGAGGATTATTTGTAACATTACAAG 29160
P M F N * C F R A L L S S R I F M T I N
L C L I K V F G R W F R V G L L C Q L T
A Y F K L L V E G F A F E * Y V N Y H E

FIG. 3 CONT'D

29161 TTGTCACAAAACCATTTCCTCCTGGAAGAGTTTTTAAACCATTACGACTTTACAATTTTCG 29220
L L T K T F S S R R L I K T I S F H * L
* C H K P L L P G E * F K P L A S I N F
V T N Q Y F L V K E F N Q Y H Q F T L A

29221 AACCATGATTACTAGGAGTCAAAGGATAAGAACGTCTTAATCGAGGATGTGGTCCACGAA 29280
K T S I I R L K R N K C F * S R C W T S
S P V L S G * N G I R A S N A G V G P A
Q Y * H D E T E * E Q L I L E * V L H K

29281 AAAAGAAACCAAGATTTAATCTGAACCAATTTTCTCTAAGGCTCCGACTGAGTGGACAAT 29340
K E K T R F * V Q N F S I G L S V * R N
K K K P E L N S K T L L S E S A S E G T
K R Q N * I L S P * F L N R P Q S V Q *

29341 TTCTACAAAACCTTGAAGTAATAAGACCAAGATAATCCAACTATCATGAAATGGTCCGA 29400
F I N K F K M I R T R N P K I T S * W A
L S T K S S * * E P E I L N S L V K G P
L H K Q V E N N Q N * * T Q Y Y K V L S

29401 AACTCTGTTAATACTTTCAAGAACTTCTCTTAAATTTACGAATGCAATTAAGATTAGTCT 29460
K L C N H F N K F L I * I S V N I R I L
K S V I I F T R S S F K F A * T L E L *
Q S L * S L E Q L S N L H K R * N * D S

29461 TGTGACTAAGACTAAGCAACTCAAGATTGGAGTCCGATTTTCTCCACAATTTGTTAATG 29520
V S I R I R Q T R F R L T F S T N F L *
F V S E S E N L E L G * R L L P T L C N
C Q N Q N T S N * V E A Y F L H * V I V

29521 GTCTTGTCAAACTGAGAGAATTAATTCACGACCATGAGTCGTGTAAGTTTACTAAAAT 29580
W F L K V R K I * T S T S L V N * I I K
G S C N S E R L K L A P V * C M E F S K
L V T Q S E * N L H Q Y E A C K L H N *

29581 GAGGACTCCTAGTATCAAATGAACGATGAGAACTACTAGGAATACATCTTCTGAGACAAC 29640
S R L I M T * K S S K I I R I Y F V R N
V G S S * L K S A V R S S G * T S S E T
E Q P D Y N V Q * E Q H D K H L L S Q Q

29641 GAATTACTCTTACTTAGGATTAAGCTGTGATCCACCATTGGGGAGCGATAATAAGCCTTA 29700
S L S F S D * N S V L H Y G R A I I R F
A * H S H I R I R C * T T V G R * * E S
K I L I F G L E V S P P L G E S N N P I

FIG. 3 CONT'D

29701 TCCTGTGAGAGATAGTCTTACTTAAGAACGACATTATTGTCTATCTCATCCAACAATGTC 29760
L V S E I L I F E Q Q L L L Y L L N N C
Y S V R * * F S N K S Y Y C I S Y T T V
P C E R D S H I R A T I V S L T P Q * L

29761 TGATATATAATTAATCATCTTTAAAATATAAAATCTGTAAACTAACAATCTCATCAATATT 29820
V I Y * N T S I K Y K S M Q N N S Y N Y
S * I N I L L F K I N L C K I T L T T I
S Y I L * Y F N * I * V N S Q * L L * L

29821 CCAAATCGACATCATATTTGCGGAGGCCCTTCTCGATAGTTAACATCACAAATTATATAT 29880
P K A T T Y V G G P L A I L Q L T * Y I
L N L Q L I F A E P F L * * N Y H K I Y
T * S Y Y L R R R S S S D I T T N L I Y

29881 ATAATCATATACTAACTTTAATTAATATCGGAAAACCTCCTTAATGTTTTTTTTTTTTTTT 29940
Y * Y I I S I L * L R K S S N C F F F F
I N T Y S Q F * N Y G K P P I V F F F F
I L I H N F N I I A K Q L F * L F F F F

29941 TT 29942
F
F

FIG. 3 CONT'D




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6




FIG. 7




FIG. 8

1 GAATAAGAGCGAATTGCGTCCGTACCGTCTATCAGCTTACGATCTCTTGTGAGATCTCAT 60
E * E R I A S V P S I S L R S L V R S H
N K S E L R P Y R L S A Y D L L S D L I
I R A N C V R T V Y Q L T I S C Q I S L

61 TAAATCTAAACTTTTTAAACAAGATTCCCTGTTATCCATGCTTGTGAGTGTGGTTAATC 120
* I * T F * T R F P V I H A C E C G L I
K S K L F K Q D S L L S M L V S V V * S
N L N F L N K I P C Y P C L * V W F N H

121 ATAATCTTGATTTTTACTTTCCACACTTTTCATCTCTCTGCCAGTGACGTGTTGGTTGTC 180
I I L Y F T F H T F H L S A S D V L V V
* S C I L L S T L F I S L P V T C W L S
N L V F Y F P H F S S L C Q * R V G C P

181 CTCAGCGTCCCTCCCATAGGTCGCAATGATTAACCAGCAAATACGGTCTCGGCTTCAA 240
L S V P P I G R N D * N Q Q I R S R L Q
S A S L P * V A M I K T S K Y G L G F K
Q R P S H R S Q * L K P A N T V S A S S

241 GTGGGCGCCAGAATTTTCGTTGGCTGCTTCCGGATGCAGCGGAGGAGTTGGCTAGTCCTAT 300
V G A R I S L A A S G C S G G V G * S Y
W A P E F R W L L P D A A E E L A S P M
G R Q N F V G C F R M Q R R S W L V L *

301 GAAGTCAGATGAGGGTGGGTTATGCCCTCTACTGGTCAAGCGATGGAAAGTGTGGATT 360
E V R * G W V M P L Y W S S D G K C W I
K S D E G G L C P S T G Q A M E S V G F
S Q M R V G Y A P L L V K R W K V L D L

361 TGTTTATGATAATCATGTGAAGATAGATTGTCGCTGCATTCTTGACAAGAATGGCATGT 420
C L * * S C E D R L S L H S W T R M A C
V Y D N H V K I D C R C I L G Q E W H V
F M I I M * R * I V A A F L D K N G M C

421 GCAGTCAAATCTTATCCGTGATATTTTTGTTTCATGAAGATCTACATGTTGTAGAAGTTCT 480
A V K S Y P * Y F C S * R S T C C R S S
Q S N L I R D I F V H E D L H V V E V L
S Q I L S V I F L F M K I Y M L * K F *

481 AACTAAAACAGCCGTAAGTCCGGTACGGCAATTTTAATTAATCACCTTTGCATAGCTT 540
N * N S R K V R Y G N F N * I T F A * L
T K T A V K S G T A I L I K S P L H S L
L K Q P * S P V R Q F * L N H L C I A W

FIG. 9

541 GGGTGGTTTTCTAAAGGGTATGTTATGGGCTTGTTCCGTTTCATACAAGACTAAACGTTA 600
G W F S * R V C Y G L V P F I Q D * T L
G G F P K G Y V M G L F R S Y K T K R Y
V V F L K G M L W A C S V H T R L N V M

601 TGTTGTACATCATCTTTCTATGACTACATCTACTACTAATTTGGTGAAGATTTTTGGG 660
C C T S S F Y D Y I Y Y * F W * R F F G
V V H H L S M T T S T T N F G E D F L G
L Y I I F L * L H L L L I L V K I F W V

661 TTGGATTGTACCTTTTGGTTTTATGCCATCTTATGTTCCAAAATGGTTTCAATTCTGTAG 720
L D C T F W F Y A I L C S Q M V S I L *
W I V P F G F M P S Y V H K W F Q F C R
G L Y L L V L C H L M F T N G F N S V G

721 GTTGATATTGAAGAGAGTGATTTAATAATTTCAAATTTTAAATTTGATGATTATGATTT 780
V V Y * R E * F N N F K F * I * * L * F
L Y I E E S D L I I S N F K F D D Y D F
C I L K R V I * * F Q I L N L M I M I L

781 TAGTGTAGAAGATGCTTATGCTGAGGTTTCATGCTGAGCCTAAAGGTAATATTCACAAAA 840
* C R R C L C * G S C * A * R * I F T K
S V E D A Y A E V H A E P K G K Y S Q K
V * K M L M L R F M L S L K V N I H K K

841 AGCTTATGCTTTACTTAGACAATATCGTGGTATTAACCCGTTACTCTTTGTAGACCAGTA 900
S L C F T * T I S W Y * T R T L C R P V
A Y A L L R Q Y R G I K P V L F V D Q Y
L M L Y L D N I V V L N P Y S L * T S M

901 TGGTTGTGACTATTCTGGTAAATTAGCAGATTGTCTTCAAGCTTATGGTCATTATTCTTT 960
W L * L F W * I S R L S S S L W S L F F
G C D Y S G K L A D C L Q A Y G H Y S L
V V T I L V N * Q I V F K L M V I I L C

961 GCAAGATATGAGACAAAAGCAGTCTGTATGGCTTGCCAATTGCGACTTTGATATTGTAGT 1020
A R Y E T K A V C M A C Q L R L * Y C S
Q D M R Q K Q S V W L A N C D F D I V V
K I * D K S S L Y G L P I A T L I L * W

1021 GGCTTGGCATGTAGTTCGTGATTACGATTTGTTATGCGCCTGCAGACTATAGCTACTAT 1080
G L A C S S * F T I C Y A P A D Y S Y Y
A W H V V R D S R F V M R L Q T I A T I
L G M * F V I H D L L C A C R L * L L F

FIG. 9 CONT.

1081 TTGTGGTATTAATATGTTGCACAACCTACAGAAGATGTAGTAGATGGAGCTGTAGTTAT 1140
L W Y * I C C T T Y R R C S R W S C S Y
C G I K Y V A Q P T E D V V D G A V V I
V V L N M L H N L Q K M * * M E L * L Y

1141 ACGTGAACCTGTACATTTATTATCTGCTGATGCAATAGTTTTAAAGCTTCCTAGTTTGAT 1200
T * T C T F I I C * C N S F K A S * F D
R E P V H L L S A D A I V L K L P S L M
V N L Y I Y Y L L M Q * F * S F L V * *

1201 GAAAGTTATGACTCATATGGATGATTTTTCTATTAATCTATATAACAATGTTGATTTGTG 1260
E S Y D S Y G * F F Y * I Y I Q C * F V
K V M T H M D D F S I K S I Y N V D L C
K L * L I W M I F L L N L Y T M L I C V

1261 TGATTGGTGGTTTTGTTATGCAGTATGGTTATGTAGATTGTTTTAATGATAAATTGTGATTT 1320
* L W F C Y A V W L C R L F * * * L * F
D C G F V M Q Y G Y V D C F N D N C D F
I V V L L C S M V M * I V L M I I V I F

1321 TTATGGTTGGGTTTCAGGTAATATGATGGATGGTTTTCTTGTCATTGTGTTGTACAGT 1380
L W L G F R * Y D G W F F L S I V L Y S
Y G W V S G N M M D G F S C P L C C T V
M V G F Q V I * W M V F L V H C V V Q F

1381 TTATGACTCTAGTGAAGTTAAAGCCCAATCATCTGGTGTATTTCCTGAGAATCCTGTGTT 1440
L * L * * S * S P I I W C Y S * E S C V
Y D S S E V K A Q S S G V I P E N P V L
M T L V K L K P N H L V L F L R I L C Y

1441 ATTTACTAATAGTACTGATACTGTTAACCCCTGATCTTTTTAATTTGTATGGTTATTCTGT 1500
I Y * * Y * Y C * P * F F * F V W L F C
F T N S T D T V N P D S F N L Y G Y S V
L L I V L I L L T L I L L I C M V I L L

1501 TACACCATTTGGTCTTGTATATATTGGTCACCGCTCCTGGATTGTGGATTCCTATCAT 1560
Y T I W F L Y I L V T A S W I V D S Y H
T P F G S C I Y W S P R P G L W I P I I
H H L V L V Y I G H R V L D C G F L S L

1561 TAAATCTTCAGTCAAGTCTTATGATGATTTGGTTTATTTCAGGTGTAGTAGGTTGTAATC 1620
* I F S Q V L * * F G L F R C S R L * I
K S S V K S Y D D L V Y S G V V G C K S
N L Q S S L M M I W F I Q V * * V V N L

FIG. 9 CONT.

1621 TATTGTTAAAGAACTGCTCTTATTACTCATGCACCTTACTTAGATTATGTTCAATGTAA 1680
Y C * R N C S Y Y S C T L L R L C S M *
I V K E T A L I T H A L Y L D Y V Q C K
L L K K L L L L L M H F T * I M F N V S

1681 GTGTGGTAATCTTGAACAAAATCATATTCTTGGTGTTAATAATTCTTGGTGTAGGCAACT 1740
V W * S * T K S Y S W C * * F L V * A T
C G N L E Q N H I L G V N N S W C R Q L
V V I L N K I I F L V L I I L G V G N C

1741 GTTGCTTAATAGAGGTGATTATAATATGCTTTTAAAAAATATTGACTTGTTTTGTTAAGCG 1800
V A * * R * L * Y A F K K Y * L V C * A
L L N R G D Y N M L L K N I D L F V K R
C L I E V I I I C F * K I L T C L L S V

1801 TCGTGCTGATTTTGCTTGCAAGTTTGCAGTTTGTGGAGATGGTTTTGTACCTTTTTTACT 1860
S C * F C L Q V C S L W R W F C T F F T
R A D F A C K F A V C G D G F V P F L L
V L I L L A S L Q F V E M V L Y L F Y *

1861 AGATGGTTTAATCCCGTAGTTATTATCTAATTCAGAGTGGTATTTTCTTTACATCTTT 1920
R W F N S P * L L S N S E W Y F L Y I F
D G L I P R S Y Y L I Q S G I F F T S L
M V * F P V V I I * F R V V F S L H L *

1921 GATGTCTCAATTTTCACAAGAAGTTTCTGATATGTGTTTAAAAATGTGTATTTTGTTTAT 1980
D V S I F T R S F * Y V F K N V Y F V Y
M S Q F S Q E V S D M C L K M C I L F M
C L N F H K K F L I C V * K C V F C L W

1981 GGACAGAGTTTCAGTTGCTACATTTTATATAGAGCATTATGTTAATAGGTTGGTTACTCA 2040
G Q S F S C Y I L Y R A L C * * V G Y S
D R V S V A T F Y I E H Y V N R L V T Q
T E F Q L L H F I * S I M L I G W L L N

2041 ATTTAAGTTATGGGTACTACACTTGTTAATAAAAATGGTTAATGGTTTAAATACCATGTT 2100
I * V I G Y Y T C * * N G * L V * Y H V
F K L L G T T L V N K M V N W F N T M L
L S Y W V L H L L I K W L I G L I P C *

2101 AGATGCTAGTGACCTGCTACAGGCTGGCTTCTTTACCAATTATGAATGGTCTTTTTGT 2160
R C * C T C Y R L A S L P I I E W S F C
D A S A P A T G W L L Y Q L L N G L F V
M L V H L L Q A G F F T N Y * M V F L *

FIG. 9 CONT.

2161 AGTATCTCAAGCCAACTTTAATTTTGTGGCTTTAATACCTGATTATGCTAAAATTTTAGT 2220
S I S S Q L * F C C F N T * L C * N F S
V S Q A N F N F V A L I P D Y A K I L V
Y L K P T L I L L L * Y L I M L K F * L

2221 TAATAAATTTTACACTTTTTTTAAGTTATTATTAGAGTGTGTACAGTTGATGTTTTAAA 2280
* * I L H F F * V I I R V C Y S * C F K
N K F Y T F F K L L L E C V T V D V L K
I N F T L F L S Y Y * S V L Q L M F * K

2281 AGATATGCCTGTTCTTAAACTATTAATGGTTTGTATTGTAGGCAATAAGTTTTTA 2340
R Y A C S * N Y * W F S L Y C R Q * V L
D M P V L K T I N G L V C I V G N K F Y
I C L F L K L L M V * F V L * A I S F I

2341 TAACGTTAGTACAGGGTTAATCCTGGTTTTGTTTTACCATGTAATGCACAGGAACAACA 2400
* R * Y R V N S W F C F T M * C T G T T
N V S T G L I P G F V L P C N A Q E Q Q
T L V Q G * F L V L F Y H V M H R N N K

2401 AATTTATTTTTTTGAAGGCGTTGCAGAATCTGTTATAGTAGAAGATGATGTTATTGAGAA 2460
N L F F * R R C R I C Y S R R * C Y * E
I Y F F E G V A E S V I V E D D V I E N
F I F L K A L Q N L L * * K M M L L R M

2461 TGTCAAATCTTCTTTATCATCTTATGAGTATTGTCAACCACCTAAATCTGTAGAAAAAAT 2520
C Q I F F I I L * V L S T T * I C R K N
V K S S L S S Y E Y C Q P P K S V E K I
S N L L Y H L M S I V N H L N L * K K F

2521 TTGTATTATAGATAATATGTACATGGGTAAGTGTGGTGATAAATTTTTCCCTATTGTCAT 2580
L Y Y R * Y V H G * V W * * I F P Y C H
C I I D N M Y M G K C G D K F F P I V M
V L * I I C T W V S V V I N F S L L S *

2581 GAATGATAAAAATATTTGTCTTTTAGATCAGGCTTGGCGTTTTCCATGTGCAGGTAGAAA 2640
E * * K Y L S F R S G L A F S M C R * K
N D K N I C L L D Q A W R F P C A G R K
M I K I F V F * I R L G V F H V Q V E K

2641 AGTTAATTTTAAACGAGAAACCTGTTGTTATGGAGATTCCGCTTTTGATGACAGTTAAGGT 2700
S * F * R E T C C Y G D S V F D D S * G
V N F N E K P V V M E I P S L M T V K V
L I L T R N L L L W R F R L * * Q L R L

FIG. 9 CONT.

2701 TATGTTTGATTAGATTCTACTTTTGTATGATATTTTAGGTAAAGTTTGTTCAGAATTTGA 2760
Y V * F R F Y F * * Y F R * S L F R I *
M F D L D S T F D D I L G K V C S E F E
C L I * I L L L M I F * V K F V Q N L K

2761 AGTAGAAAAGGGTGTACTGTAGATGATTTTGTCTGCTGTTGTTTGTGATGCTATAGAGAA 2820
S R K G C Y C R * F C R C C L * C Y R E
V E K G V T V D D F V A V V C D A I E N
* K R V L L * M I L S L L F V M L * R M

2821 TGCTTTAAACTCTTGTAAAGATCATCCAGTGGTTGGTTATCAAGTTCGTGCATTTTAA 2880
C F K L L * R S S S G W L S S S C I F K
A L N S C K D H P V V G Y Q V R A F L N
L * T L V K I I Q W L V I K F V H F * I

2881 TAACTTAATGAGAACGTTGTTTATTATTTGATGAGGCTGGTGATGAAGCAATGGCCTC 2940
* T * * E R C L F I * * G W * * S N G L
K L N E N V V Y L F D E A G D E A M A S
N L M R T L F I Y L M R L V M K Q W P L

2941 TCGTATGTATTGTACTTTTGCTATTGAGGATGTTGAAGACGTTATCAGTAGTGAAGCTGT 3000
S Y V L Y F C Y * G C * R R Y Q * * S C
R M Y C T F A I E D V E D V I S S E A V
V C I V L L L L R M L K T L S V V K L L

3001 TGAAGATACTATTGATGGTGTCTGTTGAAGACACTATTAATGATGATGAAGATGTTGTTAC 3060
* R Y Y * W C R * R H Y * * * * R C C Y
E D T I D G V V E D T I N D D E D V V T
K I L L M V S L K T L L M M M K M L L L

3061 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3120
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3121 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3180
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3181 TGGTGATAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3240
W * * * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V I M T M K M L L L V T M T M K M L L L

FIG. 9 CONT.

3241 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3300
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3301 TGGTGACAATGACGATGAAGATGTTGTTACTGGTGACAATGACGATGAAGATGTTGTTAC 3360
W * Q * R * R C C Y W * Q * R * R C C Y
G D N D D E D V V T G D N D D E D V V T
V T M T M K M L L L V T M T M K M L L L

3361 TGGTGACAATGACGATGAAGAGATTGTTACTGGTGACAATGATGACCAAATTGTTGTTAC 3420
W * Q * R * R D C Y W * Q * * P N C C Y
G D N D D E E I V T G D N D D Q I V V T
V T M T M K R L L L V T M M T K L L L L

3421 TGGTGATGATGTAGATGATATTGAAAGTGTCTATGATTTTTGATACTTATAAAGCTCTTTT 3480
W * * C R * Y * K C L * F * Y L * S S F
G D D V D D I E S V Y D F D T Y K A L L
V M M * M I L K V S M I L I L I K L F *

3481 AGTTTTTAATGATGTCTATAATGATGCTTTGTTGTTAGTTATGGTTCTAGTTGAAAC 3540
S F * * C L * * C F V C * L W F * C * N
V F N D V Y N D A L F V S Y G S S V E T
F L M M S I M M L C L L V M V L V L K Q

3541 AGAAACATATTTTTAAAGTTAATGGTTTATGGTCACCTACTATTACACATACTAACTGTTG 3600
R N I F * S * W F M V T Y Y Y T Y * L L
E T Y F K V N G L W S P T I T H T N C W
K H I L K L M V Y G H L L L H I L T V G

3601 GTTGC GTTCTGTGTTACTTGTAAATGCAGAAATACCTTTTAAGTTTAAGGATTTAGCTAT 3660
V A F C V T C N A E I T F * V * G F S Y
L R S V L L V M Q K L P F K F K D L A I
C V L C Y L * C R N Y L L S L R I * L L

3661 TGAAAATATGTGGTTATCTTATAAGGTGGGTATAATCAAAGTTTTGTTGATTATTTACT 3720
* K Y V V I L * G G L * S K F C * L F T
E N M W L S Y K V G Y N Q S F V D Y L L
K I C G Y L I R W V I I K V L L I I Y *

3721 GACCACTATTCCTAAAGCTATGTTTTGCCTCAAGGTGGTTATGTAGCTGACTTTGCTTA 3780
D H Y S * S Y C F A S R W L C S * L C L
T T I P K A I V L P Q G G Y V A D F A Y
P L F L K L L F C L K V V M * L T L L I

FIG. 9 CONT.

3781 TTGGTTTTTAAACCAGTTTGATATTAATGCGTATGCTAATTGGTGTGTTTAAAATGTGG 3840
L V F K P V * Y * C V C * L V L F K M W
W F L N Q F D I N A Y A N W C C L K C G
G F * T S L I L M R M L I G V V * N V V

3841 TTTTCTTTTGATTTAAATGGTTTGGATGCTGTGTTTTTTATGGAGATATTGTGTCTCA 3900
F F F * F K W F G C C V F L W R Y C V S
F S F D L N G L D A V F F Y G D I V S H
F L L I * M V W M L C F F M E I L C L M

3901 TGTTTGTAAGTGTGGACATAATATGACTCTAATAGCAGCGGACTTACCTGTACATTACA 3960
C L * V W T * Y D S N S S G L T L Y I T
V C K C G H N M T L I A A D L P C T L H
F V S V D I I * L * * Q R T Y L V H Y I

3961 TTTTTCATTATTTGATGACAATTTTTGTGCTTTTTGCACCCCTAAAAAATTTTTATTGC 4020
F F I I * * Q F L C F L H P * K N F Y C
F S L F D D N F C A F C T P K K I F I A
F H Y L M T I F V L F A P L K K F L L L

4021 TGCATGTGCTGTGGATGTAAACGTTTGTCACTCTGTAGCTGTTATAGGTGATGAACAAAT 4080
C M C C G C K R L S F C S C Y R * * T N
A C A V D V N V C H S V A V I G D E Q I
H V L W M * T F V I L * L L * V M N K *

4081 AGATGGTAAGTTTGTACTAAATTTAGTGGTGATAAATTTGATTTTATAGTAGGTTATGG 4140
R W * V C Y * I * W * * I * F Y S R L W
D G K F V T K F S G D K F D F I V G Y G
M V S L L L N L V V I N L I L * * V M E

4141 AATGTCATTTAGTATGTCTTCTTTTGTAGTCAATTGTATGGTTTGTGTATAACACC 4200
N V I * Y V F F * V S S I V W F V Y N T
M S F S M S S F E L A Q L Y G L C I T P
C H L V C L L L S * L N C M V C V * H L

4201 TAATGTATGTTTTGTTAAAGGTGATATTATAAATGTTGCTAGACTTGTAAAGCTGATGT 4260
* C M F C * R * Y Y K C C * T C * S * C
N V C F V K G D I I N V A R L V K A D V
M Y V L L K V I L * M L L D L L K L M L

4261 TATTGTTAACCCCTGCTAATGGGCATATGCTCCATGGTGGTGGAGTTGCAAAAGCTATAGC 4320
Y C * P C * W A Y A P W W W S C K S Y S
I V N P A N G H M L H G G G V A K A I A
L L T L L M G I C S M V V E L Q K L * L

FIG. 9 CONT.

4321 TGTAGCTGCAGGTAAAAAATTTTCTAAAGAACTGCTGCTATGGTTAAATCTAAAGGTGT 4380
C S C R * K I F * R N C C Y G * I * R C
V A A G K K F S K E T A A M V K S K G V
* L Q V K N F L K K L L L W L N L K V F

4381 TTGCCAAGTAGGAGATTGTTATGTTTCTACCGGTGGTAAATTATGTAAAACAATTCTTAA 4440
L P S R R L L C F Y R W * I M * N N S *
C Q V G D C Y V S T G G K L C K T I L N
A K * E I V M F L P V V N Y V K Q F L I

4441 TATTGTAGGTCCTGATGCTAGACAAGATGGAAGACAATCTTATGTTTTGTAGCACGTGC 4500
Y C R S * C * T R W K T I L C F V S T C
I V G P D A R Q D G R Q S Y V L L A R A
L * V L M L D K M E D N L M F C * H V L

4501 TTATAAGCATCTTAATAATTATGATTGTTGTTGTCTACTCTCATATCGGCTGGTATATT 4560
L * A S * * L * L L F V Y S H I G W Y I
Y K H L N N Y D C C L S T L I S A G I F
I S I L I I M I V V C L L S Y R L V Y L

4561 TAGTGTTCTGCTGATGTGTCATTAACCTTACCTTCTAGGTGTTGTTGATAAAACAAGTTAT 4620
* C S C * C V I N L P S R C C * * T S Y
S V P A D V S L T Y L L G V V D K Q V I
V F L L M C H * L T F * V L L I N K L S

4621 CCTTGTTAGTAATAATAAGAAGATTTTGATATTATTCAAAAATGTCAAATTACTTCAGT 4680
P C * * * * R R F * Y Y S K M S N Y F S
L V S N N K E D F D I I Q K C Q I T S V
L L V I I K K I L I L F K N V K L L Q L

4681 TGTTGGTACTAAAGCATTGGCTGTTAGATTAACCTGCTAATGTAGGCCGTGTTATTAAATT 4740
C W Y * S I G C * I N C * C R P C Y * I
V G T K A L A V R L T A N V G R V I K F
L V L K H W L L D * L L M * A V L L N L

4741 TGAGACAGATGCATACAACTTTTCTTGAGTGGTGATGATTGTTTTGTTTCAAATTCTTC 4800
* D R C I Q T F L E W * * L F C F K F F
E T D A Y K L F L S G D D C F V S N S S
R Q M H T N F S * V V M I V L F Q I L L

4801 TGTTATACAAGAAGTTTTATTGCTTCGTCATGATATACAATTGAATAATGACGTTTCGTGA 4860
C Y T R S F I A S S * Y T I E * * R S *
V I Q E V L L L R H D I Q L N N D V R D
L Y K K F Y C F V M I Y N * I M T F V I

FIG. 9 CONT.

4861 TTATTTGTTGTCTAAGATGACTAGTCTTCCCAAAGATTGGCGTCTTATCAATAAATTTGA 4920
L F V V * D D * S S Q R L A S Y Q * I *
Y L L S K M T S L P K D W R L I N K F D
I C C L R * L V F P K I G V L S I N L M

4921 TGTTATTAACGGTGTAAACTGTAAAGTACTTTGAGTGTCTTAATTCTATTTATATATG 4980
C Y * R C * N C * V L * V S * F Y L Y M
V I N G V K T V K Y F E C P N S I Y I C
L L T V L K L L S T L S V L I L F I Y V

4981 TAGTCAGGGTAAAGACTTTGGTTATGTATGTGATGGTCTTTTTTATAAAGCAACTGTAA 5040
* S G * R L W L C M * W F F L * S N C *
S Q G K D F G Y V C D G S F Y K A T V N
V R V K T L V M Y V M V L F I K Q L L I

5041 TCAAGTTTGTGTGTTATTAGCTAAGAAGATAGATGTTTTGCTTACTGTAGATGGTGTAA 5100
S S L C V I S * E D R C F A Y C R W C *
Q V C V L L A K K I D V L L T V D G V N
K F V C Y * L R R * M F C L L * M V L I

5101 TTTTAAATCTATTTCTTACTGTAGGTGAAGTTTTTGGTAAAATACTTGGTAATGTTTT 5160
F * I Y F S Y C R * S F W * N T W * C F
F K S I S L T V G E V F G K I L G N V F
L N L F L L L * V K F L V K Y L V M F S

5161 CTGTGATGGCATTGATGTTACTAAGTTAAAGTGTAGTGATTTTTATGCCGATAAAAATTT 5220
L * W H * C Y * V K V * * F L C R * N F
C D G I D V T K L K C S D F Y A D K I L
V M A L M L L S * S V V I F M P I K F Y

5221 ATATCAGTATGAAAATTTGTCTTTAGCTGATATTTCTGCTGTACAAAGTTCATTTGGGTT 5280
I S V * K F V F S * Y F C C T K F I W V
Y Q Y E N L S L A D I S A V Q S S F G F
I S M K I C L * L I F L L Y K V H L G L

5281 TGATCAGCAACAATTGCTTGCTTACTATAATTTTTTAACAGTATGTAAATGGTCTGTAGT 5340
* S A T I A C L L * F F N S M * M V C S
D Q Q Q L L A Y Y N F L T V C K W S V V
I S N N C L L T I I F * Q Y V N G L * L

5341 TGTTAACGGTCCATTTTTTTCTTTTGAACAGTCTCATAATAATTGTTATGTGAATGTAGC 5400
C * R S I F F F * T V S * * L L C E C S
V N G P F F S F E Q S H N N C Y V N V A
L T V H F F L L N S L I I I V M * M * L

FIG. 9 CONT.

5401 TTGTCTTATGTTGCAGCATATTAATCTTAAATTTAATAAATGGCAGTGGCAGGAAGCATG 5460
L S Y V A A Y * S * I * * M A V A G S M
C L M L Q H I N L K F N K W Q W Q E A W
V L C C S I L I L N L I N G S G R K H G

5461 GTATGAATTCGTGCTGGCAGACCACATAGGTTAGTTGCTCTTGTGTTTTAGCTAAAGGTCA 5520
V * I S C W Q T T * V S C S C F S * R S
Y E F R A G R P H R L V A L V L A K G H
M N F V L A D H I G * L L L F * L K V I

5521 TTTTAAATTTGATGAACCATCAGATGCTACTGATTTTATTCGTGTTGTTTTGAACAAGC 5580
F * I * * T I R C Y * F Y S C C F E T S
F K F D E P S D A T D F I R V V L K Q A
L N L M N H Q M L L I L F V L F * N K L

5581 TGATTTATCAGGTGCAATTTGTGAATTAGAACTTATTTGTGATTGTTGTTATTAACAAGA 5640
* F I R C N L * I R T Y L * L W Y * T R
D L S G A I C E L E L I C D C G I K Q E
I Y Q V Q F V N * N L F V I V V L N K K

5641 AAGTCGTGTTGGTGTGATGCTGTTATGCATTTTGGTACATTAGCAAAGACTGATCTTTT 5700
K S C W C * C C Y A F W Y I S K D * S F
S R V G V D A V M H F G T L A K T D L F
V V L V L M L L C I L V H * Q R L I F L

5701 TAATGGTTATAAGATTGGCTGTAATTGTGCAGGTAGAATTGTCCATTGTACTAAATTGAA 5760
* W L * D W L * L C R * N C P L Y * I E
N G Y K I G C N C A G R I V H C T K L N
M V I R L A V I V Q V E L S I V L N * M

5761 TGTACCATTTTTGATTTGTTCTAATACTCCTCTGAGTAAGGATTTACCTGATGATGTTGT 5820
C T I F D L F * Y S S E * G F T * * C C
V P F L I C S N T P L S K D L P D D V V
Y H F * F V L I L L * V R I Y L M M L L

5821 TGCAGCTAACATGTTTATGGGTGTAGGTGTAGGCCATTATACACATTTGAAATGTGGTTC 5880
C S * H V Y G C R C R P L Y T F E M W F
A A N M F M G V G V G H Y T H L K C G S
Q L T C L W V * V * A I I H I * N V V H

5881 ACCTTACCAACATTATGATGCTTGTAGTGTAAAAAATATACAGGTGTTAGTGGTTGTTT 5940
T L P T L * C L * C * K I Y R C * W L F
P Y Q H Y D A C S V K K Y T G V S G C L
L T N I M M L V V L K N I Q V L V V V *

FIG. 9 CONT.

5941 AACTGACTGCTTGTATCTTAAAAATTTAACCCAGACTTTTACATCTATGTTGACTAATTA 6000
N * L L V S * K F N P D F Y I Y V D * L
T D C L Y L K N L T Q T F T S M L T N Y
L T A C I L K I * P R L L H L C * L I I

6001 TTTTTGGATGATGTTGAAATGGTTGCTTATAACCCTGATCTTTCACAATATTATTGTGA 6060
F F G * C * N G C L * P * S F T I L L *
F L D D V E M V A Y N P D L S Q Y Y C D
F W M M L K W L L I T L I F H N I I V I

6061 TAATGGTAAGTATTATACAAAACCTATTATAAAGGCTCAGTTTAAACCATTGCTAAAAGT 6120
* W * V L Y K T Y Y K G S V * T I C * S
N G K Y Y T K P I I K A Q F K P F A K V
M V S I I Q N L L * R L S L N H L L K L

6121 TGACGGTGTTTATACTAACTTTAAGTTAGTTGGACATGATATTTGTGCTCAATTGAATGA 6180
* R C L Y * L * V S W T * Y L C S I E *
D G V Y T N F K L V G H D I C A Q L N D
T V F I L T L S * L D M I F V L N * M I

6181 TAAGTTAGGTTTTAATGTAGATTTGCCGTTTGTGAGTACAAAGTAACAGTCTGGCCTGT 6240
* V R F * C R F A V C * V Q S N S L A C
K L G F N V D L P F V E Y K V T V W P V
S * V L M * I C R L L S T K * Q S G L *

6241 AGCTACTGGTGATGTTGTTTGGCATCTGATGATTTATATGTTAAACGTTATTTTAAAGG 6300
S Y W * C C F G I * * F I C * T L F * R
A T G D V V L A S D D L Y V K R Y F K G
L L V M L F W H L M I Y M L N V I L K D

6301 ATGTGAAACTTTTGGTAAGCCTGTTATTTGGCTTTGTCATGATGAAGCATCATTGAATTC 6360
M * N F W * A C Y L A L S * * S I I E F
C E T F G K P V I W L C H D E A S L N S
V K L L V S L L F G F V M M K H H * I L

6361 TCTTACTTATTTTAATAAACCTAGTTTTAAATCTGAAAATAGATATAGTGTTTTGTCTGT 6420
S Y L F * * T * F * I * K * I * C F V C
L T Y F N K P S F K S E N R Y S V L S V
L L I L I N L V L N L K I D I V F C L L

6421 TGATTCTGTATCTGAGGAGTCACAAGGTAATGTGGTTACTTCTGTTATGGAATCGCAGAT 6480
* F C I * G V T R * C G Y F C Y G I A D
D S V S E E S Q G N V V T S V M E S Q I
I L Y L R S H K V M W L L L L W N R R L

FIG. 9 CONT.

6481 TAGTACTAAAGAGGTTAAGTTAAAGGGTGTAGAAAGACTGTTAAAATAGAAGATGCTAT 6540
* Y * R G * V K G C * K D C * N R R C Y
S T K E V K L K G V R K T V K I E D A I
V L K R L S * R V L E R L L K * K M L L

6541 TATTGTTAATGATGAAAATAGTTCTATTAAGGTTGTTAAAAGTTTATCTTTAGTTGATGT 6600
Y C * * * K * F Y * G C * K F I F S * C
I V N D E N S S I K V V K S L S L V D V
L L M M K I V L L R L L K V Y L * L M F

6601 TTGGGATATGTATTTGACAGGTTGTGATTATGTTGTTTGGGTTGCTAATGAATTGTCACG 6660
L G Y V F D R L * L C C L G C * * I V T
W D M Y L T G C D Y V V W V A N E L S R
G I C I * Q V V I M L F G L L M N C H A

6661 CCTAGTTAAATCACCAACAGTTAGGGAATATATACGATATGGTATTAACCTATTACTAT 6720
P S * I T N S * G I Y T I W Y * T Y Y Y
L V K S P T V R E Y I R Y G I K P I T I
* L N H Q Q L G N I Y D M V L N L L L Y

6721 ACCTATAGATTTGTTATGTTTAAAGAGATGATAATCAAACCTCTTTTAGTTCCTAAAATTTT 6780
T Y R F V M F K R * * S N S F S S * N F
P I D L L C L R D D N Q T L L V P K I F
L * I C Y V * E M I I K L F * F L K F L

6781 TAAAGCAAGAGCTATAGAATTTTATGGTTTTTTGAAGTGGTTGTTTATTTATGTTTTTATG 6840
* S K S Y R I L W F F E V V V Y L C F *
K A R A I E F Y G F L K W L F I Y V F S
K Q E L * N F M V F * S G C L F M F L V

6841 TTTATTACATTTTACAAATGATAAAACCATTTTTTATACTACAGAAATAGCTTCTAAGTT 6900
F I T F Y K * * N H F L Y Y R N S F * V
L L H F T N D K T I F Y T T E I A S K F
Y Y I L Q M I K P F F I L Q K * L L S L

6901 TACTTTTAATTTGTTTTGTTTGGCTCTTAAAATGCTTTTCAGACATTTAGATGGAGTAT 6960
Y F * F V L F G S * K C F S D I * M E Y
T F N L F C L A L K N A F Q T F R W S I
L L I C F V W L L K M L F R H L D G V Y

6961 ATTTATAAAAGGTTTTCTTGTGTAGCCACTGTGTTTTTGTFTTTGGTTTAATTTTTTGTGA 7020
I Y K R F S C C S H C V F V L V * F F V
F I K G F L V V A T V F L F W F N F L Y
L * K V F L L * P L C F C F G L I F C I

FIG. 9 CONT.

7021 TATAAATGTTATTTTTAGTGATTTTTATCTTCCTAATATTAGTGTTCCTATTTTTGT 7080
Y K C Y F * * F L S S * Y * C F S Y F C
I N V I F S D F Y L P N I S V F P I F V
* M L F L V I F I F L I L V F F L F L W

7081 GGGAGAATTGTTATGTGGATAAAGGCTACTTTTGGTTGGTTACAATTTGTGATTTTA 7140
G K N C Y V D K G Y F W F G Y N L * F L
G R I V M W I K A T F G L V T I C D F Y
E E L L C G * R L L L V W L Q F V I F I

7141 TTCTAAGTTAGGTGTAGGTTTTACAAGTCATTTTTGTAATGGTAGTTTTATATGTGAATT 7200
F * V R C R F Y K S F L * W * F Y M * I
S K L G V G F T S H F C N G S F I C E L
L S * V * V L Q V I F V M V V L Y V N C

7201 GTGTTATTCTGGTTTTGATATGTTGGATACATATGCAGCTATAGATTTTGTTCAGTATGA 7260
V L F W F * Y V G Y I C S Y R F C S V *
C Y S G F D M L D T Y A A I D F V Q Y E
V I L V L I C W I H M Q L * I L F S M K

7261 AGTAGATAGACGTGTTTTATTTGATTATGTTAGTTTAGTCAAATTAATTGTTGAACCTCGT 7320
S R * T C F I * L C * F S Q I N C * T R
V D R R V L F D Y V S L V K L I V E L V
* I D V F Y L I M L V * S N * L L N S L

7321 TATTGGTTATTCATTATATACAGTATGGTTTTATCCATTATTTTGTCTTATTGGTTTACA 7380
Y W L F I I Y S M V L S I I L S Y W F T
I G Y S L Y T V W F Y P L F C L I G L Q
L V I H Y I Q Y G F I H Y F V L L V Y N

7381 ATTATTTACTACATGGTTGCCTGATTTGTTTATGTTAGAACTATGCATTGGTTGATTAG 7440
I I Y Y M V A * F V Y V R N Y A L V D *
L F T T W L P D L F M L E T M H W L I R
Y L L H G C L I C L C * K L C I G * L D

7441 ATTTATTGTATTTGTAGCTAATATGTTACCTGCTTTTGTCTTGTTCGCGTTTTATATAGT 7500
I Y C I C S * Y V T C F C L V A V L Y S
F I V F V A N M L P A F V L L R F Y I V
L L Y L * L I C Y L L L S C C G F I * L

7501 TGTTACTGCTATGTATAAAGTAGTTGGTTTTATTAGGCATATTGTTTATGGTTGTAATAA 7560
C Y C Y V * S S W F Y * A Y C L W L * *
V T A M Y K V V G F I R H I V Y G C N K
L L L C I K * L V L L G I L F M V V I K

FIG. 9 CONT.

7561 AGCTGGTTGTTTGTGTTTTGTTATAAACGAAATTGTAGTGTTCGTGTTAAGTGTAGTACTAT 7620
S W L F V L L * T K L * C S C * V * Y Y
A G C L F C Y K R N C S V R V K C S T I
L V V C F V I N E I V V F V L S V V L L

7621 TGTTGGTGGTGAATTCGTTATTATGATATTACTGCTAATGGTGGTACTGGTTTTTGTGT 7680
C W W C N S L L * Y Y C * W W Y W F L C
V G G V I R Y Y D I T A N G G T G F C V
L V V * F V I M I L L L M V V L V F V L

7681 TAAACATCAATGGAATTGTTTAAATTGCCATTCTTTTAAACCAGGTAACACTTTTATAAC 7740
* T S M E L F * L P F F * T R * H F Y N
K H Q W N C F N C H S F K P G N T F I T
N I N G I V L I A I L L N Q V T L L * L

7741 TGTAGAAGCTGCTATAGAACCTTTCTAAAGAGCTTAAACGACCTGTAACCCCAACTGATGC 7800
C R S C Y R T F * R A * T T C K P N * C
V E A A I E L S K E L K R P V N P T D A
* K L L * N F L K S L N D L * T Q L M L

7801 TTCACATTATGTAGTTACTGATATTAAGCAAGTTGGTTGTATGATGCGTTTGTCTATGA 7860
F T L C S Y * Y * A S W L Y D A F V L *
S H Y V V T D I K Q V G C M M R L F Y D
H I M * L L I L S K L V V * C V C S M I

7861 TAGAGATGGACAGCGTGTTTACGATGATGTTGATGCTAGTTTATTTGTAGATATTAATAA 7920
* R W T A C L R * C * C * F I C R Y * *
R D G Q R V Y D D V D A S L F V D I N N
E M D S V F T M M L M L V Y L * I L I I

7921 TCTGTTACATTCTAAAGTCAAAGTTGTTCCCTAATTTGTATGTAGTTGTAGTAGAGAGTGA 7980
S V T F * S Q S C S * F V C S C S R E *
L L H S K V K V V P N L Y V V V V E S D
C Y I L K S K L F L I C M * L * * R V M

7981 TGCTGATAGAGCTAATTTTCTGAATGCTGTTGTGTTTTATGCACAATCATTGTATAGGCC 8040
C * * S * F S E C C C V L C T I I V * A
A D R A N F L N A V V F Y A Q S L Y R P
L I E L I F * M L L C F M H N H C I G L

8041 TATATTACTTGTAGACAAAAAGTTAATTACTACAGCTTGTAAATGGTATCTCTGTAACCCA 8100
Y I T C R Q K V N Y Y S L * W Y L C N P
I L L V D K K L I T T A C N G I S V T Q
Y Y L * T K S * L L Q L V M V S L * P R

FIG. 9 CONT.

8101 GACTATGTTTGGATGTTTATGTTGATACTTTTATGTCTCATTTTGGATGTTGATAGAAAGAG 8160
D Y V * C L C * Y F Y V S F * C * * K E
T M F D V Y V D T F M S H F D V D R K S
L C L M F M L I L L C L I L M L I E R V

8161 TTTTAATAATTTGTTAACATTGCTCATGCTTCTCTTAGAGAGGGTGTGCAATTAGAAAA 8220
F * * F C * H C S C F S * R G C A I R K
F N N F V N I A H A S L R E G V Q L E K
L I I L L T L L M L L L E R V C N * K R

8221 GGTTTTAGATACTTTTGTGGGATGTGTACGTAAATGTTGTTCCATTGATTCAGATGTTGA 8280
G F R Y F C G M C T * M L F H * F R C *
V L D T F V G C V R K C C S I D S D V E
F * I L L W D V Y V N V V P L I Q M L K

8281 AACAAAGATTTACTAAATCTATGATATCTGCAGTAGCTGCTGGTTTGGAAATTTACTGA 8340
N K I Y Y * I Y D I C S S C W F G I Y *
T R F I T K S M I S A V A A G L E F T D
Q D L L L N L * Y L Q * L L V W N L L M

8341 TGAAAATTATAACAATTTGGTACCTACATATTTAAAGAGTGATAATATTGTAGCTGCAGA 8400
* K L * Q F G T Y I F K E * * Y C S C R
E N Y N N L V P T Y L K S D N I V A A D
K I I T I W Y L H I * R V I I L * L Q I

8401 TTTAGGTGTTCTTATACAGAATGGTGCTAAGCATGTACAGGGTAATGTTGCTAAGGCAGC 8460
F R C S Y T E W C * A C T G * C C * G S
L G V L I Q N G A K H V Q G N V A K A A
* V F L Y R M V L S M Y R V M L L R Q L

8461 TAATATTTCTTGTATATGGTTTATTGACACTTTTAATCAACTTACTGCTGATTTACAGCA 8520
* Y F L Y M V Y * H F * S T Y C * F T A
N I S C I W F I D T F N Q L T A D L Q H
I F L V Y G L L T L L I N L L L I Y S I

8521 TAAATTAATAAAGCATGTGTAAAACCTGGCTTGAAGTTAAAATTGACTTTTAATAAGCA 8580
* I K K S M C * N W L E V K I D F * * A
K L K K A C V K T G L K L K L T F N K Q
N * K K H V L K L A * S * N * L L I S K

8581 AGAGGCAAGTGTTCCTATTCTTACAACGCCCTTTTCACTTAAAGGAGGTGTTGTATTGAG 8640
R G K C S Y S Y N A L F T * R R C C I E
E A S V P I L T T P F S L K G G V V L S
R Q V F L F L Q R P F H L K E V L Y * V

FIG. 9 CONT.

8641 TAATTTGTTATATATATATTATTTTTTATTAGTTTAACTGTTTTATATTATTGTGGGCTTT 8700
* F V I Y I I F Y * F N L F Y I I V G F
N L L Y I L F F I S L I C F I L L W A L
I C Y I Y Y F L L V * S V L Y Y C G L Y

8701 ACTGCCTACATATAGTGTTTATAAGTCTGATATTCATTTGCCTGCTTATGCTAGTTTTAA 8760
T A Y I * C L * V * Y S F A C L C * F *
L P T Y S V Y K S D I H L P A Y A S F K
C L H I V F I S L I F I C L L M L V L K

8761 AGTTATTGATAATGGTGTGTTAGAGATATTTTCAGTTAATGATTTATGTTTTGCTAATAA 8820
S Y * * W C C * R Y F S * * F M F C * *
V I D N G V V R D I S V N D L C F A N K
L L I M V L L E I F Q L M I Y V L L I N

8821 ATTTTTCCAATTTGATCAATGGTATGAGTCCACTTTTGGGTCTTTTTACTATCATAATTC 8880
I F P I * S M V * V H F W V F L L S * F
F F Q F D Q W Y E S T F G S F Y Y H N S
F S N L I N G M S P L L G L F T I I I L

8881 TATGGATTGCCCTATTGTGTGGCAGTTATGGATGAAGATATTGGTTCTACTATGTTTTAA 8940
Y G L P Y C C G S Y G * R Y W F Y Y V *
M D C P I V V A V M D E D I G S T M F N
W I A L L L W Q L W M K I L V L L C L M

8941 TGTTCTACTAAAGTTTTGAGACATGGCTTTTCATGTTTTACATTTTCTAACTTATGCATT 9000
C S Y * S F E T W L S C F T F S N L C I
V P T K V L R H G F H V L H F L T Y A F
F L L K F * D M A F M F Y I F * L M H L

9001 TGCTAGTGATAGTGTTCAGTGCTATACACCACATATTCAGATTTCTTATAATGATTTTTTA 9060
C * * * C S V L Y T T Y S D F L * * F L
A S D S V Q C Y T P H I Q I S Y N D F Y
L V I V F S A I H H I F R F L I M I F M

9061 TGCTAGTGGTTGTGTTTTATCATCTTTGTGTACTATGTTTAAAAGAGGTGATGGTACACC 9120
C * W L C F I I F V Y Y V * K R * W Y T
A S G C V L S S L C T M F K R G D G T P
L V V V F Y H L C V L C L K E V M V H H

9121 ACATCCTTATTGTTATTTCAGATGGTGTATGAAGAATGCTTCTTTGTATACATCTTTGGT 9180
T S L L L F R W C Y E E C F F V Y I F G
H P Y C Y S D G V M K N A S L Y T S L V
I L I V I Q M V L * R M L L C I H L W F

FIG. 9 CONT.

9181 TCCACATACACGTTATAGCCTTGCTAATTCTAATGGTTTTATAAGATTTCTCTGATGTTAT 9240
S T Y T L * P C * F * W F Y K I S * C Y
P H T R Y S L A N S N G F I R F P D V I
H I H V I A L L I L M V L * D F L M L L

9241 TAGTGAAGGTATTGTACGTATTGTAAGAACGCGCTCTATGACTTATTGTAGAGTGGGTGC 9300
* * R Y C T Y C K N A L Y D L L * S G C
S E G I V R I V R T R S M T Y C R V G A
V K V L Y V L * E R A L * L I V E W V H

9301 ATGTGAATATGCCGAAGAGGGTATATGTTTTAATTTAATAGTTCCTGGGTTTTGAATAA 9360
M * I C R R G Y M F * F * * F L G F E *
C E Y A E E G I C F N F N S S W V L N N
V N M P K R V Y V L I L I V P G F * I M

9361 TGATTATTATAGAAGTATGCCTGGAACTTTTGTGGTAGAGATCTTTTTGATTTGTTTTA 9420
* L L * K Y A W N F L W * R S F * F V L
D Y Y R S M P G T F C G R D L F D L F Y
I I I E V C L E L F V V E I F L I C F I

9421 TCAATTTTTAGTAGTTTAATTCGTCCTATAGATTTCTTTTCTCTTACTGCTAGTTCTAT 9480
S I F * * F N S S Y R F L F S Y C * F Y
Q F F S S L I R P I D F F S L T A S S I
N F L V V * F V L * I S F L L L L V L F

9481 TTTTGGAGCTATATTGGCTATAGTCGTTGTCTTGGTTTTTTATTATTTAATAAAACTTAA 9540
F W S Y I G Y S R C L G F L L F N K T *
F G A I L A I V V V L V F Y Y L I K L K
L E L Y W L * S L S W F F I I * * N L S

9541 GCGTGCTTTTGGAGATTATACTAGTGTGTAGTTATAAATGTTATTGTTTGGTGTATTAA 9600
A C F W R L Y * C C S Y K C Y C L V Y *
R A F G D Y T S V V V I N V I V W C I N
V L L E I I L V L * L * M L L F G V L I

9601 TTTTCTTATGCTTTTTGTTTTCAAGTTTATCCTATTTGTGCAATGTGTCTATGCTTGTTT 9660
F S Y A F C F S S L S Y L C M C L C L F
F L M L F V F Q V Y P I C A C V Y A C F
F L C F L F F K F I L F V H V S M L V F

9661 TTATTTTTATGTAACATTGTATTTTCTTCTGAAATTAGTGTAATTATGCATTTGCAATG 9720
L F L C N I V F S F * N * C N Y A F A M
Y F Y V T L Y F P S E I S V I M H L Q W
I F M * H C I F L L K L V * L C I C N G

FIG. 9 CONT.

9781 TATTGCAAACCATGTTTTATGGTTATTTTCATATTGTAGGAAAATTGGTGTAAATGTATG 9840
Y C K P C F M V I F I L * E N W C * C M
I A N H V L W L F S Y C R K I G V N V C
L Q T M F Y G Y F H I V G K L V L M Y V

9841 TAATGATAGTACATTTGAAGAAACATCTCTTACTACTTTTTATGATTACTAAAAGATTCTTA 9900
* * * Y I * R N I S Y Y F Y D Y * R F L
N D S T F E E T S L T T F M I T K D S Y
M I V H L K K H L L L L L * L L K I L I

9901 TTGTAGATTAAGAATTCTGTTTCTGATGTTGCTTACAATAGATATTTGAGTTTGTATAA 9960
L * I K E F C F * C C L Q * I F E F V *
C R L K N S V S D V A Y N R Y L S L Y N
V D * R I L F L M L L T I D I * V C I I

9961 TAAGTATCGTTACTATAGTGGTAAAATGGATACTGCTGCCTATAGAGAAGCGCGTGTTC 10020
* V S L L * W * N G Y C C L * R S G V F
K Y R Y Y S G K M D T A A Y R E A A C S
S I V T I V V K W I L L P I E K R R V L

10021 TCAGTTAGCTAAAGCTATGGAACATTTAATCACAATAATGGTAATGATGTCTTATACCA 10080
S V S * S Y G N I * S Q * W * * C L I P
Q L A K A M E T F N H N N G N D V L Y Q
S * L K L W K H L I T I M V M M S Y T N

10081 ACCTCCTACAGCATCTGTTTCTACATCTTTTTTGCAATCAGGTATTGTAAAGATGGTATC 10140
T S Y S I C F Y I F F A I R Y C K D G I
P P T A S V S T S F L Q S G I V K M V S
L L Q H L F L H L F C N Q V L * R W Y L

10141 TCCTACGTCAAAAATTGAACCTTGATTGTTAGTGTACTTATGGTAGTATGACTTTGAA 10200
S Y V K N * T L Y C * C Y L W * Y D F E
P T S K I E P C I V S V T Y G S M T L N
L R Q K L N L V L L V L L M V V * L * M

10201 TGGTTTATGTTAGATGACAAAAGTTTATTGTCCTCGTCATGTTATATGTTTATCCTCTAA 10260
W F M V R * Q S L L S S S C Y M F I L *
G L W L D D K V Y C P R H V I C L S S N
V Y G * M T K F I V L V M L Y V Y P L I

10261 TATGAATGAACCTGATTATTCTGCCTTATTATGTAGAGTTACTCTAGGTGATTTTACTAT 10320
Y E * T * L F C L I M * S Y S R * F Y Y
M N E P D Y S A L L C R V T L G D F T I
* M N L I I L P Y Y V E L L * V I L L *

FIG. 9 CONT.

9721 GATTGTTATGTATGGTGCTATAATGCCTTTTGGTTTGTGTACATATGTAGCTATGGT 9780
D C Y V W C Y N A F L V L C H I C S Y G
I V M Y G A I M P F W F C V T Y V A M V
L L C M V L * C L F G F V S H M * L W L

10321 AATGTCTGGGCGGATGAGTTTAAACAGTTGTGTCTTACCAGATGCAGGGCTGTCAACTTGT 10380
N V W A D E F N S C V L P D A G L S T C
M S G R M S L T V V S Y Q M Q G C Q L V
C L G G * V * Q L C L T R C R A V N L F

10381 TTTGACAGTCTCTTTACAAAATCCTTACACTCCAAAATATACTTTTGGTGTGTTAAACC 10440
F D S L F T K S L H S K I Y F W C C * T
L T V S L Q N P Y T P K Y T F G V V K P
* Q S L Y K I L T L Q N I L L V L L N L

10441 TGGTGAAACTTTTACTGTTTTAGCTGCGTATAATGGCCGACCACAAGGGGCATTTTCATGT 10500
W * N F Y C F S C V * W P T T R G I S C
G E T F T V L A A Y N G R P Q G A F H V
V K L L L F * L R I M A D H K G H F M L

10501 TACTATGCGTAGTAGTTATACTATTAAGGTTCTTTTTTGTGTGGGTCATGIGGATCTGT 10560
Y Y A * * L Y Y * R F F F V W V M W I C
T M R S S Y T I K G S F L C G S C G S V
L C V V V I L L K V L F C V G H V D L L

10561 TGGTTATGTATTAACAGGTGATAGTGTAAAGTTTGTATATATGCATCAATTAGAGCTCAG 10620
W L C I N R * * C * V C I Y A S I R A Q
G Y V L T G D S V K F V Y M H Q L E L S
V M Y * Q V I V L S L Y I C I N * S S V

10621 TACTGGTTGTCACACTGGCACTGATTTTACTGGTAATTTTTATGGTCCATATAGAGATGC 10680
Y W L S H W H * F Y W * F L W S I * R C
T G C H T G T D F T G N F Y G P Y R D A
L V V T L A L I L L V I F M V H I E M L

10681 TCAAGTTGTACAGTTGCCAGTTAAGGACTACGTCCAACTGTAAATGTTATTGCTTGGCT 10740
S S C T V A S * G L R P N C * C Y C L A
Q V V Q L P V K D Y V Q T V N V I A W L
K L Y S C Q L R T T S K L L M L L L G S

10741 CTATGCAGCTATACTTAATAATTGTGCTTGGTTTGTACAAAATGATGTTTGTCTATTGA 10800
L C S Y T * * L C L V C T K * C L F Y *
Y A A I L N N C A W F V Q N D V C S I E
M Q L Y L I I V L G L Y K M M F V L L K

FIG. 9 CONT.

10801 AGATTTTAATGTTTGGGCTATGACAAATGGTTTTAGCCAAGTAAAAGCAGATCTTGT TTTT 10860
R F * C L G Y D K W F * P S K S R S C F
D F N V W A M T N G F S Q V K A D L V L
I L M F G L * Q M V L A K * K Q I L F *

10861 AGATGCTTTGGCTTCAATGACAGGTGTTTCTATTGAACTTTATTGGCTGCTATTAAGCG 10920
R C F G F N D R C F Y * N F I G C Y * A
D A L A S M T G V S I E T L L A A I K R
M L W L Q * Q V F L L K L Y W L L L S V

10921 TCTATATATGGGATTTCAAGGTCGTCAAATACTAGGAAGTTGTACTTTTGAAGATGAATT 10980
S I Y G I S R S S N T R K L Y F * R * I
L Y M G F Q G R Q I L G S C T F E D E L
Y I W D F K V V K Y * E V V L L K M N W

10981 GGCACCTTCTGACGTTTATCAACAATTGGCTGGTGTAAATTGCAATCTAAAACAAAAG 11040
G T F * R L S T I G W C * I A I * N K K
A P S D V Y Q Q L A G V K L Q S K T K R
H L L T F I N N W L V L N C N L K Q K D

11041 ATTTATTAAGAAACAATTTATTGGATTTTGATATCTACATTTTGT TTTAGTTGTATAAT 11100
I Y * R N N L L D F D I Y I F V * L Y N
F I K E T I Y W I L I S T F L F S C I I
L L K K Q F I G F * Y L H F C L V V * F

11101 TTCTGCATTTGTAAATGGACTATATTATGTATATTAATACACATATGATTGGTGT TAC 11160
F C I C * M D Y I Y V Y * Y T Y D W C Y
S A F V K W T I F M Y I N T H M I G V T
L H L L N G L Y L C I L I H I * L V L H

11161 ATTATGTGTA CTTTGT TTTGTTAGTTTATGATGTTACTAGTTAAACATAAGCATT TTTTA 11220
I M C T L F C * F Y D V T S * T * A F L
L C V L C F V S F M M L L V K H K H F Y
Y V Y F V L L V L * C Y * L N I S I F I

11221 TTGACTATGTATATAATTCCTGTACTCTGTACCTGTTT TATGTAAATTATTTAGTTGT 11280
F D Y V Y N S C T L Y L V L C K L F S C
L T M Y I I P V L C T L F Y V N Y L V V
* L C I * F L Y S V P C F M * I I * L S

11281 CTATAAGGAAGGTTTTAGAGGTCTTACTTATGTCTGGCTCTCATATTTTGTTCCTGCTGT 11340
L * G R F * R S Y L C L A L I F C S C C
Y K E G F R G L T Y V W L S Y F V P A V
I R K V L E V L L M S G S H I L F L L *

FIG. 9 CONT.

11341 GAATTTTACTTATGTTTATGAAGTATTTATGGTTGTATTTATGTGTTTTGCTATTTT 11400
E F Y L C L * S I L W L Y F M C F C Y F
N F T Y V Y E V F Y G C I L C V F A I F
I L L M F M K Y F M V V F Y V F L L F L

11401 TATACTATGCATAGTATTAATCATGACATTTTTCTTTGATGTTTTGGTTGGTAGAAT 11460
Y N Y A * Y * S * H F F F D V F G W * N
I T M H S I N H D I F S L M F L V G R I
* L C I V L I M T F F L * C F W L V E *

11461 AGTTACTTTAATTTCTATGTGGTATTTGGGTCGAATTTAGAAGAGGATGTTTTGTTATT 11520
S Y F N F Y V V F W V E F R R G C F V I
V T L I S M W Y F G S N L E E D V L L F
L L * F L C G I L G R I * K R M F C Y L

11521 TATTACAGCCTTTTTAGGTACTIONTATACATGGACCACTATTTGTCCATTAGCTATAGCAAA 11580
Y Y S L F R Y L Y M D H Y F V I S Y S K
I T A F L G T Y T W T T I L S L A I A K
L Q P F * V L I H G P L F C H * L * Q K

11581 AATTGTTGCTAATTTGGTTGTCTGTTAATATATTTTTATTTTACAGATGTACCTTATATTA 11640
N C C * L V V C * Y I L F Y R C T L Y *
I V A N W L S V N I F Y F T D V P Y I K
L L L I G C L L I Y F I L Q M Y L I L N

11641 ATTGATTCTTTTGAGTTACTTATTTATAGGGTATATTTTATCTTGTATTGGGGATTTTT 11700
I D S F E L L I Y R V Y F I L L L G I F
L I L L S Y L F I G Y I L S C Y W G F F
* F F * V T Y L * G I F Y L V I G D F S

11701 CTCTCTTTAAACAGTGTTTTTAGAAATGCCTATGGGTGTTTATAATTATAAAAATTTCTGT 11760
L S F K Q C F * N A Y G C L * L * N F C
S L L N S V F R M P M G V Y N Y K I S V
L F * T V F L E C L W V F I I I K F L F

11761 TCAAGAATTGCGTTATATGAATGCTAATGGCTTACGTCCACCCCGTAATAGTTTTGAGGC 11820
S R I A L Y E C * W L T S T P * * F * G
Q E L R Y M N A N G L R P P R N S F E A
K N C V I * M L M A Y V H P V I V L R L

11821 TATTTTGTAAATTTAAACTGCTTGAATAGGTGGCGTGCCAGTTATTGAAGTTTCTCA 11880
Y F V K F K T A W N R W R A S Y * S F S
I L L N L K L L G I G G V P V I E V S Q
F C * I * N C L E * V A C Q L L K F L K

FIG. 9 CONT.

11881 AATTCAATCAAAATTGACTGATGTGAAATGTGCTAATGTTGTTTTGTTAAATTGTTTACA 11940
N S I K I D * C E M C * C C F V K L F T
I Q S K L T D V K C A N V V L L N C L Q
F N Q N * L M * N V L M L F C * I V Y S

11941 GCATTTGCATGTTGCTTCTAATTCTAGGTTGTGGCAGTATTGTAGTATTTTACATAATGA 12000
A F A C C F * F * V V A V L * Y F T * *
H L H V A S N S R L W Q Y C S I L H N E
I C M L L L I L G C G S I V V F Y I M K

12001 AATACTATCTACTTCAGATTTAAGTGTAGCTTTTGATAAGCTTGCTCAATTAATTGATTGT 12060
N T I Y F R F K C S F * * A C S I I D C
I L S T S D L S V A F D K L A Q L L I V
Y Y L L Q I * V * L L I S L L N Y * L F

12061 TTTATTCGCCAATCCTGCTGCAGTTGATACTAAGTGTCTTGCAAGTATAGATGAAGTTAG 12120
F I R Q S C C S * Y * V S C K Y R * S *
L F A N P A A V D T K C L A S I D E V S
Y S P I L L Q L I L S V L Q V * M K L A

12121 CGATGATTATGTTCAAGATAGTACTGTTTTGCAGGCTTTGCAAAGTGAGTTTGTAATAT 12180
R * L C S R * Y C F A G F A K * V C K Y
D D Y V Q D S T V L Q A L Q S E F V N M
M I M F K I V L F C R L C K V S L * I W

12181 GGCTAGTTTTGTGAATATGAAGTCGCAAAGAAAAATTTGGCTGATGCTAAAAATAGTGG 12240
G * F C * I * S R K E K F G * C * K * W
A S F V E Y E V A K K N L A D A K N S G
L V L L N M K S Q R K I W L M L K I V V

12241 TTCTGTTAATCAACAACAGATAAAACAGTTAGAAAAGGCATGTAATATAGCTAAGTCTGT 12300
F C * S T T D K T V R K G M * Y S * V C
S V N Q Q Q I K Q L E K A C N I A K S V
L L I N N R * N S * K R H V I * L S L C

12301 GTATGAACGCGATAAAGCTGTAGCTCGCAAACGTAACGTATGGCAGACCTAGCACTTAC 12360
V * T R * S C S S Q T G T Y G R P S T Y
Y E R D K A V A R K L E R M A D L A L T
M N A I K L * L A N W N V W Q T * H L L

12361 TAACATGTATAAAGAGGCTCGGATTAATGATAAGAAGAGTAAAGTTGTTCCGCTTTGCA 12420
* H V * R G S D * * * E E * S C F R F A
N M Y K E A R I N D K K S K V V S A L Q
T C I K R L G L M I R R V K L F P L C R

FIG. 9 CONT.

12421 GACAATGCTTTTTAGCATGGTTCGTAAATTGGATAATCAGGCTTTAAATTCTATTCTGGA 12480
D N A F * H G S * I G * S G F K F Y S G
T M L F S M V R K L D N Q A L N S I L D
Q C F L A W F V N W I I R L * I L F W I

12481 TAATGCTGTAAAGGTTGTGTACCTTTGAATGCTATTCCAGCGCTGGCTGCTAATACTTT 12540
* C C * R L C T F E C Y S S A G C * Y F
N A V K G C V P L N A I P A L A A N T L
M L L K V V Y L * M L F Q R W L L I L *

12541 AACTATAATAATACCAGATAAACAAGTTTTGATAAAGTTGTTGATAATGTTTATGTTGC 12600
N Y N N T R * T S F * * S C * * C L C C
T I I I P D K Q V F D K V V D N V Y V A
L * * Y Q I N K F L I K L L I M F M L H

12601 ATATGCTGGTAGTGATGGCATATACAGACTGTTCAAGATGCTGATGGTATTAATAAACA 12660
I C W * C M A Y T D C S R C * W Y * * T
Y A G S V W H I Q T V Q D A D G I N K Q
M L V V Y G I Y R L F K M L M V L I N S

12661 GTTAAGTATATTAGTGGTTGATTCTAATTGGCCTCTTGTATTATTGCTAACAGGTATAA 12720
V N * Y * C * F * L A S C Y Y C * Q V *
L T D I S V D S N W P L V I I A N R Y N
* L I L V L I L I G L L L L L L T G I M

12721 TGAAGTTGCTAATGCTGTTATGCAGAATAATGAGTTGATGCCTCATAAATTAATAAACA 12780
* S C * C C Y A E * * V D A S * I K N T
E V A N A V M Q N N E L M P H K L K I Q
K L L M L L C R I M S * C L I N * K Y K

12781 AGTTGTTAATAGTGGTTCTGATATGAATTGTAACATTCCTACTCAATGTTATTATAATAA 12840
S C * * W F * Y E L * H S Y S M L L * *
V V N S G S D M N C N I P T Q C Y Y N N
L L I V V L I * I V T F L L N V I I I M

12841 TGGTAGTAGTGGTAGAATAGTTTATGCTGTTCTTAGTGATGTTGATGGTCTTAAGTATAC 12900
W * * W * N S L C C S * * C * W S * V Y
G S S G R I V Y A V L S D V D G L K Y T
V V V V E * F M L F L V M L M V L S I L

12901 TAAGATAATAAAGATGATGGAAATTGTGTTGTTTTAGAGCTTGATCCTCCTTGAAATT 12960
* D N K R * W K L C C F R A * S S L * I
K I I K D D G N C V V L E L D P P C K F
R * * K M M E I V L F * S L I L L V N F

FIG. 9 CONT.

12961 TTCTATACAAGATGTTAAGGGACTTAAAATTAAGTATCTTTATTTTATTAAAGGATGTAA 13020
F Y T R C * G T * N * V S L F Y * R M *
S I Q D V K G L K I K Y L Y F I K G C N
L Y K M L R D L K L S I F I L L K D V T

13021 CACTTTAGCTAGAGGGTGGGTTGTTGGTACTTTATCTTCAACAATTAGATTGCAGGCTGG 13080
H F S * R V G C W Y F I F N N * I A G W
T L A R G W V V G T L S S T I R L Q A G
L * L E G G L L V L Y L Q Q L D C R L V

13081 TGTTGCTACTGAGTATGCAGCTAATTCTTCTATACTTTCATTATGTGCATTTTCTGTAGA 13140
C C Y * V C S * F F Y T F I M C I F C R
V A T E Y A A N S S I L S L C A F S V D
L L L S M Q L I L L Y F H Y V H F L * I

13141 TCCTAAGAAAACCTATTTAGATTATATACAACAAGGTGGTGTACCTATAATTAATTGTGT 13200
S * E N L F R L Y T T R W C T Y N * L C
P K K T Y L D Y I Q Q G G V P I I N C V
L R K L I * I I Y N K V V Y L * L I V L

13201 TAAAATGCTCTGTGATCATGCTGGTACTGGTATGGCTATTACTATTAAACCTGAGGCTAC 13260
* N A L * S C W Y W Y G Y Y Y * T * G Y
K M L C D H A G T G M A I T I K P E A T
K C S V I M L V L V W L L L L N L R L L

13261 TATTAATCAAGATTCTTATGGTGGTGCCTCAGTTTGTATTTACTGCCGTGCACGTGTAGA 13320
Y * S R F L W W C L S L Y L L P C T C R
I N Q D S Y G G A S V C I Y C R A R V E
L I K I L M V V P Q F V F T A V H V * S

13321 GCATCCAGATGTAGATGGTTTGTGTAAATTACGTGGTAAATTTGTACAAGTCCCTTTGGG 13380
A S R C R W F V * I T W * I C T S P F G
H P D V D G L C K L R G K F V Q V P L G
I Q M * M V C V N Y V V N L Y K S L W V

13381 TATAAAAGATCCTATTCTCTATGTGTTAACACATGATGTTTGTCAAGTTTGTGGATTTTG 13440
Y K R S Y S L C V N T * C L S S L W I L
I K D P I L Y V L T H D V C Q V C G F W
* K I L F S M C * H M M F V K F V D F G

13441 GAGAGATGGCAGTTGTTCTGTGTAGGTTTCAGGTGTCGCTGTTCAATCTAAAGATTTAAA 13500
E R W Q L F L C R F R C R C S I * R F K
R D G S C S C V G S G V A V Q S K D L N
E M A V V P V * V Q V S L F N L K I * I

FIG. 9 CONT.

13501 TTTTAAACGGGTTTCGGGTAAGTGTGAATGCCCGTCTAGTACCCTGTGCTAGTGGT 13560
F F K R V R G T S V N A R L V P C A S G
F L N G F G V L V * M P V * Y P V L V V
F * T G S G Y * C E C P S S T L C * W F

13561 TTATCTACTGATGTTCAATTAAGGGCATTGATATTTGTAATACTAATAGAGCTGGTATA 13620
L S T D V Q L R A F D I C N T N R A G I
Y L L M F N * G H L I F V I L I E L V *
I Y * C S I K G I * Y L * Y * * S W Y R

13621 GGTATATATTATAAAGTGAATTGTTGCCGTTTTCAGCGTATAGATGACGACGGTAATAAA 13680
G L Y Y K V N C C R F Q R I D D D G N K
V Y I I K * I V A V F S V * M T T V I N
F I L * S E L L P F S A Y R * R R * * I

13681 TTGGATAAGTTCCTTGTGTTAAAAGAAGTCTAGAGTTTATAATAAAGAGAAAAGT 13740
L D K F F V V K R T N L E V Y N K E K T
W I S S L L L K E L I * K F I I K R K L
G * V L C C * K N * S R S L * * R E N L

13741 TATTATGAGTTGACTAAAAGTGTGGTGTGCTGAACATGATTTCTTTACATTTGAT 13800
Y Y E L T K S C G V V A E H D F F T F D
I M S * L K V V V L W L N M I S L H L I
L * V D * K L W C C G * T * F L Y I * Y

13801 ATTGATGGTAGTCGTGTGCCACATATAGTTCGTAAGAACCTCTCAAAGTATACTATGTTA 13860
I D G S R V P H I V R K N L S K Y T M L
L M V V V C H I * F V R T S Q S I L C *
* W * S C A T Y S S * E P L K V Y Y V R

13861 GATCTTTGCTATGCATTGCGCCATTTGATTGTAATGATTGTTTCAGTATTGTGTGAAATT 13920
D L C Y A L R H F D C N D C S V L C E I
I F A M H C A I L I V M I V Q Y C V K F
S L L C I A P F * L * * L F S I V * N S

13921 CTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAAGATTGGTATGATTTT 13980
L C E Y A D C K E S Y F S K K D W Y D F
F V S M L I V K N P T F L R K I G M I L
L * V C * L * R I L L F * E R L V * F C

13981 GTTGAATACTCTGATATTATTAATATTTATAAAAAATTAGGCCCTATTTTAAATAGAGCT 14040
V E N P D I I N I Y K K L G P I F N R A
L K I L I L L I F I K N * A L F L I E L
* K S * Y Y * Y L * K I R P Y F * * S F

FIG. 9 CONT.

14041 TTA C T T A A T A C T G T C A G T T T T G C A G A T A C T T T A G T A A A A G T A G G T T T A G T T G G T G T T T T A 14100
L L N T V S F A D T L V K V G L V G V L
Y L I L S V L Q I L * * K * V * L V F *
T * Y C Q F C R Y F S K S R F S W C F N

14101 A C T T T A G A T A A T C A A G A C T T G T A T G G T C A A T G G T A T G A T T T T G G T G A T T T T A T A C A A A C A 14160
T L D N Q D L Y G Q W Y D F G D F I Q T
L * I I K T C M V N G M I L V I L Y K Q
F R * S R L V W S M V * F W * F Y T N S

14161 G C T C C A G G T T T T G G T G T G G C A G T T G C A G A T T C T T A C T A T T C T T A T A T A T G A T G C C T A T G T T G 14220
A P G F G V A V A D S Y Y S Y M M P M L
L Q V L V W Q L Q I L T I L I * C L C *
S R F W C G S C R F L L F L Y D A Y V D

14221 A C T A T G T G T C A T G T A T T A G A T T G T G A A T T A T T T G T T A A T G A T A G T T A T A G A C A A T T C G A T 14280
T M C H V L D C E L F V N D S Y R Q F D
L C V M Y * I V N Y L L M I V I D N S I
Y V S C I R L * I I C * * * L * T I R S

14281 C T T G T A C A G T A T G A T T T T A C T G A T T A T A A G T T A G A A T T G T T T A A T A A G T A T T T T A A G T A T 14340
L V Q Y D F T D Y K L E L F N K Y F K Y
L Y S M I L L I I S * N C L I S I L S I
C T V * F Y * L * V R I V * * V F * V L

14341 T G G G G T A T G A A G T A T C A T C C T A A T A C T G T G G A T T G T G A T A A T G A T A G G T G T A T T A T T C A T 14400
W G M K Y H P N T V D C D N D R C I I H
G V * S I I L I L W I V I M I G V L F I
G Y E V S S * Y C G L * * * * V Y Y S L

14401 T G T G C T A A T T T T A A T A T A T T A T T T A G T A T G G T C T T A C C T A A T A C T T G T T T T G G T C C T C T T 14460
C A N F N I L F S M V L P N T C F G P L
V L I L I Y Y L V W S Y L I L V L V L L
C * F * Y I I * Y G L T * Y L F W S S C

14461 G T T A G A C A A A T T T T T G T A G A T G G T G T T C C G T T T G T T G T T T C A A T T G G T T A C C A T T A T A A A 14520
V R Q I F V D G V P F V V S I G Y H Y K
L D K F L * M V F R L L F Q L V T I I K
* T N F C R W C S V C C F N W L P L * R

14521 G A G T T A G G T G T A G T T A T G A A C T T G G A T G T T G A T A C A C A C C G C T A T C G T T T G T C T C T T A A A 14580
E L G V V M N L D V D T H R Y R L S L K
S * V * L * T W M L I H T A I V C L L K
V R C S Y E L G C * Y T P L S F V S * R

FIG. 9 CONT.

14581 GACTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCTGCTAGTGCTCTGCTT 14640
D L L L Y A A D P A M H V A S A S A L L
T Y F F M Q Q I L L C M L H L L V L C L
L T S L C S R S C Y A C C I C * C S A *

14641 GATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGTATAAAGTTTCAAAC 14700
D L R T C C F S V A A I T S G I K F Q T
I Y E L V V L V * L P L Q V V * S F K L
F T N L L F * C S C H Y K W Y K V S N C

14701 GTTAAACCAGGTAATTTTAAACCAAGATTTTTATGAGTTTGTCAAAGTAAAGGCTTGT 14760
V K P G N F N Q D F Y E F V K S K G L F
L N Q V I L T K I F M S L S K V K A C L
* T R * F * P R F L * V C Q K * R L V *

14761 AAAGAGGGTAGTACAGTTGATTTGAAACACTTTTTCTTTACTCAAGATGGTAATGCTGCA 14820
K E G S T V D L K H F F F T Q D G N A A
K R V V Q L I * N T F S L L K M V M L Q
R G * Y S * F E T L F L Y S R W * C C N

14821 ATTACTGATTATAAATTATTATAAGTATAATTTACCTACTATGGTTGATATTAAGCAGTTA 14880
I T D Y N Y Y K Y N L P T M V D I K Q L
L L I I I I I S I I Y L L W L I L S S Y
Y * L * L L * V * F T Y Y G * Y * A V I

14881 TTGTTTTGTATTAGAAGTTGTTTTATAAGTATTTGAAATTTATGATGGTGGTTGTATACCA 14940
L F V L E V V Y K Y F E I Y D G G C I P
C L Y * K L F I S I L K F M M V V V Y Q
V C I R S C L * V F * N L * W W L Y T S

14941 GCATCACAAGTTATTGTTAATAATTATGACAAAAGTGCTGGTTATCCATTTAATAAATTT 15000
A S Q V I V N N Y D K S A G Y P F N K F
H H K L L L I I M T K V L V I H L I N L
I T S Y C * * L * Q K C W L S I * * I W

15001 GGTAAGCTAGACTTTATTATGAGGCATTATCATTTGAGGAGCAGAATGAAATTTATGCA 15060
G K A R L Y Y E A L S F E E Q N E I Y A
V K L D F I M R H Y H L R S R M K F M H
* S * T L L * G I I I * G A E * N L C I

15061 TATACTAAACGTAATGTGTTGCCCACTTTAACTCAAATGAATTTAAAATATGCTATTAGT 15120
Y T K R N V L P T L T Q M N L K Y A I S
I L N V M C C P L * L K * I * N M L L V
Y * T * C V A H F N S N E F K I C Y * C

FIG. 9 CONT.

15121 GCTAAGAATAGAGCTCGTACTGTTGCGAGGTGTTCCATTCTTAGTACTATGACAGGTCGA 15180
A K N R A R T V A G V S I L S T M T G R
L R I E L V L L Q V F P F L V L * Q V E
* E * S S Y C C R C F H S * Y Y D R S N

15181 ATGTTTCATCAAAAATGTTTGAAGAGTATAGCAGCTACTCGTGGTGTTCCTGTTGTTATA 15240
M F H Q K C L K S I A A T R G V P V V I
C F I K N V * R V * Q L L V V F L L L *
V S S K M F E E Y S S Y S W C S C C Y R

15241 GGAECTACTAAATTTTATGGTGGCTGGGATGATATGTTACGCCATCTTATAAAGGATGTT 15300
G T T K F Y G G W D D M L R H L I K D V
E L L N F M V A G M I C Y A I L * R M L
N Y * I L W W L G * Y V T P S Y K G C *

15301 GACAACCCTGTTCTTATGGGTTGGGATTATCCTAAATGTGATCGTGCCATGCCAAATATT 15360
D N P V L M G W D Y P K C D R A M P N I
T T L F L W V G I I L N V I V P C Q I F
Q P C S Y G L G L S * M * S C H A K Y F

15361 TTGCGTATTGTTAGTAGTTTAGTTTGGCTCGTAAACATGAATTTTGTGTTTCACATGGT 15420
L R I V S S L V L A R K H E F C C S H G
C V L L V V * F W L V N M N F V V H M V
A Y C * * F S F G S * T * I L L F T W *

15421 GATAGATTCTATCGCCTTGCGAATGAATGTGCTCAAGTTTGTAGTAAAATAGTTATGTGT 15480
D R F Y R L A N E C A Q V L S E I V M C
I D S I A L R M N V L K F * V K * L C V
* I L S P C E * M C S S F E * N S Y V W

15481 GCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTATGCAACCACTGCTTTT 15540
G G C Y Y V K P G G T S S G D A T T A F
A V A I M L S L V V L A V V M Q P L L L
R L L L C * A W W Y * Q W * C N H C F C

15541 GCTAACTCTGTTTTTAATATATGTCAAGCTGTACTGCTAATGTTTGTCTCTTATGGCT 15600
A N S V F N I C Q A V T A N V C S L M A
L T L F L I Y V K L L L L M F V L L W L
* L C F * Y M S S C Y C * C L F S Y G L

15601 TGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAAAAACGCTTATACTCT 15660
C N G H K I E D L S I R N L Q K R L Y S
V M A I R L K I * V Y A I Y K N A Y T L
* W P * D * R F K Y T Q F T K T L I L *

FIG. 9 CONT.

15661 AATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAGTATTATGAATTTTTA 15720
N V Y R T D Y V D Y T F V N E Y Y E F L
M F I V Q I M L I I H L L M S I M N F Y
C L S Y R L C * L Y I C * * V L * I F M

15721 TGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTTGTTGTTATAACTCTGAT 15780
C K H F S M M I L S D D G V V C Y N S D
V S I L V * * F * V M M V L F V I T L I
* A F * Y D D F E * * W C C L L * L * L

15781 TATGCTAGTAAGGGTTATATAGCCAATATAAGTGTTTTTCAACAAGTTTTGTACTATCAG 15840
Y A S K G Y I A N I S V F Q Q V L Y Y Q
M L V R V I * P I * V F F N K F C T I R
C * * G L Y S Q Y K C F S T S F V L S E

15841 AATAACGTTTTTATGTCTGAATCTAAATGTTGGGTTGAAAATGATATTACTAATGGTCCT 15900
N N V F M S E S K C W V E N D I T N G P
I T F L C L N L N V G L K M I L L M V L
* R F Y V * I * M L G * K * Y Y * W S S

15901 CATGAATTCGTTCCACAACATACTATGTTGGTTAAGATAGATGGTGACTATGTTTATCTA 15960
H E F C S Q H T M L V K I D G D Y V Y L
M N S V H N I L C W L R * M V T M F I Y
* I L F T T Y Y V G * D R W * L C L S T

15961 CCCTATCCAGACCCTTCTAGAATTTTAGGAGCTGGTTGTTTGTGATGATTTATTGAAG 16020
P Y P D P S R I L G A G C F V D D L L K
P I Q T L L E F * E L V V L L M I Y * R
L S R P F * N F R S W L F C * * F I E D

16021 ACTGACAGTGTCTTTTGATAGAGCGCTTTGTAAGTCTAGCTATAGATGCTTACCCTTTA 16080
T D S V L L I E R F V S L A I D A Y P L
L T V F F * * S A L * V * L * M L T L *
* Q C S F D R A L C K S S Y R C L P F S

16081 GTACACCATGAAAATGAAGAATACCAAAAAGTTTTTCGTGTATATTTAGAATATATAAAA 16140
V H H E N E E Y Q K V F R V Y L E Y I K
Y T M K M K N T K K F F V Y I * N I * K
T P * K * R I P K S F S C I F R I Y K K

16141 AAACATATAATGATCTTGGTAATCAGATCTTAGATAGTTATAGTGTATTTTAAGTACT 16200
K L Y N D L G N Q I L D S Y S V I L S T
N Y I M I L V I R S * I V I V L F * V L
T I * * S W * S D L R * L * C Y F K Y L

FIG. 9 CONT.

16201 TGTGATGGTTTAAAGTTCACCTGATGAATCATTTTATAAGAATATGTATTTAAAAAGTGCC 16260
C D G L K F T D E S F Y K N M Y L K S A
V M V * S S L M N H F I R I C I * K V P
* W F K V H * * I I L * E Y V F K K C R

16261 GTGATGCAGAGTGTAGGTGCATGTGTTGTTTGTTCATCACAGACGTCTTTGCGTTGTGGC 16320
V M Q S V G A C V V C S S Q T S L R C G
* C R V * V H V L F V H H R R L C V V A
D A E C R C M C C L F I T D V F A L W Q

16321 AGTTGTATACGGAAGCCTTTGTTGTGTTGTAATGTTGCTATGATCATGTTATGGCAACC 16380
S C I R K P L L C C K C C Y D H V M A T
V V Y G S L C C V V N V A M I M L W Q P
L Y T E A F V V L * M L L * S C Y G N Q

16381 AATCATAAATATGTTTTGAGTGTTCACCTTATGTGTGTAATGCACCTAACTGTGATGTG 16440
N H K Y V L S V S P Y V C N A P N C D V
I I N M F * V F H L M C V M H L T V M *
S * I C F E C F T L C V * C T * L * C E

16441 AGTGATGTCACCAAATTATATTTGGGTGGTATGTCTTATTATTGTGAAAACCATAAACCT 16500
S D V T K L Y L G G M S Y Y C E N H K P
V M S P N Y I W V V C L I I V K T I N L
* C H Q I I F G W Y V L L L * K P * T S

16501 CATTATTCATTTAAGTTAGTTATGAATGGTATGGTCTTTGGTTTGTATAACAATCTTGT 16560
H Y S F K L V M N G M V F G L Y K Q S C
I I H L S * L * M V W S L V C I N N L V
L F I * V S Y E W Y G L W F V * T I L Y

16561 ACAGGTTACCTTATATAGATGATTTTAAATAAGATAGCTAGTTGTAATGGACAGAAGTT 16620
T G S P Y I D D F N K I A S C K W T E V
Q V H L I * M I L I R * L V V N G Q K L
R F T L Y R * F * * D S * L * M D R S *

16621 GATGATTATGTTCTGGCAAATGAGTGTATTGAACGTTTAAAGTTATTTGCTGCAGAACT 16680
D D Y V L A N E C I E R L K L F A A E T
M I M F W Q M S V L N V * S Y L L Q K L
* L C S G K * V Y * T F K V I C C R N S

16681 CAAAAGGCAACTGAAGAAGCTTTTAAACAAAGCTATGCTTCTGCTACTATTCAAGAGATT 16740
Q K A T E E A F K Q S Y A S A T I Q E I
K R Q L K K L L N K A M L L L L F K R L
K G N * R S F * T K L C F C Y Y S R D C

FIG. 9 CONT.

16741 GTTAGTGATAGAGAAATTATTTTGTGTTGGGAGACAGGTAAAGTTAAACCACCACTTAAT 16800
V S D R E I I L C W E T G K V K P P L N
L V I E K L F C V G R Q V K L N H H L I
* * * R N Y F V L G D R * S * T T T * *

16801 AAAAATTATGTTTTCACTGGCTATCATTTTACTAGTACTGGTAAGACAGTTTTAGGTGAG 16860
K N Y V F T G Y H F T S T G K T V L G E
K I M F S L A I I L L V L V R Q F * V S
K L C F H W L S F Y * Y W * D S F R * V

16861 TATGTTTTGATAAAAAGTGAATTAACATAATGGTGTTTATATATCGCGCTACAACACTACTTAC 16920
Y V F D K S E L T N G V Y Y R A T T T Y
M F L I K V N * L M V F I I A L Q L L T
C F * * K * I N * W C L L S R Y N Y L Q

16921 AAACCTTCTATAGGTGATGTTTTGTCTTAACATCACATTCTGTAGCTAATCTAAGTGCA 16980
K L S I G D V F V L T S H S V A N L S A
N F L * V M F L S * H H I L * L I * V H
T F Y R * C F C L N I T F C S * S K C T

16981 CCTACACTTGTCCACAAGAGAACTATGCTAGTATAAGATTTTCTAGTGTTTATAGCGTT 17040
P T L V P Q E N Y A S I R F S S V Y S V
L H L F H K R T M L V * D F L V F I A F
Y T C S T R E L C * Y K I F * C L * R S

17041 CCTTTGCTGTTTTCAAACATAATGTTGCTAACTATCAGCACATTGGAATGAAACGTTATTGC 17100
P L L F Q T N V A N Y Q H I G M K R Y C
L C C F K L M L L T I S T L E * N V I A
F A V S N * C C * L S A H W N E T L L H

17101 ACTGTGCAAGGTCTCTCTGGTACGGCAAGTCTCACCTTGCTATAGGTTTAGCTGTTTAT 17160
T V Q G P P G T G K S H L A I G L A V Y
L C K V L L V R A S L T L L * V * L F I
C A R S S W Y G Q V S P C Y R F S C L L

17161 TACTATACAGCACGTGTAGTTTATACTGCTAGTATGCTGCTGCTAGATGCATTGTGT 17220
Y Y T A R V V Y T A A S H A A V D A L C
T I Q H V * F I L L L V M L L * M H C V
L Y S T C S L Y C C * S C C C R C I V *

17221 GAAAAAGCTTATAAGTTTTTAAATATTAATGACTGTACACGCATTATACCTGCTAAAGTT 17280
E K A Y K F L N I N D C T R I I P A K V
K K L I S F * I L M T V H A L Y L L K F
K S L * V F K Y * * L Y T H Y T C * S S

FIG. 9 CONT.

17281 CGTGTAGATTGTTATGATAAGTTTAAAATTAATGATACTACTTGTAAGTATGTTTTTACT 17340
R V D C Y D K F K I N D T T C K Y V F T
V * I V M I S L K L M I L L V S M F L L
C R L L * * V * N * * Y Y L * V C F Y Y

17341 ACAATAAATGCATTACCAGAGTTAGTCACAGATATTGTTGTTGTTGATGAAGTTAGTATG 17400
T I N A L P E L V T D I V V V D E V S M
Q * M H Y Q S * S Q I L L L L M K L V C
N K C I T R V S H R Y C C C * * S * Y A

17401 CTTACTAATTATGAATTGTCTGTTATAAATGCTCGTGTAAAGCTAAACATTATGTATAT 17460
L T N Y E L S V I N A R V K A K H Y V Y
L L I M N C L L * M L V L K L N I M Y I
Y * L * I V C Y K C S C * S * T L C I Y

17461 ATTGGAGATCCTGCTCAGTTACCTGCACCACGTGTGCTATTGAGTAAGGGTTCTTTAGAA 17520
I G D P A Q L P A P R V L L S K G S L E
L E I L L S Y L H H V C Y * V R V L * N
W R S C S V T C T T C A I E * G F F R T

17521 CCTAGGCATTTTAATTCTATTACTAAAATAATGTGCTGTTTAGGTCCTGATATTTTTTTG 17580
P R H F N S I T K I M C C L G P D I F L
L G I L I L L L K * C A V * V L I F F W
* A F * F Y Y * N N V L F R S * Y F F G

17581 GGAAATTGTTATAGATGTCCTAAAGAAATGTAGAAACTGTTTCAGCATTGGTTTATGAT 17640
G N C Y R C P K E I V E T V S A L V Y D
E I V I D V L K K L * K L F Q H W F M I
K L L * M S * R N C R N C F S I G L * *

17641 AATAAACTTAAGGCTAAGAATGATAATAGTTCATTATGCTTTAAAGTATATTTTAAGGGA 17700
N K L K A K N D N S S L C F K V Y F K G
I N L R L R M I I V H Y A L K Y I L R D
* T * G * E * * * F I M L * S I F * G T

17701 CAGACAACACATGAGAGTTCAAGTCTGTAAATATTCAACAAATATATTTAATTAGTAAA 17760
Q T T H E S S S A V N I Q Q I Y L I S K
R Q H M R V Q V L * I F N K Y I * L V N
D N T * E F K C C K Y S T N I F N * * I

17761 TTTTTGAAAGCTAATCCAGTTTGAATAGTGCTGTTTTTATTAGTCCTTATAATAGTCAG 17820
F L K A N P V W N S A V F I S P Y N S Q
F * K L I Q F G I V L F L L V L I I V R
F E S * S S L E * C C F Y * S L * * S E

FIG. 9 CONT.

17821 AACTATGTTGCTAAGCGTATTTTAGGTGTTCAAACACAACTGTTGATTCTGCTCAAGGT 17880
N Y V A K R I L G V Q T Q T V D S A Q G
T M L L S V F * V F K H K L L I L L K V
L C C * A Y F R C S N T N C * F C S R F

17881 TCTGAATATGATTATGTTATATATTCACAAACAGCAGAAAACAGCTCATTCTATTAATGTT 17940
S E Y D Y V I Y S Q T A E T A H S I N V
L N M I M L Y I H K Q Q K Q L I L L M L
* I * L C Y I F T N S R N S S F Y * C *

17941 AATCGATTTAATGTTGCCATAACTAGAGCCAAGAAGGGTATTTTCTGTGTTATGAGTAAT 18000
N R F N V A I T R A K K G I F C V M S N
I D L M L P * L E P R R V F S V L * V I
S I * C C H N * S Q E G Y F L C Y E * Y

18001 ATGCAATTATTTGAATCTCTTAATTTTATTACTTTACCTTTAGATAAAAATTCAGAATCAA 18060
M Q L F E S L N F I T L P L D K I Q N Q
C N Y L N L L I L L L Y L * I K F R I K
A I I * I S * F Y Y F T F R * N S E S N

18061 ACTTTATCTCGTTTGCATTGTACTACTAATCTTTTTAAAGATTGTAGTAAAAATTTTTTA 18120
T L S R L H C T T N L F K D C S K N F L
L Y L V C I V L L I F L K I V V K I F *
F I S F A L Y Y * S F * R L * * K F F R

18121 GGTTACCACCCAGCTCATGCTCCTTCATTTTTATCAGTTGATGATAAATATAAGGTCAAC 18180
G Y H P A H A P S F L S V D D K Y K V N
V T T Q L M L L H F Y Q L M I N I R S T
L P P S S C S F I F I S * * * I * G Q R

18181 GAAGATTTGGCTGTTTGTTTAAACATTTGGAACCTGTTTAAACATATTCTCGTTTAATA 18240
E D L A V C L N I C E P V L T Y S R L I
K I W L F V * T F V N L F * H I L V * Y
R F G C L F K H L * T C F N I F S F N I

18241 TCTCTCATGGGGTTTAAATTGGATTGACTCTTGATGGTTATTCTAAATTTTTTATTACT 18300
S L M G F K L D L T L D G Y S K F F I T
L S W G L N W I * L L M V I L N F L L L
S H G V * I G F D S * W L F * I F Y Y *

18301 AAAGACGAAGCTATTAAACGTGTAGAGGTTGGGTTGGTTTTGATGTAGAAGGAGCCCAT 18360
K D E A I K R V R G W V G F D V E G A H
K T K L L N V L E V G L V L M * K E P M
R R S Y * T C * R L G W F * C R R S P C

FIG. 9 CONT.

18361 GCTACGCGTGACAACATTGGAACAAACTTTCCATTGCAAATAGGTTTTTCAACTGGTGTT 18420
A T R D N I G T N F P L Q I G F S T G V
L R V T T L E Q T F H C K * V F Q L V L
Y A * Q H W N K L S I A N R F F N W C *

18421 GATTTTGTAGTTGAAGCTACTGGCTTATTTGCTGAGAGAGATTGTTATATATTTAAAAGA 18480
D F V V E A T G L F A E R D C Y I F K R
I L * L K L L A Y L L R E I V I Y L K E
F C S * S Y W L I C * E R L L Y I * K N

18481 ACTGTTGCTAAAGCTCCTCCTGGTGATAACTTTAAACATTTAATACCCCTTATGTCGAAA 18540
T V A K A P P G D N F K H L I P L M S K
L L L K L L L V I T L N I * Y P L C R K
C C * S S S W * * L * T F N T P Y V E R

18541 GGTCAAAAGTGGGATGTTGTTAGAATCAGAATTGTTCAAATGTTGTCTGATTATCTTTTG 18600
G Q K W D V V R I R I V Q M L S D Y L L
V K S G M L L E S E L F K C C L I I F W
S K V G C C * N Q N C S N V V * L S F G

18601 GATCTTTCTGATAGTGTAGTATTTATTACTTGGTCTGCCAGTTTGAACCTACGTGTTTA 18660
D L S D S V V F I T W S A S F E L T C L
I F L I V * Y L L L G L P V L N L R V *
S F * * C S I Y Y L V C Q F * T Y V F K

18661 AGGTATTTTGCTAAATTAGGTAGAGAGCTCAATTGTGATGTGTGCCTAATCGTGCAACA 18720
R Y F A K L G R E L N C D V C P N R A T
G I L L N * V E S S I V M C V L I V Q H
V F C * I R * R A Q L * C V S * S C N M

18721 TGCTATAATTCTAGAACTGGTTATTACGGTTGTTGGCGCCATAGTTATACTTGTGATTAT 18780
C Y N S R T G Y Y G C W R H S Y T C D Y
A I I L E L V I T V V G A I V I L V I M
L * F * N W L L R L L A P * L Y L * L C

18781 GTGTATAACCCGCTTATTGTAGATATAACAAGTGGGGTTACACAGGTTCTTTAACTAGT 18840
V Y N P L I V D I Q Q W G Y T G S L T S
C I T R L L * I Y N S G V T Q V L * L V
V * P A Y C R Y T T V G L H R F F N * *

18841 AATCATGATATAATTTGTAATGTACATAAAGGTGCACATGTTGCATCATCTGATGCAATT 18900
N H D I I C N V H K G A H V A S S D A I
I M I * F V M Y I K V H M L H H L M Q L
S * Y N L * C T * R C T C C I I * C N Y

FIG. 9 CONT.

18901 ATGACTCGGTGTTTAGCAATCTATGATTGTTTTGTAAATCTGTTAATTGGAATTTAGAG 18960
M T R C L A I Y D C F C K S V N W N L E
* L G V * Q S M I V F V N L L I G I * S
D S V F S N L * L F L * I C * L E F R V

18961 TATCCAATAATTTCCAATGAGGTTAGTATAAATACATCTTGTAGGTTATTGCAGCGTGTT 19020
Y P I I S N E V S I N T S C R L L Q R V
I Q * F P M R L V * I H L V G Y C S V L
S N N F Q * G * Y K Y I L * V I A A C Y

19021 ATGCTTAAAGCTGCCATGCTATGTAATAGATAACAATTTATGTTATGACATTGGCAATCCT 19080
M L K A A M L C N R Y N L C Y D I G N P
C L K L P C Y V I D T I Y V M T L A I L
A * S C H A M * * I Q F M L * H W Q S *

19081 AAAGGTATTGCTTGTGTCAAAGATTATGAATTTAAATCTATGATGCTTCTCCTGTTGTC 19140
K G I A C V K D Y E F K F Y D A S P V V
K V L L V S K I M N L N S M M L L L L S
R Y C L C Q R L * I * I L * C F S C C Q

19141 AAGTCTGTAAACAGTTGTTTTATGTTTATGATGTTTATAAAGATAATTTAAGGATGGT 19200
K S V K Q L F Y V Y D V H K D N F K D G
S L L N S C F M F M M F I K I I L R M V
V C * T V V L C L * C S * R * F * G W F

19201 TTATGTATGTTTTGGAATTGTAATGTTGATAAATATCCATCTAATTC AATTGTTTGTAGA 19260
L C M F W N C N V D K Y P S N S I V C R
Y V C F G I V M L I N I H L I Q L F V D
M Y V L E L * C * * I S I * F N C L * I

19261 TTTGATACTCGGGTATTAATAAATTAACCTCCCTGGATGTAATGGTGGTAGTTTGTAT 19320
F D T R V L N K L N L P G C N G G S L Y
L I L G Y * I N * T S L D V M V V V C M
* Y S G I K * I K P P W M * W W * F V C

19321 GTTAATAAACATGCATTTCACTAATCCTTTTACCAGAACGGTCTTTGAAAATCTTAAA 19380
V N K H A F H T N P F T R T V F E N L K
L I N M H F I L I L L P E R S L K I L N
* * T C I S Y * S F Y Q N G L * K S * T

19381 CCTATGCCATTTTTTTACTATTTCAGATACTCCTTGTGTGTATGTAGATGGTTTGG AATCC 19440
P M P F F Y Y S D T P C V Y V D G L E S
L C H F F T I Q I L L V C M * M V W N P
Y A I F L L F R Y S L C V C R W F G I Q

FIG. 9 CONT.

19441 AAACAAGTTGATTATGTGCCTTTAAGAAGCGCTACTTGTATCACACGATGTAATTTAGGT 19500
K Q V D Y V P L R S A T C I T R C N L G
N K L I M C L * E A L L V S H D V I * V
T S * L C A F K K R Y L Y H T M * F R W

19501 GGTGCTGTTTGTCTAAGCATGCTGAAGATTATTGTAATATCTTGAGTCTTATAATGTA 19560
G A V C S K H A E D Y C K Y L E S Y N V
V L F V L S M L K I I V N I L S L I M *
C C L F * A C * R L L * I S * V L * C S

19561 GCTACTACAGCAGGCTTTACTTTTTGGGTTTATAAGACTTTTGATTTTTATAATTTATGG 19620
A T T A G F T F W V Y K T F D F Y N L W
L L Q Q A L L F G F I R L L I F I I Y G
Y Y S R L Y F L G L * D F * F L * F M E

19621 AATACTTTCCTATGTTGCAGAGCTTAGAAAATGTAATATATAATTTGGTTAATGCTGGT 19680
N T F T M L Q S L E N V I Y N L V N A G
I L S L C C R A * K M * Y I I W L M L V
Y F H Y V A E L R K C N I * F G * C W S

19681 CATTATGATGGACGTATAGGTGAATTGCCTTGTGCTATTATGAATGACAAAGTTGTTGTT 19740
H Y D G R I G E L P C A I M N D K V V V
I M M D V * V N C L V L L * M T K L L L
L * W T Y R * I A L C Y Y E * Q S C C *

19741 AAGATTAATAATGTAGATACTGTTATTTTTAAAAATAATACATCACTTCCTACTAATATA 19800
K I N N V D T V I F K N N T S L P T N I
R L I M * I L L F L K I I H H F L L I *
D * * C R Y C Y F * K * Y I T S Y * Y S

19801 GCTGTTGAATTATTTACAAAACGTAGTATTCGCCATCACCTGAACCTAAGATTCTTAGA 19860
A V E L F T K R S I R H H P E L K I L R
L L N Y L Q N V V F A I T L N L R F L E
C * I I Y K T * Y S P S P * T * D S * K

19861 AATTGGAATATTGATATTTGTTGGAAGCATGTCCTTTGGGATTATGTTAAAGATAGTTTG 19920
N L N I D I C W K H V L W D Y V K D S L
I * I L I F V G S M S F G I M L K I V C
F E Y * Y L L E A C P L G L C * R * F V

19921 TTTTGTAGTTCTACCTATGGTGTCTGCAAATACACAGATTTAAATTTTATTGAAAATTTG 19980
F C S S T Y G V C K Y T D L N F I E N L
F V V L P M V S A N T Q I * I L L K I *
L * F Y L W C L Q I H R F K F Y * K F E

FIG. 9 CONT.

19981 AATGTACTTTTTGATGGTCGTGACAATGGTGCTTTAGAAGCTTTTAGAAAAGCAAGAAAT 20040
N V L F D G R D N G A L E A F R K A R N
M Y F L M V V T M V L * K L L E K Q E M
C T F * W S * Q W C F R S F * K S K K W

20041 GGTGTTTTTATTAGTACTGGAAAATTAAGTAGTTTGTCTATGATTAAAGGTCCGCAACGA 20100
G V F I S T G K L S S L S M I K G P Q R
V F L L V L E N * V V C L * L K V R N E
C F Y * Y W K I K * F V Y D * R S A T S

20101 GCTGATTTAAATGGCGTAATTGTGGATAAAGTTGGAGAACTCAATGTTGAGTTTTGGTTT 20160
A D L N G V I V D K V G E L N V E F W F
L I * M A * L W I K L E N S M L S F G L
* F K W R N C G * S W R T Q C * V L V C

20161 GCTATGAGAAAAGATGGTGACGATGTTATCTTCAGCCGTGCAGACAGCCTAAGCCCAAGC 20220
A M R K D G D D V I F S R A D S L S P S
L * E K M V T M L S S A V Q T A * A Q A
Y E K R W * R C Y L Q P C R Q P K P K P

20221 CATTACTGGAGCCCACAAGGTAATCTAGGTGGTAATTGTGCAGGTAATGCCAGCGGTAAT 20280
H Y W S P Q G N L G G N C A G N A S G N
I T G A H K V I * V V I V Q V M P A V M
L L E P T R * S R W * L C R * C Q R * *

20281 GATGCTCTAGCGGTTTTACTATCTTTACTCAGAGTCGTGTATTGTCAACCTTTGAACCT 20340
D A L A R F T I F T Q S R V L S T F E P
M L * R V L L S L L R V V Y C Q P L N L
C S S A F Y Y L Y S E S C I V N L * T S

20341 CGCTCAGATTTAGAACGGGATTTTATTGATATGGAGGATAGTCTGTTTATAGCCAAATAT 20400
R S D L E R D F I D M E D S L F I A K Y
A Q I * N G I L L I W R I V C L * P N M
L R F R T G F Y * Y G G * S V Y S Q I W

20401 GGTTTAGAAGATTATGCATTTGATCATATAGTTTATGGTAGTTTAAATTATAAAGTTATA 20460
G L E D Y A F D H I V Y G S F N Y K V I
V * K I M H L I I * F M V V L I I K L *
F R R L C I * S Y S L W * F * L * S Y R

20461 GGAGGTTTGCACCTTGCTTATAGGTTTATTTTCGTAGACTAAAAAATCTAATTTGGTAATT 20520
G G L H L L I G L F R R L K K S N L V I
E V C T C L * V Y F V D * K N L I W * F
R F A L A Y R F I S * T K K I * F G N S

FIG. 9 CONT.

20521 CAAGAGTTTTTGCAGTATGATTCTAGTATTCATTCATATTTTCATTACTGATCAAGAGTGT 20580
Q E F L Q Y D S S I H S Y F I T D Q E C
K S F C S M I L V F I H I S L L I K S V
R V F A V * F * Y S F I F H Y * S R V W

20581 GGTAGTAGTAAGAGTGTTTGTACAGTTATTGATTTATTATTAGATGACTTTGTTGTTATT 20640
G S S K S V C T V I D L L L D D F V V I
V V V R V F V Q L L I Y Y * M T L L L L
* * * E C L Y S Y * F I I R * L C C Y C

20641 GTTAAGTCATTAAATTTGAATTGTGTTAGTAAAGTTGTTAATATTAATGTTGACTTTAAG 20700
V K S L N L N C V S K V V N I N V D F K
L S H * I * I V L V K L L I L M L T L R
* V I K F E L C * * S C * Y * C * L * G

20701 GACTTTCAATTTATGTTGTGGTGAATGATAATAAAATTATGACTTTTTATCCTAAAATG 20760
D F Q F M L W C N D N K I M T F Y P K M
T F N L C C G V M I I K L * L F I L K C
L S I Y V V V * * * * N Y D F L S * N A

20761 CAAGCTACTAGTACTGGAAACCTGGTTATTCTATGCCTGTTTTATATAAGTATTTGAAT 20820
Q A T S D W K P G Y S M P V L Y K Y L N
K L L V T G N L V I L C L F Y I S I * M
S Y * * L E T W L F Y A C F I * V F E C

20821 GTTCCATTAGAGAGAGTTTTCTTTATGGAATTATGGTAAAGCTATTAATTTACCAACAGGT 20880
V P L E R V S L W N Y G K A I N L P T G
F H * R E F L Y G I M V K L L I Y Q Q V
S I R E S F F M E L W * S Y * F T N R L

20881 TGTATGATGAATGTTGCTAAGTATACTCAATTATGTCAGTATTTAAATACTACAACATTA 20940
C M M N V A K Y T Q L C Q Y L N T T T L
V * * M L L S I L N Y V S I * I L Q H *
Y D E C C * V Y S I M S V F K Y Y N I S

20941 GCTGTTCTGTTAATATGCGTGTCTTACACTTAGGTGCAGGATCTGATAAAGAAGTAGCC 21000
A V P V N M R V L H L G A G S D K E V A
L F L L I C V S Y T * V Q D L I K K * P
C S C * Y A C L T L R C R I * * R S S P

21001 CCTGTTCTGCTGTTTTAAGACAGTGGTTACCATCTGGTAGTATTCTTGTAGATAATGAT 21060
P G S A V L R Q W L P S G S I L V D N D
L V L L F * D S G Y H L V V F L * I M I
W F C C F K T V V T I W * Y S C R * * F

FIG. 9 CONT.

21061 TTAAATCCTTTTGGTTAGTGATAGTTTACTTATTTTGGAGATTGTATGACTTTACCA 21120
L N P F V S D S L V T Y F G D C M T L P
* I L L L V I V * S L I L E I V * L Y H
K S F C * * * F S H L F W R L Y D F T I

21121 TTTGATTGTCATTGGGATCTGATAATATCTGATATGTATGATCCTCTTACTAAGAATATT 21180
F D C H W D L I I S D M Y D P L T K N I
L I V I G I * * Y L I C M I L L L R I L
* L S L G S D N I * Y V * S S Y * E Y W

21181 GGTGATTATAATGTGAGTAAGGATGGTTTCTTTACTTATATTGTTATTTAATTCGTGAT 21240
G D Y N V S K D G F F T Y I C Y L I R D
V I I M * V R M V S L L I F V I * F V I
* L * C E * G W F L Y L Y L L F N S * *

21241 AAATTATCTTTGGGTGGTAGTGTGCTATAAAAATTACAGAATTTTCTTGAATGCTGAC 21300
K L S L G G S V A I K I T E F S W N A D
N Y L W V V V L L * K L Q N F L G M L T
I I F G W * C C Y K N Y R I F L E C * L

21301 TTATATAAATTAATGAGTTATTTGCATCTGGACAGTTTTTTGTTACTAATGTAAATGCT 21360
L Y K L M S Y F A F W T V F C T N V N A
Y I N * * V I L H S G Q F F V L M * M L
I * I N E L F C I L D S F L Y * C K C F

21361 TCTTCTAGTGAAGGGTTTTTAATAGGTATAAATTATTTGGGTAAGTCCTGCTTTGAAATA 21420
S S S E G F L I G I N Y L G K S C F E I
L L V K G F * * V * I I W V S P A L K *
F * * R V F N R Y K L F G * V L L * N R

21421 GATGGCAATGTTATGCATGCCAACTATTTGTTTTGGAGAAATAGTACAACATGGAATGGT 21480
D G N V M H A N Y L F W R N S T T W N G
M A M L C M P T I C F G E I V Q H G M V
W Q C Y A C Q L F V L E K * Y N M E W W

21481 GGTGCTTATAGTTTATTTGATATGTCTAAATTTTCTTTGAAATTGGCTGGCACTGCTGTA 21540
G A Y S L F D M S K F S L K L A G T A V
V L I V Y L I C L N F L * N W L A L L *
C L * F I * Y V * I F F E I G W H C C S

21541 GTAAATTTAAGACCAGATCAATTAATGATTTAGTTTATTCTCTTATTGAAAGAGGTAAG 21600
V N L R P D Q L N D L V Y S L I E R G K
* I * D Q I N * M I * F I L L L K E V S
K F K T R S I K * F S L F S Y * K R * V

FIG. 9 CONT.

21601 TTATTAGTGCCTGATACGCGTAAAGAAATTTTTGTTGGTGATAGTCTTGTAACACTTGT 21660
L L V R D T R K E I F V G D S L V N T C
Y * C V I R V K K F L L V I V L * T L V
I S A * Y A * R N F C W * * S C K H L L

21661 TAGATCTTTCAGTTTGTAAATATTAATCTAAACTATGTAAATTATATTTTTATTTTTTA 21720
* I F Q F V N I K S K L C * L Y F Y F L
R S F S L L I L N L N Y V N Y I F I F *
D L S V C * Y * I * T M L I I F L F F N

21721 ATTTTTGTTATGGTTTTAATGAACCTTTGAATGTTGTGTCTCATTTAAACCATGACTGGT 21780
I F V M V L M N L * M L C L I * T M T G
F L L W F * * T F E C C V S F K P * L V
F C Y G F N E P L N V V S H L N H D W F

21781 TTTTATTTGGTGATAGTCGTTCTGATTGTAACCATATTAATAATTTAAAAATTTAAAAATT 21840
F Y L V I V V L I V T I L I I * K L K I
F I W * * S F * L * P Y * * F K N * K L
L F G D S R S D C N H I N N L K I K N Y

21841 ATGTTATTTGGATATTCACCCCTAGTTTGTGTAATAATGGTAAAATTTTCATCTAGTGCTG 21900
M V I W I F T L V C V I M V K F H L V L
W L F G Y S P * F V * * W * N F I * C W
G Y L D I H P S L C N N G K I S S S A G

21901 GTGATTCTATTTTAAAGAGTTATCATTTTACCCGGTTTTATAATTACACTGGCGAGGGTG 21960
V I L F L R V I I L P G F I I T L A R V
* F Y F * E L S F Y P V L * L H W R G *
D S I F K S Y H F T R F Y N Y T G E G D

21961 ATCAAATTATTTTTATGAGGGTGTTAATTTCAATCCTCATCATAGGTTTAAGTGCTTCT 22020
I K L F F M R V L I S I L I I G L S A S
S N Y F L * G C * F Q S S S * V * V L L
Q I I F Y E G V N F N P H H R F K C F F

22021 TTAATGGTAGTAATGATGTATGGATTTTAAACAAGGTGAGGTTTTATCGTGCTTTATATT 22080
L M V V M M Y G F L T R * G F I V L Y I
* W * * * C M D F * Q G E V L S C F I F
N G S N D V W I F N K V R F Y R A L Y S

22081 CTAATATGGCTCTTTTTCGCTATCTTACCTTTGTTGATATTCTTTACAATTTTTCTTTTT 22140
L I W L F F A I L P L L I F F T I F L F
* Y G S F S L S Y L C * Y S L Q F F F F
N M A L F R Y L T F V D I L Y N F S F S

FIG. 9 CONT.

22141 CTATTAAGGCTAATATTTGTAATAGTAATATTTTATCACTTAATAATCCTATTTTTATTA 22200
L L R L I F V I V I F Y H L I I L F L L
Y * G * Y L * * * Y F I T * * S Y F Y *
I K A N I C N S N I L S L N N P I F I S

22201 G T A C T A A T T A T T C T A A G G A C G T T T A T T T C A C T T T A T C A G G G T G T T C T T T G T A T T T A G T A C 22260
V L I I L R T F I S L Y Q G V L C I * Y
Y * L F * G R L F H F I R V F F V F S T
T N Y S K D V Y F T L S G C S L Y L V P

22261 C T C T T T G T C T T T T T A A A T C T A A T T T T A G T C A G T A C T A T T A T A A T A T G G A T A C T G G C T T T G 22320
L F V F L N L I L V S T I I I W I L A L
S L S F * I * F * S V L L * Y G Y W L C
L C L F K S N F S Q Y Y Y N M D T G F A

22321 C T T A T G G T T A T T C T A A T T T T G T T T C T T C T G A T T T A G A T T G T A C A T A T A T T T C T C T T A A A C 22380
L M V I L I L F L L I * I V H I F L L N
L W L F * F C F F * F R L Y I Y F S * T
Y G Y S N F V S S D L D C T Y I S L K P

22381 C T G G T T C T T A T A A A A T T T T T T C T A C T G G T T T T G T T T T A T C C A T A C C T A C T A A A G C T C T T T 22440
L V L I K F F L L V L F Y P Y L L K L F
W F L * N F F Y W F C F I H T Y * S S L
G S Y K I F S T G F V L S I P T K A L C

22441 G C T T T A A T A A A T C T A A A C A A T T T G T A C C C G T G C A G G T T G T T G A T T C T A G G T G G A A C A A T C 22500
A L I N L N N L Y P C R L L I L G G T I
L * * I * T I C T R A G C * F * V E Q S
F N K S K Q F V P V Q V V D S R W N N L

22501 T T C G T G C A T C G G A T A C T T C A T T A T C C G A T G C A T G T C A G T T G C C T T A T T G T T A T T T T C G C A 22560
F V H R I L H Y P M H V S C L I V I F A
S C I G Y F I I R C M S V A L L L F S Q
R A S D T S L S D A C Q L P Y C Y F R N

22561 A T T C T T C T G G T A A T T A T G T T G G C A A A T A T G A T A T T A A T C A T G G T G A T A A T G G T T T A C T T 22620
I L L V I M L A N M I L I M V I M V L L
F F W * L C W Q I * Y * S W * * W F Y F
S S G N Y V G K Y D I N H G D N G F T S

22621 C T A T T C T A T C T G G T C T T T T A T A T A A T G T C T C T T G T A T T T C T T A T T A T G G C T C C T T T T T G T 22680
L F Y L V F Y I M S L V F L I M A P F C
Y S I W S F I * C L L Y F L L W L L F V
I L S G L L Y N V S C I S Y Y G S F L Y

FIG. 9 CONT.

22681 ATGACAATTTTACATCAATTTGGCCTCGTTTTCTTTTGGTAATTGTCCTACATCTGCTT 22740
M T I L H Q F G L V F L L V I V L H L L
* Q F Y I N L A S F F F W * L S Y I C L
D N F T S I W P R F S F G N C P T S A Y

22741 ATATTAAATTAATTTGTTTCTATGATCCTTTGCCTATTATTTTACAAGGTATTTTATTAT 22800
I L N * I V S M I L C L L F Y K V F Y Y
Y * I K L F L * S F A Y Y F T R Y F I I
I K L N C F Y D P L P I I L Q G I L L F

22801 TTTTAGCTTTATTGTTTATTGTGTTTTACTTTTTCTAGTTTACCATGGCTAATATTAAA 22860
F * L Y C L L C F Y F F * F T M A N I K
F S F I V Y C V F T F S S L P W L I L N
L A L L F I V F L L F L V Y H G * Y * I

22861 TCTAAACATGTTTTTAATTATTTTTATTTTGCCTACAACACTAGCTGTTATAGGTGATT 22920
S K H V F N Y F Y F A Y N T S C Y R * F
L N M F L I I F I L P T T L A V I G D F
* T C F * L F L F C L Q H * L L * V I L

22921 TAATTGTTACTAACTCTTTTATTAATGATTATAATAAAACCATTCCGCGTATAAGCGAGGA 22980
* L Y * L F Y * * L * * N H S A Y K R G
N C T N S F I N D Y N K T I P R I S E D
I V L T L L L M I I I K P F R V * A R M

22981 TGTTGTTGATGTATCTCTTGGTTTGGGCACATATTATGTTCTTAACCGTGTATTATTTAAA 23040
C C * C I S W F G H I L C S * P C L F K
V V D V S L G L G T Y Y V L N R V Y L N
L L M Y L L V W A H I M F L T V F I * I

23041 TACTACCTGTTATTTTACAGGTTATTTTCTAAATCTGGTGCTAATTTTAGAGACTTGGC 23100
Y Y L V I Y R L F S * I W C * F * R L G
T T L L F T G Y F P K S G A N F R D L A
L P C Y L Q V I F L N L V L I L E T W L

23101 TTTAAAGGGTTCTAAATATTTGAGTACTCTCTGGTATAAAACCACCTTTTCTGTCAGATT 23160
F K G F * I F E Y S L V * T T F S V R F
L K G S K Y L S T L W Y K P P F L S D F
* R V L N I * V L S G I N H L F C Q I L

23161 TAATAATGGTATTTTTTCTAAGGTTAAGAATACTAAGTTATATGTTAATAACTTTGTA 23220
* * W Y F F * G * E Y * V I C * * Y F V
N N G I F S K V K N T K L Y V N N T L Y
I M V F F L R L R I L S Y M L I I L C I

FIG. 9 CONT.

23221 TAGTGAATTTAGTACTATAGTTATAGGTAGTGTTTTTGTTAATACTTCTTATACTATTGT 23280
* * I * Y Y S Y R * C F C * Y F L Y Y C
S E F S T I V I G S V F V N T S Y T I V
V N L V L * L * V V F L L I L L I L L L

23281 TGTTCAACCTCACAATGGTATTTTGGAGATTACAGCTTGTTCAGTATACTATGTGTGAATA 23340
C S T S Q W Y F G D Y S L S V Y Y V * I
V Q P H N G I L E I T A C Q Y T M C E Y
F N L T M V F W R L Q L V S I L C V N I

23341 TCCTCACACTGTTTGTAAAGTCTAAGGGTAGTATTCGTAATGAATCTTGGCACATTGATTC 23400
S S H C L * V * G * Y S * * I L A H * F
P H T V C K S K G S I R N E S W H I D S
L T L F V S L R V V F V M N L G T L I L

23401 TTCGGAACCTTTATGCTTGTTTAAGAAAATTTTACTTATAATGTTTCTGCAGATTGGCT 23460
F G T F M L V * E K F Y L * C F C R L A
S E P L C L F K K N F T Y N V S A D W L
R N L Y A C L R K I L L I M F L Q I G C

23461 GTATTTTCATTTTATCAAGAACGTGGTGTTTTTTATGCATATTATGCAGATGTAGGTAT 23520
V F S F L S R T W C F L C I L C R C R Y
Y F H F Y Q E R G V F Y A Y Y A D V G M
I F I F I K N V V F F M H I M Q M * V C

23521 GCCTACCACTTTCTTATTTAGTTTATATTTAGGTACTATTTTATCTCATTATTATGTTAT 23580
A Y H F L I * F I F R Y Y F I S L L C Y
P T T F L F S L Y L G T I L S H Y Y V M
L P L S Y L V Y I * V L F Y L I I M L C

23581 GCCTTTGACTTGTAAGGCTATATCTTCAAATACTGACAATGAAACTTTAGAATATTGGGT 23640
A F D L * G Y I F K Y * Q * N F R I L G
P L T C K A I S S N T D N E T L E Y W V
L * L V R L Y L Q I L T M K L * N I G L

23641 TACACCGCTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTTATTAATA 23700
Y T A I * T S V S S * F * * A R C Y Y *
T P L S R R Q Y L L N F D E H G V I T N
H R Y L D V S I F L I L M S T V L L L M

23701 TGCCGTTGATTGTTCAAGTAGTTTCTTAGTGAGATTCAATGTAAAACCTCAATCTTTTGC 23760
C R * L F K * F S * * D S M * N S I F C
A V D C S S S F L S E I Q C K T Q S F A
P L I V Q V V F L V R F N V K L N L L H

FIG. 9 CONT.

23761 ACCTAATACTGGTGTTTATGATTGTCTGGTTTTACTGTAAAGCCTGTTGCAACTGTTTA 23820
T * Y W C L * F V W F Y C K A C C N C L
P N T G V Y D L S G F T V K P V A T V Y
L I L V F M I C L V L L * S L L Q L F I

23821 TCGTCGGATTCCCTAATTTACCTGATTGTGACATTGACAACCTGGCTTAATAATGTTAGTGT 23880
S S D S * F T * L * H * Q L A * * C * C
R R I P N L P D C D I D N W L N N V S V
V G F L I Y L I V T L T T G L I M L V Y

23881 ACCTTCACCTCTTAATTTGGGAACGTAGAAATTTTTCTAATTGTAACCTCAATTTAAGCAC 23940
T F T S * L G T * N F F * L * L Q F K H
P S P L N W E R R I F S N C N F N L S T
L H L L I G N V E F F L I V T S I * A L

23941 TTTACTTCGTCTAGTTCATGTTGATTCTTTTTCTTGTAAATAATCTTGATAAATCTAAAAT 24000
F T S S S S C * F F F L * * S * * I * N
L L R L V H V D S F S C N N L D K S K I
Y F V * F M L I L F L V I I L I N L K F

24001 TTTTGGTAGTTGCTTTAATAGTATTACTGTTGACAAGTTTGCTATACCTAATCGCAGACG 24060
F W * L L * * Y Y C * Q V C Y T * S Q T
F G S C F N S I T V D K F A I P N R R R
L V V A L I V L L L T S L L Y L I A D E

24061 AGATGATTGCAATTGGGCGATTCTGGCTTTTTGCAATCATCTAATTACAAAATAGATAT 24120
R * F A I G Q F W L F A I I * L Q N R Y
D D L Q L G S S G F L Q S S N Y K I D I
M I C N W A V L A F C N H L I T K * I F

24121 TTCTTCTAGTTCTTGCAATTGTATTATAGTTTACCTTTAGTTAATGTTACTATTAATAA 24180
F F * F L S I V L * F T F S * C Y Y * *
S S S S C Q L Y Y S L P L V N V T I N N
L L V L V N C I I V Y L * L M L L L I T

24181 CTTTAATCCATCTTCTTGAATAGGAGGTATGGTTTTGGTAGTTTAAATGTGTCTTCTTA 24240
L * S I F L E * E V W F W * F * C V F L
F N P S S W N R R Y G F G S F N V S S Y
L I H L L G I G G M V L V V L M C L L M

24241 TGACGTTGTTTATTCTGATCATTGTTTTCTGTTAACAGCGACTTTTGGCCCTTGTGCAGA 24300
* R C L F * S L F F C * Q R L L P L C R
D V V Y S D H C F S V N S D F C P C A D
T L F I L I I V F L L T A T F A L V Q I

FIG. 9 CONT.

24301 TCCGTCGTGTTAATTCTTGTGTTAAATCTAAGCCTCTTTCTGCCATTGTCTGCTGG 24360
S V C C * F L C * I * A S F C H L S C W
P S V V N S C V K S K P L S A I C P A G
R L L L I L V L N L S L F L P F V L L V

24361 TACTAAATATCGTCATTGCGACTTGGATACTACTCTTTATGTTAATAACTGGTGTAGATG 24420
Y * I S S L R L G Y Y S L C * * L V * M
T K Y R H C D L D T T L Y V N N W C R C
L N I V I A T W I L L F M L I T G V D V

24421 TTCTTGCTACCTGACCCCATTTCTACTTATTCTCCTAACACATGTCCTCAAAGAAGGT 24480
F L S T * P H F Y L F S * H M S S K E G
S C L P D P I S T Y S P N T C P Q K K V
L V Y L T P F L L I L L T H V L K R R S

24481 CGTTGTTGGTATAGGTGAACATTGTCCAGGTCTTGGTATTAATGAGGAAAAATGGGTAC 24540
R C W Y R * T L S R S W Y * * G K M W Y
V V G I G E H C P G L G I N E E K C G T
L L V * V N I V Q V L V L M R K N V V H

24541 ACAATTAATCATAGTTCCCTGTTCTTGTAGTCCCTGATGCCTTTTTGGGTGGTCTTTTGA 24600
T I K S * F L F L * S * C L F G L V F *
Q L N H S S C S C S P D A F L G W S F D
N * I I V P V L V V L M P F W V G L L I

24601 TAGTGTATTAGTAATAATCGTTGCAATATTTTTCTAATTTTATTTTAAATGGAATTAA 24660
* L Y * * * S L Q Y F F * F Y F * W N *
S C I S N N R C N I F S N F I F N G I N
V V L V I I V A I F F L I L F L M E L I

24661 TAGTGGCACCCTTGTCTAATGATTTGTTATATTCTAACACTGAAGTTTCTACTGGTGT 24720
* W H H L F * * F V I F * H * S F Y W C
S G T T C S N D L L Y S N T E V S T G V
V A P L V L M I C Y I L T L K F L L V F

24721 TTGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTAAAGAAGTTTCTGC 24780
L C * L * S L W H H R P R Y F * R S F C
C V N Y D L Y G I T G Q G I F K E V S A
V L I M I F M A S Q A K V F L K K F L R

24781 GGCTTATTATAATAATTGGCAGAATCTTTGTATGATTCTAATGGTAATATTATTGGTTT 24840
G L L * * L A E S F V * F * W * Y Y W F
A Y Y N N W Q N L L Y D S N G N I I G F
L I I I I G R I F C M I L M V I L L V L

FIG. 9 CONT.

24841 TAAAGATTTTTTGACTAATAAACTTACACTATACTTCCTTGTTATTCTGGTAGAGTGTC 24900
* R F F D * * N L H Y T S L L F W * S V
K D F L T N K T Y T I L P C Y S G R V S
K I F * L I K L T L Y F L V I L V E C L

24901 TGCTGCATTTTATCAAATTCCTTCCACCAGCTTTGCTTTATCGTAATTTAAAGTGAG 24960
C C I L S K F F F T S F A L S * F K V *
A A F Y Q N S S S P A L L Y R N L K C S
L H F I K I L L H Q L C F I V I * S V V

24961 TTATGTTTTGAATAATATTTCTTTATCTCACAACCATTTTATTTGATAGTTATCTTGG 25020
L C F E * Y F F Y L T T I L F * * L S W
Y V L N N I S F I S Q P F Y F D S Y L G
M F * I I F L L S H N H F I L I V I L V

25021 TTGTGTTTTGAATGCTGTTAATTTAACTAGCTATTCTGTATCCTTGTGATTTGCGTAT 25080
L C F E C C * F N * L F C I L L * F A Y
C V L N A V N L T S Y S V S S C D L R M
V F * M L L I * L A I L Y P L V I C V W

25081 GGGTAGTGGGTTTTGTATTGATTATGCTTTACCCTCTTCTCGGCGTAAGCGTAGAGGTAT 25140
G * W V L Y * L C F T L F S A * A * R Y
G S G F C I D Y A L P S S R R K R R G I
V V G F V L I M L Y P L L G V S V E V F

25141 TTCTTCTCCTTATCGCTTTGFAACTTTTGAACCCTTTAATGTTAGTTTTGTTAACGATAG 25200
F F S L S L C N F * T L * C * F C * R *
S S P Y R F V T F E P F N V S F V N D S
L L L I A L * L L N P L M L V L L T I V

25201 TGTGAAACTGTTGGTGGTTTATTTGAGATTCAGATTCCTACTAACTTTACCATAGCTGG 25260
C * N C W W F I * D S D S Y * L Y H S W
V E T V G G L F E I Q I P T N F T I A G
L K L L V V Y L R F R F L L T L P * L V

25261 TCATGAAGAATTTATTCAGACTAGTTCCTAAAGTTACTATTGATTGTTTCAGCTTTTGT 25320
S * R I Y S D * F S * S Y Y * L F S F C
H E E F I Q T S S P K V T I D C S A F V
M K N L F R L V L L K L L L I V Q L L F

25321 TTGCTCTAATTATGCTGCTTGTCATGATTATTGTCCGAATATGGCACTTTTTCGATAA 25380
L L * L C C L S * F I V G I W H F L R *
C S N Y A A C H D L L S E Y G T F C D N
A L I M L L V M I Y C R N M A L F A I I

FIG. 9 CONT.

25381 TATTAATAGTATTTTAAATGAAGTCAATGATTTACTTGATATTACTCAGTTGCAGGTTGC 25440
Y * * Y F K * S Q * F T * Y Y S V A G C
I N S I L N E V N D L L D I T Q L Q V A
L I V F * M K S M I Y L I L L S C R L L

25441 TAATGCTTTAATGCAAGGTGTTACTTAGTCTAATCTTAATACTAATCTACTACTCTGA 25500
* C F N A R C Y T * F * S * Y * S T L *
N A L M Q G V T L S S N L N T N L H S D
M L * C K V L H L V L I L I L I Y T L M

25501 TGTTGATAATATAGATTTTAAATCTCTTCTAGGTTGTTTAGGTTCAATGTGGTTCTTC 25560
C * * Y R F * I S S R L F R F T M W F F
V D N I D F K S L L G C L G S Q C G S S
L I I * I L N L F * V V * V H N V V L R

25561 GTCTAGATCTTTGTTAGAGGATTATTATTCAACAAGGTCAAACCTTCAGATGTAGGTTT 25620
V * I F V R G F I I Q Q G Q T F R C R F
S R S L L E D L L F N K V K L S D V G F
L D L C * R I Y Y S T R S N F Q M * V L

25621 TGTTGAAGCTTATAATAATTGCACTGGTGGTAGTGAATTAGAGATCTTCTCTGTGTGCA 25680
C * S L * * L H W W * * N * R S S L C A
V E A Y N N C T G G S E I R D L L C V Q
L K L I I I A L V V V K L E I F S V C N

25681 ATCTTTTAAATGGTATTAAAGTATTACCTCCCATTTTATCTGAGACTCAAATTTCTGGCTA 25740
I F * W Y * S I T S H F I * D S N F W L
S F N G I K V L P P I L S E T Q I S G Y
L L M V L K Y Y L P F Y L R L K F L A I

25741 TACTACAGCTGCTACTGTGGCGGCTATGTTCCGCCATGGTCTGCTGCTGCTGGTGTACC 25800
Y Y S C Y C G G Y V S A M V C C C W C T
T T A A T V A A M F P P W S A A A G V P
L Q L L L W R L C F R H G L L L L V Y H

25801 ATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGATGTTCTTAA 25860
I F S * C T I * N * W F G C Y Y G C S *
F S L N V Q Y R I N G L G V T M D V L N
F L L M Y N I E L M V W V L L W M F L I

25861 TAAGAATCAAAAGTTAATAGCTAATGCTTTTAAATAAGCTCTTCTTCTATCCAGAATGG 25920
* E S K V N S * C F * * S S S F Y P E W
K N Q K L I A N A F N K A L L S I Q N G
R I K S * * L M L L I K L F F L S R M V

FIG. 9 CONT.

25921 TTTTACTGCTACTAACTCTGCTCTTGCTAAAATTCAAAGTGCCTTAATGCTAATGCTCA 25980
F Y C Y * L C S C * N S K C R * C * C S
F T A T N S A L A K I Q S V V N A N A Q
L L L L T L L L L K F K V S L M L M L K

25981 AGCACTTAATAGTTTGTACAACAATTATTTAATAAATTTGGTGCTATTAGTTCTTCTTT 26040
S T * * F V T T I I * * I W C Y * F F F
A L N S L L Q Q L F N K F G A I S S S L
H L I V C Y N N Y L I N L V L L V L L Y

26041 ACAAGAAATTTGTCTCGCCTTGATAATTTAGAAGCTCAGGTTTCAGATTGATAGGCTCAT 26100
T R N F V S P * * F R S S G S D * * A H
Q E I L S R L D N L E A Q V Q I D R L I
K K F C L A L I I * K L R F R L I G S L

26101 TAATGGTCGTTTACTGCTTTAAATGCTTATGTTTCTCAACAGCTTAGTGATATTACACT 26160
* W S F D C F K C L C F S T A * * Y Y T
N G R L T A L N A Y V S Q Q L S D I T L
M V V * L L * M L M F L N S L V I L H L

26161 TATTAAGGCTGGAGCTTCTCGTGCTATTGAGAAGGTTAATGAGTGTGTTAAAAGTCAATC 26220
Y * G W S F S C Y * E G * * V C * K S I
I K A G A S R A I E K V N E C V K S Q S
L R L E L L V L L R R L M S V L K V N P

26221 CCCTCGTATAAATTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAAATGCTCC 26280
P S Y K F L W Q W * P H F I I G S K C S
P R I N F C G N G N H I L S L V Q N A P
L V * I F V A M V T T F Y H W F K M L L

26281 TTATGGTTTGCTTTTCATTCATTTAGTTATAAACCTACTTCTTTTAAAAGTCTTAGT 26340
L W F A F H S F * L * T Y F F * N C L S
Y G L L F I H F S Y K P T S F K T V L V
M V C F S F I L V I N L L L L K L S * *

26341 AAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGTTATTTTAT 26400
K S R F M F I R * * R Y C T * A R L F Y
S P G L C L S G D R G I A P K Q G Y F I
V Q V Y V Y P V I E V L H L S K V I L L

26401 TAAACAAAATGATTCCTGGATGTTTACTGGTAGTTTCTTATTATTACCCAGAACCAATTTT 26460
* T K * F L D V Y W * F L L L P R T N F
K Q N D S W M F T G S S Y Y Y P E P I S
N K M I P G C L L V V P I I T Q N Q F Q

FIG. 9 CONT.

26461 AGATAAAAATGTTGTTTTTCATGAATAGTTGCTCTGTTAATTTTACTAAAGCTCCATTTAT 26520
R * K C C F H E * L L C * F Y * S S I Y
D K N V V F M N S C S V N F T K A P F I
I K M L F S * I V A L L I L L K L H L F

26521 TTATCTTAATAATTCTATACCAAATTTGTCTGATTTTGAAGCCGAGTTTTCTCTTTGGTT 26580
L S * * F Y T K F V * F * S R V F S L V
Y L N N S I P N L S D F E A E F S L W F
I L I I L Y Q I C L I L K P S F L F G L

26581 TAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTCTCATATTAATGCTACTTT 26640
* K S Y F Y S T * F N L * F S Y * C Y F
K N H T S I A P N L T F N S H I N A T F
K I I L L * H L I * P L I L I L M L L F

26641 TTTAGACTGTATTATGAAATGAATGTTATTCAGGAATCTATTAAATCTTGAACAGTAG 26700
F R S V L * N E C Y S G I Y * I F E Q *
L D L Y Y E M N V I Q E S I K S L N S S
* I C I M K * M L F R N L L N L * T V V

26701 TTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGGCCTTGGTACAT 26760
F Y * S * R N R Y L * N V C * M A L V H
F I N L K E I G T Y E M Y V K W P W Y I
L L I L K K * V L M K C M L N G L G T F

26761 TTGGTTGTTAATGTTCATTTTATTTATAATTTTTCTTATGATACTTTTCTTTATATGCTG 26820
L V V N C H F I Y N F S Y D T F L Y M L
W L L I V I L F I I F L M I L F F I C C
G C * L S F Y L * F F L * Y F S L Y A A

26821 CTGTACTGGTTGTTGTTTCAGCATGTTTTAGTAAATGTCATAATTGTTGTGATGAGTATGG 26880
L Y W L W F S M F * * M S * L L * * V W
C T G C G S A C F S K C H N C C D E Y G
V L V V V Q H V L V N V I I V V M S M G

26881 GGGTCACAATGATTTTGTATTATAAGCATCTCATGATGATTAGATTTTAAATCTAAACTT 26940
G S Q * F C Y * S I S * * L D F K S K L
G H N D F V I K A S H D D * I L N L N F
V T M I L L L K H L M M I R F * I * T L

26941 TATATATGGAAGTTTGGAGGCCCTAGCTATAAATATCTCTTATTACTAGAGAATTTGGTG 27000
Y I W K F G G L A I N I L L L L E N L V
I Y G S L E A * L * I F S Y Y * R I W C
Y M E V W R P S Y K Y S L I T R E F G V

FIG. 9 CONT.

27001 TCACAGATCTTGAGGATTTGTGTTTTAAATATAATTATTGCCAACCTTGTGTTGGTTATT 27060
S Q I L R I C V L N I I I A N L V L V I
H R S * G F V F * I * L L P T L C W L L
T D L E D L C F K Y N Y C Q P C V G Y C

27061 GTATTGTACCTTTAAACGTTTGGTGTGCGTAAGTTTGGTAAATTTGCTTCTTATTTTGTTT 27120
V L Y L * T F G V V S L V N L L L I L F
Y C T F K R L V S * V W * I C F L F C F
I V P L N V W C R K F G K F A S Y F V L

27121 TACGTAGTCATGACACCTCTCATAAGAATAATTTTGGTGTATAACTAGTTTACTAGTT 27180
Y V V M T P L I R I I L V L * L V L L V
T * S * H L S * E * F W C Y N * F Y * L
R S H D T S H K N N F G V I T S F T S Y

27181 ATGGTAACACTGTTTCTGAGGCTGTTTCTAAATTAGTTGAATCAGCATCTGATTTTATCG 27240
M V T L F L R L F L N * L N Q H L I L S
W * H C F * G C F * I S * I S I * F Y R
G N T V S E A V S K L V E S A S D F I A

27241 CTTGGCGAGCTGAAGCACTTAATAAGTATGTTGATGATTTTTCACTGATACTGCTTGG 27300
L G E L K H L I S M V D V F F T D T A W
L A S * S T * * V W L M Y F S L I L L G
W R A E A L N K Y G * C I F H * Y C L V

27301 TATGTAGGTCAGATTTTCTTTTTAGTTTTATCTTGTGTCATTTTCTTAATTTTTGTGTT 27360
Y V G Q I F F L V L S C V I F L I F V V
M * V R F S F * F Y L V S F S * F L L L
C R S D F L F S F I L C H F L N F C C C

27361 GCACTTTTAGCAACTATTAACCTTTGTATTCAAATTTGTGGTTTTTGTAAATTTTTTATT 27420
A L L A T I K L C I Q I C G F C N I F I
H F * Q L L N F V F K F V V F V I F L L
T F S N Y * T L Y S N L W F L * Y F Y Y

27421 ATTTACCTTCTGCCTATGTTTATAATAGAGGTAGACAGTTGTATAAGTCTTATAGTGAA 27480
I S P S A Y V Y N R G R Q L Y K S Y S E
F H L L P M F I I E V D S C I S L I V N
F T F C L C L * * R * T V V * V L * * T

27481 CATGTCATACCTTCTACTTTAGATGATTTAATTTAAATCTAAACATCATGAATGAATCAA 27540
H V I P S T L D D L I * I * T S * M N Q
M S Y L L L * M I * F K S K H H E * I N
C H T F Y F R * F N L N L N I M N E S I

FIG. 9 CONT.

27541 TTTTTCCTCATTGGAATTCTGATCAAGCTATTACATTCTTAAAAGAAATGGAATTTCTCTT 27600
F F L I G I L I K L L H S * K N G I S L
F S S L E F * S S Y Y I L K R M E F L F
F P H W N S D Q A I T F L K E W N F S L

27601 TGGGTGTAATATTACTTCTCATTACTATCATACTGCAGTTTGGTTATACGAGTCGTAAGTA 27660
W V * Y Y F S L L S Y C S L V I R V V V
G C N I T S H Y Y H T A V W L Y E S * Y
G V I L L L I T I I L Q F G Y T S R S M

27661 TGTTTGTATCTTATTAAGATGATTATCTTTGGCTTATGTGGCCATTGACCATTATCT 27720
C L F I L L R * L F F G L C G H * P L S
V C L S Y * D D Y S L A Y V A I D H Y L
F V Y L I K M I I L W L M W P L T I I L

27721 TGACTATATTTAATGCTTTTATGCTTTGAATAATATCTTTCTTGGGCTTCTATACTGT 27780
* L Y L I A F M L * I I S F L G F L Y C
D Y I * L L L C F E * Y L S W A F Y T V
T I F N C F Y A L N N I F L G L S I L F

27781 TTAATATATTTCTATTGTTATATGGATTTTATATTTTGTCAACAGTATTCGGCTTTTTTA 27840
L L L F L L L Y G F Y I L S T V F G F L
Y Y Y F Y C Y M D F I F C Q Q Y S A F Y
T I I S I V I W I L Y F V N S I R L F I

27841 TCAGAACTGGCAGTTGGTGGAGTTTAAACCCAGAGACTAATAATCTTATGTGTATTGATA 27900
S E L A V G G V L T Q R L I I L C V L I
Q N W Q L V E F * P R D * * S Y V Y * Y
R T G S W W S F N P E T N N L M C I D M

27901 TGAAAGTAAGATGTATGTTAGGCCAGTTATTGAGGACTATCATAACGCTACTG 27960
* K V R C M L G Q L L R T I I H * R L L
E R * D V C * A S Y * G L S Y I N G Y C
K G K M Y V R P V I E D Y H T L T A T V

27961 TTATCCGTGGTCATCTTTATATACAGGGTGTAAACTTGGCACTGGTTACACGCTTGCCG 28020
L S V V I F I Y R V L N L A L V T R L P
Y P W S S L Y T G C * T W H W L H A C R
I R G H L Y I Q G V K L G T G Y T L A D

28021 ATTTGCCTGTTTATGTTACTGTAGCTAAGGTGCAAGTCTCTGTACTTATAAAGTGCCT 28080
I C L F M L L * L R C K S S V L I N V P
F A C L C Y C S * G A S P L Y L * T C L
L P V Y V T V A K V Q V L C T Y K R A F

FIG. 9 CONT.

28081 TTTTAGATAAGTTAGATGTTAATAGTGGTTTTGCTGTTTTGTTAAGTCTAAAGTTGGTA 28140
F * I S * M L I V V L L F L L S L K L V
F R * V R C * * W F C C F C * V * S W *
L D K L D V N S G F A V F V K S K V G N

28141 ACTATCGTTTTACCTTCTAGTAAATCTAGTGGTATGGATACTGCCTTGTTGAGAGCTTAAA 28200
T I V Y L L V N L V V W I L P C * E L K
L S F T F * * I * W Y G Y C L V E S L N
Y R L P S S K S S G M D T A L L R A * I

28201 TCTAAACTATTAGGATGTCTTATACTCCCGTCCATCATGCTGGAAGTAGAAGCTCCTCTG 28260
S K L L G C L I L P V I M L E V E A P L
L N Y * D V L Y S R S S C W K * K L L W
* T I R M S Y T P G H H A G S R S S S G

28261 GAAATCGTTCAGGAATCCTCAAGAAAACCTTCTGGGTTGACCAATCTGAGCGAAGCCATC 28320
E I V Q E S S R K L L G L T N L S E A I
K S F R N P Q E N F L G * P I * A K P S
N R S G I L K K T S W V D Q S E R S H Q

28321 AAACCTATAATAGAGGCAGAAAACCCCAACCCAAATTCACTGTGTCTACTCAACCACAAG 28380
K P I I E A E N P N P N S L C L L N H K
N L * * R Q K T P T Q I H C V Y S T T R
T Y N R G R K P Q P K F T V S T Q P Q G

28381 GAAACCCTATCCCACATTATTCTGGTTCTCTGGGATTACCCAATTTCAAAAAGGTAGAG 28440
E T L S H I I P G S L G L P N F K K V E
K P Y P T L F L V L W D Y P I S K R * R
N P I P H Y S W F S G I T Q F Q K G R D

28441 ACTTTAAATTTCCAGATGGTCAAGGAGTACCCATTGCTTACGGGATACCCCTTCTGAAG 28500
T L N F Q M V K E Y P L L T G Y P L L K
L * I S R W S R S T H C L R D T P F * S
F K F P D G Q G V P I A Y G I P P S E A

28501 CAAAAGGATATTGGTATAAACACAACCGGCGTTCTTTTAAAACAGCTGATGGTCAACAAA 28560
Q K D I G I N T T G V L L K Q L M V N K
K R I L V * T Q P A F F * N S * W S T K
K G Y W Y K H N R R S F K T A D G Q Q K

28561 AGCAGTTGTTACCAAGATGGTATTCTACTACTCTCGGTACCGGTCCATATGCCAGTTTCAT 28620
S S C Y Q D G I S T I S V P V H M P V H
A V V T K M V F L L S R Y R S I C Q F I
Q L L P R W Y F Y Y L G T G P Y A S S S

FIG. 9 CONT.

28621 CCTATGGTGATGCCACGAAGGTATCTTCTGGGTCGCTAGTCACCAAGCTGACACTTCTA 28680
P M V M P T K V S S G S L V T K L T L L
L W * C P R R Y L L G R * S P S * H F Y
Y G D A H E G I F W V A S H Q A D T S I

28681 TTCCCTCCGATGTTTCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTT 28740
F P P M F R Q G I L L F K K L S L L G F
S L R C F G K G S Y Y S R S Y P Y * V F
P S D V S A R D P T I Q E A I P T R F S

28741 CGCCTGGTACGATTTTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGGTCTGCTTCTA 28800
R L V R F C L K A I M L K A Q E G L L L
A W Y D F A S R L L C * R L R K V C F *
P G T I L P Q G Y Y V E G S G R S A S N

28801 ATAGCCGCCAGGTTACGTTCTCAATCACGTGGACCAATAATCGTTCATTAAGTAGAA 28860
I A G Q V H V L N H V D P I I V H * V E
* P A R F T F S I T W T Q * S F I K * K
S R P G S R S Q S R G P N N R S L S R S

28861 GTAATTCTAATTTTACGATTCTGATTCTATAGTAAACCTGATATGGCTGATGAGATTG 28920
V I L I L D I L I L * * N L I W L M R L
* F * F * T F * F Y S E T * Y G * * D C
N S N F R H S D S I V K P D M A D E I A

28921 CTAGTCTGTCTTGGCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTTACCAAGCAAA 28980
L V L S W P S L V K I L N L S K L P S K
* S C L G Q A W * R F * T S A S Y Q A K
S L V L A K L G K D S K P Q Q V T K Q N

28981 ATGCTAAGGAAATTAGGCATAAAATTTAATGAAACCTCGCCAAAAGCGAACTCCTAATA 29040
M L R K L G I K F * * N L A K S E L L I
C * G N * A * N F N E T S P K A N S * *
A K E I R H K I L M K P R Q K R T P N K

29041 AATTTTGAATGTTCAACAGTGTGTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATT 29100
N F V M F N S V L V K E D R S K T L V I
I L * C S T V F W * K R T A P K L W * F
F C N V Q Q C F G K R G P L Q N F G N S

29101 CTGAAATGTTAAAGCTTGGTACTAATGATCCTCAATTTCTTCTGCTGAATTAGCCC 29160
L K C * S L V L M I L N F L F L L N * P
* N V K A W Y * * S S I S Y S C * I S P
E M L K L G T N D P Q F P I L A E L A P

FIG. 9 CONT.

29161 CTACACCAGGTGCTTTTTCTTTGGCTCTAAATTAGAGTTGTTTAAAAGAGACTCTGATG 29220
L H Q V L F S L A L N * S C L K E T L M
Y T R C F F L W L * I R V V * K R L * C
T P G A F F F G S K L E L F K R D S D A

29221 CTGATTCACCTTCTAAAGACACTTTTGAACCTTCGTTATTCTGGTTCTATTAGGTTTGATa 29280
L I H L L K T L L N F V I L V L L G L I
* F T F * R H F * T S L F W F Y * V * *
D S P S K D T F E L R Y S G S I R F D S

29281 GTACTTTACCTGGTTTGGAGACAATTATGAAAGTTCTTAAAGAGAATTTAGATGCTTATG 29340
V L Y L V L R Q L * K F L K R I * M L M
Y F T W F * D N Y E S S * R E F R C L C
T L P G F E T I M K V L K E N L D A Y V

29341 TTAATTCTAATCAGAACACTGTTTCTGGTTCGCTGAGTCTAAACCTCAGCGTAAAAGAG 29400
L I L I R T L F L V R * V L N L S V K E
* F * S E H C F W F A E S * T S A * K R
N S N Q N T V S G S L S P K P Q R K R G

29401 GTGTTAAACAATCACCTGAATCGTTTACTCTCTTAATTTAAGTGCTGATACTCAGCACA 29460
V L N N H L N R L T L L I * V L I L S T
C * T I T * I V * L S * F K C * Y S A H
V K Q S P E S F D S L N L S A D T Q H I

29461 TTTCAAATGATTTTACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATG 29520
F Q M I L L L R I I V Y L L L L M I L M
F K * F Y S * G S * F T C Y S * * S L C
S N D F T P E D H S L L A T L D D P Y V

29521 TAGAAGACTCTGTTGCTTAATGAGAATGAATCCTAATTCGACACTAGGTGGTAACCCCTC 29580
* K T L L L N E N E S * F D T R W * P L
R R L C C L M R M N P N S T L G G N P S
E D S V A * * E * I L I R H * V V T P R

29581 GCTATTAGTCGGAATAGGACACTCTCTATCAGAATGAATCTTGCTGTTACAACAGATAG 29640
A I S R N R T L S I R M N S C C Y N R *
L L V G I G H S L S E * I L A V T T D R
Y * S E * D T L Y Q N E F L L L Q Q I E

29641 AGTAGGTTGTTGCAGACTATATATTAATTAGTAGAACTTTATATTTAAATATTTGATTG 29700
S R L L Q T I Y * L V E T L Y L N I * L
V G C C R L Y I N * * K L Y I * I F D C
* V V A D Y I L I S R N F I F K Y L I V

FIG. 9 CONT.

29701 TTAGAGTAGTTATAAGGTTTAGCTGTAGTATAAACGCCTCCGGGAAGAGCTAGCAATTAT 29760

L E * L * G L A V V * T P P G R A S N Y
* S S Y K V * L * Y K R L R E E L A I I
R V V I R F S C S I N A S G K S * Q L *

29761 AGTATTTAATATATATATATTAGTATATGATTGAAATTAATTATAGCCTTTTGGAGGAATTA 29820

S I * Y I Y * Y M I E I N Y S L L E E L
V F N I Y I S I * L K L I I A F W R N Y
Y L I Y I L V Y D * N * L * P F G G I T

29821 CAAAAAAAAAAAAAAAAA

29836

Q K K K K X
K K K K K
K K K K

FIG. 9 CONT.




FIG. 10

Fig. 11. Multiple alignment of the replicase genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9 and 10.

```

Patient 7      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 9      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 10     TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 6      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 4      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 8      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 2      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 5      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
Patient 1      TCTAAAGATTTAAATTTTTTAAACCGGGTTCGGGGTACTAGTGTGAATGCCCGCTAGTA 60
*****

Patient 7      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 9      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 10     CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 6      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 4      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 8      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 2      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 5      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGACATTTGTAATACC 120
Patient 1      CCCTGTGCTAGTGGTTTATCTACTGATGTTCAATTAAGGGCATTGATATTTGTAATACT 120
*****

Patient 7      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 9      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 10     AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 6      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 4      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 8      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 2      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 5      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
Patient 1      AATAGAGCTGGTATAGGTTTATATTATAAAGTGAATTGTTGCCGTTTTTCAGCGTATAGAT 180
*****

Patient 7      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 9      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 10     GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 6      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 4      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 8      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 2      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 5      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATTTAGAAGTTTAT 240
Patient 1      GACGACGGTAATAAATGGATAAGTTCCTTGTGTGCAAAAGAATAAATCTAGAAGTTTAT 240
*****

Patient 7      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 9      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 10     AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 6      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 4      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 8      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 2      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 5      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
Patient 1      AATAAAGAGAAAACCTATTATGAGTTGACTAAAAGTTGTGGTGTGTGGCTGAACATGAT 300
*****

Patient 7      TTCCTTATATTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 9      TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 10     TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 6      TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 4      TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 8      TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 2      TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 5      TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAGGAATCCTTCA 360
Patient 1      TTCCTTACATTTGATATTGATGGTAGTCGCGTGCCACATATAGTTCGTAAGAACCCTCTCA 360
*****

Patient 7      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420
Patient 9      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420
Patient 10     AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420
Patient 6      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420
Patient 4      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420
Patient 8      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420
Patient 2      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420
Patient 5      AAGTATACTATGTTAGATCTTTGCTATGCATTGCGTCATTTTGTATCGTAATGATTGTTCA 420

```

FIG. 11

Patient 1 AAGTATACTATGTTAGATCTTTGCTATGCATTGCGCCATTTTGATTGTAATGATTGTTCA 420

Patient 7 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 9 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 10 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 6 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 4 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 8 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 2 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 5 ATATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480
Patient 1 GTATTGTGTGAAATTCCTTGTGAGTATGCTGATTGTAAAGAATCCTACTTTTCTAAGAAA 480

Patient 7 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 9 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 10 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 6 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 4 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 8 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 2 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 5 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540
Patient 1 GATTGGTATGATTTTGTGAAAATCCTGATATTATTAATATATATAAAAAATTAGGCCCT 540

Patient 7 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 9 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 10 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 6 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 4 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 8 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 2 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 5 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600
Patient 1 ATTTTAAATAGAGCTTTACTTAATACTGTCATTTTTCAGACACCTTAGTTGAAGTAGGT 600

Patient 7 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 9 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 10 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 6 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 4 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 8 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 2 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 5 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660
Patient 1 TTAGTTGGTGTTTTAACTTTAGATAACCAAGATTTGTATGGTCAATGGTATGATTTTGGT 660

Patient 7 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 9 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 10 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 6 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 4 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 8 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 2 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 5 GATTTTATACAAACAGCCCAGGATTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720
Patient 1 GATTTTATACAAACAGCTCCAGGTTTGGTGTGGCAGTGCAGATTCTTACTATTCTTAT 720

Patient 7 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 9 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 10 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 6 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 4 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 8 ATGATGCCTATGTTAACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 2 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 5 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780
Patient 1 ATGATGCCTATGTTGACTATGTGTCATGTATTAGATTGTGAATTATTTGTTAATGATAGT 780

Patient 7 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840
Patient 9 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840
Patient 10 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840
Patient 6 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840
Patient 4 TATAGACAATTCGATCTTGTGCAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840
Patient 8 TATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840
Patient 2 TATAGACAATTCGATCTTGTACAGTATGATTTTACTGATTACAAGTTAGAGTTGTTTAAAT 840

FIG. 11 CONT.

Patient 5 TATAGACAATTCGATCTTGTACAGTATGATTTACTGATTACAAGTTAGAGTTGTTAAT 840
Patient 1 TATAGACAATTCGATCTTGTACAGTATGATTTACTGATTATAAGTTAGAATTGTTAAT 840

Patient 7 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 9 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 10 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 6 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 4 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 8 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 2 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 5 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900
Patient 1 AAGTATTTAAGTATTGGGGTATGAAGTATCATCCTAATACTGTGGATTGTGATAATGAT 900

Patient 7 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 9 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 10 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 6 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 4 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 8 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 2 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 5 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960
Patient 1 AGGTGTATTATTCATTGTGCTAAATTTAATATACTATTTAGTATGGTTTACCTAATACT 960

Patient 7 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 9 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 10 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 6 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 4 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 8 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 2 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 5 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020
Patient 1 TGTTTGGTCCCCTTGTAGACAAATTTTGTAGATGGGTACCGTTTGTGTTTCTATT 1020

Patient 7 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 9 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 10 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 6 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 4 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 8 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 2 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 5 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080
Patient 1 GGTTACCATTACAAAGAGTTAGGTGTAGTTATGAACCTAGATGTTGACACACCCGTTAT 1080

Patient 7 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 9 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 10 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 6 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 4 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 8 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 2 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCACGTTGCATCT 1140
Patient 5 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
Patient 1 CGTTTGTCTCTTAAAGATTTACTTCTTTATGCAGCAGATCCTGCTATGCATGTTGCATCT 1140
** *****

Patient 7 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 9 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 10 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 6 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 4 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 8 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 2 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 5 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200
Patient 1 GCTAGTGTCTGCTTGATTTACGAACTTGTGTTTTAGTGTAGCTGCCATTACAAGTGGT 1200

Patient 7 ATAAAAATTCAAACTGTAAAACCGTAACCTTAAACCAAGACTTTTACGAGTTTGTAAA 1260
Patient 9 ATAAAAATTCAAACTGTAAAACCGTAACCTTAAACCAAGACTTTTACGAGTTTGTAAA 1260
Patient 10 ATAAAAATTCAAACTGTAAAACCGTAACCTTAAACCAAGACTTTTACGAGTTTGTAAA 1260
Patient 6 ATAAAAATTCAAACTGTAAAACCGTAACCTTAAACCAAGACTTTTACGAGTTTGTAAA 1260
Patient 4 ATAAAAATTCAAACTGTAAAACCGTAACCTTAAACCAAGACTTTTACGAGTTTGTAAA 1260
Patient 8 ATAAAAATTCAAACTGTAAAACCGTAACCTTAAACCAAGACTTTTACGAGTTTGTAAA 1260

FIG. 11 CONT.

Patient 2 ATAAAATTTCAAAGTGTAAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTTAAA 1260
Patient 5 ATAAAATTTCAAAGTGTAAACCAGGTAACCTTAAACCAAGACTTTTACGAGTTTGTTAAA 1260
Patient 1 ATAAAATTTCAAAGTGTAAACCAGGTAACCTTAAACCAAGACTTTTATGAGTTTGTCAA 1260

Patient 7 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 9 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 10 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 6 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 4 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 8 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 2 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 5 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320
Patient 1 AGTAAAGGCTTGTTTAAAGAGGGTAGTACAGTTGATTTGAAACATTTTTCTTTACTCAA 1320

Patient 7 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 9 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 10 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 6 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 4 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 8 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 2 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 5 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380
Patient 1 GATGGTAATGCTGCAATTACTGATTATAATTATTATAAGTATAATTTACCTACTATGGTT 1380

Patient 7 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 9 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 10 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 6 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 4 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 8 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 2 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 5 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440
Patient 1 GATATTAAGCAGTTATTGTTTGTATTAGAAGTTGTTTATAAATATTTGAAATTTATGAT 1440

Patient 7 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 9 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 10 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 6 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 4 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 8 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 2 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 5 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500
Patient 1 GGTGGTGTATACCAGCATCACAAGTTATTGTTAATAATTATGATAAAAAGTGCCTGGTTAT 1500

Patient 7 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 9 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 10 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 6 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 4 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 8 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 2 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 5 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560
Patient 1 CCATTTAATAAAATTTGGTAAAGCCAGACTTTATTATGAGGCATTATCATTTGAAGAACAG 1560

Patient 7 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 9 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 10 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 6 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 4 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 8 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 2 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 5 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620
Patient 1 AATGAAATTTATGCAATATACTAAACGTAATGTTCTGCCACCTTAACTCAAATGAAATTTA 1620

Patient 7 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680
Patient 9 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680
Patient 10 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680
Patient 6 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680
Patient 4 AAATATGCTATCAGTGCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680

FIG. 11 CONT.

Patient 8 AAATATGCTATCAGTGCCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680
 Patient 2 AAATATGCTATCAGTGCCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680
 Patient 5 AAATATGCTATCAGTGCCTAAGAATAGAGCTCGCACTGTAGCAGGTGTTTCTATTCTTAGT 1680
 Patient 1 AAATATGCTATTAGTGCCTAAGAATAGAGCTCGTACTGTTGCAGGTGTTTCCATTCTTAGT 1680

Patient 7 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 9 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 10 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 6 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 4 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 8 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 2 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 5 ACTATGACAGGCCGAATGTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACCCGAGGT 1740
 Patient 1 ACTATGACAGGTCGAATGTTTCCATCAAAAATGTTGAAGAGTATAGCAGCTACTCGTGGT 1740

Patient 7 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 9 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 10 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 6 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 4 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 8 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 2 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 5 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800
 Patient 1 GTTCCTGTTGTTATAGGAACCACTAAATTTTATGGTGGTTGGGACGATATGTTACGTCAT 1800

Patient 7 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 9 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 10 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 6 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 4 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 8 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 2 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 5 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860
 Patient 1 CTTATAAAGGATGTTGACAACCCGTCTTATGGGTTGGGATTATCCTAAATGTGATCGT 1860

Patient 7 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 9 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 10 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 6 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 4 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 8 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 2 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 5 GCTATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCCCGCAAACATGAATTT 1920
 Patient 1 GCCATGCCAAATATTTGCGTATGTTAGTAGTTTAGITTTGGCTCGTAAACATGAATTT 1920
 ** *****

Patient 7 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 9 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 10 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 6 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 4 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 8 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 2 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 5 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980
 Patient 1 TGTTGTTACATGGTGATAGATTTTATCGCCTTGCGAATGAATGTGCTCAAGTTTGGAGT 1980

Patient 7 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 9 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 10 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 6 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 4 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 8 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 2 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 5 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040
 Patient 1 GAAATAGTTATGTTGGCGGTTGCTATTATGTTAAGCCTGGTGGTACTAGCAGTGGTGAT 2040

Patient 7 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100
 Patient 9 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100
 Patient 10 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100
 Patient 6 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATGTCAGGCTGTACTGCTAACGTT 2100

FIG. 11 CONT.

Patient 4 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATATGTCAGGCTGTACTGCTAAAGTT 2100
 Patient 8 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATATGTCAGGCTGTACTGCTAAAGTT 2100
 Patient 2 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATATGTCAGGCTGTACTGCTAAAGTT 2100
 Patient 5 GCAACTACTGCTTTTGCTAATTCTGTTTTTAATATATATGTCAGGCTGTACTGCTAAAGTT 2100
 Patient 1 GCAACCCTGCTTTTGCTAATTCTGTTTTTAATATATATGTCAGGCTGTACTGCTAAAGTT 2100

Patient 7 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 9 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 10 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 6 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 4 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 8 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 2 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 5 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160
 Patient 1 TGTTCTCTTATGGCCTGTAATGGCCATAAGATTGAAGATTTAAGTATACGCAATTTACAA 2160

Patient 7 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 9 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 10 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 6 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 4 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 8 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 2 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 5 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220
 Patient 1 AAACGCTTATACTCTAATGTTTATCGTACAGATTATGTTGATTATACATTTGTTAATGAG 2220

Patient 7 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 9 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 10 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 6 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 4 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 8 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 2 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 5 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280
 Patient 1 TATTATGAATTTTATGTAAGCATTTTAGTATGATGATTTTGAGTGATGATGGTGTGTC 2280

Patient 7 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 9 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 10 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 6 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 4 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 8 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 2 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 5 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340
 Patient 1 TGTTATAACTCTGATTATGCTAGTAAGGGTTATATAGCTAATATAAGTGTTTTCAACAA 2340

Patient 7 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 9 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 10 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 6 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 4 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 8 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 2 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 5 GTTTTGACTATCAGAATAATGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400
 Patient 1 GTTTTGACTATCAGAATAACGTTTTTATGCTGAATCTAAATGTTGGGTTGAAAATGAT 2400

Patient 7 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460
 Patient 9 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460
 Patient 10 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460
 Patient 6 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460
 Patient 4 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460
 Patient 8 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTGGTTAAGATAGATGGT 2460
 Patient 2 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTAGTTAAGATAGATGGT 2460
 Patient 5 ATTACTAATGGTCCTCATGAATTTTGTCCCAACATACTATGTTAGTTAAGATAGATGGT 2460
 Patient 1 ATTACTAATGGTCCTCATGAATTTCTGTTCCACAACTACTATGTTGGTTAAGATAGATGGT 2460

Patient 7 GATTATGTTTATTACCATATCCAGATCCTTCTAGAATTCTAGGAGCTGGTTGTTTGT 2520
 Patient 9 GATTATGTTTATTACCATATCCAGATCCTTCTAGAATTCTAGGAGCTGGTTGTTTGT 2520
 Patient 10 GATTATGTTTATTACCATATCCAGATCCTTCTAGAATTCTAGGAGCTGGTTGTTTGT 2520

FIG. 11 CONT.

Patient 6 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTGT 2520
Patient 4 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTGT 2520
Patient 8 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATCTAGGAGCTGGTTGTTTGT 2520
Patient 2 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTAGGAGCTGGTTGTTTGT 2520
Patient 5 GATTATGTTTATTTACCATATCCAGATCCTTCTAGAATTTAGGAGCTGGTTGTTTGT 2520
Patient 1 GACTATGTTTATCTACCCATCCAGACCCTTCTAGAATTTAGGAGCTGGTTGTTTGT 2520
** ***** **

Patient 7 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 9 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 10 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 6 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 4 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 8 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 2 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 5 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
Patient 1 GATGATTTATTGAAGACTGCAGTGTCTTTTGATAGAGCGCTTTGTAAGCTAGCTATA 2580
***** **

Patient 7 GATGCTTACCCTTTAGTATATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 9 GATGCTTACCCTTTAGTATATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 10 GATGCTTACCCTTTAGTATATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 6 GATGCTTACCCTTTAGTATATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 4 GATGCTTACCCTTTAGTATATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 8 GATGCTTACCCTTTAGTATATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 2 GATGCTTACCCTTTAGTACATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 5 GATGCTTACCCTTTAGTACATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
Patient 1 GATGCTTACCCTTTAGTACATCATGAAAATGAAGAATACCAAAAAGCTTTTCGTGTATAT 2640
***** * ***** **

Patient 7 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 9 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 10 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 6 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 4 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 8 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 2 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 5 TTAGAATATATAAAAAAACTGTATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
Patient 1 TTAGAATATATAAAAAAACTATATAATGATCTTGCTACTCAGATCTTAGATAGTTATAGT 2700
***** ***** **

Patient 7 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 9 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 10 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 6 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 4 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 8 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 2 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 5 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGAAGAATCATTTTACAAGAATATG 2760
Patient 1 GTTATTTAAGTACTTGTGATGGTTTAAAGTTTACTGATGAATCATTTTATAAGAATATG 2760
***** ***** **

Patient 7 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 9 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 10 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 6 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 4 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 8 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 2 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 5 TATTTAAAAAGTGCCGTGATGCAG 2784
Patient 1 TATTTAAAAAGTGCCGTGATGCAG 2784

FIG. 11 CONT.




FIG. 12

Patient 8 TTTAGTACTATAGTTATAGGTAGTGTGTTTTGTTAATACTTCTTATACTATTGTTGTTCAA 420
***** * * *****

Patient 6 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480
Patient 9 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480
Patient 10 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480
Patient 5 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480
Patient 4 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480
Patient 7 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480
Patient 2 CCTCATAATGGTGTGTTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAT 480
Patient 1 CCTCACAATGGTATTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAC 480
Patient 8 CCTCATAATGGTATTTGGAGATTACAGCTTGTCAATACACTATGTGTGAGTATCCTCAC 480
***** * * *****

Patient 6 ACTATTTGTAATCTAAAGGTAGTCTCGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 9 ACTATTTGTAATCTAAAGGTAGTCTCGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 10 ACTATTTGTAATCTAAAGGTAGTCTCGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 5 ACTATTTGTAATCTAAAGGTAGTCTCGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 4 ACTATTTGTAATCTAAAGGTAGTCTCGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 7 ACTATTTGTAATCTAAAGGTAGTCTCGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 2 ACTATTTGTAATCTAAAGGTAGTCTCGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 1 ACTGTTGTAAGTCTAAGGGTAGTATTGTAATGAATCTGGCATTGATAAACTGAA 540
Patient 8 ACTGTTGTAAGTCTAAGGGTAGTATTGTAATGAATCTGGCATTGATAAACTGAA 540
*** ***** * * *****

Patient 6 CCTTTGTGCTGTTCAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 9 CCTTTGTGCTGTTCAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 10 CCTTTGTGCTGTTCAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 5 CCTTTGTGCTGTTCAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 4 CCTTTGTGCTGTTCAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 7 CCTTTGTGCTGTTCAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 2 CCTTTGTGCTGTTCAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 1 CCTTTATGCTGTTTAAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
Patient 8 CCTTTATGCTGTTTAAAGAAAAATTTACTTATAATGTTTCTACAGATTGGTGTATTTT 600
***** * * *****

Patient 6 CATTTTTATCAAGAACGTGGCACTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 9 CATTTTTATCAAGAACGTGGCACTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 10 CATTTTTATCAAGAACGTGGCACTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 5 CATTTTTATCAAGAACGTGGCACTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 4 CATTTTTATCAAGAACGTGGCACTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 7 CATTTTTATCAAGAACGTGGCACTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 2 CATTTTTATCAAGAACGTGGCACTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 1 CATTTTTATCAAGAACGTGGTGTGTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
Patient 8 CATTTTTATCAAGAACGTGGTGTGTTTTTATGCTTATTATGCTGATTCTGGCATGCCTACT 660
***** * * *****

Patient 6 ACTTTTTATTAGTTTGTATCTGGTACTCTTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 9 ACTTTTTATTAGTTTGTATCTGGTACTCTTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 10 ACTTTTTATTAGTTTGTATCTGGTACTCTTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 5 ACTTTTTATTAGTTTGTATCTGGTACTCTTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 4 ACTTTTTATTAGTTTGTATCTGGTACTCTTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 7 ACTTTTTATTAGTTTGTATCTGGTACTCTTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 2 ACTTTTTATTAGTTTGTATCTGGTACTCTTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 1 ACTTTCTATTAGTTTATATTAGTACTATTTTATCTCATTATTATGTTTTGCCTTTG 720
Patient 8 ACTTTCTATTAGTTTATATTAGTACTATTTTATCTCATTATTATGTTTTGCCTTTG 720
***** * * *****

Patient 6 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780
Patient 9 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780
Patient 10 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780
Patient 5 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780
Patient 4 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780
Patient 7 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780
Patient 2 ACTTGTAATGCTATATCTTCTAATACTGATAATGAGACTTTACAATATTGGGTACACCT 780
Patient 1 ACTTGTAAGGCTATATCTTCTAATACTGATAATGAACTTTAGAATATTGGGTACACCG 780
Patient 8 ACTTGTAATGCTATATCTTCTAATACTGATAATGAACTTTAGAATATTGGGTACACCG 780
***** * * *****

Patient 6 TTGCTAAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840
Patient 9 TTGCTAAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840
Patient 10 TTGCTAAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840
Patient 5 TTGCTAAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840
Patient 4 TTGCTAAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840
Patient 7 TTGCTAAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840
Patient 2 TTGCTAAAACGCCAATATCTTCTTAAATTTGACAACCGTGGTGTATTACTAATGCTGTT 840

FIG. 13 CONT.

Patient 1 CTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTATTACTAATGCCGTT 840
Patient 8 CTATCTAGACGTCAGTATCTTCTTAATTTTGATGAGCACGGTGTATTACTAATGCCGTT 840
* * * * *

Patient 6 GATTGTTCTAGTAGTTTCTTTAGCGAGATTC AATGTAAAAC TAAATCTTTATTACCTAAT 900
Patient 9 GATTGTTCTAGTAGTTTCTTTAGCGAGATTC AATGTAAAAC TAAATCTTTATTACCTAAT 900
Patient 10 GATTGTTCTAGTAGTTTCTTTAGCGAGATTC AATGTAAAAC TAAATCTTTATTACCTAAT 900
Patient 5 GATTGTTCTAGTAGTTTCTTTAGCGAGATTC AATGTAAAAC TAAATCTTTATTACCTAAT 900
Patient 4 GATTGTTCTAGTAGTTTCTTTAGCGAGATTC AATGTAAAAC TAAATCTTTATTACCTAAT 900
Patient 7 GATTGTTCTAGTAGTTTCTTTAGCGAGATTC AATGTAAAAC TAAATCTTTATTACCTAAT 900
Patient 2 GATTGTTCTAGTAGTTTCTTTAGCGAGATTC AATGTAAAAC TAAATCTTTATTACCTAAT 900
Patient 1 GATTGTTCAAGTAGTTTCTTTAGTGAGATTC AATGTAAAAC TCAATCTTTTGCACCTAAT 900
Patient 8 GATTGTTCAAGTAGTTTCTTTAGTGAGATTC AATGTAAAAC TCAATCTTTTGCACCTAAT 900
* * * * *

Patient 6 ACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960
Patient 9 ACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960
Patient 10 ACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960
Patient 5 ACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960
Patient 4 ACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960
Patient 7 ACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960
Patient 2 ACTGGTGTATTGACTTATCTGGTTTTACTGTTAAGCCTGTGCAACTGTACATCGTCGT 960
Patient 1 ACTGGTGTATTGATTGTCTGGTTTTACTGTTAAGCCTGTGCAACTGTTTATCGTCGG 960
Patient 8 ACTGGTGTATTGATTGTCTGGTTTTACTGTTAAGCCTGTGCAACTGTTTATCGTCGG 960
* * * * *

Patient 6 ATTCCTGATTTACCTGATTGTGACATGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020
Patient 9 ATTCCTGATTTACCTGATTGTGACATGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020
Patient 10 ATTCCTGATTTACCTGATTGTGACATGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020
Patient 5 ATTCCTGATTTACCTGATTGTGACATGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020
Patient 4 ATTCCTGATTTACCTGATTGTGACATGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020
Patient 7 ATTCCTGATTTACCTGATTGTGACATGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020
Patient 2 ATTCCTGATTTACCTGATTGTGACATGATAAATGGCTTAACAATTTTAAATGTACCCTCA 1020
Patient 1 ATTCCTAATTTACCTGATTGTGACATGACAACCTGGCTTAATAATGTTAGTGTACCCTCA 1020
Patient 8 ATTCCTAATTTACCTGATTGTGACATGACAACCTGGCTTAATAATGTTAGTGTACCCTCA 1020
* * * * *

Patient 6 CCTCTTAATGGGAACGTAAAATTTTTCTAATGCAACTTTAATTTGAGTACTTTGCCT 1080
Patient 9 CCTCTTAATGGGAACGTAAAATTTTTCTAATGCAACTTTAATTTGAGTACTTTGCCT 1080
Patient 10 CCTCTTAATGGGAACGTAAAATTTTTCTAATGCAACTTTAATTTGAGTACTTTGCCT 1080
Patient 5 CCTCTTAATGGGAACGTAAAATTTTTCTAATGCAACTTTAATTTGAGTACTTTGCCT 1080
Patient 4 CCTCTTAATGGGAACGTAAAATTTTTCTAATGCAACTTTAATTTGAGTACTTTGCCT 1080
Patient 7 CCTCTTAATGGGAACGTAAAATTTTTCTAATGCAACTTTAATTTGAGTACTTTGCCT 1080
Patient 2 CCTCTTAATGGGAACGTAAAATTTTTCTAATGCAACTTTAATTTGAGTACTTTGCCT 1080
Patient 1 CCTCTTAATGGGAACGTAGAATTTTTCTAATGTAACCTCAATTTAAGCACTTTACTT 1080
Patient 8 CCTCTTAATGGGAACGTAGAATTTTTCTAATGTAACCTTTAAGCACTTTACTT 1080
* * * * *

Patient 6 CGTTTAGTTCATACTGATTCCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140
Patient 9 CGTTTAGTTCATACTGATTCCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140
Patient 10 CGTTTAGTTCATACTGATTCCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140
Patient 5 CGTTTAGTTCATACTGATTCCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140
Patient 4 CGTTTAGTTCATACTGATTCCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140
Patient 7 CGTTTAGTTCATACTGATTCCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140
Patient 2 CGTTTAGTTCATACTGATTCCTTTTCTTGTAATAATTTTGATGAATCTAAGATATATGGT 1140
Patient 1 CGTCTAGTTCATGTTGATTCCTTTTCTTGTAATAATCTTGATAAATCTAAAATTTTGGT 1140
Patient 8 CGTCTAGTTCATGTTGATTCCTTTTCTTGTAATAATCTTGATAAATCTAAAATTTTGGT 1140
* * * * *

Patient 6 AGTTGTTTTAAGAGTATGTTTTAGATAAAATTTGCCATACCCAAC TCCAGACGATCTGAT 1200
Patient 9 AGTTGTTTTAAGAGTATGTTTTAGATAAAATTTGCCATACCCAAC TCCAGACGATCTGAT 1200
Patient 10 AGTTGTTTTAAGAGTATGTTTTAGATAAAATTTGCCATACCCAAC TCCAGACGATCTGAT 1200
Patient 5 AGTTGTTTTAAGAGTATGTTTTAGATAAAATTTGCCATACCCAAC TCCAGACGATCTGAT 1200
Patient 4 AGTTGTTTTAAGAGTATGTTTTAGATAAAATTTGCTATACCCAAC TCCAGACGATCTGAT 1200
Patient 7 AGTTGTTTTAAGAGTATGTTTTAGATAAAATTTGCTATACCCAAC TCCAGACGATCTGAT 1200
Patient 2 AGTTGTTTTAAGAGTATGTTTTAGATAAAATTTGCCATACCCAAC TCCAGACGATCTGAT 1200
Patient 1 AGTTGCTTTAATAGTATTA CTGTTGACAAGTTTGCTATACCTAATCGCAGACGAGATGAT 1200
Patient 8 AGTTGCTTTAATAGTATTA CTGTTGACAAGTTTGCTATACCTAATCGCAGACGAGATGAT 1200
* * * * *

Patient 6 TTGCAGTTGGGCAGTCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260
Patient 9 TTGCAGTTGGGCAGTCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260
Patient 10 TTGCAGTTGGGCAGTCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260
Patient 5 TTGCAGTTGGGCAGTCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260
Patient 4 TTGCAGTTGGGCAGTCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260
Patient 7 TTGCAGTTGGGCAGTCTGGTTTTCTGCAATCTTCTAATTATAAAAATTGACACTACTTCT 1260

FIG. 13 CONT.

Patient 2 TTGCAGTTGGGCAGTTCTGGTTTTCTGCAATCTTCTAATTATAAAATTGACACTACTTCT 1260
Patient 1 TTGCAATTGGGCAGTTCTGGCTTTTTGCAATCATCTAATTACAAAATAGATATTTCTTCT 1260
Patient 8 TTGCAATTGGGCAGTTCTGGCTTTTTGCAATCATCTAATTACAAAATAGATATTTCTTCT 1260

Patient 6 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320
Patient 9 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320
Patient 10 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320
Patient 5 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320
Patient 4 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320
Patient 7 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320
Patient 2 AGTTCTTGTC AATTGTATTATAGTTTGCCTGCAATTAATGTTACTATTAATAATTATAAT 1320
Patient 1 AGTTCTTGTC AATTGTATTATAGTTTACCTTTAGTTAAATGTTACTATTAATAACTTTAAT 1320
Patient 8 AGTTCTTGTC AATTGTATTATAGTTTACCTTTAGTTAAATGTTACTATTAATAACTTTAAT 1320

Patient 6 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380
Patient 9 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380
Patient 10 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380
Patient 5 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380
Patient 4 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380
Patient 7 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380
Patient 2 CCTTCTTCTTGG AATAGAAGGTATGGTTTTAATAATTTAATTTGAGCTCTCATAGTGT 1380
Patient 1 CCATCTTCTTGG AATAGGAGGTATGGTTTTGGTAGTTTAAATGTCCTTCTTATGACGTT 1380
Patient 8 CCATCTTCTTGG AATAGGAGGTATGGTTTTGGTAGTTTAAATTTGCTTCTTATGACGTT 1380

Patient 6 GTTTACTCACGT TATTGTTTTTCTGTTAATAACTTTTTGTCCTTGTGCTAAACCTTCT 1440
Patient 9 GTTTACTCACGT TATTGTTTTTCTGTTAATAACTTTTTGTCCTTGTGCTAAACCTTCT 1440
Patient 10 GTTTACTCACGT TATTGTTTTTCTGTTAATAACTTTTTGTCCTTGTGCTAAACCTTCT 1440
Patient 5 GTTTACTCACGT TATTGTTTTTCTGTTAATAACTTTTTGTCCTTGTGCTAAACCTTCT 1440
Patient 4 GTTTACTCACGT TATTGTTTTTCTGTTAATAACTTTTTGTCCTTGTGCTAAACCTTCT 1440
Patient 7 GTTTACTCACGT TATTGTTTTTCTGTTAATAACTTTTTGTCCTTGTGCTAAACCTTCT 1440
Patient 2 GTTTACTCACGT TATTGTTTTTCTGTTAATAACTTTTTGTCCTTGTGCTAAACCTTCT 1440
Patient 1 GTTTATTCTGAT CATTGTTTTTCTGTTAACAGCGACTTTTGCCTTGTGCTAAACCTTCT 1440
Patient 8 GTTTATTCTGAT CATTGTTTTTCTGTTAACAGCGACTTTTGCCTTGTGCTAAACCTTCT 1440

Patient 6 TTTGCTTCAAGT TGC AAGAGTCATAAACACCTTCTGCTTCTGTCTTATTGGTACTAAT 1500
Patient 9 TTTGCTTCAAGT TGC AAGAGTCATAAACACCTTCTGCTTCTGTCTTATTGGTACTAAT 1500
Patient 10 TTTGCTTCAAGT TGC AAGAGTCATAAACACCTTCTGCTTCTGTCTTATTGGTACTAAT 1500
Patient 5 TTTGCTTCAAGT TGC AAGAGTCATAAACACCTTCTGCTTCTGTCTTATTGGTACTAAT 1500
Patient 4 TTTGCTTCAAGT TGC AAGAGTCATAAACACCTTCTGCTTCTGTCTTATTGGTACTAAT 1500
Patient 7 TTTGCTTCAAGT TGC AAGAGTCATAAACACCTTCTGCTTCTGTCTTATTGGTACTAAT 1500
Patient 2 TTTGCTTCAAGT TGC AAGAGTCATAAACACCTTCTGCTTCTGTCTTATTGGTACTAAT 1500
Patient 1 GTTGTTAATCT TGTGTTAAATCTAAGCCTCTTCTGCCATTTGTCTGCTGGTACTAAA 1500
Patient 8 GTTGTTAATCT TGTGTTAAATCTAAGCCTCTTCTGCCATTTGTCTGCTGGTACTAAA 1500

Patient 6 TATCGTTC TGTGAGAGTACTACTGTA CTGACCACACTGATGGTGTAGGTGTTCTTGT 1560
Patient 9 TATCGTTC TGTGAGAGTACTACTGTA CTGACCACACTGACTGGTGTAGGTGTTCTTGT 1560
Patient 10 TATCGTTC TGTGAGAGTACTACTGTA CTGACCACACTGACTGGTGTAGGTGTTCTTGT 1560
Patient 5 TATCGTTC TGTGAGAGTACTACTGTA CTGACCACACTGACTGGTGTAGGTGTTCTTGT 1560
Patient 4 TATCGTTC TGTGAGAGTACTACTGTA CTGACCACACTGACTGGTGTAGGTGTTCTTGT 1560
Patient 7 TATCGTTC TGTGAGAGTACTACTGTA CTGACCACACTGACTGGTGTAGGTGTTCTTGT 1560
Patient 2 TATCGTTC TGTGAGAGTACTACTGTA CTGACCACACTGACTGGTGTAGGTGTTCTTGT 1560
Patient 1 TATCGTCAT TGC GACTTGGATACTACTCTTTATGTTAAATAC TGGTGTAGATGTTCTTGT 1560
Patient 8 TATCGTCAT TGC GACTTGGATACTACTCTTTATGTTAAAACTGGTGTAGATGTTCTTGT 1560

Patient 6 TTACCTGAT CCTATAACTGCTTATGACCC TAGGCTTGTCTCAAAAAAAGTCTCTGGTT 1620
Patient 9 TTACCTGAT CCTATAACTGCTTATGACCC TAGGCTTGTCTCAAAAAAAGTCTCTGGTT 1620
Patient 10 TTACCTGAT CCTATAACTGCTTATGACCC TAGGCTTGTCTCAAAAAAAGTCTCTGGTT 1620
Patient 5 TTACCTGAT CCTATAACTGCTTATGACCC TAGGCTTGTCTCAAAAAAAGTCTCTGGTT 1620
Patient 4 TTACCTGAT CCTATAACTGCTTATGACCC TAGGCTTGTCTCAAAAAAAGTCTCTGGTT 1620
Patient 7 TTACCTGAT CCTATAACTGCTTATGACCC TAGGCTTGTCTCAAAAAAAGTCTCTGGTT 1620
Patient 2 TTACCTGAT CCTATAACTGCTTATGACCC TAGGCTTGTCTCAAAAAAAGTCTCTGGTT 1620
Patient 1 CTACCTGACCC CATTCTACTTATCTCCTAACACATGTCCTCAAAAAGAGGTCGTTGTT 1620
Patient 8 CTACCTGACCC CATTCTACTTATCTCCTAACACATGTCCTCAAAAAGAGGTCGTTGTT 1620

Patient 6 GGTGTTGGTGA ACATTGTG CAGGTTCCGGTGTGATGAAGAAAAGTGGTGTATTGGAT 1680
Patient 9 GGTGTTGGTGA ACATTGTG CAGGTTCCGGTGTGATGAAGAAAAGTGGTGTATTGGAT 1680
Patient 10 GGTGTTGGTGA ACATTGTG CAGGTTCCGGTGTGATGAAGAAAAGTGGTGTATTGGAT 1680
Patient 5 GGTGTTGGTGA ACATTGTG CAGGTTCCGGTGTGATGAAGAAAAGTGGTGTATTGGAT 1680
Patient 4 GGTGTTGGTGA ACATTGTG CAGGTTCCGGTGTGATGAAGAAAAGTGGTGTATTGGAT 1680

FIG. 13 CONT.

Patient 7 GGTGTTGGTGAACATTGTGCAGGGTTCCGGTGTGATGAAGAAAAGTGTGGTATTGGAT 1680
 Patient 2 GGTGTTGGTGAACATTGTGCAGGGTTCCGGTGTGATGAAGAAAAGTGTGGTATTGGAT 1680
 Patient 1 GGTATAGGTGAACATTGTCCAGGTCTTGGTATTAAATGAGGAAAAATGTGGTACAC----- 1675
 Patient 8 GGTATAGGTGAACATTGTCCAGGTCTTGGTATTAAATGAGGAAAAATGTGGTACAC----- 1675
 * * * * *

Patient 6 GGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740
 Patient 9 GGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740
 Patient 10 GGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740
 Patient 5 GGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740
 Patient 4 GGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740
 Patient 7 GGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740
 Patient 2 GGATCATATAATGTTTCTTGTCTTTGTAGTACTGATGCCTTCTAGGTTGGTCTTATGAC 1740
 Patient 1 -AATTAATCATAGTTCCTGTTCTTGTAGTCTGATGCCTTTTGGGTTGGTCTTTTGAT 1734
 Patient 8 -AATTAATCATAGTTCCTGTTCTTGTAGTCTGATGCCTTTTGGGTTGGTCTTTTGAT 1734
 * * * * *

Patient 6 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTATTTTAAATGGTATCAAT 1800
 Patient 9 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTATTTTAAATGGTATCAAT 1800
 Patient 10 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTATTTTAAATGGTATCAAT 1800
 Patient 5 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTATTTTAAATGGTATCAAT 1800
 Patient 4 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTATTTTAAATGGTATCAAT 1800
 Patient 7 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTATTTTAAATGGTATCAAT 1800
 Patient 2 ACTTGCCTCAGTAACAACCGTTGTAATATTTTTCTAATTTATTTTAAATGGTATCAAT 1800
 Patient 1 AGTTGATTAGTAATAATCGTTGCAATATTTTTCTAATTTATTTTAAATGGAATTAAT 1794
 Patient 8 AGTTGATTAGTAATAATCGTTGCAATATTTTTCTAATTTATTTTAAATGGAATTAAT 1794
 * * * * *

Patient 6 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTACTGATGTT 1860
 Patient 9 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTACTGATGTT 1860
 Patient 10 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTACTGATGTT 1860
 Patient 5 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTACTGATGTT 1860
 Patient 4 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTACTGATGTT 1860
 Patient 7 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTACTGATGTT 1860
 Patient 2 AGTGGTACCACCTGTTCTAATGATTTATTGCAGCCTAATACTGAAGTTTTACTGATGTT 1860
 Patient 1 AGTGGCACCACCTGTTCTAATGATTTGTTATATTCTAACACTGAAGTTTCTACTGGTGT 1854
 Patient 8 AGTGGCACCACCTGTTCTAATGATTTGTTATATTCTAACACTGAAGTTTCTACTGGTGT 1854
 * * * * *

Patient 6 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTAAAGAAGTTTCTGCT 1920
 Patient 9 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTAAAGAAGTTTCTGCT 1920
 Patient 10 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTAAAGAAGTTTCTGCT 1920
 Patient 5 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTAAAGAAGTTTCTGCT 1920
 Patient 4 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTAAAGAAGTTTCTGCT 1920
 Patient 7 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTAAAGAAGTTTCTGCT 1920
 Patient 2 TGTGTTGATTACGACCTTTATGGTATTACAGGACAAGGTATTTTAAAGAAGTTTCTGCT 1920
 Patient 1 TGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTAAAGAAGTTTCTGCG 1914
 Patient 8 TGTGTTAATTATGATCTTTATGGCATCACAGGCCAAGGTATTTTAAAGAAGTTTCTGCG 1914
 * * * * *

Patient 6 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCCTAATGGCAACATTATTGGTTTT 1980
 Patient 9 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCCTAATGGCAACATTATTGGTTTT 1980
 Patient 10 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCCTAATGGCAACATTATTGGTTTT 1980
 Patient 5 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCCTAATGGCAACATTATTGGTTTT 1980
 Patient 4 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCCTAATGGCAACATTATTGGTTTT 1980
 Patient 7 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCCTAATGGCAACATTATTGGTTTT 1980
 Patient 2 GTTTATTATAATAGTTGGCAAAATCTTTGTATGATTCCTAATGGCAACATTATTGGTTTT 1980
 Patient 1 GCTTATTATAAATAGTTGGCAGAACTTTGTATGATTCCTAATGGTAATATTATTGGTTTT 1974
 Patient 8 GCTTATTATAAATAGTTGGCAGAACTTTGTATGATTCCTAATGGTAATATTATTGGTTTT 1974
 * * * * *

Patient 6 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040
 Patient 9 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040
 Patient 10 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040
 Patient 5 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040
 Patient 4 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040
 Patient 7 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040
 Patient 2 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2040
 Patient 1 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034
 Patient 8 AAAGATTTTGTACTAATAAAACATATAATATTTCCCTTGTATGCAGGAAGAGTTTCT 2034
 * * * * *

Patient 6 GCTGCTTTTCATCAAAAATGCTTCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100
 Patient 9 GCTGCTTTTCATCAAAAATGCTTCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100
 Patient 10 GCTGCTTTTCATCAAAAATGCTTCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100
 Patient 5 GCTGCTTTTCATCAAAAATGCTTCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100

FIG. 13 CONT.

Patient 4 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100
Patient 7 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100
Patient 2 GCTGCTTTTCATCAAAATGCTTCCTCTTTGGCTTTACTTTATCGTAATTTAAAATGTAGC 2100
Patient 1 GCTGCATTTTATCAAAATCTTCTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094
Patient 8 GCTGCATTTTATCAAAATCTTCTCACCAGCTTTGCTTTATCGTAATTTAAAGTGTAGT 2094
***** **

Patient 6 TATGTTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157
Patient 9 TATGTTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157
Patient 10 TATGTTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157
Patient 5 TATGTTTTGAATAATATTTCTTTAAGTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157
Patient 4 TATGTTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157
Patient 7 TATGTTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157
Patient 2 TATGTTTTGAATAATATTTCTTTAGCTACTCAGCCAT---ATTTTGATAGTTATCTTGGT 2157
Patient 1 TATGTTTTGAATAATATTTCTTTATCTCACAACCATTTTATTTGATAGTTATCTTGGT 2154
Patient 8 TATGTTTTGAATAATATTTCTTTATCTCACAACCATTTTATTTGATAGTTATCTTGGT 2154
***** **

Patient 6 TGCGTTTTTAATGCTGATAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2217
Patient 9 TGCGTTTTTAATGCTGATAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2217
Patient 10 TGCGTTTTTAATGCTGATAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2217
Patient 5 TGCGTTTTTAATGCTGATAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2217
Patient 4 TGCGTTTTTAATGCTGATAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2217
Patient 7 TGCGTTTTTAATGCTGATAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2217
Patient 2 TGCGTTTTTAATGCTGATAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2217
Patient 1 TGTGTTTTGAATGCTGTTAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2214
Patient 8 TGTGTTTTGAATGCTGTTAAATTAAGTATTATCTGTTCTTCTTGCTCTTCCGATG 2214
** ***** **

Patient 6 GGTAGTGGTTTTTGTGTTGATTATAAATCACCCTTCTTCTCCTCTTCCGCTCGTAAACGT 2277
Patient 9 GGTAGTGGTTTTTGTGTTGATTATAAATCACCCTTCTTCTCCTCTTCCGCTCGTAAACGT 2277
Patient 10 GGTAGTGGTTTTTGTGTTGATTATAAATCACCCTTCTTCTCCTCTTCCGCTCGTAAACGT 2277
Patient 5 GGTAGTGGTTTTTGTGTTGATTATAAATCACCCTTCTTCTCCTCTTCCGCTCGTAAACGT 2277
Patient 4 GGTAGTGGTTTTTGTGTTGATTATAAATCACCCTTCTTCTCCTCTTCCGCTCGTAAACGT 2277
Patient 7 GGTAGTGGTTTTTGTGTTGATTATAAATCACCCTTCTTCTCCTCTTCCGCTCGTAAACGT 2277
Patient 2 GGTAGTGGTTTTTGTGTTGATTATAAATCACCCTTCTTCTCCTCTTCCGCTCGTAAACGT 2277
Patient 1 GGTAGTGGTTTTTGTATTGATTATGCTTTACCCCTCTTCT-----CGGCTAAGCGT 2265
Patient 8 GGTAGTGGTTTTTGTATTGATTATGCTTTACCCCTCTTCT-----CGGCTAAGCGT 2265
***** **

Patient 6 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAAATGTCAGTTTGT 2337
Patient 9 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAAATGTCAGTTTGT 2337
Patient 10 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAAATGTCAGTTTGT 2337
Patient 5 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAAATGTCAGTTTGT 2337
Patient 4 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAAATGTCAGTTTGT 2337
Patient 7 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAAATGTCAGTTTGT 2337
Patient 2 AGAAGTATTTCTGCTTCTTATCGTTTGTACTTTTGAACCCCTTAAATGTCAGTTTGT 2337
Patient 1 AGAGGTATTTCTTCTCCTTATCGCTTTGTAACCTTTTGAACCCCTTAAATGTTAGTTTGT 2325
Patient 8 AGAGGTATTTCTTCTCCTTATCGCTTTGTAACCTTTTGAACCCCTTAAATGTTAGTTTGT 2325
*** ***** **

Patient 6 AATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAAATCCCCTAATTTACT 2397
Patient 9 AATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAAATCCCCTAATTTACT 2397
Patient 10 AATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAAATCCCCTAATTTACT 2397
Patient 5 AATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAAATCCCCTAATTTACT 2397
Patient 4 AATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAAATCCCCTAATTTACT 2397
Patient 7 AATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAAATCCCCTAATTTACT 2397
Patient 2 AATGACAGTATTGAGTCTGTGGTGGTCTTTATGAGATCAAAATCCCCTAATTTACT 2397
Patient 1 AACGATAGTGTGAAACTGTTGGTGGTATTATTTGAGATTCAGATTCCTACTAATTTACC 2385
Patient 8 AACGATAGTGTGAAACTGTTGGTGGTATTATTTGAGATTCAGATTCCTACTAATTTACC 2385
** * **

Patient 6 ATAGTTGGTCAAGAGGAATTTATCAAATAATCTCCTAAAGTTACTATTGATTGTCT 2457
Patient 9 ATAGTTGGTCAAGAGGAATTTATCAAATAATCTCCTAAAGTTACTATTGATTGTCT 2457
Patient 10 ATAGTTGGTCAAGAGGAATTTATCAAATAATCTCCTAAAGTTACTATTGATTGTCT 2457
Patient 5 ATAGTTGGTCAAGAGGAATTTATCAAATAATCTCCTAAAGTTACTATTGATTGTCT 2457
Patient 4 ATAGTTGGTCAAGAGGAATTTATCAAATAATCTCCTAAAGTTACTATTGATTGTCT 2457
Patient 7 ATAGTTGGTCAAGAGGAATTTATCAAATAATCTCCTAAAGTTACTATTGATTGTCT 2457
Patient 2 ATAGTTGGTCAAGAGGAATTTATCAAATAATCTCCTAAAGTTACTATTGATTGTCT 2457
Patient 1 ATAGCTGGTCAAGAGGAATTTATCAGACTAGTTCTCCTAAAGTTACTATTGATTGTCA 2445
Patient 8 ATAGCTGGTCAAGAGGAATTTATCAGACTAGTTCTCCTAAAGTTACTATTGATTGTCA 2445
***** **

Patient 6 TTATTTGCTGTTCTAATTTATGACAGCTTGCCATGACTTATTGTGATGATGGCACTTTT 2517
Patient 9 TTATTTGCTGTTCTAATTTATGACAGCTTGCCATGACTTATTGTGATGATGGCACTTTT 2517
Patient 10 TTATTTGCTGTTCTAATTTATGACAGCTTGCCATGACTTATTGTGATGATGGCACTTTT 2517

FIG. 13 CONT.

Patient 10 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937
 Patient 5 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937
 Patient 4 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937
 Patient 7 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937
 Patient 2 TCTGGTTACACCACAGCCGCTACTGTTGCTGCTATGTTCCACCATGGTCAGCAGCAGCT 2937
 Patient 1 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTCCGCCATGGTCGTGCTGCT 2925
 Patient 8 TCTGGCTATACTACAGCTGCTACTGTGGCGGCTATGTTCCGCCATGGTCGTGCTGCT 2925
 ***** ** * ***** ** * ***** ** * ***** ** * ***** ** * *****

Patient 6 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997
 Patient 9 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997
 Patient 10 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997
 Patient 5 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997
 Patient 4 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997
 Patient 7 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997
 Patient 2 GGCATACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2997
 Patient 1 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2985
 Patient' 8 GGTGTACCATTTTCTCTTAATGTACAATATAGAATTAATGGTTTGGGTGTTACTATGGAT 2985
 ** *****

Patient 6 GTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057
 Patient 9 GTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057
 Patient 10 GTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057
 Patient 5 GTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057
 Patient 4 GTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057
 Patient 7 GTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057
 Patient 2 GTTCTTAATAAAAAATCAAAAGTTGATAGCTACTGCTTTAATAATGCTCTTCTTTCTATT 3057
 Patient 1 GTTCTTAATAAAGATCAAAAGTTAATAGCTAATGCTTTAATAAAGCTCTTCTTTCTATC 3045
 Patient 8 GTTCTTAATAAAGATCAAAAGTTAATAGCTAATGCTTTAATAAAGCTCTTCTTTCTATC 3045

Patient 6 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3117
 Patient 9 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3117
 Patient 10 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3117
 Patient 5 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3117
 Patient 4 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3117
 Patient 7 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3117
 Patient 2 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3117
 Patient 1 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3105
 Patient 8 CAGAATGGTTTTFAGTGCTACCAACTCTGCCTTGTCTAAAATACAAAGTGTGTTAATTCT 3105

Patient 6 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3177
 Patient 9 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3177
 Patient 10 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3177
 Patient 5 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3177
 Patient 4 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3177
 Patient 7 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3177
 Patient 2 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3177
 Patient 1 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3165
 Patient 8 AATGCTCAAGCACTTAATAGTTTGTACAGCAATTATTTAATAAATTTGGTGCAATTAGT 3165

Patient 6 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTAGATTGAT 3237
 Patient 9 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTAGATTGAT 3237
 Patient 10 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTAGATTGAT 3237
 Patient 5 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTAGATTGAT 3237
 Patient 4 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTAGATTGAT 3237
 Patient 7 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTAGATTGAT 3237
 Patient 2 TCTTCTTTACAAGAAATTTTATCTCGTCTCGATGCTTTAGAGGCTCAGGTTAGATTGAT 3237
 Patient 1 TCTTCTTTACAAGAAATTTTGTCTCGCCTTGATAAATTTAGAAGCTCAGGTTAGATTGAT 3225
 Patient 8 TCTTCTTTACAAGAAATTTTGTCTCGCCTTGATAAATTTAGAAGCTCAGGTTAGATTGAT 3225

Patient 6 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3297
 Patient 9 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3297
 Patient 10 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3297
 Patient 5 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3297
 Patient 4 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3297
 Patient 7 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3297
 Patient 2 AGGCTTATTAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3297
 Patient 1 AGGCTCATTAAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3285
 Patient 8 AGGCTCATTAAATGGTCGTTTAACTGCTTTAAATGCTTATGTCTCTCAACAGCTTAGTGAT 3285

Patient 6 ATTTCTCTGTAAAATTTGGTGCTGCTTTAGCTATGAGAAAGGTTAATGAGTGTGTTAAA 3357

FIG. 13 CONT.

Patient 9 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357
 Patient 10 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357
 Patient 5 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357
 Patient 4 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357
 Patient 7 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357
 Patient 2 ATTTCTCTGTAAAAATTTGGTGTGCTTTAGCTATGGAGAAGGTTAATGAGTGTGTTAAA 3357
 Patient 1 ATTACACTTATTAAGGCTGGAGCTTCTCGTCTATTGAGAAGGTTAATGAGTGTGTTAAA 3345
 Patient 8 ATTACACTTATTAAGGCTGGAGCTTCTCGTCTATTGAGAAGGTTAATGAGTGTGTTAAA 3345
 * * * * *

Patient 6 AGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA 3417
 Patient 9 AGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA 3417
 Patient 10 AGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA 3417
 Patient 5 AGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA 3417
 Patient 4 AGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA 3417
 Patient 7 AGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA 3417
 Patient 2 AGTCAATCTCCTCGTATTAATTTTGTGGTAATGGTAATCATATTTTGTCAATTAGTTCAA 3417
 Patient 1 AGTCAATCCCTCGTATAAAATTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAA 3405
 Patient 8 AGTCAATCCCTCGTATAAAATTTTGTGGCAATGGTAACCACATTTTATCATTGGTTCAA 3405
 * * * * *

Patient 6 AATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAAC 3477
 Patient 9 AATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAAC 3477
 Patient 10 AATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAAC 3477
 Patient 5 AATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAAC 3477
 Patient 4 AATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAAC 3477
 Patient 7 AATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAAC 3477
 Patient 2 AATGCTCCTTATGGTTTGTGTTTATGCATTTTAGTTATAAACCTATTTCTTTTAAAAC 3477
 Patient 1 AATGCTCCTTATGGTTTGTCTTTTCATTCATTTTAGTTATAAACCTACTTCTTTTAAAAC 3465
 Patient 8 AATGCTCCTTATGGTTTGTCTTTTCATTCATTTTAGTTATAAACCTACTTCTTTTAAAAC 3465
 * * * * *

Patient 6 GTTTTAGTAAGTCTGGTTTGTGTATATCAGGTGATGATAGGTATTGCACCTAAACAAGGG 3537
 Patient 9 GTTTTAGTAAGTCTGGTTTGTGTATATCAGGTGATGATAGGTATTGCACCTAAACAAGGG 3537
 Patient 10 GTTTTAGTAAGTCTGGTTTGTGTATATCAGGTGATGATAGGTATTGCACCTAAACAAGGG 3537
 Patient 5 GTTTTAGTAAGTCTGGTTTGTGTATATCAGGTGATGATAGGTATTGCACCTAAACAAGGG 3537
 Patient 4 GTTTTAGTAAGTCTGGTTTGTGTATATCAGGTGATGATAGGTATTGCACCTAAACAAGGG 3537
 Patient 7 GTTTTAGTAAGTCTGGTTTGTGTATATCAGGTGATGATAGGTATTGCACCTAAACAAGGG 3537
 Patient 2 GTTTTAGTAAGTCTGGTTTGTGTATATCAGGTGATGATAGGTATTGCACCTAAACAAGGG 3537
 Patient 1 GTCTTAGTAAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGT 3525
 Patient 8 GTCTTAGTAAGTCCAGGTTTATGTTTATCCGGTGATAGAGGTATTGCACCTAAGCAAGGT 3525
 * * * * *

Patient 6 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597
 Patient 9 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597
 Patient 10 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597
 Patient 5 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597
 Patient 4 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597
 Patient 7 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597
 Patient 2 TATTTTATTAACATAATGATCATTGGATGTTCACTGGTAGTTCCTACTATTATCCTGAA 3597
 Patient 1 TATTTTATTAACAAAATGATTCCTGGATGTTTACTGGTAGTTCCTATTATTATCCAGAA 3585
 Patient 8 TATTTTATTAACAAAATGATTCCTGGATGTTTACTGGTAGTTCCTATTATTATCCAGAA 3585
 * * * * *

Patient 6 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657
 Patient 9 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657
 Patient 10 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657
 Patient 5 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657
 Patient 4 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657
 Patient 7 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657
 Patient 2 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3657
 Patient 1 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3645
 Patient 8 CCAATTTTCAGATAAAAAATGTTGTTTTTATGAATACTTGTCTGTTAATTTTACTAAAGCG 3645
 * * * * *

Patient 6 CCTCTGTGTTTATTGAATCATTCTGTACCAAAAATGCTGATTTTGAATCTGAGTTATCT 3717
 Patient 9 CCTCTGTGTTTATTGAATCATTCTGTACCAAAAATGCTGATTTTGAATCTGAGTTATCT 3717
 Patient 10 CCTCTGTGTTTATTGAATCATTCTGTACCAAAAATGCTGATTTTGAATCTGAGTTATCT 3717
 Patient 5 CCTCTGTGTTTATTGAATCATTCTGTACCAAAAATGCTGATTTTGAATCTGAGTTATCT 3717
 Patient 4 CCTCTGTGTTTATTGAATCATTCTGTACCAAAAATGCTGATTTTGAATCTGAGTTATCT 3717
 Patient 7 CCTCTGTGTTTATTGAATCATTCTGTACCAAAAATGCTGATTTTGAATCTGAGTTATCT 3717
 Patient 2 CCTCTGTGTTTATTGAATCATTCTGTACCAAAAATGCTGATTTTGAATCTGAGTTATCT 3717
 Patient 1 CCATTTATTTATCTTAATAAATCTATACCAAAAATGCTGATTTTGAAGCCGAGTTTCT 3705
 Patient 8 CCATTTATTTATCTTAATAAATCTATACCAAAAATGCTGATTTTGAAGCCGAGTTTCT 3705
 * * * * *

FIG. 13 CONT.

Patient 6 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 9 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 10 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 5 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 4 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 7 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 2 CATTGGTTTAAAAATCAAACATCCATTGCGCCTAATTGACTTTAAATCTTCATACTATT 3777
Patient 1 CTTTGGTTTAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTCATATA---TT 3762
Patient 8 CTTTGGTTTAAAAATCATACTTCTATAGCACCTAATTTAACCTTTAATTCATATA---TT 3762
* ***** *

Patient 6 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837
Patient 9 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837
Patient 10 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837
Patient 5 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837
Patient 4 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837
Patient 7 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837
Patient 2 AATGCTACTTTTTAGATTTGTATTATGAGATGAATCTTATTCAAGAGTCTATTAAGTCT 3837
Patient 1 AATGCTACTTTTTAGATCTGTATTATGAAATGAATGTTATTCCAGGAATCTATTAATCT 3822
Patient 8 AATGCTACTTTTTAGATCTGTATTATGAAATGAATGTTATTCCAGGAATCTATTAATCT 3822
***** *

Patient 6 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATGG 3897
Patient 9 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATGG 3897
Patient 10 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATGG 3897
Patient 5 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATGG 3897
Patient 4 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATGG 3897
Patient 7 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATGG 3897
Patient 2 TTGAATAATAGTTATATCAATCTTAAAGATATAGGTACATATGAAATGTATGTAATGG 3897
Patient 1 TTGAACAGTAGTTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGG 3882
Patient 8 TTGAACAGTAGTTTTATTAATCTTAAAGAAATAGGTACTTATGAAATGTATGTTAAATGG 3882
***** *

Patient 6 CCTTGGTATGTTGGCTACTAATTCITTTTCATTATAATATTCCTTGTATTGCTCTTT 3957
Patient 9 CCTTGGTATGTTGGCTACTAATTCITTTTCATTATAATATTCCTTGTATTGCTCTTT 3957
Patient 10 CCTTGGTATGTTGGCTACTAATTCITTTTCATTATAATATTCCTTGTATTGCTCTTT 3957
Patient 5 CCTTGGTATGTTGGCTACTAATTCITTTTCATTATAATATTCCTTGTATTGCTCTTT 3957
Patient 4 CCTTGGTATGTTGGCTACTAATTCITTTTCATTATAATATTCCTTGTATTGCTCTTT 3957
Patient 7 CCTTGGTATGTTGGCTACTAATTCITTTTCATTATAATATTCCTTGTATTGCTCTTT 3957
Patient 2 CCTTGGTATGTTGGCTACTAATTCITTTTCATTATAATATTCCTTGTATTGCTCTTT 3957
Patient 1 CCTTGGTACATTTGGTTGTTAATTTGTCATTTTATTATAATTTTTCTTATGATACTTTTC 3942
Patient 8 CCTTGGTACATTTGGTTGTTAATTTGTCATTTTATTATAATTTTTCTTATGATACTTTTC 3942
***** *

Patient 6 TTTATATGTTGTTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4017
Patient 9 TTTATATGTTGTTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4017
Patient 10 TTTATATGTTGTTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4017
Patient 5 TTTATATGTTGTTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4017
Patient 4 TTTATATGTTGTTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4017
Patient 7 TTTATATGTTGTTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4017
Patient 2 TTTATATGTTGTTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4017
Patient 1 TTTATATGCTGCTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4002
Patient 8 TTTATATGCTGCTGACTGGTTGTTGTTCTGCAATGTTTGTAGTAAATGTCATAATGTTGT 4002
***** *

Patient 6 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 9 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 10 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 5 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 4 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 7 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 2 GATGAGTATGGTGGTCATCATGATTTTGTATCAAACATCTCATGATGATTAG 4071
Patient 1 GATGAGTATGGGGTCAAAATGATTTTGTATTAAAGCATCTCATGATGATTAG 4056
Patient 8 GATGAGTATGGGGTCAAAATGATTTTGTATTAAAGCATCTCATGATGATTAG 4056
***** *

FIG. 13 CONT.

Fig. 14. Multiple alignment of the nucleocapsid genes of CoV-HKU1 from patients 1, 2, 4, 5, 6, 7, 8, 9, and 10.

```
Patient 4 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 6 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 7 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 9 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 10 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 2 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 5 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 1 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
Patient 8 ATGTCTTATACTCCCGGTCATTATGCTGGAAGTAGAAGCTCCTCTGGAAATCGTTCAGGA 60
*****

Patient 4 ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 6 ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 7 ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 9 ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 10 ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAACGAAATTACCAAACCTTTAATAGA 120
Patient 2 ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAGCGAAATTACCAAACCTTTAATAGA 120
Patient 5 ATCCTCAAGAAAACCTTCTTGGGCTGACCAATCTGAGCGAAATTACCAAACCTTTAATAGA 120
Patient 1 ATCCTCAAGAAAACCTTCTTGGGTTGACCAATCTGAGCGAAGCCATCAAACCTATAATAGA 120
Patient 8 ATCCTCAAGAAAACCTTCTTGGGTTGACCAATCTGAGCGAAGCCATCAAACCTATAATAGA 120
*****

Patient 4 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 6 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 7 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 9 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 10 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 2 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 5 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAATACTATCCCA 180
Patient 1 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAACCTTATCCCA 180
Patient 8 GGCAGAAAAACCCAACTAAATTCACCTGTGTCTACTCAACCACAAGGAAACCTTATCCCA 180
*****

Patient 4 CATTATTCCTGGTTCCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 6 CATTATTCCTGGTTCCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 7 CATTATTCCTGGTTCCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 9 CATTATTCCTGGTTCCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 10 CATTATTCCTGGTTCCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 2 CATTATTCCTGGTTCCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 5 CATTATTCCTGGTTCCTCCGGGATCACTCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 1 CATTATTCCTGGTTCCTCGGGATACCCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
Patient 8 CATTATTCCTGGTTCCTCGGGATACCCAATTTCAAAAAGGTAGAGACTTTAAATTTTCA 240
*****

Patient 4 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 6 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 7 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 9 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 10 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 2 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 5 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 1 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
Patient 8 GATGGTCAAGGAGTCCCATTTGCTTTCGGAGTACCCCTTCTGAAGCAAAGGATATTGG 300
*****

Patient 4 TATAGACACAGCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 6 TATAGACACAGCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 7 TATAGACACAGCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 9 TATAGACACAGCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 10 TATAGACACAGCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 2 TATAGACACAGCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 5 TATAGACACAGCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCG 360
Patient 1 TATAAACACAACCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCA 360
Patient 8 TATAAACACAACCCGGCGTCTTTTAAAAACAGCTGATGGTCAACAAAAGCAGTTGTTACCA 360
*****

Patient 4 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 6 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 7 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 9 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 10 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 2 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 5 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
Patient 1 AGATGGTATTTCTACTATCTCGGTACCGGCCATATGCCAATGCATCCTATGGTGAATCC 420
```

FIG. 14

Patient 8 AGATGGTATTCTACTACTCTCGGTACCGGTCCATATGCCAGTTCATCCTATGGTATGCC 420

Patient 4 CTCGAAGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTT 480
 Patient 6 CTCGAAGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTT 480
 Patient 7 CTCGAAGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTT 480
 Patient 9 CTCGAAGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTT 480
 Patient 10 CTCGAAGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTT 480
 Patient 2 CTCGAAGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTT 480
 Patient 5 CTCGAAGGGTCTTCTGGGTTGCTAATCACCAAGCTGACACTTCTACTCCCTCCGATGTT 480
 Patient 1 CACGAAGGTATCTTCTGGGTCGCTAGTACCAGCTGACACTTCTATTCCTCCGATGTT 480
 Patient 8 CACGAAGGTATCTTCTGGGTCGCTAGTACCAGCTGATACCTTCTATTCCTCCGATGTT 480
 * *****

Patient 4 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 6 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 7 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 9 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 10 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 2 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 5 TCGTCAAGGGATCCTACTACTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 1 TCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 Patient 8 TCGGCAAGGGATCCTACTATTCAAGAAGCTATCCCTACTAGGTTTCCGCCTGGTACGATT 540
 *** *****

Patient 4 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 6 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 7 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 9 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 10 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 2 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 5 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 1 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600
 Patient 8 TTGCCTCAAGGCTATTATGTTGAAGGCTCAGGAAGTCTGCTTCTAATAGTCGACCAGGT 600

Patient 4 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 6 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 7 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 9 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 10 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 2 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 5 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 1 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660
 Patient 8 TCACGTTCTCAATCAGTGGACCCAATAATCGTTCATTAAGTAGAAGTAATCTAATTTT 660

Patient 4 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720
 Patient 6 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720
 Patient 7 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720
 Patient 9 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720
 Patient 10 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720
 Patient 2 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720
 Patient 5 AGACATTCAGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAATCTTGTTTTA 720
 Patient 1 AGACATTCGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAGTCTTGTCTTG 720
 Patient 8 AGACATTCGATTCTATAGTAAAACCTGATATGGCTGATGAGATTGCTAGTCTTGTCTTA 720

Patient 4 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780
 Patient 6 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780
 Patient 7 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780
 Patient 9 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780
 Patient 10 GCCAAGCTTGGTAAAGAATCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780
 Patient 2 GCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATC 780
 Patient 5 GCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATC 780
 Patient 1 GCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780
 Patient 8 GCCAAGCTTGGTAAAGATTCTAAACCTCAGCAAGTCACTAAGCAAAATGCCAAGGAAATT 780

Patient 4 AGGCATAAAATTTTAAACAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840
 Patient 6 AGGCATAAAATTTTAAACAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840
 Patient 7 AGGCATAAAATTTTAAACAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840
 Patient 9 AGGCATAAAATTTTAAACAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840
 Patient 10 AGGCATAAAATTTTAAACAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840
 Patient 2 AGGCATAAAATTTTAAACAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840
 Patient 5 AGGCATAAAATTTTAAACAAACCTCGCCAAAAGCGAACTCCTAATAAACATTGTAATGTT 840

FIG. 14 CONT.

Patient 1 AGGCATAAAATTTAATGAAACCTCGCCAAAAGCGAACTCCTAATAAATTTTGTAAATGTT 840
Patient 8 AGGCATAAAATTTAATGAAACCTCGCCAAAAGCGAACTCCTAATAAATTTTGTAAATGTT 840

Patient 4 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 6 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 7 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 9 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 10 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 2 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 5 CAACAGTGTTTTGGTAAAAGAGGACCTTCTCAAATTTTGGTAATGCTGAAATGTTAAAG 900
Patient 1 CAACAGTGTTTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATGCTGAAATGTTAAAG 900
Patient 8 CAACAGTGTTTTGGTAAAAGAGGACCGCTCCAAAACCTTGGTAATGCTGAAATGTTAAAG 900

Patient 4 CTTGGTACTAATGATCCTCAGTTTCTTATTCTTGAGAATTAGCTCCTACACCGAGTGCT 960
Patient 6 CTTGGTACTAATGATCCTCAGTTTCTTATTCTTGAGAATTAGCTCCTACACCGAGTGCT 960
Patient 7 CTTGGTACTAATGATCCTCAGTTTCTTATTCTTGAGAATTAGCTCCTACACCGAGTGCT 960
Patient 9 CTTGGTACTAATGATCCTCAGTTTCTTATTCTTGAGAATTAGCTCCTACACCGAGTGCT 960
Patient 10 CTTGGTACTAATGATCCTCAGTTTCTTATTCTTGAGAATTAGCTCCTACACCGAGTGCT 960
Patient 2 CTTGGTACTAATGATCCTCAGTTTCTTATTCTTGAGAATTAGCTCCTACACCGAGTGCT 960
Patient 5 CTTGGTACTAATGATCCTCAGTTTCTTATTCTTGAGAATTAGCTCCTACACCGAGTGCT 960
Patient 1 CTTGGTACTAATGATCCTCAATTTCTTATTCTTGCTGAATTAGCCCTACACCGAGTGCT 960
Patient 8 CTTGGTACTAATGATCCTCAATTTCTTATTCTTGCTGAATTAGCTCCTACACCGAGTGCT 960

Patient 4 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 6 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 7 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 9 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 10 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 2 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 5 TTTTCTTTGGTCTAAATTAGACTTGGTTAAAAGAGATTCCGAGGCTGACTCACCTGTT 1020
Patient 1 TTTTCTTTGGTCTAAATTAGAGTTGTTAAAAGAGACTCTGATGCTGATTCACCTTCT 1020
Patient 8 TTTTCTTTGGTCTAAATTAGAGTTGTTAAAAGAGACTCTGATGCTGATTCACCTTCT 1020

Patient 4 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 6 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 7 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 9 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 10 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 2 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 5 AAAGATGTTTTGAACCTCATTATTCTGGTCTATTAGGTTTGATAGTACTTTACCAGGC 1080
Patient 1 AAAGACACTTTTGAACCTCGTTATTCTGGTCTATTAGGTTTGATAGTACTTTACCTGGT 1080
Patient 8 AAAGACACTTTTGAACCTCGTTATTCTGGTCTATTAGGTTTGATAGTACTTTACCTGGT 1080

Patient 4 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 6 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 7 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 9 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 10 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 2 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 5 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAAATGCTTATGTTAATCTAATCAG 1140
Patient 1 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAGATGCTTATGTTAATCTAATCAG 1140
Patient 8 TTTGAGACAATTATGAAAGTTCTTGAAGAGAATTTAGATGCTTATGTTAATCTAATCAG 1140

Patient 4 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 6 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 7 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 9 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 10 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 2 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 5 AACACTGATTCGATTCGTTGAGTTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATTA 1200
Patient 1 AACACTGTTTCTGGTTCGCTGAGTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200
Patient 8 AACACTGTTTCTGGTTCGCTGAGTCTAAACCTCAGCGTAAAAGAGGTGTTAAACAATCA 1200

Patient 4 CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 6 CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 7 CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 9 CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 10 CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 2 CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260

FIG. 14 CONT.

Patient 5 CCAGAACAGTTTGACTCTCTTAATTTAAGTGCTGGTACTCAGCACATTTCAAATGATTTT 1260
Patient 1 CCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACATTTCAAATGATTTT 1260
Patient 8 CCTGAATCGTTTGACTCTCTTAATTTAAGTGCTGATACTCAGCACATTTCAAATGATTTT 1260
** ** * * * * *


Patient 4 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 6 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 7 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 9 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 10 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGACGATCCTTATGTAGAAGACTCTGTT 1320
Patient 2 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
Patient 5 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
Patient 1 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
Patient 8 ACTCCTGAGGATCATAGTTTACTTGCTACTCTTGATGATCCTTATGTAGAAGACTCTGTT 1320
* * * * *

Patient 4 GCTTAA 1326
Patient 6 GCTTAA 1326
Patient 7 GCTTAA 1326
Patient 9 GCTTAA 1326
Patient 10 GCTTAA 1326
Patient 2 GCTTAA 1326
Patient 5 GCTTAA 1326
Patient 1 GCTTAA 1326
Patient 8 GCTTAA 1326
* * * * *

FIG. 14 CONT.

	LPW1926	LPW1927	
.CoV-HKU1 (Patient 1)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 2)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 4)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 5)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 6)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 7)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 8)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 9)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
.CoV-HKU1 (Patient 10)	AAAGGATGTTGACAACCCCTGTTCTTATGGG/.../ATTTTATGTAAGCATTTTAGTATGATGAT		2258
HCoV-OC43 (NC_005147)	TAAAGATGTTGACAATCCCTGTA	CTTATGGG/.../ATTTTATAATAAGCATTTTAGTATGATGAT	2258
SARS-CoV (NC_004718)	CAGTGTATGAAACTCCACACCTTATGGG/.../TTACCTGCGTAAACATTTCTCATGATGAT		2270
HCoV-229E (NC_002645)	GGCCGATGTTGATGATCCATAAATGATGGG/.../TTATTTGCAAAGCATTTTCTATGATGAT		2255
HCoV-NL63 (NC_005831)	TGATGTTGTTGAAACCCCTATGCTTATGGG/.../TTATCTTAGCAACATTTTCAATGATGAT		2255

FIG. 16



0.02

FIG. 17

HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF

This is a continuation-in-part application of U.S. patent application Ser. No. 10/895,064 filed Jul. 21, 2004, which is incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a "lengthy" Sequence Listing which has been submitted via CD-R in lieu of a printed paper copy, and is hereby incorporated by reference in its entirety. Said CD-R, recorded on Mar. 21, 2005, are labeled "CRF", "Copy 1" and "Copy 2", respectively, and each contains only one identical 2.84 MB file (V0690044.APP).

1. INTRODUCTION

The present invention relates to a novel virus causing respiratory tract infection in humans ["coronavirus-HKU1 (CoV-HKU1)"]. Phylogenetic analysis has revealed that the CoV-HKU1 is a new group 2 coronavirus, which has, at least, two (2) genotypes, A and B. The present invention relates to nucleotide sequences comprising the complete genomic sequences of the CoV-HKU1. The invention further relates to nucleotide sequences comprising a portion of the genomic sequences of the CoV-HKU1. The invention also relates to the deduced amino acid sequences of the complete genomes of the CoV-HKU1. The invention further relates to the nucleic acids and peptides encoded by and/or derived from these sequences and their use in diagnostic methods and therapeutic methods, such as for immunogens. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies directed against polypeptides encoded by the nucleotide sequence. Furthermore, the invention relates to vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus as well as protein extracts and subunits of said virus.

2. BACKGROUND OF THE INVENTION

Since no microbiological cause has been identified in a significant proportion of patients with respiratory tract infections (Macfarlane, J. T. et al., 1993, Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community, *Lancet* 341:511-514; Ruiz, M., S. et al., 1990, Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity, *Am. J. Respir. Crit. Care Med.* 160:397-405), research has been conducted to identify possible novel agent(s). Of the three novel agents identified in the recent three years, including human metapneumovirus (Van den Hoogen, et al., 2001, A newly discovered human pneumovirus isolated from young children with respiratory tract disease, *Nat. Med.* 7:719-724), Severe Acute Respiratory Syndrome (SARS) coronavirus (SARS-CoV) (Peiris, J. S. et al., 2003, Coronavirus as a possible cause of severe acute respiratory syndrome, *Lancet* 361:1319-1325) and human coronavirus NL63 (HCoV-NL63) (Fouchier, R. A. et al., 2004, A previously undescribed coronavirus associated with respiratory disease in humans, *Proc. Natl. Acad. Sci. USA.* 101:6212-6216; van der Hoek, et al., 2004, Identification of a new human coronavirus, *Nat. Med.* 10:368-373), two were coronaviruses. Coronaviruses possess the largest genome of about 30 kb among all RNA

viruses. As a result of the unique mechanism of viral replication, coronaviruses have a high frequency of recombination.

Based on genotypic and serological characterization, coronaviruses were divided into three distinct groups, with human coronavirus 229E (HCoV-229E) being a group 1 coronavirus and HCoV-OC43 a group 2 coronavirus (Lai, M. M. et al., 1997, The molecular biology of coronaviruses, *Adv. Virus Res.* 48:1-100). They account for 5-30% of human respiratory tract infections. In late 2002 and 2003, the epidemic caused by SARS-CoV affected over 8000 people with 750 deaths (for example, Peiris, J. S. et al., 2003, Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study, *Lancet* 361:1767-1772). We have also reported the isolation of SARS-CoV-like viruses from Himalayan palm civets, which suggested that animals could be the reservoir for the ancestor of SARS-CoV (Guan, Y. et al., 2003, Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China, *Science* 302:276-278). On the basis of genome analysis, SARS-CoV belongs to a fourth group of coronavirus, or alternatively, a distant relative of group 2 coronaviruses (Eickmann, M. et al., 2003, Phylogeny of the SARS coronavirus, *Science* 302:1504-1505; Marra, M. A. et al., 2003, The Genome sequence of the SARS-associated coronavirus, *Science* 300:1399-1404; Rota, P. A. et al., 2003, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, *Science* 300:1394-1399; Snijder, E. J. et al., 2003, Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage, *J. Mol. Biol.* 331:991-1004; Yeh, S. H. et al., 2004, Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution, *Proc. Natl. Acad. Sci. USA.* 101:2542-2547). Recently, a novel group 1 human coronavirus associated with respiratory tract infections, HCoV-NL63, has been discovered, and its genome sequenced (37).

In January, 2004, a 71-year-old Chinese man was admitted to hospital because of fever and chills for two days associated with sore throat, rhinorrhoea, productive cough with purulent sputum, headache and nausea. He had history of pulmonary tuberculosis more than 40 years ago complicated by cicatrization of right upper lobe and bronchiectasis with chronic *Pseudomonas aeruginosa* colonization of airways. He was a chronic smoker and also had chronic obstructive airway disease, hyperlipidemia, and asymptomatic abdominal aortic aneurysm. He had just returned from Shenzhen of China three days before admission. During his three-day trip to Shenzhen, he had no history of contact with or consumption of wild animals. On admission, his oral temperature was 37.6° C. Physical examination showed tracheal deviation to the right and inspiratory crackles over the anterior left lower zone. His haemoglobin level was 14.7 g/dL, total white cell count $12.1 \times 10^9/L$, with neutrophil $9.7 \times 10^9/L$, lymphocyte $1.6 \times 10^9/L$ and monocyte $0.5 \times 10^9/L$, and plate count $303 \times 10^9/L$. His liver and renal function tests were within normal limits. Chest radiograph showed right upper lobe collapse and new patchy infiltrates over the left lower zone. Blood culture was performed. Empirical oral amoxicillin/clavulanate and azithromycin were commenced. Nasopharyngeal aspirates for direct antigen detection for respiratory viruses, RT-PCR for influenza A virus, human metapneumovirus and SARS-CoV, and viral cultures were negative. Sputum for bacterial culture only recovered *P. aeruginosa*. Sputum for mycobacterial culture was negative.

Blood culture was negative. Paired sera for antibodies against *Mycoplasma*, *Chlamydia*, *Legionella*, and SARS-CoV did not show any rise in antibody titres. His fever subsided two days after admission. His cough improved and he was discharged after five days of hospitalization. Amoxicillin/clavulanate and azithromycin were continued for a total of seven days. The present inventors were the group involved in the investigation of this patient. All tests for identifying commonly recognized viruses and bacteria were negative in these patients. The etiologic agent responsible for this disease was not known until the complete genome of CoV-HKU1 from this patient by the present inventors as disclosed herein. Further studies disclosed herein have revealed that CoV-HKU1 is a human coronavirus and there are, at least, two (2) genotypes, A and B, within CoV-HKU1. The invention is useful in both clinical and scientific research applications.

3. SUMMARY OF INVENTION

The present invention is based upon the inventor's complete genome sequencing of a novel virus ("CoV-HKU1") causing pneumonia in humans. The virus was first discovered from a patient suffering from pneumonia in Hong Kong. The virus is a single-stranded RNA virus of positive polarity which belongs to the order, Nidovirales, of the family, Coronaviridae. Further studies based on prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period, have revealed that there are, at least, two (2) genotypes for CoV-HKU1. Accordingly, the invention relates to CoV-HKU1 that phylogenetically relates to known members of Coronaviridae and specifically belongs to group 2 coronavirus. In a specific embodiment, the invention provides complete genomic sequences of two (2) genotypes of CoV-HKU1. In a preferred embodiment, the virus comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In another specific embodiment, the invention provides nucleic acids isolated from the virus. The virus preferably comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, in its genome. In a specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:3 or 2919, a complement thereof or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000,

13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3, or 2919, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the present invention provides isolated nucleic acid molecules comprising or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof, or a portion thereof, preferably at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. Furthermore, in another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof. In preferred embodiments, such nucleic acid molecules encode amino acid sequences that have biological activities exhibited by the polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively, consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively, consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous

nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof. The polypeptides or proteins include those having the amino acid sequences of SEQ ID NO:2, 34-2918 shown in FIGS. 2 and 3, and SEQ ID NOS:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in FIG. 9. The invention further provides proteins or polypeptides that are isolated from the CoV-HKU1, including viral proteins isolated from cells infected with the virus but not present in comparable uninfected cells. The polypeptides or the proteins of the present invention preferably have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by the nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934. In another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. Furthermore, in another embodiment, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, or a complement thereof. In

other embodiments, the polypeptides or the proteins of the present invention have a biological activity of the protein (including antigenicity and/or immunogenicity) encoded by a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof.

In one aspect, the invention relates to the use of CoV-HKU1 for diagnostic methods. In a specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-HKU1, or any proteins or polypeptides thereof. In another specific embodiment, the invention provides a method of detecting in a biological sample an antibody that immunospecifically binds to the CoV-HKU1-infected cells. In yet another specific embodiment, the invention provides a method of screening for an antibody that immunospecifically binds and neutralizes CoV-HKU1. Such an antibody is useful for a passive immunization or immunotherapy of a subject infected with CoV-HKU1.

The invention further relates to the use of the sequence information of the isolated virus for diagnostic methods. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or at least a portion of the nucleotide sequence thereof. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for hybridization to CoV-HKU1 nucleic acid, including, but not limited to, as PCR primers, Reverse Transcriptase primers, probes for Southern or Northern analysis or other nucleic acid hybridization analysis for the detection of CoV-HKU1 nucleic acids, e.g., consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof.

The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptide having the amino acid sequence of SEQ ID NO:2 or any one of SEQ ID NOS:34-2918 shown in FIGS. 2 and 3, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in FIG. 9, or encoded by a nucleic acid comprising a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and/or any CoV-HKU1 epitope, having one or more biological activities of a polypeptide of the invention. The invention further provides antibodies that specifically bind cells or tissues that

are infected by CoV-HKU1. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, and so forth. The increased or decreased activity or expression of the CoV-HKU1 in a sample relative to a control sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the CoV-HKU1. In a specific embodiment, the detecting agents are the antibodies or nucleic acid molecules of the present invention. Antibodies of the invention may also be used to detect and/or treat other coronaviruses, such as Severe Acute Respiratory Syndrome ("SARS") viruses.

In another embodiment, the invention provides vaccine preparations, comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or protein subunits of the virus. In a specific embodiment, the present invention provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific invention, the vaccine preparations of the present invention comprise a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides isolated from or produced from nucleic acid of CoV-HKU1. In a specific embodiment, the vaccine preparations comprise a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID NO:2 or any one of SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236. Furthermore, the present invention provides methods for treating, ameliorating, managing or preventing respiratory tract infections caused by CoV-HKU1 by administering to a subject in need thereof the anti-viral agents of the present invention, alone or in combination with various anti-viral agents as well as adjuvants, and/or other pharmaceutically acceptable excipients.

In another aspect, the present invention provides methods for preventing or inhibiting, under a physiological condition, binding to a host cell, or infection of a host cell, or replication in a host cell, of CoV-HKU1 or a virus comprising a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, by administering to the host cell the anti-viral agents of the present invention, alone or in combination with other anti-viral agents. In a specific embodiment, the anti-viral agent of the invention includes the immunogenic preparations of the invention or an antibody that immunospecifically binds

CoV-HKU1 or any CoV-HKU1 epitope and/or neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the present invention or a nucleic acid molecule of the invention. In a specific embodiment, the host cell is a mammalian cell, including a cell of human, primates, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats. Preferably a host cell is a primate cell, and most preferably a human cell. Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The invention also provides kits containing a pharmaceutical composition of the present invention.

3.1 Definitions

The term "an antibody or an antibody fragment that immunospecifically binds a polypeptide of the invention" as used herein refers to an antibody or a fragment thereof that immunospecifically binds to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, and does not non-specifically bind to other polypeptides. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention may cross-react with other antigens. Preferably, an antibody or a fragment thereof that immunospecifically binds to a polypeptide of the invention does not cross-react with other antigens. An antibody or a fragment thereof that immunospecifically binds to the polypeptide of the invention, can be identified by, for example, immunoassays or other techniques known to those skilled in the art.

An "isolated" or "purified" peptide or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the protein is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of a polypeptide/protein in which the polypeptide/protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, a polypeptide/protein that is substantially free of cellular material includes preparations of the polypeptide/protein having less than about 30%, 20%, 10%, 5%, 2.5%, or 1%, (by dry weight) of contaminating protein. When the polypeptide/protein is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation. When polypeptide/protein is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the polypeptide/protein have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than polypeptide/protein fragment of interest. In a preferred embodiment of the present invention, polypeptides/proteins are isolated or purified.

An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid molecule. Moreover, an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant

techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. In a preferred embodiment of the invention, nucleic acid molecules encoding polypeptides/proteins of the invention are isolated or purified. The term "isolated" nucleic acid molecule does not include a nucleic acid that is a member of a library that has not been purified away from other library clones containing other nucleic acid molecules.

The term "portion" or "fragment" as used herein refers to a fragment of a nucleic acid molecule containing at least about 10, 15, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000, or more contiguous nucleic acids in length of the relevant nucleic acid molecule and having at least one functional feature of the nucleic acid molecule (or the encoded protein has one functional feature of the protein encoded by the nucleic acid molecule); or a fragment of a protein or a polypeptide containing at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 100, 120, 140, 160, 180, 200, 220, 240, 260, 280, 300, 320, 340, 360, 380, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,100, 4,200, 4,300, 4,350, 4,360, 4,370, 4,380 amino acid residues in length of the relevant protein or polypeptide and having at least one functional feature of the protein or polypeptide.

The term "having a biological activity of the protein" or "having biological activities of the polypeptides of the invention" refers to the characteristics of the polypeptides or proteins having a common biological activity similar or identical structural domain and/or having sufficient amino acid identity to the polypeptide encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the polypeptide having any one of the amino acid sequences of SEQ ID NOS:2, 34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236, or a complement thereof. Such common biological activities of the polypeptides of the invention include antigenicity and immunogenicity.

The term "under stringent condition" refers to hybridization and washing conditions under which nucleotide sequences having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to each other remain hybridized to each other. Such hybridization conditions are described in, for example but not limited to, Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.; Basic Methods in Molecular Biology, Elsevier Science Publishing Co., Inc., N.Y. (1986), pp. 75-78, and 84-87; and Molecular Cloning, Cold Spring Harbor Laboratory, N.Y. (1982), pp. 387-389, and are well known to those skilled in the art. A preferred, non-limiting example of stringent hybridization conditions is hybridization in 6x sodium chloride/sodium citrate (SSC), 0.5% SDS at about 68° C. followed by one or more washes (e.g., about 5 to 30 min each) in 2xSSC, 0.5% SDS at room temperature. Another preferred, non-limiting example of stringent hybridization conditions is hybridization in 6xSSC at about 45° C. followed by one or more washes (e.g., about 5 to 30 min each) in 0.2xSSC, 0.1% SDS at about 45-65° C.

The term "variant" as used herein refers either to a naturally occurring genetic mutant of CoV-HKU1 or a recombinantly prepared variation of CoV-HKU1 each of which contain one or more mutations in its genome compared to CoV-HKU1. The term "variant" may also refer either to a naturally occurring variation of a given peptide or a recombinantly prepared variation of a given peptide or protein in which one or more amino acid residues have been modified by amino acid substitution, addition, or deletion.

4. BRIEF DESCRIPTION OF FIGURES

FIG. 1 shows a partial DNA sequence (SEQ ID NO:1) and its deduced amino acid sequence (SEQ ID NO:2) obtained from CoV-HKU1 that has 91% amino acid identity to the RNA-dependent RNA polymerase protein of known *Coronaviruses*.

FIG. 2 shows the entire genomic DNA sequence (SEQ ID NO:3) of the first isolate of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS:34-456; the second-frame translation and amino acid sequences: SEQ ID NOS:457-723; and the third-frame translation and amino acid sequences: SEQ ID NOS:724-1318.

FIG. 3 shows the complement (SEQ ID NO:1319) of the entire genomic DNA sequence (SEQ ID NO:3) of CoV-HKU1 in 3'→5' orientation and its deduced amino acid sequences therefrom in three frames. An asterisk (*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS:1319-1907; the second-frame translation and amino acid sequences: SEQ ID NO:1908-2453; and the third-frame translation and amino acid sequences: SEQ ID NOS:2454-2918.

FIG. 4 shows genome organization of CoV-HKU1. Overall organization of the 29926-nucleotide CoV-HKU1 genomic RNA. Predicted ORFs 1a and 1b, encoding the nonstructural polyproteins (p28, p65 and nsp1-13) and those encoding the hemagglutinin-esterase, spike, envelope, membrane and nucleocapsid structural proteins are indicated. Arrows indicate putative cleavage sites (with the corresponding nucleotide positions) of the replicase polyprotein encoded by ORF 1a and ORF 1b. ATR, PL1^{pro} and PL2^{pro} represent the acidic tandem repeat and the two papain-like proteases, respectively, in nsp1.

FIG. 5A shows the phylogenetic analysis of the chymotrypsin like protease (3CL^{pro}), RNA-dependent RNA polymerase (Pol), helicase, and hemagglutinin-esterase (HE); and FIG. 5B shows that of the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1. The trees were constructed by the neighbor joining method using the Jukes-Cantor correction and bootstrap values were calculated from 1000 trees. A total of 303, 928, 595, 418, 1356, 75, 225 and 406 amino acid positions in 3CL^{pro}, Pol, helicase, HE, S, E, M, and N, respectively, were included in the analysis. The scale bar indicates the estimated number of substitutions per 10 amino acids. HCoV-229E: human coronavirus 229E; PEDV: porcine epidemic diarrhea virus; PTGV: porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63: human coronavirus NL63; HCoV-OC43: human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; SDAV: rat sialodacryoadnitis coronavirus; ECoV: equine coronavirus NC99; PHEV: porcine hemag-

glutinating encephalomyelitis virus; IBV: infectious bronchitis virus; SARS-CoV: SARS coronavirus.

FIG. 6 shows the spike protein of CoV-HKU1 (residues 7-336 of SEQ ID NO: 420) and those of other group 2 coronaviruses (SEQ ID NOS 21-26, respectively, in order of appearance). The spike protein (1356 amino acids) of CoV-HKU1 is depicted by the horizontal bar [SS=N terminal signal sequence (amino acid residues 1 to 13), HR1=heptad repeat 1 (amino acid residues 982 to 1083), HR2=heptad repeat 2 (amino acid residues 1250 to 1297), TM=transmembrane domain (amino acid residues 1301 to 1323)], (the seven sequences below the horizontal bar disclose residues 752-766 of SEQ ID NO: 420 and SEQ ID NOS 28-33, respectively, in order of appearance). Alignment of the N-terminal region important for receptor binding (amino acid residues 1 to 330) and the region upstream to the cleavage site between S1 and S2 of CoV-HKU1 and other group 2 coronaviruses was generated with ClustalX 1.83. Residues that match the CoV-HKU1 exactly are boxed. The three conserved regions (sites I, II, and III) for receptor binding in MHV are shaded. The positions of the four conserved amino acids important for receptor binding in MHV are indicated with arrows. (GenBank accession nos. MHV: P11224; BCoV: NP 150077; HCoV-OC43: NP 937950; SDAV: AAF97738; PHEV: AAL80031; ECoV: AAQ67205).

FIG. 7 shows the sequential quantitative RT-PCR (closed squares; copies/ml) for CoV-HKU1 in nasopharyngeal aspirates; and serum IgG antibody titers against N protein of CoV-HKU1 (closed triangles).

FIG. 8 shows the Western blot analysis of purified recombinant CoV-HKU1 N protein antigen. Prominent immunoreactive protein bands of about 53 kDa (i.e., purified recombinant CoV-HKU1 N protein) were detected by the Western blot using the patient's sera obtained during the second and fourth weeks of the illness (lanes 2 and 3). Only very faint bands were observed with the serum samples obtained from the patient during the first week of the illness (lane 1) and two healthy blood donors (lane 4 and 5), respectively.

FIG. 9 shows the entire genomic DNA sequence (SEQ ID NO:2919) of CoV-HKU1 and its deduced amino acid sequences therefrom in three frames. An asterisk (*) indicates a stop codon which marks the end of a peptide. The first-frame translation and amino acid sequences: SEQ ID NOS: 2970-3474; the second-frame translation and amino acid sequences: SEQ ID NOS: 3475-3721; and the third-frame translation and amino acid sequences: SEQ ID NOS: 3722-4236.

FIG. 10 shows arrangements of proteins in replicase polyprotein in CoV-HKU1 compared with those in HCoV-OC43, BCoV, and MHV. Alignment of the AC domains of HCoV-OC43 (SEQ ID NO: 4239), BCoV (SEQ ID NO: 4238), and MHV (SEQ ID NO: 4237) and the AC domains and ATR (underlined) of CoV-HKU1 in the two patients (SEQ ID NOS 4240 and 4241) was generated with ClustalX 1.83. AC domain=acidic domain, ATR=acidic tandem repeat. (GenBank accession no. MHV: NC_001846; BCoV: NC_003045; HCoV-OC43: AY585229).

FIG. 11 shows the multiple alignments of the replicase genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2920 which encodes SEQ ID NO: 2921), 2 (SEQ ID NO: 2922 which encodes SEQ ID NO: 2923), 4 (SEQ ID NO: 2924 which encodes SEQ ID NO: 2925), 5 (SEQ ID NO: 4242 which encodes SEQ ID NO: 4243), 6 (SEQ ID NO: 2926 which encodes SEQ ID NO: 2927), 7 (SEQ ID NO: 2928 which encodes SEQ ID NO: 2929), 8 (SEQ ID NO: 2930 which encodes SEQ ID NO: 2931), 9 (SEQ ID NO: 2932

which encodes SEQ ID NO: 2933) and 10 (SEQ ID NO: 2934 which encodes SEQ ID NO: 2935).

FIG. 12 shows the chest radiographs of the two patients who died of community acquired pneumonia associated with CoV-HKU1. The chest radiograph of the first patient (FIG. 12A; patient no. 2 in Table 5) showed patchy airspace shadows in both lungs with predominant involvement of the lower zones. The chest radiograph of the second patient (FIG. 12B; patient no. 10 in Table 5), with Luque instrumentation in situ, showed extensive airspace shadows in both lungs with the middle zones more severely involved.

FIG. 13 shows the multiple alignments of the spike genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2936 which encodes SEQ ID NO: 2937), 2 (SEQ ID NO: 2938 which encodes SEQ ID NO: 2939), 4 (SEQ ID NO: 2940 which encodes SEQ ID NO: 2941), 5 (SEQ ID NO: 4244 which encodes SEQ ID NO: 4245), 6 (SEQ ID NO: 2942 which encodes SEQ ID NO: 2943), 7 (SEQ ID NO: 2944 which encodes SEQ ID NO: 2945), 8 (SEQ ID NO: 2946 which encodes SEQ ID NO: 2947), 9 (SEQ ID NO: 2948 which encodes SEQ ID NO: 2949) and 10 (SEQ ID NO: 2950 which encodes SEQ ID NO: 2951).

FIG. 14 shows the multiple alignments of the nucleocapsid genes of CoV-HKU1 from patients 1 (SEQ ID NO: 2952 which encodes SEQ ID NO: 2953), 2 (SEQ ID NO: 2954 which encodes SEQ ID NO: 2955), 4 (SEQ ID NO: 2956 which encodes SEQ ID NO: 2957), 5 (SEQ ID NO: 4246 which encodes SEQ ID NO: 4247), 6 (SEQ ID NO: 2958 which encodes SEQ ID NO: 2959), 7 (SEQ ID NO: 2960 which encodes SEQ ID NO: 2961), 8 (SEQ ID NO: 2962 which encodes SEQ ID NO: 2963), 9 (SEQ ID NO: 2964 which encodes SEQ ID NO: 2965) and 10 (SEQ ID NO: 2966 which encodes SEQ ID NO: 2967).

FIG. 15 shows phylogenetic trees and non-synonymous mutations and corresponding amino acid changes of complete pol, S and N gene sequences of CoV-HKU1 from nine patients with community acquired pneumonia. The trees were inferred from pol (FIG. 15A), S (FIG. 15B) and N (FIG. 15C) gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The trees were rooted using pol, S and N gene sequences of HCoV-OC43, respectively. 2784 nucleotide positions in each pol gene, 4071 nucleotide positions in each S gene, and 1326 nucleotide positions in each N gene, were included in the analysis. The scale bar indicates the estimated number of substitutions per 100 (FIG. 15A) and 50 (FIGS. 15B and 15C) bases, respectively, using Jukes-Cantor correction. The shaded nucleotides are those that differ from the majority at the corresponding locations. Due to the large number of non-synonymous mutations in the S gene, only the NH₂ terminal 45, out of the total of 306, non-synonymous mutations are shown.

FIG. 16 shows the multiple alignments of nucleotides 1806-1835 and 2229-2258 of the pol genes in the nine CoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV. Marked differences between the 3' ends of the two primers for RT-PCR (LPW1926; SEQ ID NO: 2968 and LPW1927; SEQ ID NO: 2969) and the corresponding bases in HCoV-OC43 (SEQ ID NOS 4250 and 4251), HCoV-229E (SEQ ID NOS: 4254 and 4255), HCoV-NL63 (SEQ ID NOS: 4256 and 4257) and SARS-CoV (SEQ ID NOS: 4252 and 4253) are observed, indicating the high specificity of the two primers for CoV-HKU1. The positions of LPW1926 (SEQ ID NO: 2968) and LPW1927 (SEQ ID NO: 2969) are boxed. The bases in

HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV that were different from those in the sequence of the primers, were shaded.

FIG. 17 show a phylogenetic tree of pol gene sequences of the 10 CoV-HKU1 from patients with community acquired pneumonia. The tree was inferred from pol gene data by the neighbor-joining method and bootstrap values calculated from 1000 trees. The tree was rooted using pol gene sequence of HCoV:229E and 393 nucleotide positions (primer sequences excluded) in each pol gene were included in the analysis. The scale bar indicates the estimated number of substitutions per 50 bases using Jukes-Cantor correction. CoV-HKU1: human coronavirus HKU1; HCoV-229E: human coronavirus 229E; HCoV-OC43: human coronavirus OC43; MHV: murine hepatitis virus; BCoV: bovine coronavirus; PHEV: porcine hemagglutinating encephalomyelitis virus.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the CoV-HKU1 that phylogenetically relates to known *Coronaviruses*. In a specific embodiment, CoV-HKU1 comprises a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a specific embodiment, the present invention provides isolated nucleic acid molecules of the CoV-HKU1, comprising, or, alternatively, consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof or a portion thereof. In another specific embodiment, the invention provides isolated nucleic acid molecules which hybridize under stringent conditions, as defined herein, to a nucleic acid molecule having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or specific genes of known member of Coronaviridae, or a complement thereof. In another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, or 2934, or a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively, consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, 1,350, 1,400, 1,450, 1,500, 1,550, 1,600, 1,650, 1,700, 1,750, 1,800, 1,850, 1,900, 1,950, 2,000, 2,100, 2,200, 2,300, 2,400, 2,500, 2,600, 2,700, 2,800, 2,900, 3,000, 3,100, 3,200, 3,300, 3,400, 3,500, 3,600, 3,700, 3,800, 3,900, 4,000, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2936, 2938, 2940, 2942, 2944, 2946, 2948, or 2950, or a complement thereof. In yet another

specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively, consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 1,250, 1,300, or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:2952, 2954, 2956, 2958, 2960, 2962, 2964, or 2966, a complement thereof. In yet another specific embodiment, the invention provides isolated polypeptides or proteins that are encoded by a nucleic acid molecule comprising or, alternatively, consisting of a nucleotide sequence that is at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1,000, 1,050, 1,100, 1,150, 1,200, 2,000, 3,000, 4,000, 5,000, 6,000, 7,000, 8,000, 9,000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, 20,000, 21,000, 22,000, 23,000, 24,000, 25,000, 26,000, 27,000, 28,000, 29,000 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:3 or 2919, or a complement thereof. The polypeptides or the proteins of the present invention preferably have one or more biological activities of the proteins encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or the native viral proteins containing the amino acid sequences encoded by the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof.

The invention further relates to the use of the sequence information of the isolated virus for diagnostic and therapeutic methods. In a specific embodiment, the invention provides the entire nucleotide sequence of CoV-HKU1 (SEQ ID NO:3 or 2919), or fragments, or complement thereof. Furthermore, the present invention relates to a nucleic acid molecule that hybridizes any portion of the genome of the CoV-HKU1 (SEQ ID NO:3 or 2919) under the stringent conditions. In a specific embodiment, the invention provides nucleic acid molecules which are suitable for use as primers consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a complement thereof, or a portion thereof. In another specific embodiment, the invention provides nucleic acid molecules which are suitable for use as hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention, consisting of or comprising the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof. The invention further encompasses chimeric or recombinant viruses or viral proteins encoded by said nucleotide sequences.

The invention further provides antibodies that specifically bind a polypeptide of the invention encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, or any CoV-HKU1 epitope as well as the polypeptides having the amino acid sequences of any one of SEQ ID NO:2, SEQ ID NOS:34-2918 shown in FIGS. 2 and 3, SEQ ID NOS:2921,

2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and 2970-4236 shown in FIG. 9. Such antibodies include, but are not limited to polyclonal, monoclonal, bi-specific, multi-specific, human, humanized, chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, disulfide-linked Fvs, intrabodies and fragments containing either a VL or VH domain or even a complementary determining region (CDR) that specifically binds to a polypeptide of the invention.

In one embodiment, the invention provides methods for detecting the presence, activity or expression of the CoV-HKU1 of the invention in a biological material, such as cells, blood, saliva, urine, sputum, nasopharyngeal aspirates, and so forth. The presence of the CoV-HKU1 in a sample can be determined by contacting the biological material with an agent which can detect directly or indirectly the presence, activity or expression of the CoV-HKU1. In a specific embodiment, the detection agents are the antibodies of the present invention. In another embodiment, the detection agent is a nucleic acid of the present invention.

In another embodiment, the invention provides vaccine preparations comprising the CoV-HKU1 recombinant and chimeric forms of said virus, or subunits of the virus.

The present invention further provides methods of preparing recombinant or chimeric forms of CoV-HKU1. In another specific embodiment, the vaccine preparations of the present invention comprise one or more nucleic acid molecules comprising or consisting of the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another embodiment, the invention provides vaccine preparations comprising one or more polypeptides of the invention encoded by a nucleotide sequence comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof, including the polypeptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NOS:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236. Furthermore, the present invention provides methods for treating, ameliorating, managing, or preventing respiratory tract infections by administering to a subject in need thereof the anti-viral agents of the present invention, alone or in combination with other antivirals [e.g., amantadine, rimantadine, gancyclovir, acyclovir, ribavirin, penciclovir, oseltamivir, foscarnet, zidovudine (AZT), didanosine (ddI), lamivudine (3TC), zalcitabine (ddC), stavudine (d4T), nevirapine, delavirdine, indinavir, ritonavir, vidarabine, nelfinavir, saquinavir, relenza, tamiflu, pleconaril, interferons, etc.], steroids and corticosteroids such as prednisone, cortisone, fluticasone and glucocorticoid, antibiotics, analgesics, bronchodilators, or other treatments for respiratory and/or viral infections. In one aspect, the anti-viral agent of the present invention prevents or inhibits the binding of the virus or viral proteins to a host cell under a physiological condition, thereby preventing or inhibiting the infection of the host cell by the virus. In another aspect, the anti-viral agent of the invention prevents or inhibits replication of the viral nucleic acid molecules in the host cell under a physiological condition by interacting with the viral nucleic acid molecules or its transcription mechanisms. In a specific embodiment, the anti-viral agent

of the invention includes the vaccine or immunogenic preparations of the invention or an antibody that immunospecifically binds CoV-HKU1 or any CoV-HKU1 epitope and may neutralizes CoV-HKU1. In another specific embodiment, the anti-viral agent is a polypeptide or protein of the invention or a nucleic acid molecule of the invention. In addition, the present invention provides a method of preventing or inhibiting replication in a host cell of a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or inhibiting the activities of the polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, a complement thereof, or a portion thereof, including the polypeptides having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, by administering to said host cell the anti-viral agent of the invention. In a specific embodiment the host cell is a mammalian cell, such as a cell of humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, arivan species and rodents. Preferably, the cell is a primate cell and most preferably a human cell.

Furthermore, the present invention provides pharmaceutical compositions comprising anti-viral agents of the present invention and a pharmaceutically acceptable carrier. The present invention also provides kits comprising pharmaceutical compositions of the present invention.

5.1 Recombinant and Chimeric CoV-HKU1

The present invention encompasses recombinant or chimeric viruses encoded by viral vectors derived from the genome of CoV-HKU 1 or natural variants thereof. In a specific embodiment, a recombinant virus is one derived from the CoV-HKU1. In a specific embodiment, the virus has a nucleotide sequence of SEQ ID NO:3 or 2919. In another specific embodiment, a recombinant virus is one derived from a natural variant of CoV-HKU1. A natural variant of CoV-HKU1 has a sequence that is different from the genomic sequence (SEQ ID NO:3 or 2919) of CoV-HKU1, due to one or more naturally occurred mutations, including, but not limited to, point mutations, rearrangements, insertions, deletions etc., to the genomic sequence that may or may not result in a phenotypic change. In accordance with the present invention, a viral vector which is derived from the genome of the CoV-HKU, is one that contains a nucleic acid sequence that encodes at least a part of one ORF of the CoV-HKU1. In a specific embodiment, the ORF comprises or consists of a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In a specific embodiment, there are more than one ORF within the nucleotide sequence of SEQ ID NO:3 or 2919, or a fragment thereof. In another embodiment, the polypeptides encoded by the ORF comprises or consists of amino acid sequences of SEQ ID NO:34-2918 shown in FIGS. 2 and 8, or SEQ ID NO:2, SEQ ID NO:2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or a fragment thereof. In accordance with the present invention

these viral vectors may or may not include nucleic acids that are non-native to the viral genome.

In another specific embodiment, a chimeric virus of the invention is a recombinant CoV-HKU1 which further comprises a heterologous nucleotide sequence. In accordance with the invention, a chimeric virus may be encoded by a nucleotide sequence in which heterologous nucleotide sequences have been added to the genome or in which endogenous or native nucleotide sequences have been replaced with heterologous nucleotide sequences.

According to the present invention, the chimeric viruses are encoded by the viral vectors of the invention which further comprise a heterologous nucleotide sequence. In accordance with the present invention a chimeric virus is encoded by a viral vector that may or may not include nucleic acids that are non-native to the viral genome. In accordance with the invention a chimeric virus is encoded by a viral vector to which heterologous nucleotide sequences have been added, inserted or substituted for native or non-native sequences. In accordance with the present invention, the chimeric virus may be encoded by nucleotide sequences derived from different strains or variants of CoV-HKU1. In particular, the chimeric virus is encoded by nucleotide sequences that encode antigenic polypeptides derived from different strains or variants of CoV-HKU1.

A chimeric virus may be of particular use for the generation of recombinant vaccines protecting against two or more viruses (Tao et al., *J. Virol.* 72, 2955-2961; Durbin et al., 2000, *J. Virol.* 74, 6821-6831; Skiadopoulos et al., 1998, *J. Virol.* 72, 1762-1768 (1998); Teng et al., 2000, *J. Virol.* 74, 9317-9321). For example, it can be envisaged that a virus vector derived from the CoV-HKU1 expressing one or more proteins of variants of CoV-HKU1, or vice versa, will protect a subject vaccinated with such vector against infections by both the native CoV-HKU1 and the variant. Attenuated and replication-defective viruses may be of use for vaccination purposes with live vaccines as has been suggested for other viruses.

In accordance with the present invention the heterologous sequence to be incorporated into the viral vectors encoding the recombinant or chimeric viruses of the invention include sequences obtained or derived from different strains or variants of CoV-HKU1.

In certain embodiments, the chimeric or recombinant viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more sequences, intergenic regions, termini sequences, or portions or entire ORF have been substituted with a heterologous or non-native sequence. In certain embodiments of the invention, the chimeric viruses of the invention are encoded by viral vectors derived from viral genomes wherein one or more heterologous sequences have been inserted or added to the vector.

The selection of the viral vector may depend on the species of the subject that is to be treated or protected from a viral infection.

In accordance with the present invention, the viral vectors can be engineered to provide antigenic sequences which confer protection against infection by the CoV-HKU1 and natural variants thereof. The viral vectors may be engineered to provide one, two, three or more antigenic sequences. In accordance with the present invention the antigenic sequences may be derived from the same virus, from different strains or variants of the same type of virus, or from different viruses.

The expression products and/or recombinant or chimeric virions obtained in accordance with the invention may

advantageously be utilized in vaccine formulations. The expression products and chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral and bacterial antigens, tumor antigens, allergen antigens, and auto antigens involved in autoimmune disorders. In particular, the chimeric virions of the present invention may be engineered to create vaccines for the protection of a subject from infections with CoV-HKU1 and variants thereof.

In certain embodiments, the expression products and recombinant or chimeric virions of the present invention may be engineered to create vaccines against a broad range of pathogens, including viral antigens, tumor antigens and autoantigens involved in autoimmune disorders. One way to achieve this goal involves modifying existing CoV-HKU1 genes to contain foreign sequences in their respective external domains. Where the heterologous sequences are epitopes or antigens of pathogens, these chimeric viruses may be used to induce a protective immune response against the disease agent from which these determinants are derived.

Thus, the present invention relates to the use of viral vectors and recombinant or chimeric viruses to formulate vaccines against a broad range of viruses and/or antigens. The present invention also encompasses recombinant viruses comprising a viral vector derived from the CoV-HKU1 or variants thereof which contains sequences which result in a virus having a phenotype more suitable for use in vaccine formulations. The mutations and modifications can be in coding regions, in intergenic regions and in the leader and trailer sequences of the virus.

The invention provides a host cell comprising a nucleic acid or a vector according to the invention. Plasmid or viral vectors containing the polymerase components of CoV-HKU1 are generated in prokaryotic cells for the expression of the components in relevant cell types (bacteria, insect cells, eukaryotic cells). Plasmid or viral vectors containing full-length or partial copies of the CoV-HKU1 genome will be generated in prokaryotic cells for the expression of viral nucleic acids in-vitro or in-vivo. The latter vectors may contain other viral sequences for the generation of chimeric viruses or chimeric virus proteins, may lack parts of the viral genome for the generation of replication defective virus, and may contain mutations, deletions or insertions for the generation of attenuated viruses.

In addition, eukaryotic cells, transiently or stably expressing one or more full-length or partial CoV-HKU1 proteins can be used. Such cells can be made by transfection (proteins or nucleic acid vectors), infection (viral vectors) or transduction (viral vectors) and may be useful for complementation of mentioned wild type, attenuated, replication-defective or chimeric viruses.

The viral vectors and chimeric viruses of the present invention may be used to modulate a subject's immune system by stimulating a humoral immune response, a cellular immune response or by stimulating tolerance to an antigen. As used herein, a subject means: humans, primates, horses, cows, sheep, pigs, goats, dogs, cats, avian species and rodents.

5.2 Formulation of Vaccines and Antivirals

In a preferred embodiment, the invention provides a proteinaceous molecule or CoV-HKU1 specific viral protein or functional fragment thereof encoded by a nucleic acid according to the invention. Useful proteinaceous molecules are for example derived from any of the genes or genomic fragments derivable from the virus according to the inven-

tion, including envelop protein (E protein), integral membrane protein (M protein), spike protein (S protein), nucleocapsid protein (N protein), hemagglutinin esterase (HE protein), and RNA-dependent RNA polymerase. Such molecules, or antigenic fragments thereof, as provided herein, are for example useful in diagnostic methods or kits and in pharmaceutical compositions such as subunit vaccines. Particularly useful are polypeptides encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-2918 in FIGS. 2 and 3, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 in FIG. 9, or antigenic fragments thereof for inclusion as antigen or subunit immunogen, but inactivated whole virus can also be used. Particularly useful are also those proteinaceous substances that are encoded by recombinant nucleic acid fragments of the CoV-HKU1 genome; of course preferred are those that are within the preferred bounds and metes of ORFs, in particular, for eliciting CoV-HKU1 specific antibody or T cell responses, whether in vivo (e.g. for protective or therapeutic purposes or for providing diagnostic antibodies) or in vitro (e.g. by phage display technology or another technique useful for generating synthetic antibodies).

The invention provides vaccine formulations for the prevention and treatment of infections with CoV-HKU1. In certain embodiments, the vaccine of the invention comprises recombinant and chimeric viruses of the CoV-HKU1.

In another aspect, the present invention also provides DNA vaccine formulations comprising a nucleic acid or fragment of the CoV-HKU1, or nucleic acid molecules having the sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a fragment thereof. In another specific embodiment, the DNA vaccine formulations of the present invention comprises a nucleic acid or fragment thereof encoding the antibodies which immunospecifically binds CoV-HKU1. In DNA vaccine formulations, a vaccine DNA comprises a viral vector, such as that derived from the CoV-HKU1, bacterial plasmid, or other expression vector, bearing an insert comprising a nucleic acid molecule of the present invention operably linked to one or more control elements, thereby allowing expression of the vaccinating proteins encoded by said nucleic acid molecule in a vaccinated subject. Such vectors can be prepared by recombinant DNA technology as recombinant or chimeric viral vectors carrying a nucleic acid molecule of the present invention.

Various heterologous vectors are described for DNA vaccinations against viral infections. For example, the vectors described in the following references may be used to express CoV-HKU1 sequences instead of the sequences of the viruses or other pathogens described; in particular, vectors described for hepatitis B virus (Michel, M. L. et al., 1995, DAN-mediated immunization to the hepatitis B surface antigen in mice: Aspects of the humoral response mimic hepatitis B viral infection in humans, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; Davis, H. L. et al., 1993, DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody, *Human Molec. Genetics* 2:1847-1851), HIV virus (Wang, B. et al., 1993, Gene inoculation generates immune responses

against human immunodeficiency virus type 1, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; Lu, S. et al., 1996, Simian immunodeficiency virus DNA vaccine trial in macaques, *J. Virol.* 70:3978-3991; Letvin, N. L. et al., 1997, Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination, *Proc Natl Acad Sci USA*. 94(17):9378-83), and influenza viruses (Robinson, H L et al., 1993, Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA, *Vaccine* 11:957-960; Ulmer, J. B. et al., Heterologous protection against influenza by injection of DNA encoding a viral protein, *Science* 259:1745-1749), as well as bacterial infections, such as tuberculosis (Tascon, R. E. et al., 1996, Vaccination against tuberculosis by DNA injection, *Nature Med.* 2:888-892; Huygen, K. et al., 1996, Immunogenicity and protective efficacy of a tuberculosis DNA vaccine, *Nature Med.*, 2:893-898), and parasitic infection, such as malaria (Sedegah, M., 1994, Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein, *Proc. Natl. Acad. Sci. USA* 91:9866-9870; Doolan, D. L. et al., 1996, Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ T cell-interferon δ , and nitric oxide-dependent immunity, *J. Exper. Med.*, 1183:1739-1746).

Many methods may be used to introduce the vaccine formulations described above. These include, but are not limited to, oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes. Alternatively, it may be preferable to introduce the chimeric virus vaccine formulation via the natural route of infection of the pathogen for which the vaccine is designed. The DNA vaccines of the present invention may be administered in saline solutions by injections into muscle or skin using a syringe and needle (Wolff J. A. et al., 1990, Direct gene transfer into mouse muscle in vivo, *Science* 247:1465-1468; Raz, E., 1994, Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses, *Proc. Natl. Acad. Sci. USA* 91:9519-9523). Another way to administer DNA vaccines is called "gene gun" method, whereby microscopic gold beads coated with the DNA molecules of interest is fired into the cells (Tang, D. et al., 1992, Genetic immunization is a simple method for eliciting an immune response, *Nature* 356:152-154). For general reviews of the methods for DNA vaccines, see Robinson, H. L., 1999, DNA vaccines: basic mechanism and immune responses (Review), *Int. J. Mol. Med.* 4(5):549-555; Barber, B., 1997, Introduction: Emerging vaccine strategies, *Seminars in Immunology* 9(5):269-270; and Robinson, H. L. et al., 1997, DNA vaccines, *Seminars in Immunology* 9(5):271-283.

5.3 Adjuvants and Carrier Molecules

CoV-HKU1-associated antigens are administered with one or more adjuvants. In one embodiment, the CoV-HKU1-associated antigen is administered together with a mineral salt adjuvants or mineral salt gel adjuvant. Such mineral salt and mineral salt gel adjuvants include, but are not limited to, aluminum hydroxide (ALHYDROGEL, REHYDRAGEL), aluminum phosphate gel, aluminum hydroxyphosphate (ADJU-PHOS), and calcium phosphate.

In another embodiment, CoV-HKU1-associated antigen is administered with an immunostimulatory adjuvant. Such class of adjuvants, include, but are not limited to, cytokines (e.g., interleukin-2, interleukin-7, interleukin-12, granulocyte-macrophage colony stimulating factor (GM-CSF),

interferon- γ interleukin-1 β (IL-1 β), and IL-1 β peptide or Sclavo Peptide), cytokine-containing liposomes, triterpenoid glycosides or saponins (e.g., QuilA and QS-21, also sold under the trademark STIMULON, ISCOPREP), Muramyl Dipeptide (MDP) derivatives, such as N-acetylmuramyl-L-threonyl-D-isoglutamine (Threonyl-MDP, sold under the trademark TERMURTIDE), GMDP, N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxy phosphoryloxy)-ethylamine, muramyl tripeptide phosphatidylethanolamine (MTP-PE), unmethylated CpG dinucleotides and oligonucleotides, such as bacterial DNA and fragments thereof, LPS, monophosphoryl Lipid A (3D-MLA sold under the trademark MPL), and polyphosphazenes.

In another embodiment, the adjuvant used is a particular adjuvant, including, but not limited to, emulsions, e.g., Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, squalene or squalane oil-in-water adjuvant formulations, such as SAF and MF59, e.g., prepared with block-copolymers, such as L-121 (polyoxypropylene/polyoxyethylene) sold under the trademark PLURONIC L-121, Liposomes, Virosomes, cochleates, and immune stimulating complex, which is sold under the trademark ISCOM.

In another embodiment, a microparticulate adjuvant is used. Microparticulate adjuvants include, but are not limited to biodegradable and biocompatible polyesters, homo- and copolymers of lactic acid (PLA) and glycolic acid (PGA), poly(lactide-co-glycolides) (PLGA) microparticles, polymers that self-associate into particulates (poloxamer particles), soluble polymers (polyphosphazenes), and virus-like particles (VLPs) such as recombinant protein particulates, e.g., hepatitis B surface antigen (HbsAg).

Yet another class of adjuvants that may be used include mucosal adjuvants, including but not limited to heat-labile enterotoxin from *Escherichia coli* (LT), cholera holotoxin (CT) and cholera Toxin B Subunit (CTB) from *Vibrio cholerae*, mutant toxins (e.g., LTK63 and LTR72), microparticles, and polymerized liposomes.

In other embodiments, any of the above classes of adjuvants may be used in combination with each other or with other adjuvants. For example, non-limiting examples of combination adjuvant preparations that can be used to administer the CoV-HKU1-associated antigens of the invention include liposomes containing immunostimulatory protein, cytokines, or T-cell and/or B-cell peptides, or microbes with or without entrapped IL-2 or microparticles containing enterotoxin. Other adjuvants known in the art are also included within the scope of the invention (see *Vaccine Design: The Subunit and Adjuvant Approach*, Chap. 7, Michael F. Powell and Mark J. Newman (eds.), Plenum Press, New York, 1995, which is incorporated herein in its entirety).

The effectiveness of an adjuvant may be determined by measuring the induction of antibodies directed against an immunogenic polypeptide containing a CoV-HKU1 polypeptide epitope, the antibodies resulting from administration of this polypeptide in vaccines which are also comprised of the various adjuvants.

The polypeptides may be formulated into the vaccine as neutral or salt forms. Pharmaceutically acceptable salts include the acid additional salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may

also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

Many methods may be used to introduce the vaccine formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The patient to which the vaccine is administered is preferably a mammal, most preferably a human, but can also be a non-human animal including but not limited to cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats.

5.4 Preparation of Antibodies

Antibodies which specifically recognize a polypeptide of the invention, such as, but not limited to, polypeptides comprising the sequence of SEQ ID NO:2 or any of SEQ ID NOS: 34-2918, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, or CoV-HKU1 epitope, or antigen-binding fragments thereof, can be used for detecting, screening, and isolating the polypeptide of the invention or fragments thereof, or similar sequences that might encode similar enzymes from the other organisms. For example, in one specific embodiment, an antibody which immunospecifically binds CoV-HKU1 epitope, or a fragment thereof, can be used for various in vitro detection assays, including enzyme-linked immunosorbent assays (ELISA), radioimmunoassays, Western blot, etc., for the detection of a polypeptide of the invention or, preferably, CoV-HKU1, in samples, for example, a biological material, including cells, cell culture media (e.g., bacterial cell culture media, mammalian cell culture media, insect cell culture media, yeast cell culture media, etc.), blood, plasma, serum, tissues, sputum, nasopharyngeal aspirates, etc.

Antibodies specific for a polypeptide of the invention or any epitope of CoV-HKU1 may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest, for example, the CoV-HKU1 epitopes or polypeptides encoded by a nucleotide sequence of SEQ ID NO:1 or 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides shown in FIG. 2 (SEQ ID NOS: 34-1318), FIG. 3 (SEQ ID NOS:1319-2918), as well as SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236, can be produced by various procedures well known in the art. For example, an antigen can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc., to induce the production of antisera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyan-

ions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful adjuvants for humans such as BCG (Bacille Calmette-Guerin) and *Corynebacterium parvum*. Such adjuvants are also well known in the art (see Section 5.4, supra).

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, pp. 563-681 (Elsevier, N.Y., 1981) (both of which are incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized with an antigen of interest or a cell expressing such an antigen. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells. Hybridomas are selected and cloned by limiting dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding the antigen. Ascites fluid, which generally contains high levels of antibodies, can be generated by inoculating mice intraperitoneally with positive hybridoma clones.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the complete light chain, and the variable region, the CH1 region and the hinge region of the heavy chain.

The antibodies of the invention or fragments thereof can be also produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

The nucleotide sequence encoding an antibody may be obtained from any information available to those skilled in the art (i.e., from Genbank, the literature, or by routine cloning and sequence analysis). If a clone containing a nucleic acid encoding a particular antibody or an epitope-binding fragment thereof is not available, but the sequence of the antibody molecule or epitope-binding fragment thereof is known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+RNA, isolated from any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified

nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

Once the nucleotide sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., supra; and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence by, for example, introducing amino acid substitutions, deletions, and/or insertions into the epitope-binding domain regions of the antibodies or any portion of antibodies which may enhance or reduce biological activities of the antibodies.

Recombinant expression of an antibody requires construction of an expression vector containing a nucleotide sequence that encodes the antibody. Once a nucleotide sequence encoding an antibody molecule or a heavy or light chain of an antibody, or portion thereof has been obtained, the vector for the production of the antibody molecule may be produced by recombinant DNA technology using techniques well known in the art as discussed in the previous sections. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The nucleotide sequence encoding the heavy-chain variable region, light-chain variable region, both the heavy-chain and light-chain variable regions, an epitope-binding fragment of the heavy- and/or light-chain variable region, or one or more complementarity determining regions (CDRs) of an antibody may be cloned into such a vector for expression. Thus-prepared expression vector can be then introduced into appropriate host cells for the expression of the antibody. Accordingly, the invention includes host cells containing a polynucleotide encoding an antibody specific for the polypeptides of the invention or fragments thereof.

The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides or different selectable markers to ensure maintenance of both plasmids. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature*, 322:52, 1986; and Kohler, *Proc. Natl. Acad. Sci. USA*, 77:2 197, 1980). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

In another embodiment, antibodies can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing

an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods*, 182:41-50, 1995; Ames et al., *J. Immunol. Methods*, 184:177-186, 1995; Kettleborough et al., *Eur. J. Immunol.*, 24:952-958, 1994; Persic et al., *Gene*, 187:9-18, 1997; Burton et al., *Advances in Immunology*, 57:191-280, 1994; PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques*, 12(6):864-869, 1992; and Sawai et al., *AJRI*, 34:26-34, 1995; and Better et al., *Science*, 240:1041-1043, 1988 (each of which is incorporated by reference in its entirety). Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Pat. Nos. 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology*, 203:46-88, 1991; Shu et al., *PNAS*, 90:7995-7999, 1993; and Skerra et al., *Science*, 240:1038-1040, 1988.

Once an antibody molecule of the invention has been produced by any methods described above, it may then be purified by any method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A or Protein G purification, and sizing column chromatography), centrifugation, differential solubility, or by any other standard techniques for the purification of proteins. Further, the antibodies of the present invention or fragments thereof may be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.

For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a constant region derived from a human immunoglobulin. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science*, 229:1202, 1985; Oi et al., *BioTechniques*, 4:214 1986; Gillies et al., *J. Immunol. Methods*, 125:191-202, 1989; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human

species that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g., Queen et al., U.S. Pat. No. 5,585,089; Riechmann et al., *Nature*, 332:323, 1988, which are incorporated herein by reference in their entirety. Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101 and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, *Molecular Immunology*, 28(4/5):489-498, 1991; Studnicka et al., *Protein Engineering*, 7(6):805-814, 1994; Roguska et al., *Proc Natl. Acad. Sci. USA*, 91:969-973, 1994), and chain shuffling (U.S. Pat. No. 5,565,332), all of which are hereby incorporated by reference in their entirety.

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For an overview of this technology for producing human antibodies, see Lonberg and Huszar, *Int. Rev. Immunol.*, 13:65-93, 1995. For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Fremont, Calif.), Medarex (NJ) and Genpharm (San Jose, Calif.) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespersen et al., *Bio/technology*, 12:899-903, 1988).

Antibodies fused or conjugated to heterologous polypeptides may be used in in vitro immunoassays and in purification methods (e.g., affinity chromatography) well known in the art. See e.g., PCT publication Number WO 93/21232; EP 439,095; Naramura et al., *Immunol. Lett.*, 39:91-99, 1994; U.S. Pat. No. 5,474,981; Gillies et al., *PNAS*,

89:1428-1432, 1992; and Fell et al., *J. Immunol.*, 146:2446-2452, 1991, which are incorporated herein by reference in their entireties.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the polypeptides of the invention or fragments, derivatives, analogs, or variants thereof, or similar molecules having the similar enzymatic activities as the polypeptide of the invention. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

5.5 Pharmaceutical Compositions and Kits

The present invention encompasses pharmaceutical compositions comprising anti-viral agents of the present invention. In a specific embodiment, the anti-viral agent is an antibody which immunospecifically binds CoV-HKU1 or variants thereof, or any proteins derived therefrom. In another specific embodiment, the anti-viral agent is a polypeptide or nucleic acid molecule of the invention. The pharmaceutical compositions have utility as an anti-viral prophylactic agent and may be administered to a subject where the subject has been exposed or is expected to be exposed to a virus.

Various delivery systems are known and can be used to administer the pharmaceutical composition of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the mutant viruses, receptor mediated endocytosis (see, e.g., Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432). Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In a preferred embodiment, it may be desirable to introduce the pharmaceutical compositions of the invention into the lungs by any suitable route. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, by means of nasal spray, or by means of an implant, said implant being of a porous, non porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) infected tissues.

In another embodiment, the pharmaceutical composition can be delivered in a vesicle, in particular a liposome (see Langer, 1990, *Science* 249:1527-1533; Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*).

In yet another embodiment, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, *supra*;

Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:201; Buchwald et al., 1980, *Surgery* 88:507; and Saudek et al., 1989, *N. Engl. J. Med.* 321:574). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Press., Boca Raton, Fla. (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., 1985, *Science* 228:190; During et al., 1989, *Ann. Neurol.* 25:351; Howard et al., 1989, *J. Neurosurg.* 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the composition's target, i.e., the lung, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of recombinant or chimeric CoV-HKU1, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical composition is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E. W. Martin. The formulation should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an

infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The pharmaceutical compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2 ethylamino ethanol, histidine, procaine, etc.

The amount of the pharmaceutical composition of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose response curves derived from in vitro or animal model test systems.

Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In a preferred embodiment, the kit contains an antiviral agent of the invention, e.g., an antibody specific for the polypeptides encoded by a nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966 or any CoV-HKU1 epitope, or a polypeptide or protein of the present invention, including those shown in FIG. 2 (SEQ ID NOS:34-1318), FIG. 3 (SEQ ID NOS:1319-2918), FIG. 9 (SEQ ID NOS:2970-4236) and SEQ ID NO:2, or a nucleic acid molecule of the invention, alone or in combination with adjuvants, antivirals, antibiotics, analgesic, bronchodilators, or other pharmaceutically acceptable excipients.

The present invention further encompasses kits comprising a container containing a pharmaceutical composition of the present invention and instructions for use.

5.6 Detection Assays

The present invention provides a method for detecting an antibody, which immunospecifically binds to the CoV-HKU1, in a biological sample, for example blood, serum, plasma, saliva, urine, etc., from a patient suffering from respiratory tract infection. In a specific embodiment, the method comprising contacting the sample with the polypep-

ptides or protein encoded by the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, including the polypeptides having the amino acid sequences of SEQ ID NOS:34-1318 shown in FIG. 2, SEQ ID NOS:1319-2918 shown in FIG. 3, or SEQ ID NO:2, 2921, 2923, 2925, 2927, 2929, 2931, 2933, 2935, 2937, 2939, 2941, 2943, 2945, 2947, 2949, 2951, 2953, 2955, 2957, 2959, 2961, 2963, 2965, 2967, and/or 2970-4236 shown in FIG. 9, directly immobilized on a substrate and detecting the virus-bound antibody directly or indirectly by a labeled heterologous anti-isotype antibody. In another specific embodiment, the sample is contacted with a host cell comprising a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, and expressing the polypeptides encoded thereby, and the bound antibody can be detected by immunofluorescent assay.

An exemplary method for detecting the presence or absence of a polypeptide or nucleic acid of the invention in a biological sample involves obtaining a biological sample from various sources and contacting the sample with a compound or an agent capable of detecting an epitope or nucleic acid (e.g., mRNA, genomic RNA) of CoV-HKU1 such that the presence of CoV-HKU1 is detected in the sample. A preferred agent for detecting CoV-HKU1 mRNA or genomic RNA of the invention is a labeled nucleic acid probe capable of hybridizing to mRNA or genomic RNA encoding a polypeptide of the invention. The nucleic acid probe can be, for example, a nucleic acid molecule comprising or consisting of the nucleotide sequence of SEQ ID NO:1, 3, 2919, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966, or a portion thereof, or a complement thereof, such as an oligonucleotide of at least 15, 20, 25, 30, 50, 100, 250, 500, 750, 1,000 or more contiguous nucleotides in length and sufficient to specifically hybridize under stringent conditions to a CoV-HKU1 mRNA or genomic RNA.

In another preferred specific embodiment, the presence of CoV-HKU1 is detected in the sample by an reverse transcription polymerase chain reaction (RT-PCR) using the primers that are constructed based on a partial nucleotide sequence of the genome of CoV-HKU1 or a genomic nucleic acid sequence of SEQ ID NO:3 or 2919, or based on a nucleotide sequence of SEQ ID NO:1, 2920, 2922, 2924, 2926, 2928, 2930, 2932, 2934, 2936, 2938, 2940, 2942, 2944, 2946, 2948, 2950, 2952, 2954, 2956, 2958, 2960, 2962, 2964 and/or 2966. In a non-limiting specific embodiment, preferred primers to be used in a RT-PCR method are: 5'-GGTTGGGACTATCCTAAAGTGTGA-3' (SEQ ID NO:4) and 5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5), or 5'-AAAGGATGTTGACAACCCTGTT-3' (LPW1926; SEQ ID NO: 2968) and 5'-ATCATCATAC-TAAAATGCTTACA-3' (LPW1927; SEQ ID NO: 2969), in the presence of 3 mM MgCl₂ and the thermal cycles are, for example, but not limited to, 94° C. for 8 min followed by 40 cycles of 94° C. for 1 min, 50° C. for 1 min, 72° C. for 1 min. In more preferred specific embodiment, the present invention provides a real-time quantitative PCR assay to detect the presence of CoV-HKU1 in a biological sample by subjecting the cDNA obtained by reverse transcription of the extracted total RNA from the sample to PCR reactions using the specific primers, such as those having nucleotide

sequences of SEQ ID NOS:4, 5, 2968 and 2969, and a fluorescence dye, such as SYBR® Green I, which fluoresces when bound non-specifically to double-stranded DNA. The fluorescence signals from these reactions are captured at the end of extension steps as PCR product is generated over a range of the thermal cycles, thereby allowing the quantitative determination of the viral load in the sample based on an amplification plot.

A preferred agent for detecting CoV-HKU1 is an antibody that specifically binds a polypeptide of the invention or any CoV-HKU1 epitope, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used.

The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The detection method of the invention can be used to detect mRNA, protein (or any epitope), or genomic RNA in a sample in vitro as well as in vivo. For example, in vitro techniques for detection of mRNA include northern hybridizations, in situ hybridizations, RT-PCR, and RNase protection. In vitro techniques for detection of an epitope of CoV-HKU1 include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of genomic RNA include northern hybridizations, RT-PCR, and RNase protection. Furthermore, in vivo techniques for detection of CoV-HKU1 include introducing into a subject organism a labeled antibody directed against the polypeptide. For example, the antibody can be labeled with a radioactive marker whose presence and location in the subject organism can be detected by standard imaging techniques, including autoradiography.

In a specific embodiment, the methods further involve obtaining a control sample from a control subject, contacting the control sample with a compound or agent capable of detecting CoV-HKU1, e.g., a polypeptide of the invention or mRNA or genomic RNA encoding a polypeptide of the invention, such that the presence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide is detected in the sample, and comparing the absence of CoV-HKU1 or the polypeptide or mRNA or genomic RNA encoding the polypeptide in the control sample with the presence of CoV-HKU1, or the polypeptide or mRNA or genomic DNA encoding the polypeptide in the test sample.

The invention also encompasses kits for detecting the presence of CoV-HKU1 or a polypeptide or nucleic acid of the invention in a test sample. The kit, for example, can comprise a labeled compound or agent capable of detecting CoV-HKU1 or the polypeptide or a nucleic acid molecule encoding the polypeptide in a test sample and, in certain embodiments, a means for determining the amount of the polypeptide or mRNA in the sample (e.g., an antibody which binds the polypeptide or an oligonucleotide probe which binds to DNA or mRNA encoding the polypeptide). Kits can also include instructions for use.

For antibody-based kits, the kit can comprise, for example: (1) a first antibody (e.g., attached to a solid

support) which binds to a polypeptide of the invention or CoV-HKU1 epitope; and, optionally, (2) a second, different antibody which binds to either the polypeptide or the first antibody and is conjugated to a detectable agent.

For oligonucleotide-based kits, the kit can comprise, for example: (1) an oligonucleotide, e.g., a detectably labeled oligonucleotide, which hybridizes to a nucleic acid sequence encoding a polypeptide of the invention or to a sequence within the CoV-HKU1 genome or (2) a pair of primers useful for amplifying a nucleic acid molecule containing a CoV-HKU1 sequence. The kit can also comprise, e.g., a buffering agent, a preservative, or a protein stabilizing agent. The kit can also comprise components necessary for detecting the detectable agent (e.g., an enzyme or a substrate). The kit can also contain a control sample or a series of control samples which can be assayed and compared to the test sample contained. Each component of the kit is usually enclosed within an individual container and all of the various containers are within a single package along with instructions for use.

6. EXAMPLES

The following examples illustrate the identification of the novel CoV-HKU1. These examples should not be construed as limiting.

METHODS AND RESULTS

As a general reference, Wiedbrauk D L & Johnston S L G. (Manual of Clinical Virology, Raven Press, New York, 1993) was used.

6.1 Example 1

6.1.1 Clinical Subject

The patient is an in-patient of the United Christian Hospital in Hong Kong. Nasopharyngeal aspirates were collected from the patient weekly from the first till the fifth week of the illness, stool and urine in the first and second week of the illness, and sera in the first, second, and fourth weeks of the illness.

6.1.2 Antibody Detection

To produce a fusion plasmid for protein purification, primers, 5'-TTTTCCTTTTTCGCGCCGCTTAAGCAACAGAGTCTTCTA-3' (SEQ ID NO:6) and 5'-CGGAATTCGATGCTTATACTCCCGGT-3'(SEQ ID NO:7) were used to amplify the gene encoding the N protein of the CoV-HKU1 by RT-PCR. The sequence coding for amino acid residues 1 to 441 of the N protein was amplified and cloned into the EcoRI and NotI sites of expression vector pET-28b (+) (Novagen, Madison, Wis., USA) in frame and downstream of the series of six histidine residues. The (His)₆-tagged (SEQ ID NO:27) recombinant N protein was expressed in *E. coli* and purified using the Ni²⁺-loaded HiTrap Chelating System (Amersham Pharmacia, USA) according to the manufacturer's instructions.

Western blot analysis was performed as follows: Two-hundred ng of purified (His)₆-tagged (SEQ ID NO:27) recombinant N protein of CoV-HKU1 were loaded into each well of a sodium dodecyl sulfate (SDS)—10% polyacrylamide gel and subsequently electroblotted onto a nitrocellulose membrane (Bio-Rad, Hercules, Calif., USA). The blot was cut into strips and the strips were incubated separately

with 1:2000 dilution of serum samples obtained during the first, second, and fourth weeks of the patient's illness. Serum samples of two healthy blood donors were used as controls. Antigen-antibody interaction was detected with an ECL fluorescence system (Amersham Life Science, Buckinghamshire, UK).

Several prominent immunoreactive bands were visible for serum samples collected during the second and fourth weeks of the patient's illness (FIG. 8, lanes 2 and 3). The sizes of the largest bands were about 53 kDa, consistent with the expected size of 52.8 kDa for the full-length (His)₆-tagged (SEQ ID NO:27) N protein, whereas the other bands were consistent with the degradation products of the (His)₆-tagged (SEQ ID NO:27) N protein. Only very faint bands were observed for serum samples obtained from the patient during the first week of the illness (FIG. 8, lane 1) and two healthy blood donors (FIG. 8, lanes 4 and 5).

ELISA was performed using the recombinant N protein of CoV-HKU1 prepared as described above. Each well of a Nunc immunoplate (Roskilde, Denmark) was coated with 20 ng of purified (His)₆-tagged (SEQ ID NO:27) recombinant N protein for 12 h and then blocked in phosphate-buffered saline with 2% bovine serum albumin. The serum samples obtained from the patient during the first, second, and fourth weeks of the illness were serially diluted and were added to the wells of the (His)₆-tagged (SEQ ID NO:27) recombinant N protein-coated plates in a total volume of 100 µl per well and incubated at 37° C. for 2 h. After washing with washing buffer five times, 100 µl per well of 1:4000 diluted horse radish peroxidase-conjugated goat anti-human IgG antibody (Zymed Laboratories Inc., South San Francisco, Calif., USA) were added to the wells and incubated at 37° C. for 1 h. After washing with washing buffer five times, 100 µl of diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at room temperature for 15 min. One hundred microliters of 0.3 M H₂SO₄ were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

Box titration was carried out with different dilutions of (His)₆-tagged (SEQ ID NO:27) recombinant N protein coating antigen and serum obtained from the fourth week of the patient's illness. The results identified 20 ng and 80 ng of purified (His)₆-tagged recombinant N protein per ELISA well as the ideal amount for plate coating and 1:1000 and 1:20 as the most optimal serum dilution for IgG and IgM detection, respectively.

To establish the baseline for the tests, serum samples (diluted at 1:1000 and 1:20 for IgG and IgM, respectively) from 100 healthy blood donors were tested in the CoV-HKU1 antibody ELISA. For the 100 sera from healthy blood donors, the mean ELISA OD₄₅₀ values for IgG and IgM detection were 0.178 and 0.224, with standard deviations of 0.070 and 0.117. Absorbance values of 0.387 and 0.576 were selected as the cutoff values (that equal the sum of the mean value from the healthy control and three times the standard deviation) for IgG and IgM, respectively. Using these cutoff values, the titers for IgG of the patient's serum samples obtained during the first, second, and fourth weeks of the illness were <1:1000, 1:2000, and 1:8000, respectively (FIG. 7), and those for IgM were 1:20, 1:40, and 1:80, respectively (data not shown).

6.1.3 RT-PCR and Real Time Quantitative PCR

RT-PCR Assay

An RT-PCR was developed to detect the CoV-HKU1 sequence from NPA samples. Total RNA from clinical samples was reverse transcribed using random hexamers and cDNA was amplified using primers 5'-GGTTGGGAC-TATCCTAAGTGTGA-3' (SEQ ID NO:4) and 5'-CCAT-CATCAGATAGAATCATCATA-3' (SEQ ID NO:5), which were constructed based on the RNA-dependent RNA polymerase-encoding sequence (SEQ ID NO:1) of the CoV-HKU1 in the presence of 2.5 mM MgCl₂ (94° C. for 8 min followed by 40 cycles of 94° C. for 1 min, 50° C. for 1 min, 72° C. for 1 min).

The summary of a typical RT-PCR protocol is as follows:

1. RNA Extraction

RNA from 140 µl of NPA samples was extracted by QIAquick® viral RNA extraction kit and was eluted in 50 µl of elution buffer.

2. Reverse Transcription

RNA	11.5 µl
0.1 M DTT	2 µl
5 × buffer	4 µl
10 mM dNTP	1 µl
Superscript II, 200 U/µl (Invitrogen)	1 µl
Random hexamers, 0.3 µg/µl	0.5 µl
Reaction condition	42° C., 50 min 94° C., 3 min 4° C.

3. PCR

cDNA generated by random primers was amplified in a 50 µl reaction as follows:

cDNA	2 µl
10 mM dNTP	0.5 µl
10 × buffer	5 µl
25 mM MgCl ₂	5 µl
25 µM Forward primer	0.5 µl
25 µM Reverse primer	0.5 µl
AmpliTaq Gold® polymerase, 5 U/µl (Applied Biosystems)	0.25 µl
Water	36.25 µl

Thermal-cycle condition: 95° C., 10 min, followed by 40 cycles of 95° C., 1 min; 50° C. 1 min; 72° C., 1 min.

4. Primer Sequences

Primers were designed based on the RNA-dependent RNA polymerase encoding sequence (SEQ ID NO:1) of the CoV-HKU1.

Forward primer:
5'-GGTTGGGACTATCCTAAGTGTGA-3' (SEQ ID NO: 4)

Reverse primer: and
5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO: 5)

Product size:
440 bps

Real-Time Quantitative PCR Assay

Total RNA from 140 µl of nasopharyngeal aspirate (NPA) was extracted by QIAamp® virus RNA mini kit (Qiagen) as instructed by the manufacturer. Ten µl of eluted RNA samples were reverse transcribed by 200 U of Superscript® II reverse transcriptase (Invitrogen) in a 20 µl reaction

mixture containing 0.15 µg of random hexamers, 10 mmol/L DTT, and 0.5 mmol/L dNTP, as instructed. Complementary DNA was then amplified in a SYBR® Green I fluorescence reaction (Roche, Ind.) mixtures. Briefly, 20 µl reaction

dent RNA polymerase (Pol), helicase (Hel), hemagglutinin-esterase (HE), spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses

TABLE 1

Coronaviruses ^a	Genome features		Pairwise amino acid identity (%)							
	Size (bases)	G + C content	3CL ^{pro}	Pol	Hel	HE	S	E	M	N
Group 1										
HCoV-229E	27317	0.38	45	54	55	—	31	26	35	28
PEDV	28033	0.42	44	56	55	—	30	34	37	37
PTGV	28586	0.38	45	57	57	—	32	34	37	27
CCoV	—	—	—	—	—	—	31	32	36	27
HCoV-NL63	27553	0.34	43	54	54	—	30	28	32	28
Group 2										
CoV-HKU1	29926	0.32	—	—	—	—	—	—	—	—
HCoV-OC43	30738	0.37	82	87	88	57	60	54	76	58
MHV	31357	0.42	85	90	89	50	61	57	84	68
BCoV	31028	0.37	84	88	88	56	61	55	76	57
SDAV	—	—	—	—	—	50	61	60	77	62
ECoV	—	—	—	—	—	53	61	56	78	59
PHEV	—	—	—	—	—	54	61	54	77	57
Group 3										
IBV	27608	0.38	41	60	57	—	32	28	38	27
SARS-CoV	29751	0.41	48	65	63	—	33	27	34	31

^aHCoV-229E, human coronavirus 229E; PEDV, porcine epidemic diarrhea virus; PTGV, porcine transmissible gastroenteritis virus; CCoV, canine enteric coronavirus; HCoV-NL63, human coronavirus NL63; HCoV-OC43, human coronavirus OC43; MHV, murine hepatitis virus; BCoV, bovine coronavirus; SDAV, rat sialodacryoadenitis coronavirus; ECoV, equine coronavirus NC99; PHEV, porcine hemagglutinating encephalomyelitis virus; IBV, infectious bronchitis virus; SARS-CoV, SARS coronavirus

mixtures containing 2 µl of cDNA, 3.5 mmol/L MgCl₂, 0.25 µmol/L of forward primer [5'-GGTTGGGACTATC-CTAAGTGTGA-3' (SEQ ID NO:4)] and 0.25 µmol/L reverse primer [5'-CCATCATCAGATAGAATCATCATA-3' (SEQ ID NO:5)] were thermal-cycled by a LightCycler® (Roche) with the PCR program, [95° C., 10 min followed by 50 cycles of 95° C., 10 min; 57° C., 5 sec; 72° C. 9 sec]. Plasmids containing the target sequence were used as positive controls. Fluorescence signals from these reactions were captured at the end of extension step in each cycle. To determine the specificity of the assay, PCR products (440 base pairs) were subjected to a melting curve analysis at the end of the assay (65° C. to 95° C., 0.1° C. per second) (data not shown).

The amount of CoV-HKU1 RNA in the nasopharyngeal aspirates was followed weekly. Quantitative RT-PCR showed that the amounts of CoV-HKU1 RNA were 8.5×10⁵ and 9.6×10⁶ copies per ml in two nasopharyngeal aspirates collected in the first week of the illness, 1.5×10⁵ copies per ml of NPA, respectively, at two time points collected in the second week of the illness, but CoV-HKU1 RNA was undetectable in the NPA collected in the third, fourth and fifth weeks of the illness (FIG. 7). CoV-HKU1 RNA was also undetectable in the urine and stool of the patient collected in the first and second weeks of the illness.

Discussion

The genome of CoV-HKU1 is a 29926-nucleotide long, polyadenylated RNA. The G+C content is 32%, which is the lowest among all known coronaviruses with genome sequences available, with a GC skew of 0.19. Table 1 shows comparison of genomic features of CoV-HKU1 and other coronaviruses and amino acid identities between the predicted chymotrypsin-like protease (3CL^{pro}), RNA depen-

The genome organization is the same as other coronaviruses, with the characteristic gene order 5'-replicase, S, E, M, N-3'. Both 5' and 3' ends contain short untranslated regions. The 5' end of the genome consists of a putative 5' leader sequence. A putative transcription regulatory sequences (TRS) motif, 5'-CUAAAC-3', was found at the 3' end of the leader sequence and precedes each translated ORF except ORF5 which encodes the putative E protein. Table 2 shows the putative transcription regulatory sequences in the genome of CoV-HKU1.

TABLE 2

Number of base up-stream of AUGORF		TRS sequence	SEQ ID NO.
-140	Leader	UUAAAUCUAAACUUUUUAA (127) AUG	8
-7	Hemagglutinin esterase	UUAAAUCUAAACU AUG	9
-6	Spike	UUAAAUCUAAAC AUG	10
-13	ORF 4	UUAAAUCUAAACUUUUUUU AUG	11
-9	Membrane	CUAAAUCUAAACAUU AUG	12
-13	Nucleocapsid	UUAAAUCUAAACUAAUAGG AUG	13

TABLE 2-continued

Number of base up-stream of AUG ORF	ORF	TRS sequence	SEQ ID NO.
-35	ORF 8	UUAAAUCUAAACUAAUUAGGAUGUCUUAU ACUCCCGGUCAU AUG	14

As in SDAV (Sialodacryoadenitis virus) and MHV (mouse hepatitis virus), ORF5 may share the same TRS with ORF 4, suggesting that the translation of the E protein is cap-independent, possibly via an internal ribosomal entry site. The 3' untranslated region contains a predicted pseudoknot structure 59-119 bp downstream of N gene. This pseudoknot structure is highly conserved among coronaviruses and plays a role in coronavirus RNA replication.

The coding potential of the CoV-HKU1 genome is shown in FIG. 4 and Table 3 and the phylogenetic analyses of the chymotrypsin-like protease (3CL^{pro}), replicase, helicase, haemagglutinin-esterase (HE), S, E, M and N, are shown in FIGS. 5A and 5B.

TABLE 3

ORFs	Start-end (base)	No. of bases	No. of amino acids	Frame	Candidate TRS
ORF 1a	206-13600	13395	4465	+2	—
ORF 1b	13600-21753	8154	2717	+1	—
HE (ORF 2)	21773-22933	1161	386	+2	Strong
S (ORF 3)	22942-27012	4071	1356	+1	Strong
ORF 4	27051-27380	330	109	+3	Strong
E (ORF 5)	27373-27621	249	82	+1	None
M (ORF 6)	27633-28304	672	223	+3	Strong
N (ORF 7)	28320-29645	1326	441	+3	Strong
ORF 8	28342-28959	618	205	+1	Strong

The replicase 1a ORF (bases 206-13600) and replicase 1b ORF (bases 13600-21753) occupy 21.5 kb of the CoV-HKU1 genome. Similar to other coronaviruses, a frame shift interrupts the protein-coding regions and separates the 1a and 1b ORFs. This ORF encodes a number of putative proteins, including papain-like protease (PLP) with two copies of the PLP domain, PLP1^{pro} and PLP2^{pro}, 3CL^{pro}, replicase, helicase, and other proteins of unknown functions. These proteins are produced by proteolytic cleavages of a large polyprotein (FIG. 4). The sequence of the resulting putative proteins is the same as that in the MHV genome. This polyprotein is synthesized by a -1 ribosomal frameshift at a conserved site (UUUAAAC) upstream of a pseudoknot structure at the junction of ORF 1 a and ORF 1b. This ribosomal frameshift would result in a polyprotein of 7182 amino acids, which has 75-77% amino acid identities with the polyprotein in other Group 2 coronaviruses and 43-47% amino acid identities with the polyprotein in other non-Group 2 coronaviruses. The replicase gene of CoV-HKU1, which encodes 928 amino acids, has 87-89% amino acid identities with the replicase of other Group 2 coronaviruses and 54-65% amino acid identities with the replicase of other non-Group 2 coronaviruses (Table 4 and FIG. 5A). Table 4 shows amino acid identities between the predicted chymotrypsin-like protease (3CL^{pro}), replicase (Rep), helicase (Hel), haemagglutinin-esterase (HE), spike (S), envelope (E),

membrane (M), and nucleocapsid (N) proteins of CoV-HKU1 and the corresponding proteins of other coronaviruses.

TABLE 4

Group	Virus	Pairwise amino acid identity (%)							
		3CL ^{pro}	Rep	Hel	HE	S	E	M	N
1	HCoV-229E	45	54	55	—	31	26	35	28
	PEDV	44	56	55	—	30	34	37	37
	PTGV	45	57	57	—	32	34	37	27
	CCoV	—	—	—	—	31	32	36	27
	HCoV-NL63	43	54	54	—	30	28	32	28
2	HCoV-OC43	82	87	88	57	60	54	76	58
	MHV	85	89	87	50	58	55	78	60
	BCoV	84	88	88	56	61	55	76	57
	SDAV	—	—	—	50	61	60	77	62
	ECoV	—	—	—	53	61	56	78	59
3	PHEV	—	—	—	54	61	54	77	57
	IBV	41	60	57	—	32	28	38	27
	SARS-CoV	48	65	63	—	33	27	34	31
	SARS-CoV	48	65	63	—	33	27	34	31
	SARS-CoV	48	65	63	—	33	27	34	31

HCoV-229E = human coronavirus 229E;
 PEDV = porcine epidemic diarrhea virus;
 PTGV = porcine transmissible gastroenteritis virus;
 CCoV = canine enteric coronavirus;
 HCoV-NL63 = human coronavirus NL63;
 HCoV-OC43 = human coronavirus OC43;
 MHV = murine hepatitis virus;
 BCoV = bovine coronavirus;
 SDAV = rat sialodacryoadenitis coronavirus;
 ECoV = equine coronavirus NC99;
 PHEV = porcine hemagglutinating encephalomyelitis virus;
 IBV = infectious bronchitis virus;
 SARS-CoV = SARS coronavirus

The catalytic histidine and cysteine amino acid residues, conserved among the 3CL^{pro} in all coronaviruses, are present in the predicted 3CL^{pro} of CoV-HKU1 (amino acids His³³⁷⁵ and Cys³⁴⁷⁹ of ORF 1a). In the N-terminal of the putative PLP (amino acid residues 945 to 1104 of ORF 1a), there are 14 tandem copies of a 30-base repeat, which encode NDDEDVVTGD (SEQ ID NO:15), followed by two 30-base regions that encode NNDEEIVTGD (SEQ ID NO:16) and NDDQIVVTGD (SEQ ID NO:17), located upstream to the first copy of PLP domain, PLP1^{pro}. This repeat is not observed in other coronaviruses.

ORF 2 (bases 21773-22933) encodes the predicted HE glycoprotein with 386 amino acids. The HE protein of CoV-HKU1 has 50-57% amino acid identities with the HE proteins of other Group 2 coronaviruses (Table 4 and FIG. 5A). PFAM and InterProScan analyses of the ORF show that amino acid residues 1 to 349 of the predicted protein is a member of the haemagglutinin esterase family (PFAM accession no.: PF03996 and INTERPRO accession no. IPR007142). This family contains membrane glycoproteins that are present on viral surface and are involved with the cell infection process. It contains haemagglutinin chain 1 (HE1) and haemagglutinin chain 2 (HE2), and forms a homotrimer with each monomer being formed by two chains linked by a disulphide bond. Furthermore, PFAM and InterProScan analyses of the ORF show that amino acid residues 122 to 236 of the predicted protein are the haemagglutinin domain of HE-fusion glycoprotein family (PFAM accession no.: PF02710 and INTERPRO accession no. IPR003860). HE is also present in other Group 2 coronaviruses and influenza C virus. SignalP analysis reveals a signal peptide probability of 0.738, with a cleavage site between residues 13 and 14. Although TMpred and TMHMM analyses of the ORF show four and three transmembrane domains, respectively, PHDhtm analysis of the ORF shows only one trans-

membrane domain at positions 354 to 376. This concurs with only one transmembrane region reported in the C terminal of the HE of BCoV (bovine coronavirus) and puffinosis virus. PrositeScan analysis of the HE protein of CoV-HKU1 reveals eight potential N-linked glycosylation (six NXS and two NXT) sites. These are located at positions 83 (NYT), 110, (NGS), 145 (NVS), 168 (NYS), 193 (NFS), 286 (NSS), 314 (NVS), and 328 (NFT). The putative active site for neuraminate O-acetyl-esterase activity, FGDS (SEQ ID NO:18), is located at positions 31-34.

ORF 3 (bases 22942-27012) encodes the predicted S glycoprotein (PFAM accession no. PF01601) with 1356 amino acids. The S protein of CoV-HKU1 has 58-61% amino acid identities with the S proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the S proteins of Group 1, Group 3, and SARS-CoV (Table 4 and FIG. 5B). InterProScan analysis predicts it as a type I membrane glycoprotein. Important features of the S protein of CoV-HKU1 are depicted in FIG. 6. PrositeScan of the S protein of CoV-HKU1 reveals 28 potential N-linked glycosylation (12 NXS and 16 NXT) sites. SignalP analysis reveals a signal peptide probability of 0.909, with a cleavage site between residues 13 and 14. By multiple alignments with the S proteins of other Group 2 coronaviruses, a potential cleavage site located after RRKRR (SEQ ID NO:19), between residues 760 and 761, where S will be cleaved into S1 and S2, is identified. Immediately upstream to RRKRR (SEQ ID NO:19), there is a series of five serine residues that are not present in any other known coronaviruses (FIG. 6). Most of the S protein (residues 15 to 1300) is exposed on the outside of the virus, with a transmembrane domain at the C terminus (TMHMM analysis of the ORF shows one transmembrane domain at positions 1301 to 1356), followed by a cytoplasmic tail rich in cysteine residues. Two heptad repeats (HR), located at residues 982 to 1083 (HR1) and 1250 to 1297 (HR2), identified by multiple alignments with other coronaviruses, are present. In MHV, it has been confirmed that the receptor for its S protein binding is CEACAMI, a member of the carcinoembryonic antigen (CEA) family of glycoproteins in the immunoglobulin superfamily. Furthermore, it has been shown, by site-directed mutagenesis, that three conserved regions (sites I, II, and III) and some amino acid residues (Thr⁶², Thr¹²¹, Tyr²¹⁴, and Tyr²¹⁶ in MHV) in the N-terminal of the S protein are particularly important for its receptor-binding activity. By multiple alignments with the N-terminal 330 amino acids of the S protein of MHV and other group 2 coronaviruses, it is observed that these conserved regions and amino acids are present in CoV-HKU1 (FIG. 6). This infers that the receptor for CoV-HKU1 could be a member of the CEA family on the surface of the cells in the respiratory tract. On the other hand, for HCoV-OC43, it has been shown in vitro that the receptor for the S protein is a sialic acid. However, the amino acid residues on the S protein of HCoV-OC43 that are important for receptor binding are not well defined.

ORF 4 (bases 27051-27380) encodes a predicted protein with 109 amino acids. This ORF overlaps with the ORF that encodes the E protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus non-structural protein NS2 family (PFAM accession no.: PF04753). TMpred and TMHMM analysis do not reveal any transmembrane helix. This predicted protein of CoV-HKU1 has 44-51% amino acid identities with the corresponding proteins of other Group 2 coronaviruses.

ORF 5 (bases 27373-27621) encodes the predicted E protein with 82 amino acids. The E protein of CoV-HKU1

has 54-60% amino acid identities with the E proteins of other Group 2 coronaviruses, but has fewer than 35% amino acid identities with the E proteins of Group 1, Group 3, and SARS-CoV (Table 4 and FIG. 5B). PFAM and InterProScan analyses of the ORF show that the predicted E protein is a member of the non-structural protein NS3/Small envelope protein E (NS3_envE) family (PFAM accession no.: PF02723). SignalP analysis predicts the presence of a transmembrane anchor (probability 0.995). TMpred analysis of the ORF shows two transmembrane domains at positions 16 to 34 and 39 to 59, and TMHMM analysis of the ORF shows two transmembrane domains at positions 10 to 32 and 39 to 58, consistent with the anticipated association of the E protein with the viral envelope. Both programs predict that both the N and C termini are located on the surface of the virus.

ORF 6 (bases 27633-28304) encodes the predicted M protein with 223 amino acids. The M protein of CoV-HKU1 has 76-78% amino acid identities with the M proteins of other Group 2 coronavirus, but has fewer than 40% amino acid identities with the M proteins of Group 1, Group 3, and SARS-CoV (Table 4 and FIG. 5B). PFAM analysis of the ORF shows that the predicted M protein is a member of the coronavirus matrix glycoprotein (Corona_M) family (PFAM accession no.: PF01635). SignalP analysis predicts the presence of a transmembrane anchor (probability 0.926). TMpred analysis of the ORF shows three transmembrane domains at positions 21 to 42, 53 to 74, and 77 to 98. TMHMM analysis of the ORF shows three transmembrane domains at positions 20 to 39, 46 to 68, and 78 to 100. The N terminal 19-20 amino acids are located on the outside and the C terminal 123-125-amino acid hydrophilic domain on the inside of the virus.

ORF 7 (bases 28320-29645) encodes the predicted N protein (PFAM accession no.: PF00937) with 441 amino acids. The N protein of CoV-HKU1 has 57-62% amino acid identities with the N proteins of other Group 2 coronaviruses, but has fewer than 40% amino acid identities with the N proteins of Group 1, Group 3, and SARS-CoV (Table 4 and FIG. 5B).

ORF 8 (bases 28342-28959) encodes a hypothetical protein (N2) of 205 amino acids within the ORF that encodes the predicted N protein. PFAM analysis of the ORF shows that the predicted protein is a member of the coronavirus nucleocapsid I protein (Corona_I) family (PFAM accession no.: PF03187). This hypothetical N2 protein of CoV-HKU1 has 32-39% amino acid identities with the N2 proteins of other Group 2 coronaviruses.

We report the characterization and complete genome sequence of a novel coronavirus detected in the nasopharyngeal aspirates of patients with pneumonia. The clinical significance of the virus in the first patient was evident by the high viral loads in the patient's nasopharyngeal aspirates during the first week of his illness, which coincided with the acute symptoms developed in the patient. The viral load decreased during the second week of the illness and was undetectable in the third week of the illness. In addition, the fall in viral load was accompanied by the recovery from the illness and development of specific antibody response to the recombinant N protein of the virus. Similar to other recently discovered viruses, such as hepatitis C virus, GB virus C, transfusion transmitted virus, and SEN virus, the present virus could not be recovered from cell cultures using the standard cell lines. This could be related to the inherently low recovery rate of coronaviruses. Human coronaviruses are particularly difficult to culture in vitro. Many decades after the recognition of HCoV-229E and HCoV-OC43, there

are still only a handful of primary virus isolates available and organ culture is required for primary isolation of HCoV-OC43. In our experience, SARS-CoV can only be recovered from less than 20% of patients with serologically and RT-PCR documented SARS-CoV pneumonia. Therefore, it is not surprising that the new coronavirus CoV-HKU1 has been so far proven difficult to culture in vitro. After the discovery of CoV-HKU1 in the first patient, we conducted a preliminary study on 400 nasopharyngeal aspirates that were collected last year during the SARS epidemic period. Among these 400 nasopharyngeal aspirates, CoV-HKU1 was detected in one specimen, with a viral load comparable to that of the first patient. These results have suggested that CoV-HKU1 is not only incidentally found in one patient, but a previously unrecognized coronavirus associated with pneumonia.

Genomic analysis has reveals that CoV-HKU1 is a Group 2 coronavirus. The genome organization of CoV-HKU1 concurs with those of other coronaviruses, with the characteristic gene order, i.e., 5'-replicase, S, E, M, N-3', short untranslated regions in both 5' and 3' ends, 5' conserved coronavirus core leader sequence, putative TRS upstream to multiple ORFs, and conserved pseudoknot in the 3' untranslated region. In contrast to coronaviruses of other groups, CoV-HKU1 contains certain features that are characteristics of Group 2 coronaviruses, including the presence of HE, ORF 4, and N2. Phylogenetic analysis of the 3CL^{pro}, replicase, helicase, S, E, M, and N proteins showed that these genes of CoV-HKU1 were clustered with the corresponding genes in other Group 2 coronaviruses. However, the proteins of CoV-HKU1 formed distinct branches in the phylogenetic trees, indicating that CoV-HKU1 is a distinct member of the group, and is not very closely related to any other known members of Group 2 coronaviruses (FIGS. 4A and 4B).

In addition to phylogenetic analysis of the putative proteins, CoV-HKU1 exhibits certain features that are distinct from other Group 2 coronaviruses. Compared to other Group 2 coronaviruses, there is a deletion of about 800 bps between the replicase ORF 1b and the HE ORF 2 in CoV-HKU1. In other Group 2 coronaviruses, including MHV, SDAV, HCoV-OC43 and BCoV, an ORF of 798-837 bp (273-278 amino acids) is present between the replicase 1b ORF and the HE ORF 2. This ORF encodes a protein of the coronavirus non-structural protein NS2a family (PFAM accession no.: PF05213). The absence of this ORF in CoV-HKU1 indicates that this is probably a non-essential gene of coronavirus. In addition to the deletion, the N-terminal of the putative PLP in ORF 1a contains 14 tandem copies of a 30-bp repeat that codes for a highly acidic domain. Similar repeats, with different amino acid compositions, have been found in the genomes of human, rat and parasites, but have not been found in other coronaviruses. The function of these repeats is not well understood, although some authors have suggested that the repeats could be important antigens, and their biological role may be related to their special three-dimensional structures. The vitellaria antigenic protein of *Clonorchis sinensis* contains 23 tandem copies of a 30-bp repeat that codes for DGGAQP-PKSG (SEQ ID NO:20). In the case of *Plasmodium falciparum*, it has been shown that the antigenicity of the circumsporozoite protein is due to its repeating epitope structure. It has also been suggested that the tandemly repeated peptide may induce strong humoral immune response in the infected host and thus may also be useful in serological diagnosis. Further experiments should be per-

formed to delineate the antigenic properties, biological role, and possible clinical usefulness of the repeat in the PLP of CoV-HKU1.

The geographical, political, and economic location of Hong Kong makes it a unique place for the study of emerging infectious disease. Hong Kong, as the gateway of southern China, with thousands of people crossing the border on surface and by air every day, has a high potential of importing and exporting infectious diseases to and from China, countries in Southeast Asia and from the rest of the world. In 1997, the first 18 human cases of avian influenza A H5N1 virus infection were reported in Hong Kong. In early 2003, two cases of human infection caused by avian influenza A (H5N1) that was acquired in Fujian, were diagnosed in Hong Kong, which provided an early warning of the impending disease threat for humans and poultry in Southeast Asia that followed in 2004. For the SARS epidemic, although both epidemiological and genomic evidence revealed that the disease had first occurred in southern China in November 2002, it did not receive as much international attention until the disease was spread to Hong Kong and through Hong Kong to Singapore, Toronto, Vietnam, and the United States of America. As for emerging bacterial infections, 50% of the patients with gastroenteritis associated with the recovery of *Laribacter hongkongensis* had recent history of travel to southern China. In this report, one of the patients also had recent history of travel to Shenzhen of China prior to the development of the respiratory illness. We speculate that he might have contacted the virus in Shenzhen. More intensive surveillance of emerging infectious pathogens in this locality is warranted.

6.2 Example 2

We prospectively collected nasopharyngeal aspirates (NPAs) from patients with community-acquired pneumonia during a 12-month period. A 453-bp fragment of the pol gene of CoV-HKU1 was amplified from the extracted RNA by RT-PCR using CoV-HKU1 specific primers. The epidemiological, clinical, laboratory and radiological features of patients with pneumonia associated with CoV-HKU1 were analyzed. Specific antibodies were detected using a recombinant CoV-HKU1 N protein based ELISA. The complete pol, S and N genes of the CoV-HKU1 were amplified and sequenced. RNA extracted from 208 nasopharyngeal swabs and fecal samples from 56 wild and domestic animals in Hong Kong and southern China were subject to RT-PCR of pol gene of CoV-HKU1 using CoV-HKU1 specific primers.

6.2.1 Patients and Microbiological Methods

All prospectively collected NPAs from patients with community-acquired pneumonia sent to the clinical microbiology laboratories of four regional hospitals in Hong Kong during a 12-month period [Mar. 22, 2003 (beginning of SARS epidemic in Hong Kong)—Mar. 21, 2004] for detection of SARS-CoV but negative for SARS-CoV RNA by RT-PCR were included in the study. Community-acquired pneumonia is defined as symptoms and signs consistent with an acute lower respiratory tract infection associated with new radiographic shadowing for which there is no other explanation that develop prior to or within 48 h after presentation to hospital. Once CoV-HKU1 was detected from NPAs, the hospital records, laboratory results and chest radiographs of the corresponding patients were retrieved and examined by two infectious disease physicians. The RNA extracted from the NPAs was subject to RT-PCR for influ-

enza A virus and human metapneumovirus (Peiris J S M et al., *Lancet* 2003; 361: 1319-25). Available stored serum samples were subject to serological assays for detection of antibodies against *Mycoplasma*, *Chlamydia*, *Legionella* and SARS-CoV by SERODIA-MYCO II (Fujirebio Inc., Tokyo, Japan), *Chlamydia pneumoniae* MIF IgG (Focus technologies, Cypress, Calif., USA), indirect immunofluorescence (MRL, San Diego, Calif., USA) and our recently developed enzyme-linked immunosorbent assay (ELISA), respectively (Woo P C Y et al., *Lancet* 2004; 363:841-5).

To determine the possible risk factors associated with CoV-HKU1 pneumonia, two age- and sex-matched controls per patient with CoV-HKU1 pneumonia were randomly selected from those with community-acquired pneumonia but their NPAs negative for CoV-HKU1. Controls were within five years older or younger than the corresponding patients with CoV-HKU1 pneumonia, and were admitted within 15 days before or after admission of the corresponding patients with CoV-HKU1 pneumonia. The hospital records, laboratory results and chest radiographs of the controls were retrieved and examined by the two infectious disease physicians.

6.2.2 RNA Extraction

Viral RNA was extracted from NPAs using QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions within 10 h upon receipt of specimens. The eluted RNA was used as the template for RT-PCR. All extracted RNA was stored immediately at -70°C . until use.

6.2.3 RT-PCR of RNA-Dependent RNA Polymerase Gene of Coronavirus-HKU1 Using Coronavirus-HKU1 Specific Primers and DNA Sequencing

A 453-bp fragment of the RNA dependent RNA polymerase (pol) gene of CoV-HKU1 was amplified by RT-PCR using CoV-HKU1 specific primers, 5'-AAAGGATGTTGACAACCCTGTT-3' (LPW1926; SEQ ID NO:2968) and 5'-ATCATCATACTAAAATGCTTACA-3' (LPW1927; SEQ ID NO:2969) designed by multiple alignment of the nucleotide sequences of the pol genes of the two CoV-HKU1 (Woo, P.C. et al., *J. of Virol.*, 2005, p. 884-895) and those of the available pol genes of other known human coronaviruses. RT was performed using the SuperScript II kit (Invitrogen, San Diego, Calif., USA) according to manufacturer's instructions. The PCR mixture (50 μl) contained cDNA, PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 3 mM MgCl_2 and 0.01% gelatin), 200 μM of each dNTPs and 1.0 U Taq polymerase (Boehringer Mannheim, Germany). The mixtures were amplified in 40 cycles of 94°C . for 1 min, 48°C . for 1 min and 72°C . for 1 min, and a final extension at 72°C . for 10 min in an automated thermal cycler (Perkin-Elmer Cetus, Gouda, The Netherlands). Distilled water was used as the negative control. To ensure the high specificity of the CoV-HKU1 specific primers, RNA extracted from 200 NPAs positive for influenza A and B viruses, parainfluenza viruses 1-3, respiratory syncytial virus (RSV), or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV were also subject to RT-PCR using the two CoV-HKU1 specific primers.

Ten microlitres of each amplified product was electrophoresed in 1.5% (w/v) agarose gel, with a molecular size marker (ΦX -174 DNA HaeIII digest, Boehringer Mannheim, Germany) in parallel. Electrophoresis in Tris-borate-

EDTA buffer was performed at 100 V for 1.5 h. The gel was stained with ethidium bromide (0.5 $\mu\text{g}/\text{ml}$) for 15 minutes, rinsed and photographed under ultraviolet light illumination.

The PCR products were gel-purified using the QIAquick gel extraction kit (QIAGEN, Hilden, Germany). Both strands of the PCR products were sequenced twice with an ABI Prism 3700 DNA Analyzer according to manufacturers' instructions (Applied Biosystems, Foster City, Calif., USA), using the two PCR primers. The sequences of the PCR products were compared with the sequences of the pol genes of the two CoV-HKU1 (Woo, P.C. et al., *J. of Virol.*, 2005, p. 884-895) and those of the pol genes of coronaviruses in the GenBank database.

6.2.4 ELISA Using Recombinant Nucleocapsid Protein of CoV-HKU1

The ELISA-based IgG and IgM antibody tests were performed according to our published protocol (Woo, P.C. et al., *J. of Virol.*, 2005, p. 884-895). Briefly, each well of a Nunc immunoplate (Roskilde, Denmark) was coated with purified (His)₆-tagged recombinant N protein (20 ng for IgG and 80 ng for IgM) for 1 h and then blocked in phosphate-buffered saline with 5% skim milk. The serum samples obtained from the patients during the acute and convalescent phase of the illness were serially diluted and were added to the wells of the (His)₆-tagged (SEQ ID NO: 27) recombinant N protein-coated plates in a total volume of 100 μl and incubated at 37°C . for 2 h. After washing with washing buffer five times, 100 μl of diluted horse radish peroxidase-conjugated goat anti-human IgG (1:4000) and mouse anti-human IgM (1:1000) antibodies (Zymed Laboratories Inc., South San Francisco, Calif., USA) were added to the wells and incubated at 37°C . for 1 h. After washing with washing buffer five times, 100 μl diluted 3,3',5,5'-tetramethylbenzidine (Zymed Laboratories Inc.) were added to each well and incubated at room temperature for 15 min. One hundred microlitres of 0.3 M H_2SO_4 were added and the absorbance at 450 nm of each well was measured. Each sample was tested in duplicate and the mean absorbance for each serum was calculated.

6.2.5 RT-PCR and Sequencing of the Complete RNA-Dependent RNA Polymerase, Spike and Nucleocapsid Genes of Coronavirus-HKU1 and Phylogenetic Analysis

The complete pol, spike (S) and N genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced using the RNA extracted from the NPAs as template. The RNA was converted to cDNA by a combined random-priming and oligo(dT) priming strategy. The cDNA was amplified by degenerate primers designed by multiple alignment of the regions encoding the pol, S and N genes in the genomes of the two CoV-HKU1 (Woo, P.C. et al., *J. of Virol.*, 2005, p. 884-895) and those of other group 2 coronaviruses and additional primers designed from the results of the first and subsequent rounds of sequencing. Sequences were assembled and manually edited to produce the complete sequences of the pol, S and N genes of CoV-HKU1 from different patients. The nucleotide and the deduced amino acid sequences of the pol, S and N genes were compared to those of the two CoV-HKU1 (Woo, P.C. et al., *J. of Virol.*, 2005, p. 884-895) and other group 2 coronaviruses. Phylogenetic tree construction was performed using PileUp method with GrowTree (Genetics Computer Group, Inc.).

6.2.6 Animal Surveillance

Two hundred and eight nasopharyngeal swabs and faecal samples from 56 wild and domestic animals [including Chinese ferret-badger (*Melogale moschata*), domestic cat (*Felis catus*), hog-badger (*Arctonyx collaris*), masked palm civet (*Paguma larvata*), racoon dog (*Nyctereutes procyonoides*), Chinese pygmy dormouse (*Typhlomys cinereus*), common pangolin (*Manis pentadactyla*), nutria (*Myocastor coypus*), dog (*Canis familiaris*), rabbit (Leporidae family), snake (Serpentes suborder) and bat (Microchiroptera suborder)] in Hong Kong and southern China (Guan Y, et al., *Science* 2003; 302: 276-8) were subjected to RNA extraction and RT-PCR of pol gene of CoV-HKU1 using the CoV-HKU1 specific primers (LPW1926; SEQ ID NO:2968 and LPW1927; SEQ ID NO:2969) and protocol described above.

6.2.7 Results

Clinical and Laboratory Characteristics

During the 12-month period, NPAs from 418 patients [male:female=198:220, age (mean±SD)=49±26] with community-acquired pneumonia, for detection of SARS-CoV but were negative for SARS-CoV RNA by RT-PCR, were identified in the four hospitals. A 453-bp fragment of the pol gene of CoV-HKU1 was amplified and sequenced in 10 (2.5%) patients. Sequence analysis revealed 0-2% nucleotide differences between the sequences of the fragments and the sequence of the pol gene of the CoV-HKU1 from the reported index patient (patient no. 5) described in Example 1 above (FIG. 11) (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895). In contrast, using our CoV-HKU1 specific primers, none of the 200 NPAs that were positive for influenza A and B viruses, parainfluenza viruses 1-3, RSV, or adenovirus antigens and RNA of HCoV-229E, HCoV-OC43, HCoV-NL63 and SARS-CoV, was RT-PCR positive.

The epidemiological, clinical and radiological characteristics of the 10 patients, including patient no. 5 (Woo, P C. et al., *J. of Virol.*, 2005, p. 884-895), with community-acquired pneumonia associated with CoV-HKU1 are summarized in Table 5. No epidemiological linkage was identified among the 10 cases. All cases occurred in either winter or spring (January-May). The median age was 71.5 (range: 13-96). Seven were males and three were females. Nine were Chinese and one was an Arabian. Eight had underlying diseases, and four had underlying diseases of the respiratory tract. Four had recent travel histories to southern China. Five were smokers. Clinically, the illness was not distinguishable from other community-acquired pneumonia. Fever, productive cough and dyspnoea were common presenting symptoms. Upper respiratory tract symptoms were present in only two patients (patient nos. 1 and 5). One patient (patient no. 7) had loose stool diarrhea. Oxygen saturation on room air upon admission was <95% in two. Airspace shadows were observed in the right lungs of six patients and the left lungs of six patients. The upper, middle and lower zones were affected in two, four and nine patients respectively. All patients, except patient no. 10, had normal platelet counts and normal liver and renal function tests. Bacterial or mycobacterial pathogens were not detected in any of the sputum samples from the patients. Direct antigen detection for influenza A and B viruses, parainfluenza viruses 1-3, RSV, adenovirus (Woo P C Y et al., *J Clin Microbiol* 1997; 35: 1579-81) and RT-PCR for influenza A virus and metapneumovirus, was negative in all NPAs. Antibodies against *M. pneumoniae*, *C. pneumoniae*, *C. psittaci*, *L. pneumophila* and SARS-CoV were negative in all the six patients (patient nos. 1, 4, 5, 6, 8 and 9) whose serum samples were available. All these six patients showed a four-fold change in IgG titer (patient nos. 4, 5 and 6) and/or the presence of IgM (patient nos. 1, 5, 8 and 9) against CoV-HKU1.

TABLE 5

Characteristics	Patient no.				
	1	2	3	4	5
Month/Year	Mar/03	Apr/03	May/03	Jan/04	Jan/04
Sex/Age	F/35	M/66	M/13	M/75	M/71
Ethnic origin	Chinese	Arabian	Chinese	Chinese	Chinese
Underlying diseases	-	Diabetes mellitus, old myocardial infarction, gastric lymphoma	Asthma, situs inversus, dextrocardia	Hypertension	Chronic obstructive airway disease, hyperlipidaemia, abdominal aortic aneurysm
History of travel within two weeks of disease onset	-	-	Shenzhen, China	Guangdong, China	Shenzhen, China
History of smoking	-	-	-	+	+
Clinical features					
Fever	+	-	+	-	+
Chills	-	-	-	-	+
Rigor	-	-	-	-	-
Myalgia	-	-	-	-	-
Headache	-	-	-	-	+
Cough	+	-	+	+	+
Sputum	-	-	+	+	+

TABLE 5-continued

production					
Dyspnoea	-	+	-	+	-
Pleurisy	-	-	-	-	-
Rhinorrhoea	-	-	-	-	+
Sore throat	+	-	-	-	+
Oxygen saturation on room air (%)	99	83	100	99	99
Chest radiograph features	RLZ airspace shadows	Bilateral airspace shadows	LMZ and LLZ airspace shadows	LLZ airspace shadows	LLZ airspace shadows
Outcome	Survived	Died	Survived	Survived	Survived
Duration of hospitalization (no. of days)	2	Died on day 12	3	7	5
Patient no.					
Characteristics	6	7	8	9	10
Month/Year	Jan/04	Jan/04	Jan/04	Mar/04	Mar/04
Sex/Age	F/96	M/78	M/68	F/83	M/72
Ethnic origin	Chinese	Chinese	Chinese	Chinese	Chinese
Underlying diseases	Hypertension	Chronic obstructive airway disease, diabetes mellitus	-	Chronic obstructive airway disease, parathyroid adenoma, dementia	Prostate carcinoma, cerebrovascular accident, diabetes mellitus
History of travel within two weeks of disease onset	-	-	Guangdong, China	-	-
History of smoking	-	+	-	+	+
Clinical features					
Fever	+	+	+	+	+
Chills	-	-	-	-	-
Rigor	-	-	-	-	-
Myalgia	-	-	-	-	-
Headache	-	-	-	-	-
Cough	-	+	+	-	+
Sputum production	-	+	+	-	+
Dyspnoea	-	+	+	+	+
Pleurisy	-	-	-	-	-
Rhinorrhoea	-	-	-	-	-
Sore throat	-	-	-	-	-
Oxygen saturation on room air (%)	97	97	95	99	88
Chest radiograph features	RLZ airspace shadows	LLZ airspace shadows	RMZ airspace shadows	RLZ airspace shadows	Bilateral airspace shadows
Outcome	Survived	Survived	Survived	Survived	Died
Duration of hospitalization (no. of days)	7	13	5	6	Died on day 6

+ = present;
 - = absent;
 RUZ = right upper zone;
 LUZ = left upper zone;
 RMZ = right middle zone;
 LMZ = left middle zone;
 RLZ = right lower zone;
 LLZ = left lower zone

In comparison with age- and sex-matched controls with non-CoV-HKU1 pneumonia, no epidemiological, clinical, haematological, serum biochemical and radiological risk factors were identified in patients with CoV-HKU1 pneumonia (Table 6).

TABLE 6

Characteristics	Pneumonia*		P value
	CoV-HKU1 (n = 10)	Non-CoV-HKU1 (n = 20)	
<u>Underlying diseases</u>			
Underlying diseases	8	12	0.42
History of travel within two weeks of disease onset	4	6	0.69
History of smoking	5	7	0.46
<u>Clinical features</u>			
Fever	8	14	0.68
Cough	7	17	0.37
Sputum production	6	12	1.00
Dyspnoea	6	6	0.12
Rhinorrhoea	1	2	1.00
Sore throat	2	2	0.58
<u>Haematological features</u>			
Haemoglobin (g/dl)	12.4	13.2	0.27
Leukocyte count ($\times 10^9/l$)	9.9	9.7	0.95
Neutrophil count ($\times 10^9/l$)	7.35	7.4	0.71
Lymphocyte count ($\times 10^9/l$)	0.95	1.02	0.48
Monocyte count ($\times 10^9/l$)	0.55	0.65	0.35
Platelet count ($\times 10^9/l$)	240	292	0.20
<u>Serum biochemical features</u>			
Sodium (mmol/l)	136	137	0.59
Potassium (mmol/l)	3.9	4.0	0.42
Creatinine ($\mu\text{mol/l}$)	92	76.5	0.06
Urea (mmol/l)	5.25	4.9	0.62
Albumin (g/l)	37	38	0.59
Globulin (g/l)	36.5	30	0.07
Bilirubin ($\mu\text{mol/l}$)	12	10	1.00
ALT (U/l)	20	17	0.42
Alkaline phosphatase (U/l)	102	91	0.95
Oxygen saturation on room air (%)	96	98	0.86
<u>Radiological features</u>			
Bilateral involvement	2	5	1.00
No. of zones involved	1	1	0.81
Mortality	2	0	0.10

*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.

Two of the 10 patients died of CoV-HKU1 pneumonia. The first patient (patient no. 2) was a 66-year old man who presented with dyspnoea for one day. He had type 2 diabetes mellitus, old myocardial infarction and gastric lymphoma with total gastrectomy in 2002 and was put on chemotherapy. He had severe lymphopenia ($0.2 \times 10^9/L$) and an oxygen saturation of only 83% on admission. Chest radiograph revealed patchy airspace shadows in both lungs with predominant involvement of the lower zones (FIG. 12A). He died 11 days after admission. The other patient (patient no. 10) was a 72-year old man who presented with fever and productive cough for one week. He had type 2 diabetes mellitus, cerebrovascular accident and prostatic carcinoma with bone metastasis complicated by spinal cord compression with laminectomy and Luque instrumentation performed. He had lymphopenia ($0.9 \times 10^9/L$), thrombocytopenia ($33 \times 10^9/L$), deranged liver and renal function tests and an oxygen saturation of only 88% on admission. Chest radiograph revealed extensive airspace shadows in both

lungs, with the middle zones more severely involved (FIG. 12B). He died 5 days after admission.

The clinical, laboratory and radiological characteristics of patients who survived and those who died with community acquired pneumonia associated with CoV-HKU1 were compared (Table 7). Patients who died had lower hemoglobin concentration ($P=0.04$), monocyte count ($P=0.04$), serum albumin ($P=0.04$) and oxygen saturation on admission ($P=0.03$) and bilateral involvement ($P=0.003$) and more number of zones involved ($P=0.01$) on chest radiograph.

TABLE 7

Characteristics	Outcome*		
	Survived (n = 8)	Died (n = 2)	P value
<u>Characteristics</u>			
Sex (M:F)	5:3	2:0	1.00
Age	73	69	0.60
Underlying diseases	6	2	0.45
History of travel within two weeks of disease onset	4	0	0.24
History of smoking	4	1	1.00
<u>Clinical features</u>			
Fever	7	1	0.26
Cough	6	1	0.51
Sputum production	5	1	0.76
Dyspnoea	4	2	0.22
Rhinorrhoea	1	0	0.62
Sore throat	2	0	0.45
<u>Haematological features</u>			
Haemoglobin (g/dl)	13.4	9	0.04
Leukocyte count ($\times 10^9/l$)	9.7	7.85	0.43
Neutrophil count ($\times 10^9/l$)	7.4	6.9	0.79
Lymphocyte count ($\times 10^9/l$)	1.35	0.55	0.15
Monocyte count ($\times 10^9/l$)	0.7	0.3	0.04
Platelet count ($\times 10^9/l$)	292	200.5	0.79
<u>Serum biochemical features</u>			
Sodium (mmol/l)	137.5	134	0.11
Potassium (mmol/l)	3.9	4.5	0.06
Creatinine ($\mu\text{mol/l}$)	79	76.5	0.69
Urea (mmol/l)	4.6	10.75	0.19
Albumin (g/l)	38.5	26	0.04
Globulin (g/l)	30	30	1.00
Bilirubin ($\mu\text{mol/l}$)	10	30.5	0.79
ALT (U/l)	16.5	30.5	0.36
Alkaline phosphatase (U/l)	86	190.5	0.07
Oxygen saturation on room air (%)	99	85.5	0.03
<u>Radiological features</u>			
Bilateral involvement	0	2	0.003
No. of zones involved	1	6	0.01

*Continuous variables are expressed as median and categorical variables as no. of patients with the presence of the characteristics.

RT-PCR and Sequencing of the Complete RNA-Dependent RNA Polymerase, Spike and Nucleocapsid Genes of Coronavirus-HKU1 and Phylogenetic Analysis

The complete pol (FIG. 11), S (FIG. 13) and N (FIG. 14) genes of CoV-HKU1 from NPAs of nine of the 10 patients, with adequate amount of RNA available, were amplified and sequenced. The phylogenetic trees and non-synonymous mutations and the corresponding amino acid changes are shown in FIG. 15. In all three genes, the phylogenetic trees using nucleotides or amino acids for construction showed the same topologies. For the S gene, there were 317 and 306 nucleotide positions with synonymous and non-synonymous mutations respectively (FIG. 15B). For the N gene, there were 42 and 53 nucleotide positions with synonymous and non-synonymous mutations respectively (FIG. 15C). The

nucleotide sequences of seven of the nine S or N genes showed similar sequences (genotype A, FIGS. 15B and 15C) and those of the other two also showed similar sequences (genotype B, FIGS. 15B and 15C). For the CoV-HKU1 from patient 1, two peaks (T and C) were consistently observed at nucleotide position 1300 of the N gene, suggesting the presence of quasi-species (FIG. 15C). For the pol gene, there were 95 and 13 nucleotide positions with synonymous and non-synonymous mutations respectively (FIG. 15A). The nucleotide sequences of the pol genes in the seven CoV-HKU1 of genotype A were also clustered together (FIG. 15A). Interestingly, the seven CoV-HKU1 of genotype A were from seven patients with underlying diseases and the two of genotype B were from the two patients without underlying diseases (Table 5). Furthermore, multiple alignments of the nucleotides sequences of the pol genes of the nine CoV-HKU1 and those of HCoV-OC43, HCoV-229E, HCoV-NL63 and SARS-CoV revealed that the primers we used in the present study should be specific for CoV-HKU1 (FIG. 16).

Animal Surveillance

None of the 208 nasopharyngeal swabs and faecal samples from 56 wild and domestic animals in Hong Kong and southern China was positive for CoV-HKU1 RNA.

6.2.8 Discussion

CoV-HKU1, a novel group 2 coronavirus, is associated with community-acquired pneumonia. Since the SARS epidemic in 2003, we have started to prospectively collect NPAs and store the extracted RNA from patients with community-acquired pneumonia so that when a novel virus is discovered, the epidemiology and hence the clinical, laboratory and radiological features of the disease can be studied timely. In January 2004, we discovered a novel coronavirus, CoV-HKU1, from a patient with community-acquired pneumonia (Woo, P. C. et al., *J. of Virol.*, 2005, p. 884-895). The RNA extracted from prospectively collected NPAs were immediately retrieved and the presence of CoV-HKU1 RNA looked for. Ten of the 418 NPAs were positive for RNA of CoV-HKU1, giving an incidence of 2.5%. The presence of CoV-HKU1 RNA in these specimens was genuine, instead of due to contamination, as amplification and sequencing of multiple genes (pol, S and N) of CoV-HKU1 indicated the presence of CoV-HKU1 with different nucleotide sequences in the NPAs from the different patients. Moreover, the clinical significance of CoV-HKU1 was further confirmed by the presence of specific antibody responses in all six patients whose serum samples were available.

Similar to HCoV-229E, HCoV-OC43 and HCoV-NL63, CoV-HKU1 is probably a human coronavirus that is endemic in human. Similar to other human coronavirus infections, cases of CoV-HKU1 pneumonia also occurred in winter and spring. Most patients with CoV-HKU1 pneumonia were old (80% older than 65) with major underlying diseases, especially those of the respiratory and cardiovascular systems. In order to study the phylogeny and relationships among the 10 CoV-HKU1, we sequenced the pol, S and N genes of the nine CoV-HKU1 cases which provided adequate amount of RNA. Combined with the data of partial sequencing of the pol genes of the 10 CoV-HKU1 (FIG. 17), results showed that unlike the epidemiology of SARS-CoV, the 10 CoV-HKU1 were not clonal and the topology of the phylogenetic trees did not follow the pattern of a clonal outbreak (FIG. 15). Interestingly, the phylogenetic tree

constructed using the sequences of both the S and N genes showed that CoV-HKU1 of genotype B was associated with the two patients without underlying diseases, but CoV-HKU1 of genotype A was associated with patients with underlying diseases (Table 5; and FIGS. 16B and 16C). Sequencing of more CoV-HKU1 may reveal the presence of genotypes or clades of CoV-HKU1 with differential virulence. To investigate for the possibility of an animal reservoir of CoV-HKU1, we tried to look for the presence of CoV-HKU1 RNA from wild and domestic animals in Hong Kong and southern China by RT-PCR. Our results revealed that none of the specimens showed the presence of CoV-HKU1 RNA. With the results of these clinical epidemiology, molecular epidemiology and eco-epidemiology studies, we conclude that CoV-HKU1 is probably a human coronavirus.

Compared with SARS-CoV pneumonia, CoV-HKU1 pneumonia is a monophasic disease and most patients had relatively mild symptoms that were localized to the respiratory tract and were only briefly hospitalized. SARS-CoV pneumonia is often described as a biphasic disease, with the first phase due to cell lysis as a result of active viral replication, and the second phase may be due to immunopathological damage (Peiris J S M et al., *Lancet* 2003; 361: 1319-25; Peiris J S M et al., *Lancet* 2003; 361: 1767-72). On the other hand, all 10 patients with CoV-HKU1 pneumonia showed the pattern of a monophasic disease. Although dyspnoea was present in half of the patients with CoV-HKU1 pneumonia at initial presentation, as compared to only about 20% of patients with SARS-CoV pneumonia at initial presentation (Peiris J S M et al., *Lancet* 2003; 361: 1319-25), patients with CoV-HKU1 pneumonia often recovered quickly, but patients with SARS-CoV pneumonia deteriorated after 7-10 days (Peiris J S M et al., *Lancet* 2003; 361:1319-25; Peiris J S M et al., *Lancet* 2003; 361: 1767-72). For the eight patients who recovered, the median duration of hospitalization was only 5.5 days. This rapid recovery of patients with CoV-HKU1 pneumonia could be related to the rapid control of the virus by the immune system. This is in line with our previous study showing the index patient (patient 5) with CoV-HKU1 pneumonia had his peak viral load at around day 3 after onset of illness (Woo, P. C. et al., *J. of Virol.*, 2005, p. 884-895). Moreover, only one of the patients had extrapulmonary symptoms and all available extrapulmonary specimens (stool, urine and serum) were RT-PCR negative for CoV-HKU1 (unpublished data). On the other hand, for SARS-CoV pneumonia, patients usually had their peak viral loads 7-10 days after the onset of illness (Peiris J S M et al., *Lancet* 2003; 361: 1767-72). Furthermore, the virus can be readily detected in extrapulmonary specimens, in which the viral loads correlated with the manifestations in the corresponding systems (Hung, I F N et al., *Emerg Infect Dis* 2004; 10: 1550-1557). These imply that the virus was not well controlled by the immune system in the initial phase of the illness.

Despite the relatively mild disease in most patients, CoV-HKU1 pneumonia is associated with mortality in a minority of patients who had lower haemoglobin concentration, monocyte count, serum albumin and oxygen saturation on admission and more extensive involvement on chest radiograph. As in most cases of pneumonia, more extensive involvement in the lungs will result in poor gaseous exchange and hence hypoxia and eventually fatality. The lower haemoglobin concentration, monocyte count and serum albumin could represent poorer pre-morbid states and narrower margins to fight against infections. Both patients

who died had underlying diabetes mellitus, malignancy (gastric lymphoma in one and carcinoma of the prostate in the other) and cardiovascular disease (old myocardial infarct in one and cerebrovascular accident in the other).

7. MARKET POTENTIAL

The two genomic types of CoV-HKU1 are completely sequenced. These sequences allow the development of various diagnostic tests and therapeutic methods as described hereinabove. In addition, the genetic information of CoV-HKU1 is extremely important and valuable for clinical and scientific research applications.

8. EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain many equivalents to the specific embodiments of the invention described herein using no more than routine experimentation. Such equivalents are intended to be encompassed by the following claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference into the specification.

Citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

SEQUENCE LISTING

The patent contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (<http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US07371837B2>). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed:

1. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:2919, or the full length complement thereof.
2. An isolated nucleic acid molecule comprising a replicase gene of coronavirus HKU1 strain (CoV-HKU1), wherein the said replicase gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:2920, 2922, 2924, 2926, 2928, 2930, 2932 and 2934.
3. A vector comprising the nucleic acid molecule of claim 1.
4. A vector comprising the nucleic acid molecule of claim 2.
5. An isolated host cell comprising the vector of claim 3.
6. An isolated host cell comprising the vector of claim 4.
7. An isolated replicase polypeptide encoded by the nucleic acid molecule of claim 2.
8. An isolated nucleic acid molecule encoding the polypeptide of claim 7.

* * * * *